Programme Key:

I	**Invited Speaker**
O/LBO	**Selected Oral Presentation/Late Breaking Selected Oral Presentation**
P/LBP	**Poster Presentation/Late Breaking Poster Presentation** (on display at the venue and on the virtual platform)
VP/LBVP	**Virtual Poster Presentation/ Late Breaking Virtual Poster Presentation** (on display on the virtual platform and on ePoster boards at the venue)

Please note, all times stated in the programme are in local Prague, Czechia (CET) time.

WMS 2024 Full Programme

Version: 011024

Monday 7th October 2024

08:30-19:00	**Pre-Congress Teaching Course** Congress Venue, Club D+E (separate registration required)

Tuesday 8th October 2024

08:00-11:00	**Pre-Congress Teaching Course** Congress Venue, Club D+E (separate registration required)	
11:00-16:00	**WMS Executive Board Meeting** South Boardroom 1	
14:30-18:00	**Registration and poster set up** Congress Venue, Second Floor Foyers	
14:30-16:00	**Meet the Exhibitors** Congress Venue, Second Floor Foyers (Catering provided)	
16:30-17:30	**Industry Symposium 1** South Hall 1	**Industry Symposium 2** South Hall 2 **Catering provided by the sponsor for this session**, available from 30 minutes prior to the start of the symposium
18:00-18:45	**Opening Ceremony** Congress Hall (separate registration required) *Moderators: Jana Haberlová, University Hospital Motol, Czechia & Radim Mazanec, Charles University, Czechia*	
18:45-21:00	**Networking Reception** Congress Venue, Panorama Hall and Zoom Room, First Floor (separate registration required)	

Wednesday 9th October 2024

06:30-19:30	**Congress desk open**	
07:45-08:45	**Industry Symposium 3** South Hall 1 **Catering provided by the sponsor for this session**, available from 30 minutes prior to the start of the symposium	**Industry Symposium 4** South Hall 2 **Catering provided by the sponsor for this session**, available from 30 minutes prior to the start of the symposium
09:00-09:15	**Congress Welcome - Message from the President** Congress Hall	
09:15-10:45	**Topic 1: Acquired Muscle Disorders** Congress Hall *Moderators: Suur Biliciler, Uthealth Science Center Houston, Mcgovern Medical School, USA & Heřman Mann, Institute of Rheumatology Prague, Czechia*	

09:15-09:45	**01INV** Acquired muscle disorders: Introduction to CART cells and Tregs ***Villalta, A***[1,2,3] *[1]Physiology and Biophysics, [2]Muscle Biology and Disease Research Center, [3]Institute for Immunology, University of California Irvine*
09:45-10:15	**02INV** Current and prospective uses of CAR and CAAR T-cell therapies in muscle disorders ***Mozaffar, T***[1] *[1]University of California Irvine*
10:15-10:30	**01O** Response to rozanolixizumab across treatment cycles in patients with generalised Myasthenia Gravis: A post hoc analysis ***Vissing J***[1], *Grosskreutz J[2], Habib A[3], Mahuwala Z[4], Mantegazza R[5], Pascuzzi R[6], Sacconi S[7], Vu T[8], Beau Lejdstrom R[9], Greve B[10], Grimson F[11], Tarancón T[12], Bril V[13]* *[1]University of Copenhagen, [2]University of Lübeck, [3]University of California, [4]Department of Neuromuscular Medicine and Clinical Neurophysiology, University of Kentucky, USA, [5]Istituto Nazionale Neurologico Carlo Besta, [6]Indiana University School of Medicine, [7]Université Côte d'Azur, 8University of South Florida Morsani College of Medicine, [9,10,11,12]UCB Pharma, [13]University Health Network Canada*
10:30-10:45	**02O** Characterization of a mouse model for Jo-1, PL-7 and PL-12 associated Anti-synthetase syndrome ***Bachir D***[1], *Preusse C[2], Lichtenberg S[1], Koch-Hölsken K[1], Umathum V[3,4], Herrmann A[1], Schaenzer A[3], Meuth S[1], Stenzel W[2], Ruck T[1]* *[1]Heinrich Heine University, [2]Charité-Universitätsmedizin Berlin, [3]Justus Liebig University, [4]German Armed Force Hospital*
10:45-11:15	**Morning refreshments, exhibition and posters** Congress Hall Foyer, Forum Hall and Forum Foyer
10:45-11:15	**Myology Café - Meet the WMS EDI Committee** Forum Hall Foyer
11:15-13:15	**Topic 1: Acquired Muscle Disorders** Congress Hall *Moderators: Ichizo Nishino, National Institute of Neuroscience, Japan & Corinna Preusse, Charité-universitätsmedizin Germany*
11:15-11:45	**03INV** Idiopathic inflammatory myopathies: current state of the field, new insights and treatment ***Vencovský J***[1], *Mann H[1]* *[1]Institute of Rheumatology, Czechia*
11:45-12:15	**04INV** Acquired muscle disease - a paediatric perspective ***Ramdas S***[1] *[1]Oxford University Hospitals NHS foundation Trust, Oxford, UK, [2]University of Oxford, Oxford, UK*
12:15-12:30	**03O** Identification of Class I HLA genetic predispositions and prediction of autoantigenic epitopes in dermatomyositis patients of Indian origin ***Jassal B***[1], *Deepak R[2], Venugopalan Y V [3], Suri V[1], Sharma M[1]* *[1]Neuropathology Lab, All India Institute of Medical Sciences, [2]Department of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, [3]Department of Neurology, All India Institute of Medical Sciences*
12:30-12:45	**04O** In-silico Interactomics as a way to elucidate Inclusion Body Myositis ***De Los Reyes F***[1], *Hayashi S[1], Noguchi S[1], Nishino I[1]* *[1]Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry*
12:45-13:00	**05O** Unravelling the role of early mitochondrial dysfunction in Inclusion Body Myositis: a chicken or egg dilemma reloaded ***Kleefeld F***[1], *Cross E[2], Lagos D[2], Preusse C[1], Roos A[3,4,5,6], Horvath R[2], Stenzel W[1]* *[1]Charité - Universitätsmedizin Berlin, [2]University of Cambridge, [3]Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University, [4]Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute, [5]Leibniz-Institut für Analytische Wissenschaften-ISAS e.V, [6]Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioural Sciences, University Duisburg-Essen*
13:00-13:15	**06O** NLRP3 inflammasome activation and altered mitophagy are key pathways in Inclusion Body Myositis. ***Naddaf E***[1], *Nguyen T[1], Watzlawik J[2], Gao H[3], Hou X[2], Fiesel F[2,4], Mandrekar J[1,5], Kokesh E[1], Harmsen W[5], Lanza I[6], Springer W[2,4], Trushina E[1,3]* *[1]Department of Neurology, Mayo Clinic, [2]Department of Neuroscience, Mayo Clinic, [3]Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, [4]Neuroscience PhD Program, Mayo Clinic Graduate School of Biomedical Sciences, [5]Department of Quantitative Health Sciences, Mayo Clinic, [6]Division of Endocrinology and Metabolism, Mayo Clinic*

13:15-14:30	**Lunch, exhibition and posters** Congress Hall Foyer, Forum Hall and Forum Foyer
13:15-14:30	**Meet the Experts Lunch** Zoom and Panorama Rooms, 1st Floor (separate registration required and lunch is provided)
14:30-15:30	**Poster Session 1** Forum Hall (lunch is provided)

113P-146P, 147VP: SMA Clinical

113P Quality of life and participation of adults with spinal muscular atrophy: QOLSMA
Ribault S[1], *Rippert P*[1], *Lopinet T*[1], *Le Goff L*[1], *Barrière A*[1], *Morard M*[1], *Theuriet J*[1], *Pegat A*[1], *Boyer F*[2], *Vuillerot C*[1]
[1]*Hospices Civils De Lyon,* [2]*CHU de Reims*

114P Epidemiology and therapeutic outcomes of patients with Spinal Muscular Atrophy: results from a 12-year real-world study based on the French National Healthcare database (SNDS)
Quijano-Roy S[1], *Bourget I*[2], *Lot A*[1], *Desguerre I*[3], *Urtizberea J*[4], *de Chasteigner A*[5], *Leiba G*[5], *Affinito S*[5], *Panes A*[6], *Denis H*[6], *Schmidt A*[6]
[1]*APHP Raymond Poincare Hospital,* [2]*Gustave Roussy Hospital,* [3]*APHP Necker Enfants Hospital,* [4]*GH Pitie Salpetriere,* [5]*Novartis GT France SAS,* [6]*HEVA*

115P MRI of whole-body muscles and tongue of patients with Spinal Muscular Atrophy
Froelich S[1], *Receveur N*[1], *Scharff Poulsen N*[1], *Espe Hansen A*[2], *Vissing J*[1]
[1]*Copenhagen Neuromuscular Center, (CNMC), Department of Neurology, Rigshospitalet,* [2]*Department of Radiology, Rigshospitalet*

116P Exploring neurobehavioral disorders in type 1 and presymptomatic patients with Spinal Muscular Atrophy
Buchignani B[1,2], *Coratti G*[2,3], *Cutrì C*[3], *Palermo C*[2], *Leone D*[2], *Antonaci L*[2], *Pera M*[2,3], *Pane M*[2,3], *Mercuri E*[2,3]
[1]*Università Di Pisa,* [2]*Centro Clinico Nemo Pediatrico,* [3]*Università Cattolica del Sacro Cuore*

117P Prevalence of neurodevelopmental anomalies in patients with Spinal Muscular Atrophy Type I registered in CUIDAME
Alvarez Molinero M[1], *Gómez Andrés D*[1], *Garcia Uzquiano R*[2], *Expósito Escudero J*[2], *Costa Comellas L*[1], *Garcia Romero M*[3], *Martinez Salcedo E*[4], *Nungo Garzón C*[5], *Grimalt Calatayud M*[6], *Lopez Lobato M*[7], *Munell Casadesús F*[1], *Fernández Ramos J*[8], *Calzada, Garcia-Mora C*[9], *Gómez Martín H*[10], *Calvo R*[11], *Toledo Bravo de Laguna L*[12], *González Barrios D*[13], *Navarrio Abia V*[14], *Fernández Garcia M*[3], *CUIDAME Investigators Group*[15]
[1]*Vall Hebron University Hospital,* [2]*Sant Joan de Deu Hospital,* [3]*La Paz University Hospital,* [4]*Virgen de la Arrixaca University Hospital,* [5]*La Fe Valencia Hospital,* [6]*Son Espases University Hospital,* [7]*Virgen del Rocio Hospital,* [8]*Reina Sofía Hospital,* [9]*Toledo University Hospital,* [10]*Salamanca University Hospital,* [11]*Regional University Hospital of Malaga,* [12]*Materno-Infantil Hospital of Las Palmas de Gran Canaria,* [13]*Nuestra Señora de Candelaria University Hospital,* [14]*University Hospital of Burgos,* [15]*Cuidame Investigators Group*

118P Characterization of patients with Type 1 Spinal Muscular Atrophy in advanced disease state treated with Nusinersen
Balkenhol J[1], *Beytia M*[1], *Jofre J*[2], *Suarez B*[2], *Hervias C*[3], *Calcagno G*[3], *Castiglioni C*[2]
[1]*Pontificia Universidad Católica De Chile, División Pediatrìa, Unidad Neurología Pediátrica,* [2]*Clinica Meds, Neurology Service,* [3]*Clinica Meds, Neurokinesiology Service*

119P Evaluation of physical function before and after medical treatment in patients with Spinal Muscular Atrophy aged 11-25 years
Werlauff U[1], *Busk L*[1], *Drivsholm P*[1], *Heiden B*[1], *Iversen R*[1], *Laustsen H*[1], *Mahoney A*[1], *Olesen L*[1], *Handberg C*[1,2]
[1]*The Danish National Rehabilitation Centre for Neuromuscular Diseases,* [2]*Department of Public Health, Faculty of Health, Aarhus University*

120P Diagnostic delay in Korean adults with Spinal Muscular Atrophy
Kim S[1], *Choi Y*[1], *Cho J*[2], *Choi Y*[1], *Park H*[1]
[1]*Department Of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine,* [2]*Department of Neurology, National Health Insurance Service Ilsan Hospital*

121P Insulin resistance and liver fibrosis and - steatosis in adult patients with Spinal Muscular Atrophy
Receveur N[1], *Frølich S*[1], *Scharff Poulsen N*[1], *Ewertsen C*[2], *Espe Hansen A*[2], *Vissing J*[1]
[1]*Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet,* [2]*Department of Radiology, Rigshospitalet*

122P A retrospective review of changes in upper limb function following spinal surgery in Spinal Muscular Atrophy
Martineau O[1,2], *Milev E*[1,2], *Main M*[1], *Scoto M*[1,2], *Muntoni F*[1,2], *Baranello G*[1,2]
[1]*Great Ormond Street Hospital,* [2]*University College London*

123P The difficult path to diagnosis of the patient with spinal muscular atrophy

Bolano Diaz C[1,2], Morosini M[1], Chloca F[1], Mesa L[1], Jauregui A[1], Pirra L[1], Vazquez G[1], Flores D[1], Dubrovsky A[1]

[1]Favaloro Foundation - Neurosciences Institut, [2]John Walton Muscular Dystrophy Research Centre

124P Hidden in plain sight: genome reanalysis to identify an intragenic novel variant in the SMN locus in a patient with an undiagnosed lower motor neuron disease

Haliloğlu G[1], Donkervoort S[2], Weisburd B[3,4], Öz Yıldız S[1], Ceylaner S[5], Pais L[3,6], O'Donnell-Luria A[3,6], Bönnemann C[2]

[1]Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Neurology, [2]Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, [3]Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, [4]Center for Genomic Medicine, Massachusetts General Hospital, [5]Intergen Genetic Diagnosis and Research Center, [6]Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School

125P A review of the management and outcomes of children with SMA in the West Midlands, UK during 2017-2022

Willis T[1,2], Kulshrestha R[1], Alhaswani Z[3], Parasuraman D[3], Kuiper J[1], Jones J[1], Perry C[1]

[1]Robert Jones and Agnes Hunt hospital, [2]University of Chester Medical School, [3]University Hospitals Birmingham

126P Retrospective assessment of feeding and nutrition after 2 years of risdiplam treatment in children with Type 1 SMA using a novel scale

Baranello G[1,2], Conway E[1], Li Y[3], Gorni K[4]

[1]Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital Trust, [2]Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, [3]Pharma Development, Data Sciences, F. Hoffmann-La Roche Ltd, [4]PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd

127P UK real-world longitudinal data collection and analysis in adult SMA: theAdult SMA REACH Data collection study

Karkkainen E[1,2], Murphy L[1,2], Muni Lofra R[1,2], Segovia S[1,2], Page J[1,2], Verdu-Diaz J[1], Michell-Sodhi J[1,2], Alvarez G[1,2], Marini-Bettolo C[1,2]

[1]The John Walton Muscular Dystrophy Research Centre, [2]Newcastle University and Newcastle Hospitals NHS Foundation Trust

128P Treatment with gene therapy in patients with spinal muscular atrophy. Current experience in CuidAME registry

Exposito Escudero J[1], Costa Comellas L[2], García Romero M[3], Toledo Bravo De Laguna L[4], Gomez Martin H[5], Calvo Medina R[6], Navarro Abia V[7], Ñungo Garzón C[8], Martinez Gonzalez M[9], Martínez Salcedo E[10], Grimalt Calatayud M[11], Martínez González M[12], Álvarez Molinero M[2], Fernández García M[3], Puig Ram C[1], Garcia Uzquiano R[1], Hervás D[8], Nascimento Osorio A[1], CUIDAME investigators Group[13]

[1]Hospital Sant Joan De Deu, [2]Hospital Vall d'Hebron, [3]Hospital Universitario La Paz, [4]Hospital Materno-Infantil de Canarias, [5]Complejo Asistencial Universitario de Salamanca, [6]Hospital Regional Universitario de Malaga, [7]Hospital Universitario de Burgos, 8Hospital Universitario y Politecnico la Fe, [9]Hospital Universitario de Cruces, [10]Hospital Clinico Universitario Virgen de la Arrixaca, [11]Hospital Son Espases, [12]Complejo Universitario Hospital de Albacete, [13]CUIDAME investigators Group

129P Newborn screening for Spinal Muscular Atrophy in Poland – a summary of 3-year experience

Gos M[2], Wasiluk J[2], Landowska A[2], Jurzyk M[2], Wawer W[2], Kubiszyn P[2], Wieczorek J[2], Kordowska O[2], Nosarieva L[2], Durda K[3], Fraczyk M[2], Jedrzejowska M[1], Ołtarzewski M[2]

[1]Medical University of Warsaw, [2]Institute of Mother and Child, [3]Pomeranian Medical University

130P Real-life outcome data on Risdiplam therapy for Spinal Muscular Atrophy

Lavi R[1,2], Sagi L[1,2], Katzenellenbogen S[1], Shtamler A[1], Weizman A[1], Opincariu I[1,3], Fattal-Valevski A[1,2]

[1]Sourasky Medical Center, [2]Faculty of Medicine Tel Aviv University, [3]Schonbrunn Academic School of Nursing, Sourasky Medical Center

131P Social communication abilities in treated children with Spinal Muscular Atrophy type 1 (SMA1): a cross-sectional study from two tertiary neuromuscular centres

Brusa C[1,2], Buchignani B[3,4], Cutri C[5], Coratti G[3,5], Weststrate H[1,2], Clark E[2], Johnson E[2], Barritt E[2], Antonaci L[3], Leone D[3], Palermo C[3], Cornell N[1,2], Munot P[2], Manzur A[2], Scoto M[1,2], Pane M[3,5], Mercuri E[3,5], Muntoni F[1,2], Baranello G[1,2]

[1]UCL - Great Ormond Street Institute of Child Health, [2]Great Ormond Street Hospital for Children, [3]Centro Clinico Nemo, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, [4]University of Pisa, 5Pediatric Neurology, Università Cattolica del Sacro Cuore

132P Early-onset motor neuropathies and novel genetic causes: a Chilean series

Castiglioni Toledo C[1]

[1]Clinica Meds-Inrpac

133P Description of UK SMA cohorts since the introduction of disease modifying therapies

Muni Lofra R[1,2], *Rowher A*[3], *Muntoni F*[3], *Marini-Bettolo C*[1,2], *SMAREACH UK Sterring Group, Adult SMAREACH Steering Group*

[1]*John Walton Muscular Dystrophy Research Centre-Newcastle University,* [2]*Newcastle Hospitals NHS Foundation Trust,* [3]*Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health*

134P Beyond the "walker" label: functional diversity and disease impact in spinal muscular atrophy patients with walking ability

Cattinari M[1], *Hervás D*[2], *de Lemus M*[1,3,4], *Tizzano E*[1,5]

[1]*Fundame, Madrid, Spain,* [2]*Department of Applied Statistics and Operations Research and Quality, Universitat Politècnica de València,* [3]*SMA Europe Germany,* [4]*Committee of Advanced Therapies at the European Medicines Agency,* [5]*Department of Clinical and Molecular Genetics and Rare Diseases Unit and Medicine, Genetics Group, VHIR, Hospital Vall d'Hebron*

135P Use of electrophysiologic data and physical therapy assessments in SMA monitoring

Wright M[1,2], *Yang M*[1,2], *Moore Burk M*[2], *Kelley C*[2], *Stratton A*[1,2], *Apkon S*[1,2], *Gibbons M*[1,2], *Browning K*[1,2], *Kupfer O*[1,2], *Watne L*[2], *Foster H*[2], *Parsons J*[1,2]

[1]*University of Colorado School of Medicine,* [2]*Children's Hospital Colorado*

136P Medical treatment of children with spinal muscular atrophy - An investigation of parents' experiences of hopes, worries and need for rehabilitation for their child

Handberg C[1,2], *Werlauff U*[1], *Drivsholm P*[1,2], *Lorenzen S*[1], *Mahoney A*[1]

[1]*National Rehabilitation Center for Neuromuscular Diseases,* [2]*Department of Public Health, Faculty of Health, Aarhus University*

137P Mortality in Spinal Muscular Atrophy in the era of disease-modifying therapies

Finnegan R[1], *Rohwer A*[1], *Scoto M*[1,2], *Main M*[1], *Baranello G*[1,2], *Manzur A*[1], *Muntoni F*[1,2], *Munot P*[1]

[1]*Dubowitz Neuromuscular Centre, Great Ormond Street Hospital for Children,* [2]*NIHR Great Ormond Street Hospital Biomedical Research Centre*

138P Long-term motor responses to disease-modifying therapies in Spinal Muscular Atrophy (SMA) adults: a prospective study

Duong T[1], *Tang W*[1], *Gu B*[1], *Dunaway Young S*[1], *Corratti G*[2], *Pasternak A*[4], *Glanzman A, de Monts C*[1], *Rodriguez-Torrres R*[3], *Maczek E*[4], *Martens B*[5], *Salvator S*[1], *Smith S*[1], *Yatsu L*[1], *Hailu R*[1], *Park T*[1], *He Z*[1], *Mercuri E*[2], *Day J*[1]

[1]*Stanford University,* [2]*Catholic University of Sacred Heart,* [3]*Columbia University,* [4]*Boston Children's Hospital,* [5]*University of Rochester,* [6]*Childrens Hospital of Philadelphia,*

139P Treatment effects on ambulation loss in Spinal Muscular Atrophy Type III: insights from the Italian ISMAC registry

Coratti G[1], *D'Amico A*[2], *Sansone V*[3], *Masson R*[4], *Maggi L*[5], *Mongini T*[6], *Pegoraro E*[7], *Pini A*[8], *Vacchiano V*[9], *Coccia M*[10], *Filosto M*[11], *Ticci C*[12], *D'Errico E*[13], *Nigro V*[14], *Bruno C*[15], *Messina S*[16], *Pera M*[1], *Pane M*[1], *Mercuri E*[1]

[1]*Child Neurology Unit E Centro Nemo, IRCCS Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore,* [2]*Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesú Children's Hospital IRCCS,* [3]*Centro Clinico NeMo,* [4]*Pediatric Neurology and Myopathology Units, Neurological Institute "Carlo Besta",* [5]*Neurology IV, Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta,* [6]*Neuromuscular Center, "Rita Levi Montalcini" Department of Neuroscience, University of Turin,* [7]*Department of Neurosciences DNS, University of Padova,* [8]*Department of Biomedical and Neuromotor Sciences, IRCCS Istituto delle Scienze Neurologiche di Bologna, University of Bologna,* [9]*UOC Clinica Neurologica, IRCCS Istituto delle Scienze Neurologiche di Bologna,* [10]*Centro NeMO Ancona,* [11]*Department of Clinical and Experimental Sciences, University of Brescia; NeMO-Brescia Clinical center for Neuromuscular Diseases,* [12]*SOC Malattie Metaboliche e Muscolari Ereditarie, Meyer Children's Hospital IRCCS,* [13]*Neurology Unit, Azienda Ospedaliero-Universitaria, Policlinico of Bari,* [14]*Medical Genetics and Cardiomyology, Department of Precision Medicine, University of Campania "Luigi Vanvitelli",* [15]*Center of Translational and Experimental Myology and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS Istituto Giannina Gaslini and University of Genoa,* [16]*Department of Clinical and Experimental Medicine, University of Messina*

140P Need for tube feeding in SMA type I patients treated with disease modifying therapies: bulbar function before treatment matters

Coratti G[1], *Pane M*[1], *Stanca G*[1], *D'Amico A*[2], *Sansone V*[3], *Berti B*[1], *Fanelli L*[1], *Albamonte E*[3], *Ausili C*[1], *Cerchiari A*[4], *Catteruccia M*[2], *De Sanctis R*[1], *Leone D*[1], *Palermo C*[1], *Buchignani B*[1], *Tosi M*[2], *Pera M*[1], *Bertini E*[2], *Mercuri E*[1]

[1]*Child Neurology Unit e Centro Nemo, IRCCS Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore,* [2]*Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesú Children's Hospital IRCCS,* [3]*Centro Clinico NeMo,* [4]*Feeding and Swallowing Services Unit, Bambino Gesù Children's Hospital IRCCS*

141P Spinal Muscular Atrophy is also a disorder of spermatogenesis

Magot, A[1], *Reignier, A*[2], *Binois, O*[3], *Vuillerot,C*[4,5], *Yann, P*[1] *and the Fermasi Study Group*

[1]*Centre de Référence des Maladies Neuromusculaires AOC, CHU de Nantes, Filnemus, Euro-NMD, Nantes,* [2]*Service de Médecine et Biologie de la Reproduction, gynécologie médicale, CHU de Nantes,* [3]*Service de Biologie de la Reproduction - CECOS, Hôpital Antoine Béclère, AP-HP, Université Paris Saclay,* [4]*Centre de Référence PACA Réunion Rhône Alpes, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, L'Escale, Service de Médecine Physique et de Réadaptation Pédiatrique, Bron,* [5]*NeuroMyogen Institute, CNRS UMR 5310 - INSERM U1217, University of Lyon*

142P A preliminary machine learning retrospective observational study to predict treatment response to nusinersen in non-sitter Spinal Muscular Atrophy

Stimpson G[1,2,6], *O'Reilly E*[1,2], *Coratti G*[3,4], *Ridout D*[5], *Chakraborti T*[6,7], *Mitra R*[6,8], *Mercuri E*[3,4], *Scoto M*[3,4], *Muntoni F*[3,4], *Baranello G*[3,4]

[1]*Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health,* [2]*National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre,* [3]*Pediatric Neurology Unit, Catholic University,* [4]*Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS,* [5]*Population, Policy & Practice Department, UCL Great Ormond Street Institute of Child Health,* [6]*Turing-Roche Strategic Partnership, Alan Turing Institute,* [7]*Dept of Medical Physics and Biomedical Engineering and the Dept of Pathology, UCL Cancer Institute,* [8]*Department of Statistical Science, University College London*

143P Swallowing physiology and function in untreated patients with Spinal Muscular Atrophy type 1: establishing natural history reference values

McGrattan K[1], *Graham R*[2], *Miles A*[3], *Allen J*[3], *Hofelich Mohr A*[1], *Rao V*[4], *Alfano L*[5], *Smith L*[11], *Brandesma J*[6], *Leon Astudillo C*[7], *Levy D*[8], *Tang W*[10], *Brown A*[13], *Spoden A*[1], *Schenck G*[9], *Darras B*[2]

[1]*University Of Minnesota,* [2]*Boston Children's Hospital,* [3]*University of Auckland,* [4]*Lurie Children's Hospital,* [5]*Nationwide Children's Hospital,* [6]*Children's Hospital of Philadelphia,* [7]*University of Florida,* [8]*Hospital de Clínicas de Porto Alegre,* [9]*Gillette Children's Hospital,* [10]*Stanford University,* [11]*Primary Children's Hospital,* [12]*Texas Children's Hospital*

144P Gene therapy for Spinal Muscular Atrophy amid the dengue outbreak in Brazil: a case report

Graca F[1], *C França Jr M*[1]

[1]*University Of Campinas*

145P Efficacy of SMA NBS: 4-year comparative study with control group

Dangouloff T[1], *De Waele L*[2], *Beysen D*[3], *Smeets N*[4], *Vanlander A*[5], *Benmhammed N*[1], *Tychon C*[1], *Daron A*[1], *Deconinck N*[6], *Dontaine P*[6], *Servais L*[1,7]

[1]*Division of Child Neurology, Reference Center for Neuromuscular Diseases, Department of Paediatrics, University Hospital Liège & University of Liège,* [2]*Department of Child Neurology, University Hospitals Leuven,* [3]*Division of Paediatric Neurology, Department of Paediatrics, Antwerp University Hospital/University of Antwerp,* [4]*Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Department of Pediatrics, Child Neurology Unit,* [5]*Ghent University Hospital, Pediatric neurology and metabolism; Ghent University, Pediatric and internal medicine,* [6]*Neuromuscular Reference Center and Paediatric Neurology Department, Hôpital des Enfants Reine Fabiola (HUDERF), Hopital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles,* [7]*MDUK Neuromuscular Centre, Department of Paediatrics, University of Oxford*

146P Investigation of bone health in a large cohort of naïve SMA patients

Panicucci C[1], *Brolatti N*[1], *Casalini S*[1], *Coratti G*[2], *Pedemonte M*[1], *Ricci F*[3], *Mongini T*[4], *Sansone V*[5], *Filosto M*[6], *Bello L*[7], *Pegoraro E*[7], *Bruno I*[8], *Verriello L*[9], *Ricci G*[10], *D'Amico A*[11], *Mercuri E*[2], *Maghnie M*[1], *Di Iorgi N*[1], *Bruno C*[1], *working group ITASMAC*[12]

[1]*IRCCS Gaslini Institute,* [2]*Fondazione Policlinico Gemelli Centro clinico Nemo,* [3]*Città della Salute,* [4]*Università di Torino,* [5]*Centro NEMO Milano,* [6]*Centro NEMO Brescia, Brescia, Italy,* [7]*Università di Padova, Padova, Italy,* [8]*IRCCS Burlo Garofolo Trieste,* [9]*Santa Maria della Misericordia Ospedale Univ. Udine,* [10]*Azienda Osped. Univ. Pisana,* [11]*IRCCS Ospedale Pediatrico Bambin Gesù*

147VP Efficacy and safety of Nusinersen in the treatment of Spinal Muscular Atrophy in adolescents and adults

Ningning W[1,4,5], *Hu Y*[2], *Yu L*[3], *Zhu W*[1,4,5]

[1]*Department of Neurology, Huashan Hospital, Fudan University,* [2]*Department of Neurology, The First Affiliated Hospital of Anhui Medical University,* [3]*Department of Neurology, The First Affiliated Hospital of Soochow University,* [4]*National Center for Neurological Disorders (NCND),* [5]*Huashan Rare Disease Center, Huashan Hospital, Shanghai Medical College, Fudan University*

204P-231P, 232VP-233VP: Clinical trials, access to health care and outcome measures

204P A phase 1 study of antisense oligonucleotide NS-035 in patients with Fukuyama Congenital Muscular Dystrophy

Fujino G[1], Kitamura A[1], Takahashi A[1], Maeda M[1], Kubota A[1], Tokuyama Y[2], Wada I[2], Kobayashi K[3], Komaki H[4], Taniguchi-Ikeda M[5], Ishigaki K[6], Toda T[1]

[1]The University of Tokyo, [2]The University of Tokyo Hospital, [3]Kobe University, [4]National Center of Neurology and Psychiatry, [5]Fujita Health University Hospital, [6]Tokyo Women's Medical University

205P Early diagnosis for Duchenne muscular dystrophy (DMD) to shape and influence the model of care to support children and families following an early diagnosis of DMD

Lee S[1], Bradley C[1], Evans K[1], Lorentzos M[2], Servais L[3], Parsons J[4]

[1]TREAT-NMD Services Ltd, [2]The Children's Hospital at Westmead, [3]University of Oxford and University of Liège, [4]Children's Hospital Colorado

206P A quality improvement proposal: improving care management of complex neuromuscular patients – establishing a neuromuscular complex care centre as part of the translational neuromuscular pathway

Marini Bettolo C[1], Wong K[1], Segovia S[1], Muni Lofra R[1], Elseed M[1]

[1]John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust

207P Mobile muscle clinics operating from a UK centre of excellence: report of patient experience and quality of care

Kulshrestha R[1], Emery N[1], Strachan K[1], Willis T[1], Bassie C[1]

[1]Robert Jones and Agnes Hunt Orthopaedic Hospital

208P Are people living with neuromuscular disorders in the north of England satisfied with National Health Service wheelchair service provision?

Michell-Sodhi J[1], Moat D[1], Dias T[1], Mason J[1], Robinson E[1], Schiava M[1], Barr E[1], Bolano C[1], Doaa S[1], Wong K[1], Maha E[1], Emma G[1], Michela G[1], Michelle M[1], Tasca G[1], Diaz-Manera J[1], James M[1], Straub V[1], Marini-Bettolo C[1], Muni-Lofra R[1]

[1]John Walton Muscular Dystrophy Research Centre

209P Custom orthosis improves mobility and caregiver experience in an adolescent with Congenital Myasthenic syndrome and Myofibrillar Myopathy

Varghese V[1], Rajadurai I[1], Paul M[1], Banavara Shyamprasad S[2], Mathew A A[1,2]

[1]Bangalore Baptist Hospital, [2]Synapse Neuro and Child Development Centre

210P Advancing upper limb motor function evaluation in Duchenne muscular dystrophy and Spinal Muscular Atrophy via kinematic parameterization with the wearable device "ArmTracker"

Natera De Benito D[1], Favata A[2], Expósito-Escudero J[1], Gallart R[3], Moya O[1], Roca S[1], Marzabal Gatell A[2], van Noort L[2], Ortez C[1], Torras C[3], Nascimento A[1], Medina-Cantillo J[1], Pàmies Vilà R[2], Font-Llagunes J[2]

[1]Neuromuscular Unit, [2]Biomechanical Engineering Lab, Department of Mechanical Engineering and Research Center for Biomedical Engineering, Universitat Politècnica de Catalunya, [3]Institut de Robòtica i Informàtica Industrial, CSIC-UPC

211P Following patient mobility in daily life: the EJP-DT4RD project

Hogrel J[1], Muni-Lofra R[2], Santmarty P[1], Decostre V[1], Marques T[1], Haf Davies E[3], Straub V[2], the DT4RD Project Group

[1]Institute of Myology, [2]John Walton Muscular Dystrophy Research Centre, [3]Aparito

212P Identifying biomarkers for prediction of fall-risk in patients with Inclusion Body Myositis (IBM)

Hunn S[1], Weihl C[1]

[1]Washington University School of Medicine

213P Sensitivity to change of the Motor Function Measure (MFM) in myotonic dystrophy type 1

Ribault S[1], Rippert P[1], Bassez G[2], Duong T[3], Vuilllerot C[1]

[1]Hospices Civils De Lyon, [2]Stanford University, 3Hôpital de la Pitié Salpêtrière

214P The 10-meter model: predicting the 6-minute walk test in Pompe disease

El Kaim A[1], Fer F1, Hogrel J1

[1]Institute Of Myology

215P Evaluating the responsiveness of patient reported outcome measures (PROs) to change in valosin-containing protein multisystem proteinopathy (MSP1) over 24 months

Iammarino M[1], Reash N[1], Lowes L[1,2], Pietruszewski L[3], Adderley K[1], Humphrey L[1], Beale A[1], Steiner C[1], Smith M[1], Alfano L[1,2]

[1]Center for Gene Therapy, The Abigail Wexner Research Institue at Nationwide Children's Hospital, [2]Department of Pediatrics, The College of Medicine, The Ohio State University Wexner Medical Center, [3]Center for Cerebral Palsy, University of California Los Angeles

216P A questionnaire-based investigation into levels physical disability and of physical activity in adults with neuromuscular disease in a UK neuromuscular centre

Willis T[1,2], *Strachan K*[1], *Emery N*[1]

[1]*Robert Jones and Agnes Hunt hospital,* [2]*University of Chester Medical School,*

217P Comparing IBMFRS and sIFA as progression indicators in Inclusion Body Myositis patients from the INSPIRE-IBM trial

Gaid P[1], *Wencel M*[1], *Hernandez I*[1], *Goyal N*[1], *Dimachkie M*[2], *Lloyd T*[3], *Mohassel P*[3], *Weihl C*[4], *Freimer M*[5], *Shaibani A*[6], *Wicklund M*[7], *Dixon S*[8], *Chahin N*[9], *Wang L*[10], *Shieh P*[11], *Amato A*[12], *Quinn C*[13], *Carbunar O*[14], *Mozaffar T*[1], *INSPIRE-IBM Study Group*[1]

[1]*University of California, Irvine,* [2]*University of Kansas Medical Center,* [3]*Johns Hopkins University,* [4]*Washington University in St. Louis,* [5]*Ohio State University,* [6]*Nerve and Muscle Center of Texas,* [7]*University of Texas Health San Antonio,* [8]*University of Colorado,* [9]*Oregon Health and Science University,* [10]*University of Washington,* [11]*University of California, Los Angeles,* [12]*Brigham and Women's Hospital,* [13]*University of Pennsylvania,* [14]*University of Miami*

218P Inter-rater reliability of adapted test of neuromuscular disorders (ATEND) wheelchair-based assessment

Nelson L[1], *Tang W*[2], *Pasternak A*[3], *Glanzman A*[4], *Muni Lofra R*[5], *Duong T*[2]

[1]*Department of Physical Therapy, UT Southwestern Medical Center,* [2]*Department of Neurology, Stanford University School of Medicine,* [3]*Department of Physical and Occupational Therapy, Boston Children's Hospital,* [4]*Department of Neurology and Physical therapy, Children's Hospital of Philadelphia,* [5]*John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

219P Enhancing clinical trial eligibility criteria in FSHD: validating whole-body MRI as a key outcome measure

Widholm P[1,2,3], *Karlsson M*[1], *Pini J*[4,5], *Puma A*[4], *Villa L*[4], *Cavali M*[4], *Ezaru A*[4], *Bassez G*[6], *Marty B*[6], *Evangelista T*[6], *Thomas R*[7,8], *Danjoux L*[7,8], *Tard C*[7,8], *Sacconi S*[4,5]

[1]*Amra Medical, Linköping, Sweden,* [2]*Department of Radiology, and Department of Health, Medicine and Caring Sciences, Linköping University,* [3]*Centre for Medical Image Science and Visualization (CMIV), Linköping University,* [4]*Peripheral Nervous System and Muscle Department, University Côte d'Azur, CHU Nice,* [5]*University Cote d'Azur, Inserm, CNRS, Institute for Research on Cancer and Aging of Nice (IRCAN),* [6]*Unité de Morphologie Neuromusculaire, Institut de Myologie Sorbonne University – Pitié Salpêtrière Hospital – Assistance Public Hôpitaux de Paris,* [7]*Lille University, Inserm, CHU Lille, U1172 – LilNCog – Lille Neuroscience & Cognition,* [8]*Centre de référence des maladies neuromusculaires Nord/Est/Ile-de-France, CHU Lille*

220VP Wearable sensors to evaluate and monitor neuromuscular patients in real world environment

Diella E[1], *Storm F*[1], *Molteni L*[1], *Delle Fave M*[1], *Canella G*[1], *Meola G*[2], *Biffi E*[1], *D'Angelo M*[1]

[1]*IRCCS E Medea,* [2]*University of Milan*

221P Initial data from the achieve trial of DYNE-101 in adults with myotonic dystrophy type 1 (DM1)

Wolf D[1], *Lilleker J*[2], *Bassez G*[3], *Diaz-Manera J*[4], ***Kools J***[5], *Pane M*[6], *Roxburgh R*[7], *Schoser B*[8], *Turner C*[9], *Mix C*[1], *Ray S*[1], *Han B*[1], *Farwell W*[1], *Sansone V*[10]

[1]*Dyne Therapeutics, Waltham, USA,* [2]*Muscle Disease Unit, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre,* [3]*Institut de Myologie,* [4]*John Walton Muscular Dystrophy Research Centre, Newcastle University,* [5]*Radboud University Medical Center,* [6]*Fondazione Policlinico Universitario A. Gemelli,* [7]*Neurogenetics Clinic Centre for Brain Research, University of Auckland,* [8]*Friedrich-Baur-Institute, Dep. of Neurology LMU Clinics, Ludwig-Maximilians University,* [9]*University College London Hospitals,* [10]*Centro Clinico NEMO, University of Milan,*

222P Development of a standardized information model for rare neuromuscular diseases

Gazzerro E[1], *Hübner M*[2], *Nyoungui E*[3], *Krefting D*[3], *Spuler S*[1], *Zschüntzsch J*[3], *Schepers J*[2], *Röttger R*[4]

[1]*Unit of Muscle Research, ECRC, Charite University and Max Delbrück Center for Molecular Medicine,* [2]*Berlin Institute of Health at Charité,* [3]*University Medical Center Göttingen,* [4]*University of Southern Denmark*

223P Mental health support for children and young people with Duchenne muscular dystrophy – who, when and how across the UK

Geagan C[1], *Sandhu A*[1], *Bouquillon L*[2], *Conn R*[3], *Bindman D*[2], *Pattni J*[2], *Turner C*[1], *McDonald R*[2], *Alex J*[5], *Rodney S*[4], *Quinlivan R*[2], *Guglieri M*[1], *Straub V*[1]

[1]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [2]*University College London NHS Foundation Trust,* [3]*Devon Partnership NHS Trust,* [4]*Duchenne Research Fund,* [5]*Duchenne UK*

224P Psychosocial discussions in neuromuscular clinics from a professional lens: evidence from a service evaluation regarding barriers to discussions

Geagan C[1], *Sandhu A*[1], *Mason J*[1], *McCallum M*[1], *Muni-Lofra R*[1], *Moat D*[1], *Wong K*[1], *Robinson E*[1], *Grover E*[1], *Michel-Sodhi J*[1], *Bolaño Diaz C*[1], *Schiava M*[1], *Salman D*[1], *James M*[1], *Tasca G*[1], *Diaz Manera J*[1], *Guglieri M*[1], *Straub V*[1], *Elseed M*[1], *Marini Bettolo C*[1]

[1]*John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

225P Initial data from the DELIVER trial of DYNE-251 in males with DMD Mutations amenable to Exon 51 skipping

De Waele L[1], *Campbell C*[2], *Deconinck N*[3], *Flanigan K*[4], *Lorentzos M*[5], *Phan H*[6], *Shieh P*[7], *Mix C*[8], *Ray S*[8], *Wang D*[8], *Farwell W*[8], *Dugar A*[8], *Naylor M*[8], *Guglieri M*[9], *on behalf of the DELIVER study investigators*

[1]*Neuromuscular Reference Center UZ Leuven, Department of Child Neurology, University Hospital Leuven,* [2]*London Health Sciences Centre,* [3]*Neuromuscular Reference Center UZ Gent,* [4]*Nationwide Children's Hospital,* [5]*Children's Hospital at Westmead,* [6]*Rare Disease Research,* [7]*University of California Los Angeles,* [8]*Dyne Therapeutics, Inc.,* [9]*Royal Victoria Infirmary, Newcastle University*

226P Phase 3, randomized, global study assessing efficacy and safety of del-desiran for the treatment of Myotonic Dystrophy Type 1: HARBOR trial design

Fowler M[5], *Johnson N*[1], *Thornton C*[2], *Day J*[3], *Sansone V*[4], *McEvoy B*[5], *Tai L*[5], *Knisely B*[5], *Brandt T*[5], *Gallagher K*[5], *Hughes S*[5], *Ackermann E*[5]

[1]*Virginia Commonwealth University,* [2]*University of Rochester,* [3]*Stanford University Medical Center,* [4]*University of Milan,* [5]*Avidity Biosciences*

227P Advancing neuromuscular education and care within physiotherapy: POD-NMD (Physiotherapy Online Delivery - Neuromuscular Diseases)

Slim C[1], *Mayhew A*[2]

[1]*TREAT-NMD,* [2]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

228P Don't lose your HEAD: a quality improvement proposal for early recognition of neuromuscular diseases in floppy neonates in the North of England

Reeves T[1,2], *Muni-Lofra R*[1], *Harris L*[1], *Richardson R*[2], *Guglieri M*[1], *Marini-Bettolo C*[1]

[1]*John Walton Muscular Dystrophy Research Centre,* [2]*Newcastle upon Tyne Hospitals, NHS Foundation Trust*

229P Home mechanical ventilation in paediatric neuromuscular disorders in a resource limited setting

Ramesh Babu R[1,2], *Kinimi I*[3], *Shinde S*[3], *Mohan Rao N*[3], *Sahoo A*[3], *Maganthi M*[1], *Agnes Mathew A*[1,2]

[1]*Bangalore Baptist Hospital,* [2]*Synapse Neuro Centre and Child Development Centre,* [3]*Respiratory Medicine, Manipal Hospitals*

230P Physiotherapy for rare hereditary NMDs- an open and free e-learning course for physiotherapists. Results after 18 months online at sjelden.no

Rosenberger A[1], *Schandy R*[2], *Lysne S*[2], *Hæstad H*[1]

[1]*National Neuromuscular Centre Norway, University Hospital of North-Norway,* [2]*National advisory unit on rare disorders, Oslo University Hospital*

231P Efficacy of tranilast in preventing exacerbating cardiac function and death from heart failure in Muscular dystrophy patients with advanced-stage heart failure: a single-arm, open-label, multicenter study

Matsumura T[1], *Fukudome T*[2], *Motoyoshi Y*[3], *Nakamura A*[4], *Kuru S*[5], *Segawa K*[6], *Kitao R*[7], *Watanabe C*[8], *Tamura T*[9], *Takahashi T*[10], *Hashimoto H*[11], *Sekimizu M*[11], *Saito A*[11], *Asakura M*[12], *Kimura K*[13], *Iwata Y*[14]

[1]*NHO Osaka Toneyama Medical Center,* [2]*NHO Nagasaki Kawatana Medical Center,* [3]*NHO Shimoshizu National Hospital,* [4]*NHO Matsumoto Medical Center,* [5]*NHO Suzuka Hospital, Suzuka,* [6]*National Center of Neurology and Psychiatry,* [7]*NHO Hakone Hospital,* [8]*NHO Hiroshima-Nishi Medical Center,* [9]*NHO Higashisaitama Hospital,* [10]*NHO Sendai-Nishitaga Hospital,* [11]*NHO Nagoya Medical Center,* [12]*Hyogo College of Medicine,* [13]*The Institute of Medical Science, The University of Tokyo,* [14]*National Cerebral and Cardiovascular Center Research Institute, Suita*

232VP Patient knowledge of the risks of glucocorticoid management in a specialist adult muscle clinic

Kent L[1], *Begeti F*[1], *Turner H*[1], *Brady S*[1]

[1]*Oxford University Hospitals NHS Foundation Trust*

233VP Review of inpatient care of children affected by neuromuscular disorders or complex neurodisability from the carer perspective

Thomas S[1,2], *Gallagher S*[1,2], *Khalid A*[1,2], *Alhaswani Z*[1,2]

[1]*Birmingham Heartlands Hospital,* [2]*University Hospitals Birmingham*

267P-279P: Cell insights, muscle homeostasis

267P Circulating alpha-Klotho combats TGF-beta-induced sarcopenia

Ohsawsa Y[1], *Nishimatsu S*[1], *Saito F*[2], *Sunada Y*[1]
[1]*Kawasaki Medical School,* [2]*School of Medicine, Teikyo University*

268P Age and sex affect human skeletal muscle secretome

Crisol B[1], *Pinzon N*[1], *Orio J*[1], *Gaut-Serey L*[1], *Ohana J*[1], *Bensalah M*[1], *Peterson C*[2], *Butler-Browne G*[1], *Mouly V*[1], *Bigot A*[1], *Trollet C*[1]
[1]*Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie,* [2]*University of Kentucky*

269P Human neuroblastoma cell-derived neurons and iPSC-derived neurons as models for neuromuscular disorders

Wang H[1], *Pommerenke C*[1], *Hauer V*[1], *Rand U*[1], *Eberth S*[1], *Nagel S*[1], *Dirks W*[1], *Werr L*[2,3], *Fischer M*[2,3], *Steenpaß L*[1]
[1]*Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures,* [2]*University Children's Hospital of Cologne,* [3]*University of Cologne*

270P Single nucleus RNA sequencing reveals unique myonuclei populations in Late-Onset Myopathy

Soule T[1], *Pontifex C*[1], *Rosin N*[1,2], *Joel M*[1], *Lee S*[1], *Nguyen M*[1,3], *Chhibber S*[3], *Pfeffer G*[1,3,4]
[1]*Hotchkiss Brain Institute,* [2]*Faculty of Veterinary Medicine,* [3]*Department of Clinical Neurosciences, Cumming School of Medicine,* [4]*Department of Medical Genetics, Cumming School of Medicine*

271P Exploring the effects of the epi-drug Remodelin on murine myoblasts differentiation

Sian V[1,2], *Sarparanta J*[1,3], *Hentschel A*[4], *Jonson P*[1,3], *Roos A*[5,6], *Natraj Gayathri S*[1,3], *Udd B*[1,7], *Savarese M*[1,3], *Nebbioso A*[2]
[1]*Folkhälsan Research Center,* [2]*Department of Precision Medicine, University of Campania Luigi Vanvitelli,* [3]*University of Helsinki, Faculty of Medicine,* [4]*Leibniz-Institut für Analytische Wissenschaften-ISAS e.V.,* [5]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen,* [6]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute,* [7]*Neuromuscular Research Centre, Tampere University and University Hospital*

272P High phosphate levels induce atrophy and FGF23 expression in skeletal muscle

Heitman K[1], *Fajol A*[1], *Thomas M*[1], *Li Q*[1], *Campos I*[1], *Westbrook D*[1], *Komarova S*[1], *Alexander M*[1], *White K*[2]
[1]*University of Alabama Birmingham,* [2]*Indiana University*

273P Estrogen deficiency results in reduced maximal running capacity without changes in the phosphorylation of myosin regulatory light chain in female rats

Karvinen S[1], *Lee E*[1,2], *Nissinen T*[1], *Ylä-Outinen L*[1], *Jalkanen A*[3], *Karppinen J*[1,4], *Vieira-Potter V*[5], *Lipponen A*[1]
[1]*University of Jyväskylä,* [2]*University of Montréal,* [3]*University of Eastern Finland,* [4]*University of Helsinki,* [5]*University of Missouri*

274P Generation of cardiac organoids from DuchenneMuscularDystrophy patient-derived induced pluripotent stem cells: a novel approach to understanding cardiomyopathy

Przymuszała M[1], *Stępniewski J*[1], *Florczyk-Soluch U*[1], *Dulak J*[1]
[1]*Jagiellonian University*

275P Feasibility of assessing muscle oxygenation in patients with neuromuscular disease using near-infrared spectroscopy

Tang W[1], *Salvatore S*[1], *Khonde S*[1], *Montalvo S*[1], *de Monts C*[1], *Smith S*[1], *Hageman N*[1], *Blumberg Y*[1], *Ataide P*[1], *Ni Ghiollagain N*[1], *Parker D*[1], *Wheeler M*[1], *Day J*[1], *Christle J*[1], *Duong T*[1]
[1]*Stanford University*

276P Exploring muscle endurance in a neuromuscular population: insights from the assisted 6-minute cycling test combined with cardiopulmonary exercise testing and near-infrared spectroscopy

Tang W[1], *de Monts C*[1], *Montalvo S*[1], *Dunaway Young S*[1], *Salvatore S*[1], *Khonde S*[1], *Smith S*[1], *Hageman N*[1], *Blumberg Y*[1], *Ataide P*[1], *Ni Ghiollagain N*[1], *Parker D*[1], *Wheeler M*[1], *Day J*[1], *Wheeler M*[1], *Duong T*[1]
[1]*Stanford University*

277P Single-nuclei RNAseq in myotonic dystrophy type I: DMPK accumulation and myofiber repair

Todorow V[1], *Hayashi S*[2], *Meinke P*[1], *Schoser B*[1], *Nishino I*[2]
[1]*Friedrich-Baur-Institute, LMU,* [2]*Department of Neuromuscular Research, National Center of Neurology and Psychiatry (NCNP)*

278P Mapping human skeletal muscle enhancers to increase rates of genetic diagnosis

Taylor R[1,2], *Taylor J*[1,2], *Denisenko E*[1,2], *Jones M*[1,2], *Clayton J*[1,2], *Laing N*[1,2], *Forrest A*[1,2], *Alinejad-Rokny H*[3], *Ravenscroft G*[1,2]

[1]*Harry Perkins Institute of Medical Research,* [2]*Centre for Medical Research, University of Western Australia,* [3]*Graduate School of Biomedical Engineering, University of New South Wales*

279P Exploring myogenic tremor in an animal model of MYBPC1-Associated Myopathy: a comprehensive study

Inashkina I[1], *Zdanovica A*[1], *Lunge M*[1], *Zayakin P*[1], *Upite J*[2], *Dzirkale Z*[2], *Alnis J*[4], *Lace B*[3], *Jansone B*[2], *Stavusis J*[1]

[1]*Latvian Biomedical Research and Study Centre,* [2]*Department of Pharmacology, Faculty of Medicine, University of Latvia,* [3]*Riga East University Hospital,* [4]*Institute of Atomic Physics and Spectroscopy, University of Latvia*

361P-400P: DMD - imaging and outcome measures

361P Development of a next-generation multiplex ddPCR assay for measurement of in-frame dystrophin mRNA in people with DMD treated with BMN 351

Tamura S[1], *Sidhu I*[1], *Ilagan J*[1], *Yu A*[1], *Byer A*[1], *Kamath S*[1], *Staskus L*[1], *Russell C*[1], *Melton A*[1], ***Larimore K***[1]

[1]*BioMarin Pharmaceutical Inc*

362P Whole-body MRI reveals common and distinctive muscle involvement in "clinically asymptomatic" female carriers of pathogenic DMD variants

Giliberto F[1,2], *Vigliano A*[3], *Luce L*[1,2,4], *Pastor Rueda J*[3], *Chaves H*[3], *Mesa L*[5], *Carcione M*[1,2], *Mazzanti C*[1,2], *Llames Massini C*[1,2], *Radic P*[6], *Cejas C*[3]

[1]*Laboratorio de Distrofinopatías, Cátedra de Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires,* [2]*Instituto de Inmunología, Genética y Metabolismo (INIGEM), UBA-CONICET,* [3]*Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia-FLENI,* [4]*John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [5]*Instituto de Neurociencias, Fundación Favaloro,* [6]*CONICET-Academia Nacional de Medicina, Instituto de Medicina Experimental (IMEX)*

363P A cross-sectional survey upper limb functional using PUL 2.0 at large clinical centers and registries in patients with Duchenne muscular dystrophy

Coratti G[1], *Niks E*[2], *van der Holst M*[3], *Tian C*[4], *Mercuri E*[1], *Muntoni F*[5,6], *Servais L*[7,8], *Ward S*[9]

[1]*Child Neurology Unit e Centro Nemo, IRCCS Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore,* [2]*Department of Neurology, Leiden University Medical Center,* [3]*Department of Orthopedics, Rehabilitation and Physiotherapy, Leiden University Medical Center (LUMC),* [4]*Cincinnati Children's Hospital Medical Center (CCHMC); College of Medicine University of Cincinnati,* [5]*Dubowitz Neuromuscular Centre, UCL, Great Ormond Street Institute of Child Health & Great Ormond Street Hospital,* [6]*National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health,* [7]*MDUK Oxford Neuromuscular Center, Department of Paediatrics, University of Oxford,* [8]*Neuromuscular Center of Liège, Division of Paediatrics, CHU and University of Liège (NMCL),* [9]*Collaborative Trajectory Analysis Project*

364P Gross motor delays in boys with Duchenne muscular dystrophy are seen in infancy

Lowes L[1,2], *Reash N*[1], *Iammarino M*[1], *Connolly A*[2], *Pietruszewski L*[3], *Smith M*[1], *Peng J*[4], *Steiner C*[1], *Tsao C*[2], *Waldrop M*[1,2], *Flanigan K*[1,2], *Chagat S*[1], *Meyer A*[1], *Mendell J*[5], *Alfano L*[1,2]

[1]*Abigail Wexner Research Institute at Nationwide Children's Hospital,* [2]*The Ohio State University College of Medicine,* [3]*Center for Cerebral Palsy, University of California, Los Angeles,* [4]*Center for Biostatistics, The Ohio State University Wexner Medical Center,* [5]*Sarepta Therapeutics*

365P Duchenne video assessment 2.0 scorecard performance: evaluation of inter-item and inter-scorecard relationships

Contesse M[1], *Sapp A*[1], *Zigler C*[2], *Chen W*[1], *Marshall J*[1], *Gensler G*[1], *Brown C*[1], *Barnes R*[1], *King D*[1], *Wilson S*[1], ***Leffler M***[1]

[1]*Emmes, 2Duke University School of Medicine*

366P Social Vulnerability and Fluid Cognition in Duchenne Muscular Dystrophy: The Impact on Boys and Carrier Mothers

Penumalee V[1], *Karra H*[2], *Javalkar S*[1], *Arun S*[1], *Kaat A*[3], *Thangarajh M*[1]

[1]*Virginia Commonwealth University,* [2]*University of Virginia,* [3]*Northwestern University*

367P Mortality among males with muscular dystrophy in the USA: estimation from whole-population cause-of-death records

Hayes E[1], *Giafaglione J*[1], *Signorovitch J*[2], *Sajeev G*[2], *Zhu A*[2], *Shell R*[1], *Waldrop M*[3], *Cripe L*[1], *Wright L*[1], *Nandi D*[1]

[1]*Department of Pediatrics, Nationwide Children's Hospital,* [2]*Analysis Group, Inc,* [3]*Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital*

368P Ankle contractures in Duchenne muscular dystrophy: using real world data to study the influence of the gastrocnemius and soleus muscles on functional decline

Fleerakkers E[1,2,3], *Pelsma M*[4], *Krom Y*[1,3], *Hoek R*[1,3], *Kan H*[5], *van Zwet E*[6], *Houwen-van Opstal S*[3,4], *Niks E*[1,3], *van der Holst M*[2,3]

[1]*Department of Neurology, Leiden University Medical Center,* [2]*Department of Orthopaedics, Rehabilitation & Physical therapy, Leiden University Medical Center,* [3]*Duchenne Center Netherlands,* [4]*Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Amalia Children's Hospital,* [5]*Department of Radiology, Leiden University Medical Center,* [6]*Department of Biomedical Data Sciences, Leiden University Medical Center*

369P Elbow function and thumb pinch strength are relevant for activities of daily living for non-ambulant DMD patients

Michaëls M[1,2], *Naarding K*[1,2], *van der Holst M*[1,2], *van Zwet E*[1], *Kan H*[2,3], *Niks E*[1,2]

[1]*Leiden University Medical Center,* [2]*Duchenne Center Netherland,* [3]*C.J. Gorter MRI Center*

370P Gait analysis in children with Duchenne muscular dystrophy: overground vs. treadmill walking

Deconinck N[1], *Ruiz P*[2], *Kaleeta J*[3], *Cheron G*[2], *Cebolla A*[2]

[1]*Pediatric neurology Department and Neuromuscular reference center, ULB* [2]*Laboratory of Neurophysiology and Movement Biomechanics, ULB* [3]*Paediatric Orthopedic Surgery, HUDERF, ULB*

371P Screening for psychosocial needs in adults with Duchenne muscular dystrophy: preliminary findings on using the GAD7 and PHQ9

Bouquillon L[1], *Pattni J*[1], *Bindman D*[1], *Geagan C*[2], *Conn R*[3], *McDonald R*[1], *Turner C*[2], *Rodney S*[4], *Johnson A*[5], *Guglieri M*[2], *Straub V*[2], *Quinlivan R*[1]

[1]*University College London Hospitals NHS Foundation Trust,* [2]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [3]*Devon Partnership NHS Trust,* [4]*Duchenne Research Fund 5Duchenne UK*

372VP MRI fat fraction in Duchene muscular dystrophy (DMD): inter-reader variability of the 90th percentile fat fraction value

Hammond M[1], *Harris J*[1], *Mesbah S*[1], *Roche F*[2], *Berger M*[1], *Zabbatino S*[1], *Scheyer R*[3], *Holland S*[1]

[1]*Medpace Core Laboratories,* [2]*Medpace Core Laboratories, 3Medpace*

373P Association between the time of diagnosis and muscle breakdown in DMD patients diagnosed under two years of age

Coşkun A[1], *Topaloğlu H*

[1]*Ankara Atatürk Sanatory Train and Research Hospital*

374P Relationship between the Pediatric Outcomes Data Collection Instrument (PODCI) and EQ-5D-3L utility score in Duchenne muscular dystrophy

Posner N[1], *Merla V*[1], *Aslam Z*[1], *Bushmakin A*[1], *Cappelleri J*[1]

[1]*Pfizer, Inc.*

375P Relationship between Pediatric Outcomes Data Collection Instrument (PODCI) and North Star Ambulatory Assessment (NSAA)

Posner N[1], *Merla V*[1], *Aslam Z*[1], *Bushmakin A*[1], *Cappelleri J*[1]

[1]*Pfizer, Inc.*

376P Ataluren in patients with nonsense mutation DMD (nmDMD): retrospective evaluation from a tertiary referral center in Turkey

Öz Yıldız S[1,3], *Bulut N*[2], *Gürbüz İ*[2], *Öztoprak Ü*[1], *Tunca Yılmaz Ö*[2], *Haliloğlu G*[1]

[1]*Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Neurology,* [2]*Hacettepe University Faculty of Physical Therapy and Rehabilitation,* [3]*Necip Fazıl City Hospital, Ministry of Health*

377P Patterns of disease progression in Duchenne muscular dystrophy: heterogeneous changes in motor function tasks among patients with similar trajectories over one year

Posner N[1], *Talaga A*[1],*Johnson M*[2], *Gomez-Lievano A*[2], *Akbarnejad H*[2], *Ma Y*[2], *Aslam Z*[1], *Kane A*[1], *Bhambri R*[1], *Dukacz S*[3], *Cappelleri J*[1], *Signorovitch J*[2]

[1]*Pfizer New York,* [2]*Analysis Group,* [3]*Pfizer Toronto*

378P Geospatial driver of cognition in biological mothers of sons with Dystrohinopathy

Javalkar S[1], *Penumalee V*[1], *Arun S*[1], *Karra H*[1,2], *Kaat A*[3], *Thangarajh M*[1]

[1]*Virginia Commonwealth University,* [2]*University of Virginia,* [3]*Northwestern University*

379P A qualitative study on people with Duchenne muscular dystrophy and caregivers' experiences during the transition process from pediatric to adult healthcare

Marcassoli A[1], Moroni I[2], Guastafierro E[1], Brigliadori B[2], Nardocci N[2], Leonardi M[1], De Angelis F[3], Langer T[4], Rodger S[4], Willems J[4], Kraus De Camargo O[5], Frei J[5], Swain A[5], Ringer D[5], Gorter J[5], Pozniak K[5], Rajapakse N[5], Fournier A[6], Gutierrez R[6], Osman H[7], Reeskau G[8], McCauley D[5], Wang E[5], Friedrich S[4]

[1]Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, [2]Department of Paediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, [3]Parent Project APS, [4]Universitätsklinikum Freiburg, 5CanChild - McMaster University, 6CHU Sainte-Justine Montréal, 7Muscular Dystrophy Canada, 8Deutsche Gesellschaft für Muskelkranke e.V.

380VP Assessment of lung function and respiratory muscles using ultrasonography in Duchenne muscular dystrophy

Ferreira Lima K[1], Arruda P[1], Albuquerque M[1], Zanoteli E[1]

[1]Hospital Das Clinicas De São Paulo/FMUSP

381P Survey results for use of the Performance of the Upper Limb Module in patients with Duchenne muscular dystrophy: UK North Star national registry

Wolfe A[1,2], Brooke M[2], Aslam N[2], Manzur A[1,2], Muntoni F[1,2], Baranello G[1,2]

[1]Great Ormond Street Hospital for Children NHS Foundation Trust, [2]Institute of Child Health, University College London

382P Decreased quality of life in Duchenne muscular disease patients related to functional neurological and cardiac impairment

Jurikova L[1], Masarova L[2,11], Panovsky R[2,3], Pesl M[2,3,4], Zondra Revendova K[5,6], Volny O[2,5,6], Feithova V[2,7], Holecek T[2,7,8], Kincl V[2,3], Danhofer P[1], Vohanka S[9], Haberlova J[10], Podolska K[10]

[1]Dep. of Children's Neurology University Hospital in Brno and Faculty of Medicine Masaryk University in Brno, [2]International Clinical Research Center, St. Anne's University Hospital, Faculty of Medicine, Masaryk University, [3]1st Department of Internal Medicine-Cardio-angiology, Faculty of Medicine, St. Anne's University Hospital, [4]Department of Biology, Faculty of Medicine, Masaryk University, [5]Department of Neurology, University Hospital Ostrava, [6]Centre for Clinical Neurosciences, Faculty of Medicine, University Ostrava, [7]Department of Medical Imaging, St. Anne's University Hospital, [8]Department of Biomedical Engineering, University of Technology, [9]Department of Neurology, Faculty of Medicine, University Hospital Brno, Masaryk University, [10]Department of Paediatric Neurology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, [11]Centre of Cardiovascular and Transplantation Surgery, Faculty of Medicine, Masaryk University in Brno

383P A qualitative evaluation of meaningful change on the north star ambulatory assessment and performance of upper limb in Duchenne muscular dystrophy

Murphy A[1], Ciobanu T[2], Davies E[2], Gillman A[3], Barrett L[3], Johnson A[4], Mills J[3], Heinrich P[3], Przydzial K[3], Ewens B[3], Vandenberg G[3], Cano S[3], Mayhew A[5]

[1]Roche Products Ltd, [2]F. Hoffmann-La Roche Ltd, [3]Modus Outcomes, a company of THREAD, [4]Duchenne UK, [5]John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trusts

384P Functional Outcome Measures (FOMs) guiding clinical care of children with Duchenne muscular dystrophy

Khandekar G[1], Banavara Shyamprasad S[1], Ramesh Babu R[1,2], Kumar A[2], Satyam P[1,2], Maganthi M[2], Krishna G[1], Mathew A[1,2]

[1]Synapse Neuro and Child Development Center, [2]Banglore Baptist Hospital

385P Quantitative magnetic resonance of masticatory muscles in adolescents with Duchenne muscle dystrophy

Avila Smirnow D[1,2,3], Meza C[1,2], González C[1,2], Uribe S[4,5], Salinas L[1,2]

[1]Pediatric Neurology Section, Pediatrics Division, School of Medicine, Pontificia Universidad Católica de Chile, [2]Neurodevelopment Unit, Red Salud UC-Christus, [3]Pediatric Neurology Unit, Pediatrics Service, Hospital Dr. Sótero del Río, [4]Biomedical Imaging Center and Radiology department, Faculty of Medicine Pontificia Universidad Católica, [5]Department of Medical Imaging and Radiation Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University

386P Dark-adaptation visual thresholds in Duchenne muscular dystrophy patients with genetic backgrounds affecting different dystrophin proteins

Dias S[1], Barboni M[1,2], Brasil A[1], Lima K[3], Camelo C[3], Sindeaux R[3], Resende M[3], Albuquerque M[3], Zanoteli E[3], Ventura D[1]

[1]Department of Experimental Psychology, Institute of Psychology, University of São Paulo, [2]Department of Ophthalmology, Semmelweis University, [3]Department of Neurology, University of São Paulo

387P Quantifying function from birth through adulthood in Duchenne muscular dystrophy: a cross-sectional evaluation of the Neuromuscular Gross Motor Outcome

Iammarino M[1], Reash N[1], Smith M[1], Steiner C[1], Beale A[1], Humphrey L[1], Lowes L[1], Alfano L[1]

[1]Nationwide Children's Hospital

388P Remote evaluation of functional outcomes in Duchenne muscular dystrophy: navigating opportunities and obstacles

Banavara Shyamprasad S[1], *Khandekar G*[1], *Ramesh Babu R*[1,2], *Krishna G*[1], *Mathew A*[1,2]
[1]*Synapse Neuro Center,* [2]*Bangalore Baptist Hospital*

389P Natural history of bone health in Duchenne muscular dystrophy: A systematic review and implications for the design of a clinical trial

De Ford C[1], *Guridi M*[1], *Chen Y*[2], *Murphy A*[3], *Wood C*[4], *McMillan H*[5], *Mercuri E*[6], *Crabtree N*[7], *Ward L*[8,9]
[1]*F. Hoffmann-La Roche Ltd,* [2]*Genentech, Inc.,* [3]*Roche Products Ltd,* [4]*Department of Paediatric Endocrinology, Royal Victoria Infirmary,* [5]*Department of Pediatrics, Division of Neurology, Children's Hospital of Eastern Ontario, University of Ottawa,* [6]*Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS,* [7]*Birmingham Women's and Children's NHS Foundation Trust,* [8]*Department of Pediatrics, Division of Endocrinology, Children's Hospital of Eastern Ontario, University of Ottawa,* [9]*The Ottawa Pediatric Bone Health Research Group, Children's Hospital of Eastern Ontario Research Institute*

390P Assessing biomarkers of bone metabolism and the role of the IL-6 signalling pathway in patients with Duchenne muscular dystrophy

De Ford C[1], *Guridi M*[1], *Fruechtenicht C*[1], *See C*[1], *Houghton R*[1], *Chen Y*[2], *Murphy A*[3], *Wood C*[4], *Ward L*[5,6], *Crabtree N*[7], *Mercuri E*[8], *McMillan H*[9]
[1]*F. Hoffmann-La Roche Ltd,* [2]*Genentech, Inc.,* [3]*Roche Products Ltd,* [4]*Department of Paediatric Endocrinology, Royal Victoria Infirmary,* [5]*Department of Pediatrics, Division of Endocrinology, Children's Hospital of Eastern Ontario, University of Ottawa,* [6]*The Ottawa Pediatric Bone Health Research Group, Children's Hospital of Eastern Ontario Research Institute,* [7]*Birmingham Women's and Children's NHS Foundation Trust,* [8]*Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS,* [9]*Department of Pediatrics, Division of Neurology, Children's Hospital of Eastern Ontario, University of Ottawa*

391P Agreement and accuracy of ambulatory definitions in Duchenne muscular dystrophy (DMD): a cross-sectional analysis

Macedo A[1], *Logan J*[1], *Dai D*[1], *Ricchetti-Masterson K*[1]
[1]*Sarepta Therapeutics Inc.*

392P Investigating the data landscape of Duchenne muscular dystrophy: Answering your research questions with the right data source

Furby H[1], *Johnson M*[1], *Signorovitch J*[2], *Moride Y*[3], *Castillon G*[3], *Simpson A*[4]
[1]*Real-World Data Science, Product Development Data Sciences, Roche Products Ltd,* [2]*Analysis Group,* [3]*YOLARX Consultants, Montreal,* [4]*Global Access, F. Hoffmann-La Roche Ltd*

393P Understanding oropharyngeal dysphagia in Duchenne muscular dystrophy: A 10-year longitudinal cohort study

Scholten S[1], *Lagarde M*[1], *Knuijt S*[2], *Houwen-van Opstal S*[1], *Erasmus C*[3], *Groothuis J*[2]
[1]*Radboud university medical center, Department of Rehabilitation, Amalia Children's Hospital,* [2]*Radboud university medical center, Department of Rehabilitation,* [3]*Radboud university medical center, Department of Pediatric Neurology, Amalia Children's Hospital*

394P Longitudinal changes in the North Star Ambulatory Assessment and leg muscle fat fraction in DMD

Forbes S[1], *Nair K*[2], *Willcocks R*[1], *Barnard A*[1], *Lott D*[1], *Senesac C*[1], *Rock K*[1], *Finanger E*[3], *Brandsema J*[4], *Subramony S*[1], *Wang D*[4], *Rooney W*[5], *Walter G*[1], *Vandenborne K*[1]
[1]*University of Florida,* [2]*Temple University,* [3]*Shriners Hospitals for Children,* [4]*Childrens Hospital of Philadelphia,* [5]*Oregon Health & Science University*

395P Age at loss of ambulation in patients with nmDMD from the STRIDE Registry: sensitivity analyses

Muntoni F[1], *Buccella F*[2], *Nascimento Osorio A*[3], *Tulinius M*[4], *Bernadete Dutra de Resende M*[5], *Johnson S*[6], *Werner C*[7], *Anbu B*[6], *Liu E*[6], *Mercuri E*[8]
[1]*University College London Institute of Child Health,* [2]*Parent Project APS Italy,* [3]*Unidad de Patología Neuromuscular, Hospital Sant Joan de Déu, Universidad de Barcelona,* [4]*Department of Pediatrics, Queen Silvia Children's Hospital, University of Gothenburg,* [5]*Department of Neurology, Faculty of Medicine, University of São Paulo,* [6]*PTC Therapeutics Inc.,* [7]*PTC Therapeutics Germany GmbH,* [8]*Department of Pediatric Neurology, Catholic University Rome*

396P 6-year follow-up on muscle affection in female carriers of Dystrophinopathy

Lyu Z[1], *Poulsen N*[1], *Joensen H*[1], *Dunø M*[2], *Bundgaad H*[3], *Vejlstrup N*[3], *Lando C*[1], *Hansen A*[4], *Vissing J*[1]
[1]*Copenhagen Neuromuscular Center, Rigshospitalet,* [2]*Department of Clinical Genetics, Rigshospitalet,* [3]*Department of Cardiology, Rigshospitalet,* [4]*Department of Radiology, Rigshospitalet*

397P 6-year follow-up on cardiac affection in female carriers of Dystrophinopathy

Lyu Z[1], *Poulsen N*[1], *Joensen H*[1], *Bundgaad H*[2], *Vejlstrup N*[2], *Lando C*[1], *Hansen A*[3], *Vissing J*[1]
[1]*Copenhagen Neuromuscular Center, Rigshospitalet,* [2]*Department of Cardiology, Rigshospitalet,* [3]*Department of Radiology, Rigshospitalet,*

398P Magnetic resonance imaging detects bone alterations in corticosteroid treated boys with DMD

Kunnath Ravindranunni R[1], *Grewal R*[2], *Cottrell C*[2], *Bernier A*[1], *Tuna I*[1], *Vandenborne K*[1], *Walter G*[1], *Rajapakse C*[2], *Willcocks R*[1]
[1]*University of Florida,* [2]*University of Pennsylvania*

399P MRI assessment of microdystrophin gene therapy in DMD: a five year longitudinal study

Willcocks R[1], *Lott D*[1], *Forbes S*[1], *Vandenborne K*[1], *Walter G*[1]
[1]*University of Florida*

400P Longitudinal evaluation of ambulatory function with ankle wearable technology in ambulant DMD

Poleur M[1], *Parinello G*[2], *Vrščaj E*[3], *Kumhera M*[4], *Bisson C*[2], *Aragon-Gawińska K*[5], *Anghelescu C*[6], *Daron A*[1], *Szabo L*[7], *Leanca M*[8,9,10], *Mirea A*[8,9,10], *Kodsy S*[11], *Saleh A*[11], *Osredkar D*[3], *Haberlova J*[4], *Potulska-Chromik A*[5], *Butoianu N*[6,8], *Eggenspieler D*[2], *Strijbos P*[12], *Servais L*[13,14]
[1]*University Department of Neurology, Citadelle Hospital,* [2]*Sysnav,* [3]*University Children's Hospital,* [4]*Motol University Hospital,* [5]*Department of Neurology, Medical University of Warsaw,* [6]*Department of Paediatric Neurology, Alexandru Obregia Clinical Hospital,* [7]*Pediatric Center, Semmelweis University,* [8]*University of Medicine and Pharmacy Carol Davila,* [9]*National Clinical Hospital for Children Neurorehabilitation "Dr. Nicolae Robanescu",* [10]*Neuromuscular Disease Academy,* [11]*Galaa Military Medical Complex,* [12]*F. Hoffmann-La Roche Ltd.,* [13]*University of Oxford,* [14]*Department of Paediatrics, University Hospital of Liège*

538P-577P, 578VP: Acquired, inflammatory, myositis

538P Muscle haptoglobin biomarks cachexia induced by anti-acute myeloid leukemia chemotherapy

Rybalka E[1,2,3], *Campelj D*[1,4], *Spiesberger G*[1,2], *Formosa L*[5], *Steele J*[6], *Zhang H*[6], *Schittenhelm R*[6], *Leow L*[3], *Bhandari N*[1], *Goodman C*[7], *Timpani C*[1,2,3]
[1]*Victoria University, Institute for Health and Sport,* [2]*Australian Institute for Musculoskeletal Science, Inherited and Acquired Myopathies Program,* [3]*The University of Melbourne, Department of Medicine—Western Health,* [4]*Centenary Institute, Centre for Healthy Ageing,* [5]*Monash University, Monash Biomedicine Discovery Institute, Department of Biochemistry and Molecular Biology,* [6]*Monash University, Monash Proteomics and Metabolomics Platform, Department of Biochemistry and Molecular Biology,* [7]*The University of Melbourne, Centre for Muscle Research*

539P A late-onset multiple-acyl-CoA-dehydrogenase deficiency-like condition is more common in West of Scotland than primary genetic MADD, and is likely multifactorial

Watson-Fargie T[1], *Coomber A*[2], *Barr M*[3], *Brennan K*[1], *Dale J*[4], *Fletcher E*[5], *Gallagher P*[1], *Molinari E*[1], *Miller-Hodges E*[6], *O'Sullivan D*[7], *Stewart K*[8], *Taylor R*[9], *Topf A*[10], *Straub V*[10], *Edwards R*[3], *Stewart W*[11], *Farrugia M*[1], *Longman C*[8]
[1]*Institute of Neurological Sciences, Queen Elizabeth University Hospital,* [2]*University of Glasgow,* [3]*Department of Biochemistry, Queen Elizabeth University Hospital,* [4]*Department of Rheumatology, NHS Lanarkshire,* [5]*South East Scotland Genetic Service, Western General Hospital,* [6]*Scottish Inherited Metabolic Disorders Service,* [7]*Laboratory Genetics and Molecular Pathology Service, Aberdeen Royal Infirmary,* [8]*West of Scotland Centre for Genomic Medicine, Queen Elizabeth University Hospital,* [9]*Wellcome Centre for Mitochondrial Research,* [10]*John Walton Muscular Dystrophy Research Centre,* [11]*Department of Neuropathology, Queen Elizabeth University Hospital*

540P Assessing the effect of chronic nitrate supplementation on muscle mass and physical function outcomes

Edwards H[1,2], *Morton J*[2], *Moseley J*[3], *Marshall T*[3], *Berry A*[2], *Igwesi-Chidobe C*[3], *El-Khamisy S*[2], *Jones H*[2], *Farrow M*[4]
[1]*University of Bradford, Faculty of Life Sciences,* [2]*University of Bradford, Institute of Cancer Therapeutics,* [3]*University of Bradford, School of Allied Health Professions and Midwifery,* [4]*University of Melbourne*

continued on next page

541P Comparative evaluation of pulmonary function tests and self-reported respiratory function in Inclusion Body Myositis based on NT5c1A antibody serology status

Wencel M[1], *Bjazevic K*[1], *Goyal N*[1], *Carbunar O*[2], *Freimer M*[14], *Dimachkie M*[3], *Quinn C*[4], *LLoyd T*[5], *Mohassel P*[5], *Weihl C*[6], *Shaibani A*[7], *Wang L*[8], *Chahin N*[9], *Amato A*[10], *Wicklund M*[11], *Shieh P*[12], *Herbelin L*[13], *Barohn R*[13], *Mozaffar T*[1]

[1]*University of California, Irvine,* [2]*University of Miami,* [3]*Kansas University Medical Center,* [4]*Pennsylvania State University,* [5]*Johns Hopkins University,* [6]*Washington University in St Louis,* [7]*Nerve and Muscle Center of Texas,* [8]*University of Washington,* [9]*Oregon Health & Science University,* [10]*Brigham and Women's Hospital,* [11]*University of Colorado,* [12]*University of California, Los Angeles,* [13]*University of Missouri,* [14]*The Ohio State University*

542P INSPIRE-IBM: an NIH-funded, two-year, multicenter, observational study in inclusion body myositis (IBM)-an update

Wencel M[1], *Goyal N*[1], *Carbunar O*[2], *Freimer M*[3], *Dimachkie M*[4], *Quinn C*[5], *Lloyd T*[6], *Mohassel P*[6], *Weihl C*[7], *Shaibani A*[8], *Wang L*[9], *Nizar C*[10], *Amato A*[11], *Wicklund M*[12], *Dixon S*[12], *Shieh P*[13], *Herbelin L*[14], *Herbelin L*[14], *Mozaffar T*[1]

[1]*University of California, Irvine,* [2]*University of Miami,* [3]*The Ohio State University,* [4]*Kansas University Medical Center,* [5]*Pennsylvania State University,* [6]*Johns Hopkins University,* [7]*Washington University in St. Louis,* [8]*Nerve and Muscle Center of Texas,* [9]*University of Washington,* [10]*Oregon Health & Science University,* [11]*Brigham and Women's Hospital,* [12]*University of Colorado,* [13]*University of California, Los Angeles,* [14]*University of Missouri*

543P Riboflavin-responsive MADD, a modern day problem?

Hustinx M[1], *Brady S*[2]

[1]*Neuromuscular Reference Centre, CHR Citadelle,* [2]*Oxford Adult Muscle Service, John Radcliffe Hospital, Oxford University Hospitals Trust*

544P A single center Indian cohort of Inclusion Body Myositis

George J[1], *Rajalakshmi P*[2], *Sundaram S*[1], *Nair S*[1]

[1]*Sree Chitra Tirunal Institute for Medical Sciences and Technology & Technology,* [2]*Department of Pathology, Sree Chitra Tirunal Institute for Medical Sciences and Technology*

545P Capillary abnormalities in Immune-Mediated Necrotizing Myopathy: more than collateral damage?

Eisenlohr P[1,2], *Preusse C*[1], *Roos A*[4], *Stenzel W*[1], *Kleefeld F*[2]

[1]*Dpt of Neuropathology Charité Universitätsmedizin Berlin,* [2]*Dpt of Neurology Charité Universitätsmedizin Berlin,* [3]*Dpt of Neuropaediatrics Essen and ISAS,* [4]*Department of Neurology, Medical Faculty and University Hospital Düsseldorf, 5 Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute, 6 Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen*

546VP Deep immunoprofiling in inclusion body myositis and trajectory analysis

Roy B[1], *DiStasio M*[1], *Hackbarth R*[2], *Bahrassa F*[1], *Joo D*[1], *Pham M*[1], *O'Connor K*[1]

[1]*Yale University School of Medicine,* [2]*University of Hamburg*

547P The diagnostic value of serum periostin for myocardial involvement in immune-mediated necrotizing myopathy

Xu L[1], *Yang M*[1], *Kosari M*[2], *Li Y*[1], *Bu B*[1], *Ji S*[1]

[1]*Department of Neurology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology* [2]*MBBS student, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology*

548P A role of heparin-binding epidermal growth factor-like growth factor in myocardial involvement in immune-mediated necrotizing myopathy

Xu L[1], *Meng-ge Y*[1], *Kosari M*[2], *Li Y*[1], *Bu B*[1], *Ji S*[1]

[1]*Department of Neurology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology* [2]*MBBS student, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology*

549VP High dose intravenous corticosteroids in refractory Immune Checkpoint Inhibitor-related Myocarditis/Myositis/Myasthenia overlap syndrome

Forcina F[1], *Tufano L*[1], *Lauletta A*[1], *Morino S*[1], *Musumeci B*[2], *Antonini G*[1], *Garibaldi M*[1]

[1]*NESMOS Department, Sapienza University of Rome,* [2]*Cardiology, Clinical and Molecular Medicine Department, Sapienza University of Rome, Sant'Andrea Hospital*

550P Immune checkpoint inhibitor-induced myositis in a patient with cholangiocarcinoma

Joe S[1], ***Kim S***[1], *Choi Y*[1], *Choi Y*[1], *Park H*[1]

[1]*Department Of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine*

551P BiP (GRP78) as potential blood and tissue biomarker in systemic sclerosis

Preusse C[1,2,3], Dobelmann V[4], Kleefeld F[1], Hentschel A[5], Holla E[6], Ruck T[4], Stenzel W[3], Siegert E[7], Roos A[4,6,8]
[1]Department of Neurology and NeuroCure Clinical Research Center, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), [2]Department of Neuropediatrics and NeuroCure Clinical Research Center, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), [3]Department of Neuropathology, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), [4]Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University, [5]Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., [6]Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioural Sciences, University Duisburg-Essen, [7]Department of Rheumatology, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH)
[8]Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute

552P Binding immunoglobulin protein (BiP) abundance and distribution in Idiopathic Inflammatory Myopathies (IIM)

Kleefeld F[1], Preusse C[1], Hentschel A[4], Stenzel W[1], Dobelmann V[2], Roos A[2,3,5]
[1]Charité - Universitätsmedizin Berlin, [2]Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University, [3]Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioural Sciences, University Duisburg-Essen, [4]Leibniz-Institut für Analytische Wissenschaften, [5] Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute

553P Brachio-cervical Inflammatory Myopathy, an unknown disease with diverse serological and histopathological findings and poor response to treatment

Kapetanovic Garcia S[1,2], Jimenez-Almonacid J[3], Toldos-Gonzalez O[3], Ruiz-Lucea E[4], Rodrigo-Armenteros P[1,2], Hernandez-Lain A[3], Dominguez-Gonzalez C[5,6]
[1]ALS and Neuromuscular Unit. Neurology Department, Hospital Universitario de Basurto, [2]Nucleic Acid Therapeutics for Rare Diseases (NAT-RD), Biobizkaia Health Research Institute, [3]Neuropathology Unit, imas12 Research Institute, Hospital Universitario 12 de Octubre, [4]Reumathology Department, Hospital Universitario Basurto, [5]Neuromuscular Unit, Neurology Department, imas12 Research Institute, Hospital Universitario 12 de Octubre, , [6]Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III

554P Mitochondrial pathology in Myositis: a multicentric case series

Lauletta A[1], Bosco L[2], Merlonghi G[1], Falzone Y[2], Cheli M[3], Bencivenga R[4], Léonard-Louis S[5], Benveniste O[6], Ruggiero L[4], Maggi L[3], Previtali S[2], Garibaldi M[1]
[1]Neuromuscular Disease Centre, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), SAPIENZA University of Rome, Sant'Andrea Hospital, [2]Institute of Experimental Neurology and Division of Neuroscience, Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, [3]Neuroimmunology and Neuromuscular Disease Unit, Foundation IRCCS Carlo Besta Neurological Institute, [4]Department of Neuroscience, Reproductive and Odontostomatological Science, University of Naples "Federico II", [5]Service de Neuromyologie, GH Pitié-Salpêtrière, University Hospital, [6]Sorbonne Université, Assistance Publique - Hôpitaux de Paris, Inserm U974, Department of Internal Medicine and Clinical Immunology, Pitié-Salpêtrière University Hospital

555P Assessment of IBM-FRS total score and specific domains in a large cohort of Inclusion Body Myositis patients

Vicino A[1,2], Lauletta A[3], Barbaccia A[4], Valentino L[5], Cheli M[6], Saccani E[7], Grandis M[8], Coccia M[9], Barp A[10], Ravaglia S[11], Bortolani S[12], Ruggiero L[13], Mongini T[14], Verriello L[15], Vattemi G[6], Filosto M[16], Liguori R[5], Rodolico C[4], Garibaldi M[3], Maggi L[1]
[1]Neuroimmunology and Neuromuscular Disease Unit, Foundation IRCCS Carlo Besta Neurological Institute, [2]Nerve-Muscle Unit, Neurology Service, Department of Clinical Neurosciences, Lausanne University Hospital and University of Lausanne, [3]Neuromuscular and Rare Disease Centre, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), SAPIENZA University of Rome, Sant'Andrea Hospital, [4]Department of Clinical and Experimental Medicine, University of Messina, [5]IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, [6]Department of Neurosciences, Biomedicine and Movement Sciences, Section of Clinical Neurology, University of Verona, [7]Neurology Unit, Department of Specialized Medicine, University Hospital of Parma, [8]Department of Neuroscience, Ophthalmology, and Genetics, University of Genoa, [9]Department of Neurological Sciences, AOU Ospedali Riuniti di Ancona, [10]NeuroMuscular Omnicentre (NeMO) Trento, [11]Neurological Institute-Foundation IRCCS C. Mondino, [12]Unità Operativa Complessa di Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, [13]Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples, [14]Department of Neuroscience Rita Levi Montalcini, Università degli Studi di Torino, [15]Neurology Unit, Department of Neurosciences Santa Maria della Misericordia University Hospital, [16]Department of Clinical and Experimental Sciences, University of Brescia

556P Contractile properties of permeabilised single muscle fibres from female patients with Idiopathic Inflammatory Myopathies

Henning F[1], Kohn T[2]
[1]Stellenbosch University, [2]University of the Western Cape

557P Skin manifestations of immune-mediated necrotizing myopathy with anti-HMGCR antibody

Kurashige T[1], *Nakamura R*[2], *Murao T*[1], *Mine N*[4], *Sato M*[3], *Katsumata R*[1], *Kanaya Y*[1], *Dodo Y*[1], *Sugiura T*[1], *Ohshita T*[1]
[1]*Nho Kure Medical Center and Chugoku Cancer Center,* [2]*Hiroshima City North Medical Center Asa Citizens Hospital,* [3]*Hiroshima University Hospital, 4Chugoku Rosai Hospital*

558P Contactin-1 antibody-associated chronic inflammatory demyelinating polyneuropathy (CIDP) in a pediatric patient: beyond the tip of an iceberg

Özel E[1], *Öncel İ*[1], *Öztoprak Ü*[1], *Temuçin Ç*[2], *Haliloğlu G*[1]
[1]*Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Neurology,* [2]*Hacettepe University Faculty of Medicine, Department of Neurology*

559P Immunological biomarkers in immune-mediated and hereditary polyneuropathies

Kodal L[1], *Krag T*[1], *Dysgaard T*[1]
[1]*Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet,*

560VP Immune-mediated necrotizing myopathy in 14 Polish patients – clinical course and treatment outcome

Rajczewska Oleszkiewicz C[1], *Kierdaszuk B*[1], *Kostera-Pruszczyk A*[1]
[1]*Department of Neurology, Medical University of Warsaw*

561P PDGFRa as a reliable surface marker for fibro-adipogenic progenitor (FAP) cells

Park J[1], *Walli S*[1], *Bachir D*[1], *Dobelmann V*[1], *Preuße C*[2], *Stenzel W*[2], *Brunn A*[3], *Meuth S*[1], *Ruck T*[1], *Nelke C*[1]
[1]*Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf,* [2]*Department of Neuropathology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin,* [3]*Institute of Neuropathology, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf*

562P Rare mimics of idiopathic inflammatory myopathies – a single centre cohort from India

Sivaraman Nair S[1], *George J*[1], *Poyuran R*[1]
[1]*Sree Chitra Tirunal Institute for Medical Sciences and Technology*

563P Abatacept, the solution for a patient with immune-mediated necrotizing myopathy

Calabria Gallego M[1]
[1]*Hospital Universitario De Salamanca*

564VP Investigating motor and bulbar severity in NT5c1A seropositive and seronegative IBM participants in the INSPIRE-IBM trial

Herrera M[1], *Wencel M*[1], *Hernandez I*[1], *Goyal N*[1], *Dimachkie M*[2], *Lloyd T*[3], *Mohassel P*[3], *Weihl C*[4], *Freimer M*[5], *Shaibani A*[6], *Wicklund M*[7], *Dixon S*[8], *Chahin N*[9], *Wang L*[10], *Shieh P*[11], *Amato A*[12], *Quinn C*[13], *Carbunar O*[14], *Mozaffar T*[1], *INSPIRE-IBM Study Group*[1]
[1]*Department of Neurology, University of California, Irvine,* [2]*University of Kansas Medical Center,* [3]*Johns Hopkins University,* [4]*Washington University in St. Louis,* [5]*Ohio State University,* [6]*Nerve and Muscle Center of Texas,* [7]*UT Health San Antonio,* [8]*University of Colorado Anschutz,* [9]*Oregon Health and Science University,* [10]*University of Washington,* [11]*University of California, Los Angeles,* [12]*Brigham and Women's Hospital,* [13]*University of Pennsylvania,* [14]*University of Miami Health Systems*

565VP Investigating highly differentiated cytotoxic T cells and functional severity in participants with Inclusion Body Myositis in the INSPIRE-IBM trial

Herrera M[1], *Wencel M*[1], *Hernandez I*[1], *Goyal N*[1], *Dimachkie M*[2], *Lloyd T*[3], *Mohassel P*[3], *Weihl C*[4], *Freimer M*[5], *Shaibani A*[6], *Wicklund M*[7], *Dixon S*[8], *Chahin N*[9], *Wang L*[10], *Shieh P*[11], *Amato A*[12], *Quinn C*[13], *Carbunar O*[14], *Mozaffar T*[1], *INSPIRE-IBM Study Group*[1]
[1]*Department of Neurology, University of California, Irvine,* [2]*University of Kansas Medical Center,* [3]*Johns Hopkins University,* [4]*Washington University in St. Louis,* [5]*Ohio State University,* [6]*Nerve and Muscle Center of Texas,* [7]*UT Health San Antonio,* [8]*University of Colorado Anschutz,* [9]*Oregon Health and Science University,* [10]*University of Washington,* [11]*University of California, Los Angeles,* [12]*Brigham and Women's Hospital,* [13]*University of Pennsylvania,* [14]*University of Miami Health Systems*

566P CIC-1 chloride channel inhibition improves disease symptoms and survival in a rat model of muscle-specific kinase (MuSK) Myasthenia Gravis

Skals M[1], *Morgen J*[1], *Huus N*[1], *Skov M*[1], *Kelly N*[1], ***Broch-Lips M***[1]
[1]*NMD Pharma A/S*

567P A prospective observational study on the effect of intravenous immunoglobulin on small fiber neuropathy after SARS-CoV-2 infection or vaccination

Shin J[1], *Lee J*[2]
[1]*Hallym Medical Center, Dongtan Sacred Heart University,* [2]*Kyungpook National University Hospital*

568P Unraveling interferon-related autophagic signatures in Immune Myopathies

Authier F[1], *Hou C*[1], *Periou B*[1], *Souvannanorath S*[1], *Malfatti E*[1], *Martin L*[1]
[1]*Paris Est-creteil University*

569P Revisiting Systemic Sclerosis Myopathy: unveiling unique histopathological signatures and overlaps with immune myopathies features

Authier F[1], *Zaidan L*[1], *Le Gouellec N*[2], *Periou B*[3], *Relaix F*[1], *Mouthon L*[4], *Hachulla E*[5]
[1]*Paris Est-creteil University,* [2]*Hospital of Valenciennes,* [3]*Henri Mondor University Hospital, APHP,* [4]*Cochin University Hospital, APHP,* [5]*Lille University Hospital*

570P Physiological and molecular mechanisms underlying chronic alcoholic-related myopathy

Baumann C[1], *Ganjayi M*[1], *Brown A*[1], *Willis C*[2]
[1]*Ohio University,* [2]*University of Bradford*

571P Muscular metabolic plasticity in 3D in vitro models against systemic stress factors in ME/CFS and long COVID-19

Mughal S[1,4], *Andújar-Sánchez F*[3,4], *Sabater-Arcis M*[1], *Fernández-Costa J*[1], *Ramón-Azcón J*[1,2]
[1]*Institute For Bioengineering Of Catalonia BIST,* [2]*ICREA Institució Catalana de Recerca i Estudis Avançats,* [3]*Institut d'Investigacions Biomèdiques August Pi i Sunyer,* [4]*Universitat de Barcelona*

572P Dysphagia pattern in Inclusion Body Myositis as a distinguishing feature: insight from a patient initially presenting with rapidly progressing dysphagia

Park Y[1,2], *Bae J*[3,4], *Jung Y*[3,4]
[1]*Department of Neurology, Pusan National University Hospital,* [2]*Department of Neurology Pusan National University School of Medicine,* [3]*Department of Neurology Kangdong Sacred Heart Hospital,* [4]*Department of Neurology Hallym University College of Medicine*

573P The interlocution of autophagy and interleukin-6 in immune-mediated necrotizing myopathy

Liang W[1,2,3], *Chang S*[1], *Lin P*[5], *Jong Y*[1,3,4], *Liu H*[5]
[1]*Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan,* [2]*Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University,* [3]*Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University,* [4]*Laboratory Medicine, Kaohsiung Medical University Hospital,* [5]*Master of Science Program in Tropical Medicine, College of Medicine, Kaohsiung Medical University*

574P Infectious muscles diseases: a comprehensive case study of 7 patients from Indian cohort

Sharma M[1], *Bhatia R*[1], *Venugopalan Y V*[1]
[1]*Neuropathology Lab, AIIMS*

575P FORTIFY: a phase 3 study to evaluate efficacy & safety of BBP-418 in individuals with Limb-Girdle muscular dystrophy 2I, LGMDR9 FKRP-related (LGMD2I/R9)

Sproule D[1], *Reddy D*[1], *Blankenbiller T*[1], *Rainey A*[1], *Reklis L*[1]
[1]*ML Bio Solutions, A BridgeBio Company*

576P High precision quantification of ICAM-1 highlights similarities and differences between subgroups of Idiopathic inflammatory myopathies

Nishimura A[1], *Nelke C*[2], *Huber M*[3], *Mensch A*[4], *Roth A*[1], *Oberwittler C*[5], *Zimmerlein B*[6], *Krämer H*[7,8], *Neuen-Jacob E*[9], *Stenzel W*[10], *Müller-Ladner U*[3], *Ruck T*[2], *Schänzer A*[1]
[1]*Institute of Neuropathology, Justus Liebig University Giessen,* [2]*Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf,* [3]*Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen,* [4]*Department of Neurology, University Medicine Halle,* [5]*Department of Neurology, St. Vincenz Hospital Limburg,* [6]*Department of Neurology, Hospital Nordwest Frankfurt,* [7]*Department of Neurology, Justus Liebig University Giessen,* [8]*TGNN, Justus Liebig University Giessen,* [9]*Institute of Neuropathology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany,* [10]*Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin*

577P Evaluation of mitochondrial dysfunction as a potential mediator of inflammatory pathways in inclusion body myositis

Walli S[1], *Abdennebi D*[1], *Görg B*[2], *Bachir D*[1], *Dobelmann V*[1], *Preuße C*[3], *Stenzel W*[3], *Schoser B*[4], *Roos A*[1,6,7], *Brunn A*[5], *Meuth S*[1], *Ruck T*[1], *Nelke C*[1]
[1]*Department of Neurology, Medical Faculty And University Hospital Duesseldorf, Heinrich Heine University Duesseldorf,* [2]*Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Duesseldorf, Medical Faculty at Heinrich Heine University Duesseldorf,* [3]*Department of Neuropathology, Charité–University Medicine Berlin,* [4]*Friedrich Baur Institute at the Department of Neurology, LMU University Hospital, LMU Munich,* [5]*Institute of Neuropathology, Heinrich Heine University, University Hospital of Duesseldorf,* [6]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute,* [7]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioural Sciences, University Duisburg-Essen*

578VP Recurrent rhabdomyolysis as the presenting feature of mixed connective tissue disease
Kent L[1], *Butterworth R*[2], *Hofer M*[1], *Giavri E*[2], *Brady S*[1]
[1]*Oxford University Hospitals NHS Foundation Trust,* [2]*Milton Keynes University Hospital*

644P-655P: Muscle MRI & new imaging techniques

644P Muscle MRI in Glycogen Storage disease type 5 (McArdle disease) – single centre experience
Mohamed K[1], *Pula S*[1], *Finnigan P*[1], *Godfrey R*[1], *Hammam A*[1], *Morrow J*[1], *Løkken N*[2], *Quinlivan R*[1]
[1]*Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery; UCL Institute of Neurology,* [2]*Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, Copenhagen University Hospital*

645P The utility and limitations of artificial intelligence in diagnosing rare disorders
Alawneh I[1], *Gonorazky H*[1], *Repalo A*[2], *Mashouri P*[2]
[1]*The Hospital for Sick Children,* [2]*University of Toronto*

646P Towards integration of quantitative MRI in the diagnostic protocol of neuromuscular disorders in three Dutch NMD expert centers
Rauh S[1], *Cameron D*[2], *Heskamp L*[3], *van Doorn J*[2], *Kruit M*[1], *Nievelstein R*[3], *Becks R*[2], *Niks E*[1], *van der Pol L*[3], *Houwen S*[2], *Braakman H*[2], *Erasmus C*[2], *van Alfen N*[2], *Bartels B*[3], *Froeling M*[3], *Kan H*[1]
[1]*Leiden University Medical Center,* [2]*Radboud University Medical Center,* [3]*University Medical Center Utrecht*

647P Tongue volume evaluation in Spinal and Bulbar Muscular Atrophy (SBMA) by AI-assisted automatic MRI-analysis
Rosenbohm A[1], *Vernikouskaya I*[2], *Müller H*[1], *Chadraabal K*[1], *Gadelkareem M*[1], *Ludolph A*[1,3], *Rasche V*[2,4], *Kassubek J*[1,3]
[1]*Department of Neurology, University of Ulm,* [2]*Department of Internal Medicine II, Ulm University Medical Center,* [3]*German Center for Neurodegenerative Diseases (DZNE),* [4]*Core Facility Small Animal MRI, University of Ulm*

648P MRI demonstrates altered skeletal muscle membrane permeability in Becker muscular dystrophy, representing a potential biomarker for disease activity
Schrama E[1], *Hooijmans M*[2], *Niks E*[1,3], *Kan H*[3,4], *Cameron D*[5]
[1]*Department of Neurology, Leiden University Medical Center,* [2]*Biomedical Engineering and Physics, Amsterdam University Medical Center,* [3]*Duchenne Center Netherlands,* [4]*C.J. Gorter MRI Center, Department of Radiology, Leiden University Medical Center,* [5]*Department of Medical Imaging, Radboud University Medical Center*

649P Comparing unsupervised AI techniques for visualizing MRI fat infiltration patterns in muscular dystrophies
Pizarro-Galleguillos B[1], *Goméz-Andrés D*[2], *Tobar F*[3], *Andia M*[4], *Díaz-Manera J*[5], *Verdú-Díaz J*[5], *Suazo Rojas L*[6], *Díaz Jara J*[6], *Bevilacqua J*[7]
[1]*Porgrama de Doctorado en Ciencias Médicas y Especialidad, Facultad de Medicina Universidad De Chile,* [2]*Pediatric Neurology, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron,* [3]*Centro de Modelamiento Matemático e Iniciativa de Ciencias de Datos FCFM Universidad de Chile,* [4]*Centro de Imágenes Biomédicas, Pontificia Universidad Católica de Chile,* [5]*John Walton Muscular Dystrophy Research Centre, Newcastle University,* [6]*Centro de Imagenología, Hospital Clínico Universidad de Chile,* [7]*Departamento de Neurología y Neurocirugía, Hospital Clínico Universidad de Chile*

650VP Development and implementation of enhanced AI-derived DTI features for precision mapping of neural tract damage in Myotonic dystrophy
Kamali T[1], *Hageman N*[1], *Yazdavar T*[1], *C Piccolli*[1], *Day JW*[1], *Sampson J*[1], *Wozniak J*[2]
[1]*Department of Neurology and Neurological Sciences, Stanford University School of Medicine,* [2]*Department of Psychiatry & Behavioural Sciences, University of Minnesota*

651VP Quantitative MRI pre- and post-skeletal muscle biopsy reveals correlations with histopathological findings
Schlaffke L[1], *Forsting J*[1], *Kneifel M*[1], *Rehmann R*[1], *De Lorenzo A*[1], *Enax-Krumova E*[1], *Froeling M*[2], *Vorgerd M*[1,3], *Güttsches A*[1,3]
[1]*BG Universitätsklinikum Bergmannsheil gGmbH | Department of Neurology,* [2]*University Medical Center Utrecht, Utrecht, Netherlands,* [3]*Heimer Institute for Muscle Research*

continued on next page

652P Muscle MRI-phenotyping of patients with likely pathogenic anoctamin 5 variants

Poulsen N[1], *Palmio J*[2], *Jokela M*[2,3], *Claeys K*[4,5,15], *Iterbeke L*[5,15], *De Bleecker J*[6], *De Vos E*[6], *Domínguez-González C*[7], *Bermejo-Guerrero L*[7], *Muelas N*[8,9,10], *Vilchez J*[8,9], *Gonzalez-Chamorro A*[11], *Diaz-Manera J*[11], *Straub V*[11], *Straathof C*[12], *Niks E*[12], *Voermans N*[13], *Cameron D*[14], *Vissing J*[1], *On behalf of the study group*

[1]*Copenhagen Neuromuscular Center,* [2]*Neuromuscular Research Center, Tampere University and Tampere University Hospital,* [3]*Clinical Neurosciences, University of Turku,* [4]*Department of Neurology, University Hospitals Leuven,* [5]*Department of Neurosciences, Laboratory for Muscle Diseases and Neuropathies,* [6]*Department of Neurology, Ghent University Hospital,* [7]*Neuromuscular Disorders Unit, Hospital 12 de Octubre,* [8]*Neurology Department, Hospital Universitari i Politècnic La Fe,* [9]*Neuromuscular Research Group, Instituto de Investigación Sanitaria La Fe,* [10]*(CIBERER), U763, Instituto de Salud Carlos III,* [11]*John Walton Muscular Dystrophy Research Centre,* [12]*Department of Neurology, Leiden University Medical Center,* [13]*Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center,* [14]*Department of Medical Imaging, Radboud University Medical Center,* [15]*Leuven Brain Institute (LBI)*

653P Rapid quantitative assessment of sodium dynamics after exercise using 23Na-MRI in dysferlinopathy and healthy controls

Bolano Diaz C[1], *Neal M*[2,3], *Richardson M*[1], *Muni Lofra R*[1], *Michell-Sodhi J*[1], *James M*[1], *Mayhew A*[1], *Hilsden H*[1], *Wilson I*[2,3], *Hollingsworth K*[2,3], *Blamire A*[2,3], *Straub V*[1], *Thelwall P*[2,3], *Diaz-Manera J*[1,4,5], ***Diaz-Manera J***[1,4,5]

[1]*John Walton Muscular Dystrophy Research Centre, Newcastle University,* [2]*Newcastle Magnetic Resonance Centre, Health and Innovation Neighbourhood, Newcastle University,* [3]*Translational and Clinical Research Institute, Newcastle University,* [4]*Laboratori de Malalties Neuromusculars, Institut de Recerca de l'Hopital de la Santa Creu i San Pau,* [5]*Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER)*

654P Different lower limb muscle MRI patterns in autosomal dominant titinopathies

Gomez Andres D[1], *Costa Comellas L*[1], *Díaz-Manera J*[2], *Õunap K*[3], *Álvarez-Molinero M*[1], *Urcuyo G*[1], *Savarese M*[4], *Munell F*[1], *Udd B*[5]

[1]*Child Neurology, Hospital Universitari Vall d'Hebron,* [2]*The John Walton Muscular Dystrophy Research Center, Newcastle University,* [3]*Department of Clinical Genetics, Genetics and Personalized Medicine Clinic, Tartu University Hospital,* [4]*Folkhalsan Research Center, Helsinki University,* [5]*Tampere Neuromuscular Center, University Hospital*

655P Predictive modelling of dysferlinopathy progression: a longitudinal fat fraction analysis

Bolano Diaz C[1], *Wilson I*[2], *Hilsden H*[1], *James M*[1], *Araujo E*[3], *Reyngoudt H*[3], *Blamire A*[2], *Jain COS Consortium*[4], *Carlier P*[3], *Straub V*[1], *Diaz Manera J*[1]

[1]*John Walton Muscular Dystrophy Research Centre, Newcastle University,* [2]*Magnetic Resonance Centre, Translational and Clinical Research Institute, Newcastle University,* [3]*NMR Laboratory, Neuromuscular Investigation Center, Institute de Myologie,* [4]*The Jain Foundation*

688P-704P: Therapies for NMD

688P Sleep and health-related quality of life in rare neuromuscular disorders

Fjermestad K[1], *Brørs E*

[1]*Frambu Resource Centre for Rare Disorders,* [2]*University of Oslo*

689P Highlights and key learnings from 15 years of the TREAT-NMD Advisory Committee for Therapeutics (TACT)

Turner C[1], *Robertson L*[2], *Bushby K*[1], *Csimma C*[3], *De Luca A*[4], *Heslop E*[1], *Wells D*[5], *Aartsma-Rus A*[6], *Straub V*[1]

[1]*John Walton Muscular Dystrophy Research Centre at Newcastle University,* [2]*TREAT-NMD Services,* [3]*Sardona Therapeutics,* [4]*University of Bari,* [5]*Royal Veterinary College,* [6]*Leiden University Medical Center*

690P The prospect of direct benefit in first-in-human gene therapy studies in minors - an ethical analysis

Pirson I[1], *Niks E*[1], *de Vries M*[1], *de Graeff N*[1]

[1]*Leids Universitair Medisch Centrum*

691P Substantial improvement of shoulder function with a new physiotherapy approach in children with LGMD, MD and FSHD

Pelsma M[1,2], *Ijspeert J*[2], *Braakman H*[1], *Houwen S*[1,2], *Hendrix- van der Stegen A*[1,2]

[1]*Radboud University Medical Centre-Amalia Children's Hospital,* [2]*Radboud University Hospital – Rehabilitation*

692P Determination of in vitro phenotype of Myofibrillar myopathy type 6 (MFM6), caused by the P209L mutation in the BAG3 gene, using patient-derived fibroblasts, and the role of autophagy stimulators in the cell recovery

Snoch W[1], *Rintz E*[1], *Węgrzyn G*[1]

[1]*University Of Gdańsk*

693P Proposed NIH core for advanced genetic therapies: spotlight on clinical development of AAV products for neuromuscular disorders

Todd J[1,2], *Reoma L*[2], *Nath A*[2], *Martin S*[2], *Brooks K*[2], *Ano S*[3], *Dukhanina O*[3], *Lawal T*[4], *Brooks P*[5], *Ottinger E*[5], *Lomash R*[5], *Stan R*[5], *Goldfeder L*[6], *Venditti C*[7], *Bönnemann C*[1]

[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke,* [2]*Clinical Trials Unit, National Institute of Neurological Disorders and Stroke,* [3]*Office of Technology Transfer, National Institute of Neurological Disorders and Stroke,* [4]*Muscle Disease Unit, National Institute of Nursing Research,* [5]*Therapeutic Development Branch, National Center for Advancing Translational Sciences,* [6]*Office of Research Support and Compliance, NIH Clinical Center,* [7]*Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute*

694P AAV-based gene replacement for SELENON-related myopathy

Moghadaszadeh B[1], *Troiano E*[1], *Barraza-Flores P*[1], *Lee W*[1], *Beggs A*[1]

[1]*Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School*

695P Unveiling the mosaic of quality of life in muscular dystrophy: an analysis of PROMIS survey data in adults

Dixon M[1], *Vordos K*[1], *Krikov S*[1], *Reeder M*[1], *Butterfield R*[1]

[1]*University Of Utah, Department of Pediatrics*

696P ADAPT-NMD: a hybrid II study exploring the feasibility of delivering, evaluating, and implementing a self-management programme for people with neuromuscular disorders at a specialist neuromuscular centre

Lee L[1], *Kulnik S*[2], *Curran G*[3], *Boaz A*[4], *Ramdharry G*[1]

[1]*University College London,* [2]*Ludwig Boltzmann Institute for Digital Health and Prevention,* [3]*University of Arkansas for Medical Sciences,* [4]*King's College London*

697P Clinicians' perspectives on a new self-management support programme for people living with neuromuscular disorders

Lee L[1], *Kulnik S*[2], *Boaz A*[3], *Ramdharry G*[1]

[1]*University College London,* [2]*Ludwig Boltzmann Institute for Digital Health and Prevention,* [3]*King's College London*

698P Adapting to life with a neuromuscular disorder: a qualitative exploration of the patient perspective

Lee L[1], *Kulnik S*[2], *Boaz A*[3], *Ramdharry G*[1]

[1]*University College London,* [2]*Ludwig Boltzmann Institute for Digital Health and Prevention,* [3]*King's College London*

699P Exon skipping for the second Calponin Homology Domain of dystrophin using AAV.U7snRNA - In vitro & Intramuscular studies using a novel murine model of Duchenne muscular dystrophy

Brinkman A[1], *Lesman D*[1], *Li D*[1], *Rajakumar D*[1], *Atre C*[1], *Rodriguez Y*[1], *Almeida C*[1], ***Wein N***[1]

[1]*Nationwide Children's Hospital*

700P Alternative delivery of adeno-associated virus 9 for the treatment of Duchenne muscular dystrophy to target CSF and muscles– GFP Biodistribution study in WT mice

Iyer A[1], *Gomez C*[1], *Rodriguez Y*[1], *Almeida C*[1], *Bobbili P*[2], *McGovern V*[2], *Arnold D*[2], *Burghes A*[2], *Meyer K*[1], ***Wein N***[1]

[1]*Nationwide Children's Hospital,* [2]*The Ohio State University*

701P AAV.U7.ex44 Mediates Efficient Exon Skipping, Protein Restoration & Phenotype Rescue – Pre-Clinical Intramuscular and Dose Escalation Study for a Mutational Hotspot of the Duchenne Muscular Dystrophy (DMD)

Rajakumar D[1], *Almeida C*[1], *Atre C*[1], *Lesman D*[1], *Li D*[1], *Rodriguez Y*[1], *Young C*[2], *Spencer M*[2], *Flanigan K*[1], ***Wein N***[1]

[1]*Nationwide Children's Hospital,* [2]*University of California, Los Angeles*

continued on next page

702P SEPN1/SELENON-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA

Ferreiro A[1,2], *Germani S*[3,4], *Tri Van Ho A*[1], *Cherubini A*[3], *Varone E*[3], *Chernorudskiy A*[3], *Renna G*[3], *Fumagalli S*[3], *Bolis M*[5], *Rastelli G*[6], *Nogara L*[7,8], *Poggio E*[9], *Brini M*[9,10], *Cattaneo A*[11], *Bachi A*[11], *Simmen T*[12], *Calì T*[7], *Boncompagni S*[6], *Blaauw B*[7,14], *Zito E*[3,4]

[1]*UMR8251 Université Paris Cité/CNRS,* [2]*Neuromyology Department, Reference Center for Neuromuscular Disorders Nord-Est-Ile de France, Institute of Myologie, Pitié-Salpêtrière Hospital,* [3]*Istituto di Ricerche Farmacologiche Mario Negri IRCCS,* [4]*Department of Molecular and Developmental Medicine, University of Siena,* [5]*Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland, Bellinzona CH 6500 and Bioinformatics Core Unit, Swiss Institute of Bioinformatics,* [6]*CAST, Center for Advanced Studies and Technology & DNICS, Department of Neuroscience, Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara,* [7]*Department of Biomedical Sciences, University of Padua,* [8]*Department of Pharmaceutical Sciences, University of Padova,* [9]*Department of Biology, University of Padova,* [10]*Study Center for Neurodegeneration (CESNE), University of Padova,* [11]*IFOM-FIRC Institute of Molecular Oncology,* [12]*Department of Cell Biology, Faculty of Medicine and Dentistry, University of Alberta,* [13]*Padova Neuroscience Center, University of Padova,* [14]*Venetian Institute of Molecular Medicine*

703P Integrated Organ-on-Chip platform with PINP plasmonic biosensor for fibrosis monitoring in Duchenne muscular dystrophy

Fernández-Costa J[1], *Ruíz-Gutiérrez M*[1], *Ninfali C*[1], *Torabi M*[1], *Fernández-Simón E*[2], *Díaz-Manera J*[2], *Ramón-Azcón J*[1,3]

[1]*Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST),* [2]*John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University,* [3]*ICREA-Institució Catalana de Recerca i Estudis Avançats*

704P Translating RNAi-based gene therapy for Facioscapulohumeral muscular dys-trophy

Wallace L[1], *Camp J*[1], *Neal K*[1], *Zender G*[1], *Taylor N*[1], *Zhou B*[1], *Ye F*[1], *Price B*[2], *Triplett M*[2], *Harper S*[1,3]

[1]*Nationwide Children's Hospital,* [2]*Armatus Bio,* [3]*Department of Pediatrics, The Ohio State University College of Medicine*

15:30-16:00	**Short Oral Presentations 1** North Hall **146P, 145P, 231P, 576P, 577P** *Moderator: Werner Stenzel, Charité University Hospital*	**Short Oral Presentations 2** Terrace 2A **278P, 703P, 702P, 279P, 704P** *Moderator: Perry Shieh, University of California*	**Short Oral Presentations 3** Terrace 2B **400P, 399P, 654P, 655P, 653P** *Moderator: Krista Vandenborne, University of Florida*
16:15-17:00	**Debate: Can the costs of gene therapies in neuromuscular disorders be justified?** Congress Hall *Moderators: Francesco Muntoni, University College London, Great Ormond Street Hospital, UK & Teresinha Evangelista, Institut de Myologie, France*		
	14INV *Olga Germanenko, SMA Family Foundation, Russia* **15INV** *Josie Godfrey, JG Zebra Consulting, United Kingdom*		

continued on next page

17:15-18:15	**Poster Session 2** Forum Hall (refreshments provided)

01P-51P, 52VP-54VP: CM - CMD

01P Structural variation in nebulin and its implications on phenotype and inheritance: establishing a dominant distal phenotype caused by large deletions

Sagath L[1,2], *Kiiski K*[1,3], *Naidu K*[4,5], *Djordjevic D*[6], *Yoon G*[6,7], *Rogers C*[8], *Scherer K*[9], *Koparir E*[10], *Kunstmann E*[11], *Davis M*[12], *Purwa J*[13], *Zygmunt A*[14], *Bönnemann C*[15,16], *Biancalana V*[17], *Echaniz-Laguna A*[18,19], *Beggs A*[20], *Henning F*[4], *Wallgren-Pettersson C*[1,2], *Pelin K*[1,2,21], *Lehtokari V*[1,2]

[1]*Folkhälsan Research Center, Helsinki, Finland,* [2]*Department of Medical Genetics, Medicum, University of Helsinki, Finland,* [3]*Laboratory of Genetics, Division of Genetics and Clinical Pharmacology, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland,* [4]*Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa,* [5]*Neuroscience Institute, University of Cape Town; Division of Neurology, Department of Medicine,Groote Schuur Hospital, Cape Town, South Africa,* [6]*Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Canada,* [7]*Division of Clinical and Metabolic Genetics, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada,* [8]*Greenville Office Greenwood Genetic Center, Greenville, SC, USA,* [9]*Department of Neurology, University of Arizona, Tucson, AZ, USA,* [10]*Institute for Human Genetics, Biocenter, Julius-Maximilians-University Würzburg, Würzburg,Germany,* [11]*Praxis für Humangenetik, Würzburg, Germany,* [12]*Department of Diagnostic Genomics, PathWest Laboratory Medicine WA, Nedlands WA 6008, Australia,* [13]*Department of Neurology, Wellington Regional Hospital, Wellington, New Zealand,* [14]*Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA,* [15]*Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA,* [16]*Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA,* [17]*Laboratoire de Diagnostic Génétique CHRU de Strasbourg, Strasbourg, France,* [18]*Department of Neurology, Centre Hospitalo-Universitaire, AP-HP, INSERM U 1195, University Paris, Saclay, Le Kremlin-Bicêtre Cedex, France,* [19]*Centre de référence national pour les neuropathies rares, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France,* [20]*The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA,* [21]*Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland*

02P Exploring genotype-phenotype correlations in NEB-related Myopathies

Ogasawara M[1], *Nishimori Y*[1], *Eura N*[1], *Yoshioka W*[1], *Yae Y*[1], *Yamanaka A*[1], *Hashizume L*[2], *Miyazaki N*[2], *Sugie K*[2], *Hayashi S*[1], *Noguchi S*[1], *Iida A*[1], *Nishino I*[1]

[1]*National Center of Neurology and Psychiatry (NCNP),* [2]*Nara Medical University*

03P Modulation of the cyclin inhibitor p27 can ameliorate muscular dystrophy in LAMA2-RD

Bonaccorso R[1], *Porrello E*[1], *Tonlorenzi R*[1], ***Previtali S***[1]

[1]*Irccs San Raffaele Scientific Institute*

04P Characterising patient iPSC-derived models of RYR1-related myopathies

Crane J[1,2], *Clayton J*[1,2], *Vo C*[1,2], *Driver K*[1,2], *Malfatti E*[3,4], *Romero N*[5,6], *Laing N*[1,2], *Ravenscroft G*[1,2], *Taylor R*[1,2]

[1]*Harry Perkins Institute of Medical Research,* [2]*Centre for Medical Research, University of Western Australia,* [3]*APHP, Centre de Référence de Pathologie Neuromusculaire Nord-Est-Ile-de-France,* [4]*Université Paris Est, U955, INSERM, IMRB, F-94010,* [5]*Sorbonne Université, Myology Institute, Neuromuscular Morphology Unit, Center for Research in Myology,* [6]*Centre de Référence de Pathologie Neuromusculaire Paris-Est*

05P Pediatric cardiomyopathy may be more prevalent amongst ACTA1 mutation related myopathies: a single center case-series

Nandi D[1], *Meyer A*[2], *Connolly A*[3,4], *Waldrop M*[3,4], *Flanigan K*[3,4], *Cripe L*[1], *Hayes E*[1]

[1]*Division of Cardiology, Department of Pediatrics, Nationwide Children's Hospital,* [2]*Division of Genetics, Department of Pediatrics, Nationwide Children's Hospital,* [3]*Division of Neurology, Department of Pediatrics, Nationwide Children's Hospital,* [4]*Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital*

06VP In vivo modulation of novel modifier genes for LAMA2-RD

Pini V[1,2], *Bonaccorso R*[1], *Porrello E*[1], *Burris T*[3], *Morgan J*[2], *Muntoni F*[2], *Previtali S*[1]

[1]*Neuromuscular Repair Unit, Institute of Experimental Neurology, Ospedale San Raffaele,* [2]*Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health,* [3]*University of Florida Genetics Institute*

07P Development of cell therapy for Ullrich congenital muscular dystrophy by iPSC-derived mesenchymal stromal cell

Sakurai H[1], *Goto M*[1], *Takenaka-Ninagawa N*[1], *Harada A*[1], *Ikeya M*[1]

[1]*Center for iPS Cell Research and Application (CiRA), Kyoto University*

08P SRPK3-TTN related myopathy: early clinical characteristics and muscle imaging findings

Orbach R[1], *Donkervoort S*[1], *Saade D*[2], *D'Souza P*[3], *Haugland J*[1], *Foley A*[1], *Bharucha Goebel D*[1,4], *Potticary A*[1], *Chao K*[5], *Macnamara E*[3], *Finkel R*[6], *Beggs A*[7], *Tifft C*[3], *Bönnemann C*[1]

[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health,* [2]*Department of Neurology, University of Iowa, Carver College of Medicine,* [3]*NIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health,* [4]*Department of Neurology, Children's National Hospital,* [5]*Program in Medical and Population Genetics, Center for Mendelian Genomics, Broad Institute of MIT and Harvard,* [6]*Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital,* [7]*Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School*

09P Delineating collagen VI genes expression patterns in mice skeletal muscles using RNAscope

Guirguis F[1,2], *Bolduc V*[1], *Zhou H*[3,4], *Muntoni F*[2,3], *Bönnemann C*[1]

[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, NIH,* [2]*The Dubowitz Neuromuscular Centre, Molecular Neurosciences Section, Developmental Neurosciences Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London,* [3]*NIHR Great Ormond Street Hospital Biomedical Research Centre,* [4]*Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London*

10P Characterization of the severe phenotype of COL6-related dystrophy due to the recurrent deep intronic pseudoexon-inducing variant COL6A1 c.930+189C>T

Foley A[1], *Bolduc V*[1], *Guirguis F*[1], *Donkervoort S*[1], *Hu Y*[1], *Orbach R*[1], *Mohassel P*[1], *Zhou H*[2], *Aguti S*[3], *Jimenez-Mallebrera C*[4], *Lamandé S*[5], *Allamand V*[6], *Gualandi F*[7], *Ferlini A*[7], *Wilton S*[8,9], *Wagener R*[10], *Bertini E*[11], *Muntoni F*[12,13], *Bönnemann C*[1], *The COL6A1 Intron 11 Study Group*

[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health,* [2]*National Institute of Health Research, Great Ormond Street Hospital Biomedical Research Centre, Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London,* [3]*Neurodegenerative Disease Department, UCL Queen Square Institute of Neurology, University College London,* [4]*Laboratorio de Investigación Aplicada en Enfermedades Neuromusculares, Unidad de Patología Neuromuscular, Servicio de Neuropediatría, Institut de Recerca Sant Joan de Déu,* [5]*Department of Paediatrics, University of Melbourne, The Murdoch Children's Research Institute,* [6]*INSERM, Institut de Myologie, Centre de Recherche en Myologie, Sorbonne Université,* [7]*Unit of Medical Genetics, Department of Medical Sciences and Department of Mother and Child, University Hospital S. Anna Ferrara,* [8]*Centre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University,* [9]*Centre for Neuromuscular and Neurological Disorders, Perron Institute for Neurological and Translational Science, The University of Western Australia,* [10]*Center for Biochemistry, Medical Faculty, University of Cologne,* [11]*Research Unit of Neuromuscular and Neurodegenerative Disorders, IRCCS Ospedale Pediatrico Bambino Gesù,* [12]*Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children,* [13]*National Institute of Health Research, Great Ormond Street Hospital Biomedical Research Centre*

11P Autosomal dominant centronuclear myopathy caused by variants in the DNM2 gene – Results of an international, prospective natural history study

Braun F[1,2], *Seferian A*[3], *Behin A*[4], *Fer F*[3], *Peretti M*[3], *Duchêne D*[3], *Schara-Schmidt U*[1], *Annoussamy M*[3], *Baets J*[5,6], *Servais L*[3], *NatHis-CNM Study Group*[7]

[1]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen,* [2]*Institute Of Human Genetics, University Hospital Essen, University Duisburg-Essen,* [3]*Assistance Publique Hôpitaux de Paris, Sorbonne Université, Institut de Myologie, AFM-Téléthon, Essais cliniques I-Motion Enfants, Hôpital Armand Trousseau,* [4]*Assistance Publique Hôpitaux de Paris, Sorbonne Université, Centre de référence neuro musculaire Paris Est, Institut de Myologie, GH Pitié Salpetrière,* [5]*Translational Neurosciences, Faculty of Medicine and Health Sciences and Institute Born-Bunge, University Antwerp,* [6]*Neuromuscular Reference Center, Department of Neurology, Antwerp University Hospital,* [7]*NatHis-CNM Study Group: Nicol Voermans*

12P Female carriers of X-linked Myotubular Myopathy (XL-MTM) in Germany – extending the knowledge about the impact of heterozygous variants in the MTM1 gene

Braun F[1,2], *Kaiser F*[2], *Schara-Schmidt U*[1]

[1]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen,* [2]*Institute Of Human Genetics, University Hospital Essen, University Duisburg-Essen*

13P Centronuclear Myopathy in DNM2 E368K mice: behavioral and pathological insights

Uy G[1], *Ogawa M*[3], *Inoue Y*[2], *Takeda T*[3], *Inoue T*[2], *Hayashi S*[1], *Nishino I*[1], *Noguchi S*[1]

[1]*Department of Neuromuscular Research, National Center of Neurology and Psychiatry,* [2]*Department of Biochemistry and Cellular Biology, National Center of Neurology and Psychiatry,* [3]*Department of Biochemistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University*

14P X-linked myotubular myopathy: 3-year follow-up of a prospective international natural history

Seferian A[1], *Annoussamy M*[2], *Fer F*[2], *Lilien C*[1,3], *Gidaro T*[1], *Schara-Schmidt U*[4], *Braun F*[4,5], *D'Amico A*[6], *Daron A*[7], *Hernández González A*[8], *de Lattre C*[9,10], *Villerot C*[11], *Behin A*[12], *Arnal J*[13], *Mayer M*[14], *Bellance R*[15], *Davion J*[16], *Hogrel J*[17], *Servais L*[1], *on behalf of NatHis CNM Study Group*

[1]Assistance Publique Hôpitaux de Paris, Sorbonne Université, Institut de Myologie, AFM-Téléthon, Essais cliniques I-Motion Enfants, Hôpital Armand Trousseau, [2]Institut de Myologie, [3]STRONG, MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, [4]Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, [5]Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, [6]Bambino Gesu Children's Research Hospital IRCCS, Laboratory of Molecular Medicine, [7]Centre de Référence neuromusculaire, CHR La Citadelle, [8]UCI Pediatrica, Hospital Puertas del Mar, [9]Centre de référence maladies neuromusculaires adultes, Hôpital de la Croix-Rousse, Lyon, France, [10]Centre de compétence maladies neuromusculaires enfant, ESEAN APF France Handicap, [11]Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de médecine physique et réadaptation pédiatrique, Neuron Interaction Team, NeuroMyogène Institute, Lyon University, [12]Assistance Publique Hôpitaux de Paris, Sorbonne Université, Centre de référence neuro musculaire Paris Est, Institut de Myologie, GH Pitié Salpetrière, [13]Service de réanimation polyvalente, Hôpital Sainte Musse, [14]Centre de référence de diagnostic et de suivi des maladies neuromusculaires, Unité d'électrophysiologie clinique, Hôpital Armand Trousseau, [15]CeRCa - Hôpital Pierre-Zobda-Quitman, CHU de Martinique, [16]Service de Neuropédiatrie Hôpital Roger Salengro- CHRU de Lille, [17]Neuromuscular Investigation Center, Institute of Myology

15P Prospective, longitudinal study of the natural history of paediatric patients in France with LAMA2 related dystrophies

Seferian A[1], *Gasnier E*[2], *Peretti M*[2], *Duchene D*[2], *Lagrue E*[2], *Vuillerot C*[3], *Walther-Louvier U*[4], *Gómez García-de-la-Banda M*[5], *Grange A*[2], *Carlier R*[6], *Reyngoudt H*[7], *Marty B*[7], *Colella M*[1], *Quijano-Roy S*[5]

[1]Assistance Publique Hôpitaux de Paris, Sorbonne Université, Institut de Myologie, I-Motion clinical trials platform, Hôpital Armand Trousseau, [2]Institut de Myologie, [3]Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de médecine physique et réadaptation pédiatrique, Neuron Interaction Team, NeuroMyogène Institute, Lyon University, [4]Centre de Référence des Maladies Neuromusculaires - Pôle Femme Mère Enfant, CHU de Montpellier - Hôpital Gui de Chauliac, [5]Assistance Publique des Hôpitaux de Paris (AP-HP), Unit of Neuromuscular Disorders, Department of Pediatric Intensive Care, Neurology and Rehabilitation, Hôpital Raymond Poincaré, [6]Department of Radiology, APHP, Hôpitaux R. Poincaré-Ambroise Paré, DMU Smart Imaging, GH Université Paris-Saclay, U 1179 UVSQ/Paris-Saclay, [7]NMR Laboratory, CEA, DRF and Institut de Myologie

16P Limitation of short-reads NGS sequencing on genomic DNA: interest of functional studies in the diagnosis of congenital Ullrich muscular dystrophy

Metay C[1,2], *Ghanem R*[1], *Toutain A*[3], *Bloch A*[1], *Blin E*[1], *Jobic V*[1], *Pham T*[4], *Lejeune E*[5], *Buratti J*[5], *Keren B*[5], *Ader F*[1,6,7,8], *Richard P*[1,6,7]

[1]APHP DMU BioGem UF molecular and cellular cardiogenetics and myogenetics, Center of Molecular and Chromosomic Genetics, [2]INSERM UMRS 974, Institut de Myologie Paris France, [3]Service de Génétique CHRU de Tours Université François Rabelais , [4]DMU BioGem, Center of Molecular and Chromosomic Genetics, [5]DMU BioGem UF of developmental genetics, Center of Molecular and Chromosomic Genetics, [6]Inserm UMRS 1166, Paris, France, [7]ICAN Institute, [8]Faculté de Pharmacie Paris Descartes Département 3 Université Paris Cité Paris France

17P Decoding TTN gene mutations in Indian cohort: detection and characterization using insights from sequencing and structural analysis

Dhall A[1], *Jassal B*[1], *Faruq M*[2], *Shamim U*[2], *Kumar D*[1], *Bhatia D*[1], *Venugopalan Y V* [1], *Suri D*[1], *Sharma D*[1]

[1]All India Institute of Medical Sciences, [2]CSIR-Institute of Genomics and Integrative Biology

18P Cohort of Czech patients with RYR1-related disorders

Lauerová B[1], *Zidkova J*[2,3], *Rohlenova M*[1], *Dolanska A*[1], *Gloser M*[1], *Kumhera M*[1], *Lassuthova P*[4], *Kramarova T*[2,3], *Kopcilova J*[2], *Fajkusova L*[2,3], *Haberlova J*[1]

[1]Department of Paediatric Neurology, Second Faculty of Medicine and University Hospital Motol, [2]Centre of Molecular Biology and Genetics, University Hospital Brno, [3]Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, [4]Neurogenetics Laboratory, Department of Paediatric Neurology, Second Faculty of Medicine and University Hospital Motol

19P Recurrent TTN missense variants in biallelic titinopathies: collecting all the puzzle pieces

Di Feo M[1,2], *Rees M*[3], *Gautel M*[3], *Jungbluth H*[3,4], *Fiorillo C*[1,5], *Bruno C*[5,6], *Udd B*[2,6], *Savarese M*[2], *On behalf of the Titin Study Group*[7]

[1]University of Genoa [2]Folkhälsan Research Center, [3]Randall Centre for Cell and Molecular Biophysics, Muscle Biophysics, King's College London BHF Centre of Research Excellence, [4]Paediatric Neurology, Neuromuscular Service, Evelina's Children Hospital, Guy's and St Thomas' Hospitals NHS Trust, [5]IRCCS G.Gaslini Hospital, University of Genoa, [6]Tampere University Hospital Department of Musculoskeletal Diseases, [7]Titin Study Group

20P A novel DNM2 variant causing Centronuclear Myopathy with respiratory involvement

Urra A[1], *Fajre F*[1], *Pizarro B*[2], *Gonzalez D*[3], *Maquilon C*[4], *Antolini M*[4], *Bevilacqua J*[1,5]

[1]*Departamento de Neurología y Neurocirugía, Clínica Dávila, Santiago, Chile,* [2]*Centro de Imageneología, Hospital Clínico Universidad de Chile,* [3]*Servicio de Neurología, Hospital de Talca,* [4]*Departamento de Broncopulmonar y Enfermedades Respiratorias, Clínica Dávila,* [5]*Departamento Neurología y Neurocirugía, Hospital Clínico Universidad de Chile*

21P Tongue ultrasound assessment in patients with Nemaline myopathy

Moreno C[1], *Moreira A*[1], *Gontijo Camelo C*[1], *Zanoteli E*[1]

[1]*Universidade de São Paulo*

22P Clinical and ultrasonographic evaluation of dysphagia in patients with LAMA2-CMD

Camelo C[1], *Sampaio P*[1], *Moreira A*[1], *Moreno C*[1], *Artilheiro M*[1], *Silva A*[1], *Reed U*[1], *Zanoteli E*[1]

[1]*University Of Sao Paulo*

23P Establishing the genetic diagnosis in patients with suspected recessive Titinopathy

Mueller J[1], *Savarese M*[2], *Lillback V*[2], *Perry L*[1], *Zaharieva I*[1], *Pini V*[1], *Sagath L*[3], *Steyaert W*[3], *Hoischen A*[3], *Yepez V*[4], *Esteve-Codina A*[5], *Neveling K*[3], *Topf A*[6], *Muntoni F*[1], *Sarkozy A*[1]

[1]*Dubowitz Neuromuscular Centre, University College London,* [2]*Folkhälsan Research Center, University of Helsinki,* [3]*Radboud University Medical Center, Department of Human Genetics, Research Institute for Medical Innovation,* [4]*Technical University of Munich,* [5]*CNAG-CRG, Centre for Genomic Regulation,* [6]*John Walton Muscular Dystrophy Research Centre*

24P Improving gross motor function in pediatric Centronuclear Myopathy with acetylcholinesterase inhibitors: a case report

Paprad T[1], *Laohapongsomboon S*[1], *Amornvit J*[2]

[1]*King Chulalongkorn Memorial Hospital,* [2]*Faculty of Medicine, Chulalongkorn University*

25P Data trends and highlights from The Global Registry for COL6-related Dystrophies

McDonald S[1], *Allamand V*[2], *Alvarez R*[3], *Dziewczapolski G*[3], *Boddy H*[4], *Deconinck N*[5], *Ferré X*[6], *McAlister B*[4], *Mejat A*[7], *Sarkozy A*[8], *Copier J*[9], *Straub V*[1]

[1]*The John Walton Muscular Dystrophy Research Centre,* [2]*Institut de Myologie,* [3]*Cure CMD,* [4]*Patient and family representative, NA, NA,* [5]*Hôpital Universitaire des Enfants Reine Faibola,* [6]*Fundación Noelia, Tarragona, Spain,* [7]*AFM-Téléthon,* [8]*Dubowitz Neuromuscular Centre, Great Ormond Street Hospital,* [9]*Muscular Dystrophy UK*

26P Is oral salbutamol a possible treatment for congenital myopathies?

Michael E[1,2], *Hedberg-Oldfors C*[3], *Gudmundsson M*[4], *Weichbrodt J*[4], *Oldfors A*[3], *Darin N*[2]

[1]*Department of pediatrics, Region Västra Götaland, Sahlgrenska university hospital,* [2]*Department of pediatrics, institute of clinical sciences, Sahlgrenska academy, Gothenburg University,* [3]*Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg,* [4]*Regional Pediatric Rehabilitation Centre, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital*

27P Muscle ultrasound findings in paediatric patients with TTN gene related congenital myopathy

Sarkozy A[1], *Perry L*[1], *Cicala G*[1,2], *Manzur A*[1], *Vanegas M*[3], *Khries M*[3], *Sudhakar S*[4], *Clark C*[5], *Muntoni F*[1,6], *Jungbluth H*[3], *Baranello G*[1]

[1]*Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital,* [2]*Pediatric Neurology, Università Cattolica del Sacro Cuore,* [3]*Department of Paediatric Neurology, Neuromuscular Service, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust,* [4]*Department of Neuroradiology, Great Ormond Street Hospital for Children NHS Foundation Trust,* [5]*Great Ormond Street Institute of Child Health, UCL Great Ormond Street Institute of Child Health,* [6]*NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL & Great Ormond Street Hospital Trust*

28P CHKB muscular dystrophy: beyond Megamitochondria

Codina Bergada A[1,2], *Nascimento A*[1], *Lavilla R*[2], *Ortez C*[1], *Natera-de Benito D*[1,3], *Expósito J*[1], *Estévez-Arias B*[1,4], *Carrera L*[1], *Martorell L*[5], *Isaí A*[1], *Colomer J*[1], *Jou C*[1,2,3,6]

[1]*Neuromuscular Unit, Hospital Sant Joan De Déu,* [2]*Biobanc Sant Joan de Déu, Hospital Sant Joan de Déu,* [3]*Center for Biomedical Research Network on Rare Diseases (CIBERER); ISCIII,* [4]*Laboratory of Neurogenetics and Molecular Medicine – IPER, Institut de Recerca Sant Joan de Déu, 5Genetic and Molecular Medicine Unit, Hospital Sant Joan De Déu, 6Pathology Unit, Hospital Sant Joan de Déu*

29P Temporal requirement of dystroglycan glycosylation during brain development and rescue of cortical dysplasia via gene delivery in the fetal stage

Sudo A[1], *Kanagawa M*[2], *Kobayashi K*[2], *Endo M*[3], *Minami Y*[3], *Aiba A*[4], *Toda T*[1]

[1]*Department of Neurology, The University of Tokyo,* [2]*Division of Molecular Brain Science, Kobe University,* [3]*Division of Cell Physiology, Kobe University,* [4]*Laboratory of Animal Resources, The University of Tokyo*

30P Nemaline Myopathy-linked TNNT1 mutations are associated with aberrant thin filament extensibility and myofibre hyper-contractility

Laitila J[1,2], *Lewis C*[2], *Hessel A*[3,4], *Primiano G*[5,6], *Hernandez-Lain A*[7,8], *Fiorillo C*[9], *Lawlor M*[10], *Ottenheijm C*[11], *Ochala J*[2]

[1]*Folkhälsan Research Center,* [2]*Department of Biomedical Sciences, University of Copenhagen,* [3]*Institute of Physiology II, University of Muenster,* [4]*Accelerated Muscle Biotechnologies ,* [5]*Fondazione Policlinico Universitario Agostino Gemelli IRCCS,* [6]*Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore,* [7]*Neuropathology Unit, Department of Pathology, 12 de Octubre University Hospital,* [8]*4imas12 Research Institute, Rare Diseases Network Biomedical Research Center (CIBERER), 12 de Octubre University Hospital,* [9]*Neuromuscular Disorders Unit, IRCCS Istituto Giannina Gaslini, DINOGMI, University of Genoa,* [10]*Diverge Translational Science Laboratory and Medical College of Wisconsin, Milwaukee, WI, USA,* [11]*Amsterdam UMC, Location VUMC, Physiology, De Boelelaan*

31P Nutritional status of patients with nemaline myopathy and related congenital myopathies in Finland

Lehtokari V[1,2], *Similä M*[3], *Tammepuu M*[4], *Isohanni P*[5], *Auranen M*[6], *Hiekkala S*[7], *Wallgren-Pettersson C*[1,2], *Strang-Karlsson S*[8]

[1]*Folkhälsan Research Center,* [2]*Department of Medical and Clinical Genetics, Medicum, University of Helsinki,* [3]*Clinical Nutrition Unit, Internal Medicine and Rehabilitation, Helsinki University Hospital, University of Helsinki,* [4]*Department of Pediatric Neurology, Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital,* [5]*Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki,* [6]*Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital,* [7]*The Finnish Association of People with Physical Disabilities,* [8]*Department of Clinical Genetics, HUS Diagnostic Center, Helsinki University Hospital and University of Helsinki*

32P Investigating myosin dysregulation in X-linked myotubular myopathy

Rostedt F[1,2], *Gerlach Melhedegaard E*[1], *Zanoteli E*[3], *Primiano G*[4], *Nishino I*[5], *Laporte J*[6], *Gineste C*[6], *Romero N*[7], *Lawlor M*[8], *Wallgren-Pettersson C*[2,9], *Laitila J*[1,2], *Ochala J*[1]

[1]*Department of Biomedical Sciences, University of Copenhagen,* [2]*Folkhälsan Research Center,* [3]*Department of Neurology, Faculdade de Medicina (FMUSP), Universidade de São Paulo,* [4]*Fondazione Policlinico Universitario Agostino Gemelli IRCCS,* [5]*National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP),* [6]*Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Inserm U1258, Cnrs UMR7104, Université de Strasbourg,* [7]*Institut de Myologie, GHU La Pitié-Salpêtrière,* [8]*Diverge Translational Science Laboratory and Medical College of Wisconsin, Department of Pathology and Laboratory Medicine,* [9]*Department of Medical Genetics, Medicum, University of Helsinki*

33P Description of natural history baseline characteristics of a paediatric cohort of recessive TTN myopathy patients in the UK – a prospective study

Wolfe A[1,2], *Cicala G*[1,2], *Joefield T*[2], *Sheehan J*[3], *Main M*[1], *Vanegas M*[3], *Khries M*[3], *Clark C*[1,2], *Sudhakar S*[1], *Perry L*[1], *Bilby J*[1], *Jungbluth H*[3], *Muntoni F*[1,2,4], *Baranello G*[1,2,4], *Sarkozy A*[1,2]

[1]*Great Ormond Street Hospital for Children NHS Foundation Trust,* [2]*Dubowitz Neuromuscular Centre, Institute of Child Health, University College London,* [3]*Department of Paediatric Neurology – Neuromuscular Service, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust,* [4]*UCL NIHR GOSH Biomedical Research Centre*

34P Investigating sarcomeric changes in Cullin-3 knockout muscles

Fochi V[1], *Blondelle J*[2], *Medelyte B*[1], *Seto J*[3,4], *Jones Y*[2], *Castillon G*[2], *Ghassemian M*[5], *Singer J*[6], *Lange S*[1,2,7]

[1]*Aarhus University, Department of Biomedicine,* [2]*University of California San Diego, Department of Medicine,* [3]*Murdoch Children's Research Institute, Royal Children's Hospital,* [4]*University of Melbourne,* [5]*University of California San Diego, Department of Chemistry and Biochemistry,* [6]*Portland State University, Department of Biology,* [7]*Steno Diabetes Center Aarhus, Aarhus University Hospital*

35P Generation of a zebrafish knock-in model of Exertional Heat Stroke

Endo Y[1,2], *Geissah S*[2], *Cui X*[2], *Noche R*[2], *Dowling J*[2]

[1]*Juntendo University,* [2]*Hospital for Sick Children*

continued on next page

36P Liver involvement in Myotubular and Centronuclear Myopathy: review of one year's data collected by the MTM & CNM Patient Registry

Bohill J[1], *Ward E*[2], *Lennox A*[3], *Lawlor M*[4], *Jungbluth H*[5,6], *Beggs A*[7], *Graham R*[8], *Heidemann M*[9], *Wood M*[2], *Ward M*[2], *Page J*[1], *Cowling B*[10], *Haselkorn T*[11], *Voermans N*[12], *Foley A*[13], *Kyrana E*[14], *Marini-Bettolo C*[1], *Dhawan A*[14], *Dowling J*[15]

[1]*Newcastle University,* [2]*MTM-CNM Family Connection,* [3]*Myotubular Trust,* [4]*Diverge Translational Science Laboratory and Medical College of Wisconsin,* [5]*Department of Paediatric Neurology – Neuromuscular Service, Evelina Children's Hospital, Guy's & St Thomas' NHS Foundation Trust,* [6]*Randall Centre for Cell and Molecular Biophysics, Muscle Signalling Section, Faculty of Life Sciences and Medicine (FoLSM),* [7]*The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School,* [8]*Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital,* [9]*Independent consultant,* [10]*Dynacure,* [11]*Astellas Gene Therapies,* [12]*Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center,* [13]*Neuromuscular and Neurogenetic Disorders of Childhood Section, NINDS, National Institutes of Health,* [14]*Paediatric Liver, GI and Nutrition Centre and Mowat Labs, King's College Hospital NHS Foundation Trust,* [15]*Division of Neurology, Program for Genetics and Genome Biology, Hospital for Sick Children*

37P TreatMYPN: In vivo mouse characterization and in vitro 3D muscle studies followed by 15P AAV gene therapy for the ultrarare myopalladin-related Congenital Myopathy

Onnée M[1], *Taglietti V*[1], *Gicquel E*[2], *Bastu S*[1], *Periou B*[1,3], *Banos G*[1], *Mignot J*[1], *Bleuzen A*[1], *Roudaut C*[2], *Tiret L*[1], *Didier N*[1], *Richard I*[2], *Relaix F*[1], *Malfatti E*[1,3]

[1]*Université Paris Est Créteil, INSERM U955 Team Relaix, IMRB, EFS, ENVA,* [2]*Université Pari-Saclay/Université Evry Est Créteil, INSERM, Généthon, Integrare Research Unit, UMR_S951,* [3]*AP-HP, Centre de Référence de Pathologie Neuromusculaire Nord-Est-Ile-de-France, Hôpital Henri Mondor*

38P Collablot, a new immunodetection assay for the quantification of collagen VI expression and secretion in cell culture

Sendino M[1], *Martín-Gonzalez S*[1], *Osegui-Barcenilla N*[1], *López-Márquez A*[2], *González-Moro I*[1], *Benito-Agustino A*[1], *López-Martínez A*[1], *Jimenez-Mallebrera C*[2], ***Arechavala Gomeza V***[1,3]

[1]*Biobizkaia Health Reseach Institute,* [2]*Institut de Recerca Sant Joan de Déu,* [3]*Ikerbasque, Basque Foundation for Science*

39P Studying markers of metabolism, apoptosis, and necrosis in cullin-3 skeletal muscle knockouts

Herskind J[1], *Fujita K*[2], *Dato V*[2], *Fochi V*[1], *Blondelle J*[2], *Medelyte B*[1], *Seto J*[3,4], *Jones Y*[2], *Castillon G*[2], *Ghassemian M*[5], *Singer J*[6], *Lange S*[1,2,7]

[1]*Aarhus University,* [2]*University of California, Department of Medicine,* [3]*Murdoch Children's Research Institute,* [4]*University of Melbourne,* [5]*University of California, Dept. of Chemistry and Biochemistry,* [6]*Portland State University,* [7]*Steno Diabetes Center Aarhus*

40P Muscle ultrasound pattern in Merosin-deficient muscular dystrophy

Costa Comellas L[1,2,3], *Gómez-Andrés D*[1,2,3], *Urcuyo G*[1,3], *Toro-Tamargo E*[1], *López-López J*[4], *Álvarez-Molinero M*[1,5], *Munell F*[1,2,3]

[1]*Hospital Universitari Vall D'hebron,* [2]*Universitat Autonoma Barcelona,* [3]*Vall d'Hebron Institut de Recerca,* [4]*Hospital Universitario Infanta Sofía,* [5]*Hospital Universitari de Tarragona Joan XXIII*

41P Rigid spine syndrome revealing nemaline myopathy caused by a novel mutation in cofilin-2 gene (CFL2)

Farhat E[1,3], *Miladi N*[1,4], *Chaabouni M*[1,2]

[1]*Faculty of Medicine of Tunis, University of Tunis,* [2]*Genetic lab, Centre Médical les Jasmins,* [3]*The Muscle lab, Iris Medical Center,* [4]*Maghreb medical center,*

42P Characterizing MRI brain abnormalities in X-linked Myotubular Myopathy

Vogt L[1], ***Amburgey K***[1], *Widjaja E*[2], *Dowling J*[1]

[1]*Hospital For Sick Children,* [2]*Lurie Children's Hospital*

43P Characterization of RYR1 variants in congenital myopathy zebrafish models

Sinclair J[1], *Todd J*[1], *Feldman B*[1], *Lawal T*[1]

[1]*National Institutes of Health*

44P Novel TTN mutation causing a congenital onset, slowly progressive myopathy with contractures in two siblings

Figueroa Bonaparte S[1], *Martinez -Viguera A*[1], *Juanola-Mayos E*[1], *Lucente G*[1], *Almendrote M*[1], *Gasch-Navalon E*[2], *Corral-Juan M*[2], *Matilla-Dueñas A*[2], *Martinez-Piñeiro A*[1]

[1]*Neuromuscular Disorders Unit, Neurology Service, Germans Trias i Pujol Universitary Hospital,* [2]*Neurogenetics Unit, Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona-Can Ruti Campus*

45P Strategies to improve the design of gapmer antisense oligonucleotide on allele-specific silencing in COL6-related congenital muscular dystrophies

*Aguti S[1], Cheng S[1], Briggs S[1], Ala P[1], Muntoni F[1], **Zhou H**[1]*
[1]University College London

46P Congenital Myopathies and Muscular Dystrophies in the UK: a comprehensive next generation sequencing analysis of frequencies over an 8-year period (2016-2023)

***Cicala G**[1,2], Mccauley J[3], Mein R[4], Walsh C[3], Muntoni F[1,5], Sarkozy A[1]*
[1]Dubowitz Neuromuscular Centre, University College London, and MRC Centre for Neuromuscular Diseases, Neurosciences Unit, Great Ormond Street Hospital, [2]Pediatric Neurology, Università Cattolica del Sacro Cuore, [3]Genetics Laboratory, Synnovis Analytics, Guy's Hospital, [4]Genomics Unit, NHS England, Wellington House, [5]NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL & Great Ormond Street Hospital Trust

47P MYBPC1 mutation in a family: spectrum of phenotype in three generations

***Shekhar L**[1], Majumdar A[1]*
[1]Bristol Royal Hospital for Children

48P Digging into histological-genetic correlations in MYH2-myopathy: a case series and review of the literature

***Labella B**[1,2], Brochier G[1,3], Beuvin M[1], Méneret A[3], Leonard-Louis S[3], Maisonobe T[3], Stojkovic T[1], Métay C[3], Evangelista T[1,3]*
[1]Association Institut De Myologie, [2]University of Brescia, [3]APHP- Hôpital Pitié-Salpêtrière

49P Epidemiologic study of XLMTM and clinical expression in the liver (EXCEL): study design of an observational, patient-centric study

***Beggs A**[1], **Haselkorn T**[2], Dhawan A[3], Lawlor M[4], Kim J[2], Ward E[5], Hughes Z[6], Baima J[2], James L[2], Coats J[2], Gentyala R[2], Brandon T[2], Jesus Perez Inigo Garcia-Malo M[7], Marini Bettolo C[8], Graham R[9], Dowling J[10]*
[1]Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, [2]Astellas Gene Therapies, [3]Pediatric Liver GI and Nutrition Centre and Mowat Labs, King's College Hospital, [4]Diverge Translational Science Laboratory and Medical College of Wisconsin, [5]MTM-CNM Family Connection, Inc, [6]Myotubular Trust, [7]Astellas Pharma, S.A., [8]The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, [9]Department of Anesthesiology, Critical Care and Pain Medicine, Boston Children's Hospital, [10]Division of Neurology, Program for Genetics and Genome Biology, Hospital for Sick Children

50P Monoallelic DAG1 truncating variants in patients with hyperCKemia

***Segarra-casas A**[1,2], Trainor C[1], Polavarapu K[3], Díaz-Manera J[1], Gonzalez-Quereda L[2,4], Kirschner J[5], López de Munain A[6,7,8,9], Nascimento A[4,10,11], Roos A[3,12,13], Dowling J[14,15], Muntoni F[16,17], DAG1 Study Group, Töpf A[1], Straub V[1]*
[1]John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trusts, [2]Genetics Department, Institut de Recerca Sant Pau (IR SANT PAU), Hospital de la Santa Creu i Sant Pau, [3]Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute, [4]Center for Biomedical Research Network on Rare Diseases (CIBERER), [5]Department of Neuropediatrics and Muscle Disorders, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, [6]Department of Neurosciences, Biodonostia Health Research Institute, University of the Basque Country, [7]Department of Neurology, Donostia University Hospital, Osakidetza Basque Health Service, [8]CIBERNED, ISCIII (CIBER, Carlos III Institute, Spanish Ministry of Sciences and Innovation), [9]Faculty of Medicine, University of Deusto, [10]Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de Déu, [11]Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de Déu, [12]Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, [13]Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, [14]Genetics and Genome Biology Program, Division of Neurology, Hospital for Sick Children, [15]Departments of Paediatrics and Molecular Genetics, University of Toronto, [16]Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, [17]NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, UCL & Great Ormond Street Hospital Trust

51P Clinical characterization of Collagen XII-related disease caused by biallelic COL12A1 variants

***Donkervoort S**[1], McCarty R[1], Saade D[1], Munot P[2], Laverty C[3], Pinz H[4], Zou Y[1], McNally M[1], Yun P[1], Tian C[5], Töpf A[6], Phadke R[7], Malicki D[3], Friedman J[3], Foley A[1], Gleeson J[8], Lotze T[9], Muntoni F[2], Straub V[6], Study Group, Bönnemann C[1]*
[1]NNDCS, National Institutes of Health, [2]Great Ormond Street Institute of Child Health, [3]Rady Children's Hospital, [4]Saint Louis University, [5]Cincinnati Children's Hospital, [6]Newcastle University and Newcastle Hospitals NHS Foundation Trust, [7]UCL Queen Square Institute of Neurology, [8]University of California San Diego, [9]Texas Children's Hospital

52VP Muscle ultrasound as a potential biomarker in patients with LAMA2-related dystrophy under 6 years of age

Haugland S[1], *Orbach R*[1], *McAnally M*[1], *Donkervoort S*[1], *Foley A*[1], *Bonnemann C*[1]
[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health*

53VP A 5-year natural history study in LAMA2-related muscular dystrophy and SELENON-related myopathy: the extended last strong study

De Laat I[1], *Bouman K*[1,2], *van de Camp S*[1], *Dittrich A*[3], *van Tilburg W*[4], *Cameron D*[5], *Doorduin J*[1], *van Alfen N*[1], *Kamsteeg E*[6], *Houwen S*[7], *Groothuis J*[7], *Erasmus C*[2], *Voermans N*[1]
[1]*Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center,* [2]*Department of Pediatric Neurology, Radboud university medical center,* [3]*Department of Pediatrics, Amalia Children's Hospital, Radboud university medical center,* [4]*Department of Radiology, Radboud university medical center,* [5]*Department of Medical Imaging, Radboud university medical center,* [6]*Department of Clinical genetics, Radboud university medical center,* [7]*Department of Rehabilitation, Radboud university medical center*

54VP Emerging muscle ultrasound patterns as a diagnostic aid in TTN-related myopathy

Potticary A[1], *McAnally M*[1], *Donkervoort S*[1], *Bönnemann C*[1]
[1]*NIH NINDS*

79P-97P: LGMD

79P Profiling of pathogenic variants in Japanese patients with Sarcoglycanopathy

Shimazaki R[1], *Saito Y*[1,2], *Awaya T*[3,4], *Minami N*[2], *Kurosawa R*[3], *Hosokawa M*[3], *Ohara H*[3], *Hayashi S*[1], *Takeuchi A*[5], *Hagiwara M*[3], *K. Hayashi Y*[6], *Noguchi S*[1], *Nishino I*[1,2]
[1]*Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry,* [2]*Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry,* [3]*Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University,* [4]*Center for Anatomical Studies, Kyoto University, Graduate School of Medicine, Kyoto University,* [5]*Department of Developmental Biology and Functional Genomics, Ehime University Graduate School of Medicine,* [6]*Department of Pathophysiology, Tokyo Medical University*

80P Evaluating the clinical significance of single heterozygous likely pathogenic and pathogenic variants for autosomal recessive limb-girdle muscular dystrophies in a highly specialised service for rare neuromuscular disorders

Oliwa A[1], *Hudson J*[1], *Topf A*[1], *Graham E*[1], *Salman D*[1], *Straub V*[1], *Harris E*[1], *Marini-Bettolo C*[1]
[1]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust*

81P Minimal clinically important differences in Dysferlinopathy from the 10-year, multicenter Jain Clinical Outcome Study

Gordish-Dressman H[1,2], *James M*[3], *Rufibach L*[4], *Hilsden H*[3], *Day J*[5], *Mendell J*[6], *Fernandez-Torron R*[7], *Harms M*[8], *Pestronk A*[9], *Vissing J*[10], *Desai U*[11], *Yoshimura M*[12], *Shin J*[13], *Mozaffar T*[14], *Stojkovic T*[15], *Pegoraro E*[16], *Bevilacqua Rivas J*[17], *Olive M*[18], *Paradas C*[19], *COS consortium on behalf of the Jain Foundation, Straub V*[3]
[1]*Children's National Hospital,* [2]*George Washington University School of Medicine and Health Sciences,* [3]*The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University,* [4]*The Jain Foundation,* [5]*Stanford University School of Medicine,* [6]*Nationwide Children's Hospital,* [7]*Donostia University Hospital,* [8]*Columbia University Irving Medical Center,* [9]*Washington University School of Medicine,* [10]*University of Copenhagen,* [11]*Carolinas MDA Care Center,* [12]*National Center Hospital,* [13]*Pusan National University Yangsan Hospital,* [14]*University of California – Irvine,* [15]*Groupe Hospitalier Pitié-Salpêtrière,* [16]*University of Padova,* [17]*Clínica Dávila,* [18]*Hospital de la Santa Creu i Sant Pau,* [19]*Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla*

82P Diagnostic approach to ANO5-Related Muscular Dystrophy in a series of female siblings: an interdisciplinary perspective

Correa Arrieta C[1], *Castellar Leones S*[1,2,3], *Calderon Castro A*[1,2,3], *Rodriguez P*[1,2], *Saldaña D*[1], *Maradei Anaya S*[1,2]
[1]*Biotecgen,* [2]*Universidad Nacional de Colombia,* [3]*Hospital Universitario Nacional de Colombia,*

83P Should we include HACD1 variants in the differential diagnosis of slowly progressive adult-onset limb-girdle weakness?

Da Silveira Massaro C[1], *Ferreira W*[1], *Farias I*[1], *Oliveira H*[1], *Serrano P*[1], *Badia B*[1], *Souza P*[1], *Bezerra M*[1], *Pinto W*[1], *Nunes K*[1], *Oliveira A*[1]
[1]*Universidade Federal de São Paulo- UNIFESP - EPM*

continued on next page

84P A rare homozygous CAPN3 variant with distinct clinical features in unrelated families of Iraqi Jewish descent

Aharoni S[2,4], *Assia Batzir N*[1], *Orenstein N*[1,2], *Yaron Y*[2,3], *Kuzminsky A*[4], *Nevo Y*[2,4], *Konen O*[2,5], *Bazak L*, *Lidzbarsky G*[6], *Basel-Salmon L*[2,6,7]

[1]*Pediatric Genetics Unit, Schneider Children's Medical Center of Israel,* [2]*Faculty of Medicine, Tel Aviv University,* [3]*The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center,* [4]*Institute of Pediatric Neurology, Schneider Children's Medical Center of Israel,* [5]*Diagnostic Imaging, Schneider Children & Medical Center of Israel,* [6]*Raphael Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital,* [7]*Felsenstein Medical Research Center, Rabin Medical Center*

85P Myopathy secondary to SCN4A C.3502C>T variant

Calabria Gallego M[1]

[1]*Hospital Universitario De Salamanca*

86P Muscle 3D models to investigate LGMDD2 Transportin 3 Related Deficiency: insights into myogenic processes and contractile dysfunction

Pacilio S[1,4], *Costa R*[1], *Rodia M*[1], *Lombardi S*[1], *Di L*[2], *Banos G*[3], *Didier N*[3], *Malfatti E*[4], *Focarete M*[2], *Cenacchi G*[1]

[1]*Department of Biomedical and Neuromotor Sciences DIBINEM, Alma Mater Studiorum-Università di Bologna,* [2]*Department of Chemistry "Giacomo Ciamician" Alma Mater Studiorum-Università di Bologna,* [3]*Université Paris Est Créteil, INSERM, EFS, IMRB,* [4]*Université Paris Est Créteil, INSERM, U955, IMRB*

87P MRI characterization of the cardiac involvement in LGMD2i/R9

Fromes Y[1], *Olivier S*[2], *Zanfongnon R*[3], *Thevenot E*[3], *Stojkovic T*[1,4], *Marty B*[1], *Reyngoudt H*[1]

[1]*Institute of Myology,* [2]*Atamyo Therapeutics,* [3]*Genethon,* [4]*La Pitié-Salpêtrière Hospital,*

88P Clinical progression of 43 patients with Sarcoglycanopathy at a single centre

Kocak G[1], *Michel-Sodhi J*[1], *Marini-Bettolo C*[1], *Moat D*[1], *Guglieri M*[1], *Robinson E*[1], *Schiava M*[1], *Bolano-Díaz C*[1], *Wong K*[1], *Grover E*[1], *James M*[1], *Segovia S*[1], *Elseed M*[1], *Salman D*[1], *Harris E*[1], *Topf A*[1], *Luce L*[1], *Hudson J*[2], *Henderson M*[2], *Parkhurst Y*[2], *Graham E*[2], *Straub V*[1], *Tasca G*[1], *Muni Lofra R*[1], *Diaz-Manera J*[1]

[1]*Newcastle University,* [2]*Newcastle upon Tyne Hospitals NHS Foundation Trust*

89P The LGMD2A/Calpainopathy Registry: A patient-powered natural history study and trial recruitment tool

Levy J[1], *Boslego J*[1], *Guglieri M*[2], *Martin A*[3], *Mathews K*[4], *Wrubel M*[1]

[1]*Coalition To Cure Calpain 3,* [2]*John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trusts,* [3]*Parent Project Muscular Dystrophy,* [4]*University of Iowa Carver College of Medicine,*

90P Genetic heterogeneity of limb girdle myopathies in Tunisia: more than sarcoglycanopathies

Farhat E[1], *Miladi N*[1], *Chaabouni M*[1,2], *Amouri R*[3], *Leturcq F*[4]

[1]*Faculty of Medicine of Tunis, University of Tunis El Manar,* [2]*Genetic lab, Centre médical les Jasmins,* [3]*Neurogenetics lab. National Institute Mongi ben Hamida of neurology,* [4]*Service de Génétique et Biologie moléculaires, Hôpital Cochin-Port-Royal, APHP. Centre Université de Paris*

91P Determination of gene/protein expression and protein functionality in carriers of Limb-Girdle Muscular Dystrophy (LGMD)

Gaynor A[1]

[1]*Virginia Commonwealth University*

92P Development and characterization of induced pluripotent stem cells derived from Calpainopathy patients, carrying the CAPN3 c.1746-20C>G variant

Inashkina I[1], *Goluba K*[2], *Tvoronoviča A*[1], *Parfejevs V*[2], *Lāce B*[2,3], *Riekstiņa U*[2]

[1]*Latvian Biomedical Research and Study Centre,* [2]*Pharmaceutical sciences centre, Faculty of Medicine, University of Latvia,* [3]*Riga East Clinical University Hospital*

continued on next page

93P The International Clinical Outcome Study for Dysferlinopathy II: validation of motor outcome measures in a new patient cohort

Hilsden H[1], *James M*[1], *Gordish Dressman H*[2], *Rufibach L*[3], *Day J*[4], *Mendell J*[5], *Fernandez Torron R*[6], *Harms M*[7], *Pestronk A*[8], *Vissing J*[9], *Desai U*[10], *Yoshimura M*[11], *Shin J*[12], *Mozaffar T*[13], *Stojkovic T*[14], *Pegoraro E*[15], *Bevilacqua Rivas J*[16], *Olive M*[17], *Paradas C*[18], *Straub V*[1]

[1]*John Walton Muscular Dystrophy Research Centre, Newcastle University,* [2]*Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System; Pediatrics, Epidemiology and Biostatistics, George Washington University,* [3]*The Jain Foundation,* [4]*Department of Neurology and Neurological Sciences, Stanford University School of Medicine,* [5]*Nationwide Children's Hospital, Columbus,* [6]*Neuromuscular Area, Biodonostia Health Research Institute, Neurology Service, Donostia University Hospital ,* [7]*Department of Neurology, Columbia University Irving Medical Center,* [8]*Department of Neurology, Washington University School of Medicine,* [9]*Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen,* [10]*Carolinas MDA Care Center, Atrium Health, Charlotte,* [11]*Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry,* [12]*Laboratory of Molecular Neurology, Pusan National University Yangsan Hospital,* [13]*Department of Neurology, MDA ALS and Neuromuscular Center, University of California, Irvine,* [14]*Institut de Myologie, Groupe Hospitalier Pitié-Salpêtiere,* [15]*Department of Neuroscience, University of Padova,* [16]*Departamento de y Neurología Neurocirugía Clínica, Clínica Dávila,* [17]*Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau,* [18]*Neuromuscular Unit, Department of Neurology, Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla*

94P JOURNEY: a natural history study of Limb Girdle muscular dystrophies R3–R5: baseline characteristics of study cohort

Lowes L[1], ***Ortez Gonzalez C***[2], *Claeys K*[3], *Laverty C*[4], *Gangfuss A*[5], *Proud C*[6], *Manera J*[7], *James M*[7], *Alfano L*[1], *Stevenson H*[8], *Yu L*[8], *Comi G*[9,10]

[1]*Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital,* [2]*Neuromuscular Unit, Hospital Sant Joan de Deu,* [3]*Department of Neurology, University Hospitals Leuven and KU Leuven,* [4]*University of California,* [5]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen,* [6]*Children's Hospital of The King's Daughter,* [7]*The John Walton Muscular Dystrophy Research Center, Newcastle University Newcastle Upon Tyne Hospitals NHS,* [8]*Sarepta Therapeutics, Inc.,* [9]*Dino Ferrari Center, Department of Pathophysiology and Transplantation, University of Milan,* [10]*Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurology Unit*

95P Development of a myotropic gene therapy towards a first treatment for LGMDR7

Heier C[1], *Fiorillo A*[1], *Provenzano M*[1], *McMichael G*[1], *Crumbaugh C*[1], *Hawkins E*[1], *Johnson N*[1], *Hale M*[1]

[1]*Virginia Commonwealth University*

96P The impact of losing the ability to sit to stand on social participation in people with Dysferlinopathy: clinical outcome study for Dysferlinopathy

Robinson E[1], *James M*[1], *Hilsden H*[1], *Rufibach L*[2], *Roper W*[3], *Holsten S*[4], *Lowes L*[5], *De Monts C*[6], *Yochai C*[7], *Zabala Pardo A*[8], *Ogasawara Y*[9], *Rudolph K*[10], *Weber J*[11], *Montiel Morillo E*[12], *Birnbaum S*[13], *Rojas Rojas J*[14], *Mayhew A*[1], *Straub V*[1], *COS Consortium on behalf of the Jain Foundation*[3]

[1]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS,* [2]*The Jain Foundation,* [3]*Washington University School of Medicine,* [4]*Carolinas Healthcare System,* [5]*Abigail Wexner Research Institute at Nationwide Children's Hospital,* [6]*Stanford University,* [7]*Columbia University Irving Medical Centre,* [8]*Hospital Universitario Donostia,* [9]*National Centre Hospital, National Centre of Neurology and Psychiatry,* [10]*Copenhagen Neuromuscular Centre, Rigshopitalet,* [11]*Clinica Davila,* [12]*Physical medicine and rehabilitation, Hospital de la Santa Creu i Sant Pau,* [13]*Institute of Myology, 14Hospital Virgen del Rocio*

97P Spectrum of limb girdle muscular dystrophies in a cohort of inherited myopathies with limb girdle weakness

Venugopalan Y V[1], *Macken W*[2,3], *Dalal A*[4], *Rani N*[1], ***Reyaz A***[1], *Ahmad T*[1], *Tarane K*[1], *Danish M*[1], *ICGNMD Consortium*[5], *Bhatia R*[1], *Wilson L*[2], *Bugiardini E*[2], *Vandrovcova J*[2], *Houlden H*[2], *Pitceathly R*[2,3], *Thangaraj K*[4,6], *Topf A*[7], *Straub V*[7], *Hanna M*[2], *Srivastava P*[1]

[1]*All India Institute of Medical Sciences,* [2]*Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology,* [3]*NHS Highly Specialised Service for Rare Mitochondrial Disorders, Queen Square Centre for Neuromuscular Diseases, The National Hospital for Neurology and Neurosurgery,* [4]*Centre for DNA Fingerprinting and Diagnostics,* [5]*ICGNMD Consortium,* [6]*Centre for Cellular & Molecular Biology,* [7]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

401P-436P, 437VP: DMD – treatments

continued on next page

401P Moderate-term dimethyl fumarate treatment reduces fibrosis of skeletal and cardiac muscle in in the mdx mouse model of Duchenne muscular dystrophy

Timpani C[1,2,3], Kourakis S[1,2], Bagaric R[1,2], Qi B1[2], Ali B[1,2], Spiesberger G[1,2], Boyer R[1], Kandhari N[4], Yan X[1,5], Stupka N[3,2,1], van Putten M[6], Aartsma-Rus A[6], Deveson-Lucas D[4], Fischer D[7], Rybalka E[1,2,3]

[1]Victoria University, Institute for Health & Sport, [2]Australian Institute for Musculoskeletal Science, Inherited and Acquired Myopathy Program, [3]The University of Melbourne, Department of Medicine - Western Health, Melbourne Medical School, [4]Monash University, Monash Genomics and Bioinformatics Platform, Biomedical Discovery Institute, [5]Australian Institute for Musculoskeletal Science, Sarcopenia Research Program, [6]Leiden University Medical Center, Department of Human Genetics, [7]University Children's Hospital of Basel, Division of Neuropediatric and Developmental Medicine

402P Faecal microbiota transplantation: a potential novel therapeutic avenue for Duchenne muscular dystrophy

Timpani C[1,2,3], Debrincat D[1], Van Der Beek J[1], Eri R[4,5], Diwakarla S[6,3], McQuade R[6,3,2], Rybalka E[1,2,3]

[1]Victoria University, Institute for Health & Sport, [2]Australian Institute for Musculoskeletal Science, [3]The University of Melbourne, Department of Medicine - Western Health, Melbourne Medical School, [4]University of Tasmania, School of Health Sciences, [5]RMIT University, School of Science, STEM College, [6]The University of Melbourne, Gut Barrier and Disease Laboratory, Department of Anatomy and Physiology

403P CONNECT1-EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping

Mellion M[1], McMillan H[2], Chrestian N[3], Gonorazky H[4], O'Connell C[5], Vacca S[1], Peterson M[1], Marcos B[1], Batra S[1], Lonkar P[1], Holland A[1], Foy J[1], Lamore S[1], Garg B[1], Yu S[1], Larkindale J[1]

[1]Pepgen Inc., [2]Children's Hospital of Eastern Ontario, [3]CHU De Quebec-Universite Laval, [4]Hospital for Sick Children, [5]Stan Cassidy Centre for Rehabilitation

404P CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping

Mellion M[1], Marcos B[1], Vacca S[1], Peterson M[1], Batra S[1], Lonkar P[1], Holland A[1], Foy J[1], Lamore S[1], Garg B[1], Yu S[1], Larkindale J1

[1]Pepgen Inc.

405P Single- and repeat-dose nonclinical data for PGN-EDO51 demonstrated favorable pharmacology and safety profiles for the treatment of DMD

Sweeney C[1], Gilbert J[1], Lamore S[1], Lonkar P[1], Foy J[1], Holland A[1]

[1]PepGen Inc.

406P Effects of telerehabilitation-based motor imagery training on motor imagery ability and motor function in children with Duchenne muscular dystrophy

Bora Zereyak M[1], Bulut N[1], Yılmaz Ö[1], Gürbüz İ[1], Haliloğlu G[2]

[1]Hacettepe University, Faculty of Physical Therapy and Rehabilitation, [2]Hacettepe University, Faculty of Medicine, Department of Pediatrics, Division of Pediatric Neurology

407P RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: interim clinical data

Dastgir J[1], Veerapandiyan A[2], Rao V[3], Tesi-Rocha C[4], Harper A, Iannacone S[6], Falabella P[1], Pakola S[1], Philips D[1], Wilson C[1], Boulos N[1], Gilmor M[1], Yang L[1], Patel H[1], Fiscella M[1], Danos O[1]

[1]Regenxbio, [2]Arkansas Children's Hospital, [3]Lurie Children's Hospital, [4]Stanford School of Medicine, [5]Children's Hospital of Richmond at Virginia Commonwealth University, [6]The University of Texas Southwestern Medical Center

408P Dose escalation and repeatability for ultrasound-guided intramuscular administration of local treatment in Duchenne muscular dystrophy

Findik Sener O[1], Sage F[1], Niks E[1,2], de Ruiter M[1], Engelse M[1], Geijsen N[1], Burgmans M[1], Kan H[1,2]

[1]Leiden University Medical Center, [2]Duchenne Center

409P Short-term and long-term safety profile of Givinostat in Duchenne muscular dystrophy

Vučinić D[1], Nascimento A[2], Finkel R[3], Brandsema J[4], Finanger E[5], Harper A[6], Acsadi G[7], Nevo Y[8], Houwen-van Opstal S[9], Blaschek A[10], Coceani N[11], Cazzaniga S[11], Bettica P[11], Muelas N[12]

[1]Clinic Of Neurology And Psychiatry For Children And Youth, [2]Neuromuscular Pathology Unit, Hospital Sant Joan de Deu, [3]St. Jude Children's Research Hospital, [4]Children's Hospital, [5]Shriners Hospitals for Children, [6]Virginia Commonwealth University, [7]Connecticut Children's Medical Center, [8]Schneider Children's Medical Center, [9]Radboud University Medical Centre, [10]Ludwig Maximilian University of Munich, [11]Italfarmaco Group, [12]Hospital Universitari i Politècnic La Fe

410P GNT0004, Genethon's AAV8 vector-delivered microdystrophin gene therapy of Duchenne muscular dystrophy, first data of the phase I/II part of the GNT-016-MDYF all-in-one clinical trial in ambulant boys

*Laugel V[1], De Lucia S[2], Davion J[3], Daniele N[4], **Cao F**[4], Sanz M[4], Buscara L[4], Blaie S[4], Thibaut L[4], Sagot M[4], Riviere A[4], Creoff E[4], Lelait M[4], Valent A[4], Perret G[4], Braun S[4], Muntoni F[5]*

[1]Hôpital de Hautepierre, [2]I-Motion Plateforme d'essais cliniques pédiatriques Hôpital Armand Trousseau, [3]Service de Neurologie pédiatrique, CHU Lille, [4]Genethon, [5]Hospital for Children Foundation Trust, Great Ormond Street Hospital

411P Phenotypical differences in 2 immortalized dystrophic cell lines from pediatric patients: a glimpse into pharmacological personalized therapy

*Cappellari O[1], Quarta R[1], Cristiano E[1], Boccanegra B[1], Cerchiara A[1], Marinelli M[1], Barile S[2], Mouly V[3], Lasorsa M[2], Imbrici P[1], **De Luca A**[1]*

[1]Department of Pharmacy-Drug Sciences, University Of Bari Aldo Moro, [2]Department of Biosciences Biotechnology and Environment, University of Bari Aldo Moro, [3]Institute of Myology, University of Sorbonne

412P Duchenne muscular dystrophy fibro-adipogenic progenitors impair muscle function of co-cultured healthy myotubes in a functional 3D model

***Ninfali C**[1], Fernández-Garibay X[1], Tejedera-Villafranca A[1], Díaz-Manera J[2], Ramón-Azcón J[1,3], Fernández-Costa J[1]*

[1]Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), [2]John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle University, [3]ICREA-Institució Catalana de Recerca i Estudis Avançats,

413P Natural history of renal dysfunction in Duchenne muscular dystrophy

***Arahata H**[1]*

[1]Nho Omuta Hospital

414P Pulmonary function in Colombian non-ambulatory patients with Duchenne muscular dystrophy treated with Ataluren

***Gordillo Gonzalez G**[1,2], Villamil-Osorio M[3], Restrepo-Gualteros S[4], Vallejo-Mesa D[5,6], Rivera-Nieto C[7], Contreras-García G[8,9], Guerra-Araujo V[10], Ospina-Lagos S[11,12], Paredes-Brijaldo Á[4], Hernández-Forero M[13], Becerra-Ortíz P[14], Silvera-Redondo C[15], Arias C[16], Campo-Ternera C[17,18], Curiel-Acosta J[19]*

[1]Sociedad de Cirujanos y Pediatras Asociados, Barranquilla, [2]Asociación Colombiana de genética Médica y Medicina Genómica (ACMGen), Bogotá, [3]Fundación Hospital de la Misericordia, [4]Hospital San Ignacio, Bogotá [5]Department of Neurology, Medical School, and Alma Mater Hospital, Universidad de Antioquia, Medellín, [6]Neuro Clínica, Medellín, [7]Fundación Cardioinfantil, Bogotá, [8]Department of Basic Sciences, Pediatrics Department – Hospital Universitario de Santander, Bucaramanga, [9]Human Genetics UIS Research Group, Faculty of Health, Universidad Industrial de Santander, Bucaramanga, [10]Asociación Colombiana de Neurología Infantil (ASCONI), Valledupar, [11]Universidad Nacional de Colombia, Bogotá, [12]GenCell Pharma, Bogotá, [13]Hospital regional de Sogamoso, Sogamoso, [14]Sociedad de Medicina Física y Rehabilitación SOMEFYR, Cúcuta, [15]Universidad del Norte, Barranquilla, [16]Universidad Cooperativa de Colombia, Pasto, [17]Hospital San Vicente Fundación, Medellín, [18]Hospital Infantil Concejo de Medellín, [19]Asociación Colombiana de Neurología Infantil (ASCONI), Santa Marta

415P Cardiac function in Colombian non-ambulatory patients with Duchenne muscular dystrophy treated with Ataluren

***Gordillo Gonzalez G**[1,2,10], Huertas-Quiñones V[3], Silvera-Redondo C[4], Vallejo-Mesa D[5,6], Gómez-Castillo C[7], Rivera-Nieto C[3], Contreras-García G[8,9], Guerra-Araujo V, Ospina-Lagos S[11,12], Paredes-Brijaldo Á[13], Hernández-Forero M[14], Becerra-Ortíz P[15], Campo-Ternera C[16,17], Curiel-Acosta J[18]*

[1]Sociedad de Cirujanos y Pediatras Asociados, Barranquilla, [2]Asociación Colombiana de genética Médica y Medicina Genómica (ACMGen), Bogotá, [3]Fundación Cardioinfantil, Bogotá, [4]Universidad del Norte, Barranquilla, [5]Department of Neurology, Medical School, and Alma Mater Hospital, Universidad de Antioquia, Medellín, [6]Neuro Clínica, Medellín, [7]Hospital Alma Mater de Antioquia. Medellín, [8]Department of Basic Sciences, Pediatrics Department – Hospital Universitario de Santander, Bucaramanga, [9]Human Genetics UIS Research Group, Faculty of Health, Universidad Industrial de Santander, Bucaramanga, [10]Asociación Colombiana de Neurología Infantil (ASCONI), Valledupar, [11]Universidad Nacional de Colombia, Bogotá, [12]GenCell Pharma, Bogotá, [13]Hospital San Ignacio, Bogotá, [14]Hospital Regional de Sogamoso, Sogamoso, [15]Sociedad de Medicina Física y Rehabilitación SOMEFYR, Cúcuta, [16]Hospital San Vicente Fundación, Medellín, [17]Hospital Infantil Concejo de Medellín, Medellín, [18]Asociación Colombiana de Neurología Infantil (ASCONI), Santa Marta

416P Effect of ataluren on upper limb function in nmDMD patients from the STRIDE Registry

***Muntoni F**[1], Buccella F[2], Nascimento Osorio A[3], Tulinius M[4], Bernadete Dutra de Resende M[5], Johnson S[6], Werner C[7], Anbu B[6], Liu E[6], Mercuri E[8]*

[1]University College London Great Ormond Street Institute of Child Health, [2]Parent Project APS Italy, [3]Unidad de Patología Neuromuscular, Hospital Sant Joan de Déu, Universidad de Barcelona, [4]Department of Pediatrics, Queen Silvia Children's Hospital, University of Gothenburg, [5]Department of Neurology, Faculty of Medicine, University of São Paulo, [6]PTC Therapeutics Inc., [7]PTC Therapeutics Germany GmbH, [8]Department of Pediatric Neurology

417P Comparison of changes in 6-minute walk distance for Colombian patients with Duchenne muscular dystrophy treated with Ataluren with different rates of decline

Ruiz Ospina E[1,2], *Castellar Leones S*[1,3], *Bobadilla Quesada E*[2], *Bolaños Almeida C*[2], *Ladino Cortes L*[2], *Ruiz Arbelaez C*[2], *Maradei Anaya S*[2], *Parra Dugarte N*[4], *Contreras García G*[5,6], *Ramírez Rodríguez S*[7,8], *Gomez Castillo C*[9], *Ospina Lagos S*[1], *Sierra del Villar G*[4], *Becerra Ortiz P*[10], *Silvera Redondo C*[11], *Sierra Rosales G*[12]
[1]*Universidad Nacional De Colombia,* [2]*Fundación Hospital La Misericordia,* [3]*Hospital Universitario Nacional de Colombia,* [4]*Fundación Hospital Infantil Napoleón Franco Pareja ,* [5]*Hospital Universitario de Santander,* [6]*Universidad Industrial de Santander,* [7]*Universidad Von Humboldt,* [8]*Neuroimágenes S.A.,* [9]*Hospital Alma Máter de Antioquía,* [10]*Somefyr,* [11]*Universidad del Norte,* [12]*Infaneuro*

418P Ambulatory function in Colombian patients with Duchenne muscular dystrophy treated with Ataluren after a baseline 6-minute walk distance <300m

Ruiz Ospina E[1,2], *Castellar Leones S*[1,3], *Vallejo Mesa D*[4,5], *Contreras García G*[6,7], *Acosta Aragón M*[8], *Ospina Lagos S*[1], *Guerra Araújo V*[9], *Becerra Ortíz P*[10], *Silvera Redondo C*[11], *Campo Ternera C*[12,13], *Gomez Castillo C*[5], *Curiel Acosta J*[14], *Ramírez Rodríguez S*[15,16]
[1]*Universidad Nacional De Colombia,* [2]*Fundación Hospital La Misericordia,* [3]*Hospital Universitario Nacional,* [4]*Universidad de Antioquía,* [5]*Hospital Alma Máter de Antioquía,* [6]*Hospital Universitario de Santander,* [7]*Universidad Industrial de Santander,* [8]*Hospital Universitario San José de Popayán,* [9]*Psicokids And Teens,* [10]*Somefyr,* [11]*Universidad del Norte,* [12]*Hospital San Vicente Fundación,* [13]*Hospital Infantil Concejo de Medellín,* [14]*Medical Center, Santa Marta,* [15]*Universidad Von Humboldt,* [16]*Neuroimágenes S.A.*

419P A stapled inhibitory core peptide of myostatin improves dystrophic pathology in DBA/2-mdx mice

Sunada Y[1], *Nishimatsu S*[1], *Fujino M*[1], *Ohsawa Y*[1]
[1]*Kawasaki Medical School*

420P Potential benefits of JMV2894, a growth hormone secretagogue, in Duchenne muscular dystrophy: insights from a preclinical study in the D2-mdx mouse

Mantuano P[1], *Boccanegra B*[1], *Cappellari O*[1], *Mele A*[1], *Marinelli M*[1], *Cristiano E*[1], *Tulimiero L*[1], *Conte E*[1], *Torsello A*[2], *Denoyelle S*[3], *Liantonio A*[1], *De Luca A*[1]
[1]*Department of Pharmacy – Drug Sciences, University of Bari "Aldo Moro",* [2]*School of Medicine and Surgery, University of Milan-BICOCCA,* [3]*Institut des Biomolécules Max Mousseron, UMR 5247 CNRS-Université Montpellier-ENSCM, Faculté de Pharmacie*

421P Early therapeutic benefit of delandistrogene-moxeparvovec-rokl in Duchenne muscular dystrophy

Acsadi G[1], *Stolgitis N*[1], *Ng E*[1]
[1]*Connecticut Children's Hospital*

422P U7snRNA-mediated exon 17 skipping restores dystrophin expression in cells and in a novel mouse model of Duchenne muscular dystrophy

Gushchina L[1], *Dufresne G*[1], *Saylam E*[1], *Bradley A*[1], *Rohan N*[1], *Lowery A*[1], *Suhaiba A*[1], *Lin H*[1], *Wein N*[1], *Flanigan K*[1]
[1]*The Abigail Wexner Research Institute, Nationwide Children's Hospital*

423P Safety and efficacy of delandistrogene moxeparvovec versus placebo in Duchenne muscular dystrophy: phase 3 EMBARK primary results

Mendell J[1,2], *Muntoni F*[3], *McDonald C*[4], *Mercuri E*[5], *Ciafaloni E*[6], *Komaki H*[7], *Leon-Astudillo C*[8], ***Nascimento A***[9], *Proud C*[10], *Schara-Schmidt U*[11], *Veerapandiyan A*[12], *Zaidman C*[13], *Murphy A*[14], *Reid C*[14], *Asher D*[15], *Darton E*[15], *Mason S*[15], *Fontoura P*[16], *Elkins J*[15], *Rodino-Klapac L, on behalf of the EMBARK Study Group*[15]
[1]*Center for Gene Therapy, Nationwide Children's Hospital,* [2]*The Ohio State University,* [3]*The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health and Institute of Neurology, University College London, & Great Ormond Street Hospital Trust,* [4]*UC Davis Health,* [5]*Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS,* [6]*University of Rochester Medical Center,* [7]*Translational Medical Center, National Center of Neurology and Psychiatry,* [8]*Department of Pediatrics, University of Florida,* [9]*Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Déu, CIBERER – ISC III,* [10]*Children's Hospital of the King's Daughters,* [11]*Department of Pediatric Neurology, Center for Neuromuscular Disorders in Children and Adolescents, University Clinic Essen, University of Duisburg-Essen,* [12]*Department of Pediatrics, Division of Neurology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital,* [13]*Department of Neurology, Washington University in St Louis,* [14]*Roche Products Ltd,* [15]*Sarepta Therapeutics, Inc.,* [16]*F. Hoffmann-La Roche Ltd*

424P Micro-dystrophin expression and safety with delandistrogene moxeparvovec gene therapy for DMD in a broad population: phase 1B trial (ENDEAVOR)

Proud C[1], *Zaidman C*[2], *McDonald C*[3], *Day J*[4], *Thrasher P*[5], *Asher D*[5], *Murphy A*[6], *Guridi M*[7], *Ding K*[5], *Reid C*[6], *Lewis S*[5], *Magistrado-Coxen P*[5], *Palatinsky E*[5], *Wandel C*[7], *Potter R*[5], *Rodino-Klapac L*[5], *Mendell J*[8,9]

[1]*Children's Hospital Of The King's Daughters,* [2]*Department of Neurology, Washington University in St Louis,* [3]*UC Davis Health,* [4]*Department of Neurology, Stanford University, Palo Alto, USA,* [5]*Sarepta Therapeutics, Inc.,* [6]*Roche Products Ltd,* [7]*F. Hoffmann-La Roche Ltd,* [8]*Center for Gene Therapy, Nationwide Children's Hospital,* [9]*The Ohio State University,*

425P Five-year outcomes with delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD): a phase 1/2a study

Mendell J[1,2], *Sahenk Z*[1,2], *Lowes L*[1,2], *Reash N*[1], *Iammarino M*[1], *Alfano L*[1], *Signorovitch J*[3], *Jin J*[4], *Gao P*[4], ***Mason S***[4], *Elkins J*[4], *Rodino-Klapac L*[4]

[1]*Center for Gene Therapy, Nationwide Children's Hospital,* [2]*The Ohio State University,* [3]*Analysis Group,* [4]*Sarepta Therapeutics, Inc.*

426P Ankle foot orthosis prescription for Duchenne muscular dystrophy patients: a retrospective study

Prufer De Q. C. Araujo A[1], *Ferreira Rebel M*[1], *Almeida Pereira J*[1], *Mello Brasil L*[1], *Chacon Pereira A*[1], *Horokoski Kovacs A*[1], *Pereira Dias Drumond Fortes C*[1], *Nardes dos Santos F*[1], *de Fatima Landgraaf J*[1], *Stajnbock F*[1]

[1]*Federal University of Rio De Janeiro*

427P An open-label study to collect long-term safety and efficacy data from boys with DMD who have completed prior studies with vamorolone (GUARDIAN Study)

Nip K[1], *de Vera A*[1], *Hasham S*[1], *Charef P*[1], *Wong S*

[1]*Santhera Pharmaceuticals, 2Royal Hospital for Children*

428P Cardiac MRI outcomes in patients with Duchenne muscular dystrophy treated with delandistrogene moxeparvovec: findings from EMBARK Part 1

Walter G[1], *Vandenborne K*[2], *Bourke J*[3], *Soslow J*[4], *Mason S*[5], *Palatinsky E*[5], *Wandel C*[6], *Ding K*[5], *Reid C*[7], *Murphy A*[7], *Manfrini M*[6], *Richardson J*[5], *Elkins J*[5]

[1]*Department of Physiology and Aging, University of Florida,* [2]*Department of Physical Therapy, University of Florida,* [3]*Department of Cardiology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust,* [4]*Department of Pediatrics, Division of Pediatric Cardiology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center,* [5]*Sarepta Therapeutics, Inc.,* [6]*F. Hoffmann-La Roche Ltd,* [7]*Roche Products Ltd*

429P Givinostat in Duchenne muscular dystrophy: natural history comparison applying propensity score matching

Gomez Andres D[1], *Sansone V*[2], *Phan H*[3], *Willis T*[4], *Guglieri M*[5], *Scoto M*[6], *Vandenborne K*[7], *Cazzaniga S*[8], *Coceani N*[8], *Bettica P*[8], *McDonald C*[9]

[1]*Hospital Universitario Vall De Hebron,* [2]*ASST Grande Ospedale Metropolitano Milan,* [3]*MD Rare Disease Research, LLC ,* [4]*The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust,* [5]*The John Walton Muscular Dystrophy Research Centre Freeman Hospital,* [6]*UCL Great Ormond Street Institute of Child Health, Dubowitz Neuromuscular Centre and MRC Centre for NMD ,* [7]*Imaging DMD group, Department of Physical Therapy, University of Florida,* [8]*Italfarmaco S.p.A., 9Neuromuscular Research Center UC Davis Department of Physical Medicine and Rehabilitation*

430P The damaged lysosome is a therapeutic target for combined therapy in Duchenne muscular dystrophy

Jaber A[1,2], *Bakour R*[1,2], *Palmieri L*[1,2], *Bourg N*[1,2], *Albini S*[1,2], *Richard I*[1,2], *Israeli D*[1,2]

[1]*Genethon,* [2]*Paris-Saclay University, Inserm, Integrare Research Unit UMR_S951*

431P Exon 45 skipping and dystrophin production with ENTR-601-45 in preclinical models of Duchenne muscular dystrophy

Girgenrath M[1], *Estrella N*[1], *Kumar A*[1], *Hicks A*[1], *Brennan C*[1], *Blake S*[1], *Li X*[1], *Pathak A*[1], *Kheirabadi M*[1], *Dougherty P*[1], *Lian W*[1], *Liu N*[1], *Gao N*[1], *Wang D*[1], *Streeter M*[1], *Stadheim A*[1], *Dhanabal M*[1], *Qian Z*[1]

[1]*Entrada Therapeutics*

432P Hydrogen sulfide attenuates skeletal muscle abnormalities in a murine model of Duchenne Muscular Dystrophy

Łoboda A[1], *Myszka M*[1,2], *Mucha O*[1], *Hajok K*[1], *Jakubczak E*[1], *Waśniowska U*[1], *Dulak J*[1]

[1]*Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Krakow,* [2]*2 Doctoral School of Exact and Natural Sciences, Jagiellonian University*

433P Therapeutic potential of ENTR-601-44, an Endosomal Escape Vehicle (EEV™) - Oligonucleotide Conjugate for the treatment of exon 44 skip amenable DMD

Oldham M[1], *Estrella N*[1], *Kumar A*[1], *Hicks A*[1], *Brennan C*[1], *Blake S*[1], *Li X*[1], *Pathak A*[1], *Kheirabadi M*[1], *Dougherty P*[1], *Lian W*[1], *Liu N*[1], *Gao N*[1], *Streeter M*[1], *Stadheim A*[1], *Dhanabal M*[1], *Qian Z*[1], *Girgenrath M*[1]

[1]*Entrada Therapeutics*

434P SAT-3247: an oral small molecule inhibitor targeting AAK1, a critical effector of skeletal muscle regeneration

Mitchell R[1]

[1]*Satellos Bioscience*

435P Correction of a common Duchenne muscular dystrophy mutation by CRISPR/Cas9 gene editing using homology-independent targeted integration

Nicolau S[1,2], *Sarff J*[1], *Vetter T*[1,2], *Stephenson A*[1], *Flanigan K*[1,2]

[1]*Nationwide Children's Hospital,* [2]*Ohio State University*

436P Optimizing the efficacy of antisense oligonucleotides for the treatment of Duchene muscular dystrophy

Aghaeipour A[1,2], *Torres-Masjoan L*[1], *Aguti S*[1], *Zhou H*[3,4], *Muntoni F*[1,2,4]

[1]*Neurodegenerative Diseases, UCL Queen Square Institute of Neurology,* [2]*The Dubowitz Neuromuscular Centre, Molecular Neuroscience Section, Developmental Neurosciences Research and Teaching Department,* [3]*Genetics and Genomic Medicine Research and Teaching Department, UCL Great Ormond Street Institute of Child Health,* [4]*National Institute for Health Research, UCL Great Ormond Street Institute of Child Health*

437VP Cystatin C monitoring in DMD boys with viltolarsen therapy

Gremiakova T[1], *Gremiakova O*[1], *Stepanov A*[2]

[1]*Charity Fund "Gordey",* [2]*Federal State Budget Institution, Central Clinical Hospital with Ambulance*

472P-496P: Genetics of NMD (new genes and NGS, diagnostic etc.)

472P Utilizing next-generation sequencing for pediatric-onset neuromuscular patients unidentified by traditional diagnostic techniques

Kulsirichawaroj P[1,2], *Sanmaneechai O*[1,2]

[1]*Division of Neurology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University,* [2]*Center of Excellence for Neuromuscular Diseases, Faculty of Medicine, Siriraj Hospital, Mahidol University*

473P Using RNAseq analysis in a cohort of undiagnosed congenital myopathy patients

Barraza-Flores P[1], *Genetti C*[1], *Shao W*[1], *French C*[1], *Rockowitz S*[1], *Beggs A*[1]

[1]*Boston Children's Hospital*

474P Identifying biological pathomechanisms of TTN-affected Myopathies using RNA-sequencing data

Natraj Gayathri S[1,2], *Jonson P*[1,2], *Oghabian A*[1], *Lillback V*[1], *Sian V*[1], *Roos A*[3,4], *Hackman P*[1,2], *Udd B*[1,5], *Savarese M*[1,2]

[1]*Folkhälsan Research Center, Helsinki, Finland,* [2]*University of Helsinki , Helsinki, Finland,* [3]*Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen,* [4]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute,* [5]*Tampere University and University Hospital*

475P A novel clinic to resolve variants of uncertain significance in neuromuscular patients

Johnson K[1], *Schneider T*[1], *Babaian N*[1], *Azage M*[1], *McIntosh P*[1]

[1]*University Of Pennsylvania*

476P Functional studies of three novel CASQ1 variants

Laarne M[1,2], *Sarparanta J*[1,2], *Wallgren-Pettersson C*[1,2], *Jokela M*[4], *Udd B*[1,2,3], *Hackman P*[1,2], *Lehtokari V*[1,2], *Pelin K*[1,2,5]

[1]*Folkhälsan Research Center,* [2]*Department of Medical Genetics, Medicum, University of Helsinki,* [3]*Neuromuscular Research Center, Tampere University Hospital and Fimlab Laboratories,* [4]*Division of Clinical Neurosciences, Turku University Hospital and University of Turku,* [5]*Molecular and Integrative Biosciences Research Programme, Faculty of Biological and Environmental Sciences, University of Helsinki*

477P An integrated transcriptomics and genomics approach to detect an X/autosome translocation in a female with Duchenne muscular dystrophy

Segarra-Casas A[1,2], *Yépez V*[3], *Demidov G*[4], *Laurie S*[5], *Esteve A*[5], *Gagneur J*[3,6,7], *Parkhurst Y*[8], *Muni-Lofra R*[1], *Harris E*[1], *Marini-Bettolo C*[1], *Straub V*[1], *Töpf A*[1]

[1]*John Walton Muscular Dystrophy Research Centre,* [2]*Genetics Department, Institut de Recerca Sant Pau ,* [3]*School of Computation, Information and Technology,Technical University of Munich,* [4]*Universitätsklinikum Tübingen– Institut für Medizinische Genetik und angewandte Genomik,* [5]*Centro Nacional de Análisis Genómico (CNAG),* [6]*Institute of Human Genetics, School of Medicine, Technical University of Munich,* [7]*Computational Health Center, Helmholtz Center Munich,* [8]*Muscle Immunoanalysis Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust,*

478P RNA sequencing as a diagnostic tool in a cohort of 54 undiagnosed patients with neuromuscular diseases

Segarra-casas A[1], *Domínguez-González C*[2,3], *Natera-de-Benito D*[4], *Ortez C*[3,4], *Nascimiento A*[3,4], *Hernández-Laín A*[5], *Kapetanovic S*[6], *Rodríguez M*[1], *González-Mera L*[7], *Nedkova V*[7], *Fernández-Torrón R*[8], *López-de Munain A*[8], *Jimenez-Mallebrera C*[3,4], *Rodríguez-Santiago B*[1,3], *Gallardo E*[3,9], *Olivé M*[3,9], *Gallano P*[1,3], *González-Quereda L*[1,3]
[1]*Genetics Department, Institut de Recerca Sant Pau (IR SANT PAU), Hospital de la Santa Creu i Sant Pau,* [2]*Neuromuscular Unit, Neurology Department, imas12 Research Institute, Hospital Universitario 12 de Octubre,* [3]*Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III,* [4]*Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de Déu,* [5]*Neuropathology Unit, imas12 Research Institute, Hospital Universitario 12 de Octubre,* [6]*Neurology Department, Hospital de Basurto,* [7]*Neuromuscular Diseases Unit, Neurology Department, IDIBELL-Hospital Universitari de Bellvitge, Hospitalet de Llobregat,* [8]*Biodonostia Neurosciences Area Group of Neuromuscular Diseases Biodonostia-Osakidetza Basque Health Service,* [9]*Neuromuscular Diseases Unit, Neurology Department, Institut de Recerca Sant Pau (IR SANT PAU), Hospital de la Santa Creu i Sant Pau*

479P Hereditary Sensory & Autonomic Neuropathy Type 2A (HSAN2A): insights into genetic aetiology and variant classification

Shekhar L[1], *Lazarova A*[2], *Berry I*[2], *Majumdar A*[1]
[1]*Bristol Royal Hospital for Children,* [2]*Bristol genetics laboratory*

480P Comparative analysis of CRISPR/Cas9-targeted Nanopore long-read sequencing approaches in repeat expansion disorders

Bonne G[1,2], *Benarroch L*[1], *Boëlle P*[3], *Labrèche K*[3], *Madry H*[2], *Mohand-Oumoussa B*[2], *Eura N*[4], *Nishino I*[4], *Gourdon G*[1], *Tomé S*[1]
[1]*Sorbonne Université, Inserm, Institut de Myologie, Centre de recherche en Myologie,* [2]*Sorbonne Université, Inserm, UMS Pass, Plateforme Post-génomique de la Pitié-Salpêtrière (P3S),* [3]*Sorbonne Université, Inserm UMS Pass, Center for Informatics-Bioanalysis Sorbonne Université (CINBIOS),* [4]*Department of Neuromuscular Research, National Center of Neurology and Psychiatry (NCNP)*

481P Acute respiratory failure revealing DNAJB4 myopathy: a case report

Chitimus D[1], *Adam C*[2], *Cauquil C*[3], *Amthor S*[4], *Heming N*[4], *Annane D*[4], *Keren B*[5], *Nicolas G*[1,6], *Laforêt P*[1,6], *Metay C*[7], *Lefeuvre C*[1]
[1]*Department of Neurology, Raymond Poincaré University Hospital, APHP,* [2]*Department of Pathology, CHU Bicêtre, AP-HP,* [3]*Department of Neurology, CHU Bicetre, APHP,* [4]*Department of Intensive Care, Raymond Poincaré University Hospital, APHP, France,* [5]*Departement of Genetics, APHP, Hopital La Pitie Salpetriere,* [6]*U 1179 INSERM, Université Versailles Saint Quentin en Yvelines,* [7]*Unité Fonctionnelle de Cardiogénétique et Myogénétique moléculaire et cellulaire. Centre de Génétique Moléculaire et Chromosomique et INSERM UMRS 974, Institut de Myologie. Groupe Hospitalier La Pitié-Salpêtrière-Charles Foix, Paris, INSERM UMRS1166, Sorbonne Université*

482P Closing the gap in diagnosis of neuropathies and late-onset neurological disorders – a trans-Australia collaboration

Laing N[1,2], *Kennerson M*[3,4], *Lamont P*[5], *Vucic S*[3], *Davis M*[1,6], *Bryson-Richardson R*[7], *Ravenscroft G*[1,2], *Perez-Siles G*[3,4], *Ghaoui R*[8], *Narayanan R*[3,4], *McCombe P*[9], *Deveson I*[10], *Bryen S*[11], *Grosz B*[3,4], *Johari M*[1,2], *Rick A*[1,2], *Folland C*[1,2], *Scriba C*[1,2], *Parmar J*[1,2], *Ellis M*[3,4]
[1]*University of Western Australia,* [2]*Harry Perkins Institute of Medical Research,* [3]*University of Sydney,* [4]*ANZAC Research Institute,* [5]*Royal Perth Hospital,* [6]*PathWest Laboratory Services,* [7]*Monash University,* [8]*Royal Adelaide Hospital,* [9]*University of Queensland,* [10]*Garvan Institute of Medical Research,* [11]*Centre for Population Genomics*

483P Comprehensive investigation of neuromuscular manifestations in Triple-A syndrome: A combined clinical, molecular genetic and proteomic study

Oeztuerk M[1], *Nelke C*[1], *Hentschel A*[2], *Schänzer A*[3], *Meuth S*[1], *Weis J*[4], *Ruck T*[1], *Roos A*[5,6]
[1]*Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf,* [2]*Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V.,* [3]*Institute of Neuropathology, Justus Liebig University,* [4]*Institute of Neuropathology, RWTH Aachen University Hospital,* [5]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen,* [6]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute*

484P New IRF2BPL variant in a patient with a neuromuscular phenotype

Winkler M[1], *Kornblum C*[1], *Reimann J*[1]
[1]*Clinic Of Neuromuscular Diseases*

485P Familial case of Bethlem myopathy caused by an ALU insertion in COL6A2

Luce L[1], Demidov G[2], Duff J[1], McFarlane A[1], Segarra Casas A[1,3], Laurie S[4,5], de Visser M[6], van der Kooi A[6], Straub V[1], Töpf A[1]

[1]John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, [2]Universitätsklinikum Tübingen– Institut für Medizinische Genetik und angewandte Genomik, [3]Genetics Department, Institut de Recerca Sant Pau (IR SANT PAU), Hospital de la Santa Creu i Sant Pau, Genetics and Microbiology Department, Universitat Autonoma de Barcelona, [4]Centro Nacional de Análisis Genómico, C/Baldiri Reixac 4,08028, [5]Universitat de Barcelona (UB), 6Department of Neurology, Amsterdam University Medical Centers, Location AMC, Neuroscience Institute, University of Amsterdam

486P Spatial analysis of skeletal muscle identifies markers of histopathological tissue alterations in Duchenne mouse models

Heezen L[1], Abdelaal T[2,3,4], van Putten M[1], Aartsma-Rus A[1], Mahfouz A[1,4,5], Spitali P[1]

[1]Department of Human Genetics, Leiden University Medical Center, [2]Department of Radiology, Leiden University Medical Center, [3]Systems and Biomedical Engineering Department, Faculty of Engineering Cairo University, [4]Delft Bioinformatics Lab, Delft University of Technology, [5]Leiden Computational Biology Center, Leiden University Medical Center

487P 2024 update of the national French consensus on gene lists for the diagnosis of muscular diseases using high-throughput sequencing

Gorokhova S[13], Pion E[1], Cossée M[2], Biancalana V[3], Acquaviva Bourdain C[4], Bouchet-Seraphin C[5], Fauré J[6], Leturcq F[7], Menassa R[8], Metay C[9], Michel-Calemard L[8], Nectoux J[7], Petit F[10], Rendu J[6], Richard P[9], Sternberg D[11], Vuillaumier-Barrot S[5], Attarian S[12], Krahn M[13]

[1]FILNEMUS, Laboratoire de Génétique Moléculaire, CHU de Montpellier, [2]Laboratoire de Génétique Moléculaire, CHU de Montpellier / PhyMedExp, Physiologie et Médecine Expérimentale du Sœur et des Muscles, Université de Montpellier, [3]Laboratoire de Diagnostic Génétique CHRU de Strasbourg, [4]Service de Biochimie et Biologie Moléculaire, UM Maladies Héréditaires du Métabolisme, Centre de Biologie et de Pathologie Est, CHU de Lyon, [5]Biochimie et Département de Génétique, CHU Paris Nord-Val de Seine, Hopital Bichat-Claude Bernard, 6Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, [7]Service de Médecine Génomique des Maladies de Système et D'organe, DMU Biophygen, APHP, Université de Paris, Hopital Cochin, [8]Service de Biochimie et Biologie Moléculaire, UM Pathologies Neurologiques, Musulaires et Cardiaques, Centre de Biologie et Pathologie Est, CHU de Lyon HCL, GH Est, [9]UF Cardiogénétique et Myogénétique Moléculaire et Cellulaire, Centre de Génétique Moléculaire et Chromosomique, Hopitaux Universitaire Pitié-Salpétrière, [10]Laboratoire de Génétique Moléculaire Service de Biochimie et Hormonologie Hopital Antoine Béclère, APHP, [11]Service de Biochimie Métabolique, Hopitaux Universitaires Pitié Salpétrière, APHP, [12]Service de Maladies Neuromusculaires et SLA, Hôpital la Timone, APHM, [13]Marseille Medical Genetics, U1251, INSERM, Aix-Marseille University; Department of Medical Genetics, La Timone Children's Hospital, APHM

488P SEPN1-Related Myopathy with acute respiratory onset in middle age: a clinical and genetic study

Risi B[1], Caria F[1], Damioli S[1], Labella B[2,3], Bertella E[1], Giovanelli G[1], Ferullo L[2,3], Olivieri E[2,3], Poli L[3], Padovani A[1], Filosto M[1,2]

[1]NeMO-Brescia Clinical Center for Neuromuscular Diseases, [2]Department of Clinical and Experimental Sciences, University of Brescia, [3]Unit of Neurology, Spedali Civili Hospital of Brescia

489P PIEZO2-associated distal arthrogryposis: phenotypic spectrum and genotype-phenotype correlations in a multicenter case series

Akinci G[1], Cinar E[1], Gunay C[2], Ardicli D[3], Degerliyurt A[3], Ozyilmaz B[4], Ceylan A[5], Yis U[2], Topaloglu H[6]

[1]UHS, Izmir Faculty of Medicine, Dr Behcet Uz Children's Hospital, Department of Pediatric Neurology, [2]Dokuz Eylul University, School of Medicine, Department of Pediatric Neurology, [3]Bilkent City Hospital, Department of Pediatric Neurology, [4]UHS, Izmir Faculty of Medicine, Department of Medical Genetics, [5]Bilkent City Hospital, Department of Medical Genetics, [6]Yeditepe University, Department of Pediatric Neurology

490P Reclassification of missense variant pathogenicity from a hereditary spastic paraplegia gene panel using ClinGen recommendations for in silico predictor scores

Dube J[1], Kim S[2,3], Lau L[2,3], Higginbotham T[2,3], Marshall C[2,3], Jobling R[1,3]

[1]Division of Clinical and Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, [2]Laboratory Medicine and Pathobiology, University of Toronto, [3]Genome Diagnostics, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children

491P PIEZO2 loss of function syndrome: a highly specific and recognizable phenotype

Bharucha-Goebel D[1,2], *Lee M*[1], *Saade D*[1,3], *Donkervoort S*[1], *Yun P*[1], *Mohassel P*[1,4], *Neuhaus S*[1,5], *Ogata T*[1,6], *Averion G*[1], *Mendoza C*[1], *Alter K*[7], *Matsubara J*[7], *Stanley C*[7], *Zampieri C*[7], *Lehky T*[8], *Nickolls A*[9,10], *Chesler A*[10,11], *Foley A*[1], *Bonnemann C*[1], *and the PIEZO2 Study Team*[1]

[1]*National Institutes of Health, Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke,* [2]*Children's National Hospital, Department of Neurology,* [3]*University of Iowa Carver College of Medicine, Department of Neurology,* [4]*Johns Hopkins University School of Medicine, Department of Neurology and Neurosurgery,* [5]*Prevail Therapeutics,* [6]*NuVasive,* [7]*National Institutes of Health, Neurorehabilitation and Biomechanics Research Section,* [8]*National Institutes of Health, EMG Section, National Institute of Neurological Disorders and Stroke,* [9]*National Institutes of Health, National Center for Advancing Translational Sciences,* [10]*National Institutes of Health, National Center for Complementary and Integrative Health,* [11]*National Institutes of Health, National Institute of Neurological Disorders and Stroke*

492P Mass spectrometry as a technique for robust quantification of titin and other large muscle disease-associated proteins

Smolnikov A[1], *Padoani D*[1], *Jurczyluk J*[1], *Su Z*[1], *Hamey J*[1], *Wilkins M*[1], *Yuen M*[1,2,3,4], *Oates E*[1,5]

[1]*School of Biotechnology and Biomolecular Sciences, Faculty of Science, University Of New South Wales,* [2]*Kids Neuroscience Centre, Kids Research Institute, The Children's Hospital at Westmead,* [3]*Functional Neuromics, Children's Medical Research Institute, The University of Sydney,* [4]*Faculty of Medicine and Health, The University of Sydney,* [5]*Sydney Children's Hospital Network*

493P Gene prioritization for enhancing molecular diagnosis in rare muscle diseases of singletons

Lillback V[1], *Bergant G*[2], *Di Feo M*[1], *Bozović I*[2], *Torella A*[3], *Johari M*[1,4], *Maver A*[2], *Pelin K*[1], *Santorelli F*[5], *Nigro V*[3], *Hackman P*[1], *Peterlin B*[2], *Udd B*[1], *Savarese M*[1]

[1]*Folkhälsan Research Center,* [2]*Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana,* [3]*Università degli studi della Campania "Luigi Vanvitelli",* [4]*Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia,* [5]*Molecular Medicine and Neurogenetics, IRCCS Fondazione Stella Maris*

494P Evaluation of transcriptome forward computational strategies to improve molecular diagnosis in rare pediatric neuromuscular disease

Silverstein S[1,2,3], *Ganapathy K*[4], *Donkervoort S*[1], *Moy J*[5], *Uapinyoying B*[1,6], *Gorokhova S*[7,8], *Ganesh V*[9], *Weisburd B*[9], *Orbach R*[1], *Foley A*[1], *Mohammadi P*[4,10,11,12], *Adams D*[2], *Bonnemann C*[1]

[1]*Neuromuscular and Neurogenetics Disorders of Childhood Section, NINDS, NIH,* [2]*Undiagnosed Diseases Program, NIH,* [3]*Rutgers New Jersey Medical School,* [4]*Department of Integrative Structural and Computational Biology, Scripps Research Institute,* [5]*Graduate College of Computing and Data Science, Boston University,* [6]*Center for Genetic Medicine Research, Children's Research Institute, Children's National Hospital,* [7]*Aix Marseille Univ, INSERM, MMG,* [8]*Department of Medical Genetics, Timone Children's Hospital,* [9]*The Broad Institute of MIT and Harvard,* [10]*Center for Immunity and Immunotherapies, Seattle Children's Research Institute,* [11]*Department of Pediatrics, University of Washington School of Medicine,* [12]*Department of Genome Sciences, University of Washington*

495P Genetic mosaicism, an underestimated event in genetically unsolved neuromuscular patients: study of two families

Estévez-Arias B[1,2], *Segarra-Casas A*[3], *Ortez C*[1,4,5], *Matalonga L*[6], *Carrera-García L*[1,4], *Expósito-Escudero J*[1,4], *Jou C*[4,5,7], *Codina A*[4,7], *Jiménez-Mallebrera C*[4,5,8], *Martorell L*[5,9], *Lochmüller H*[6,10,11], *Töpf A*[12], *Beltran S*[6,8], *Hoenicka J*[2,6], *Palau F*[2,6,9,13,14], *Martí I*[15], *Gallano P*[3,5], *Nascimento A*[1,4,5], *Natera-de Benito D*[1,4], *González-Quereda L*[3,5]

[1]*Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de Déu,* [2]*Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de Déu,* [3]*Genetics Department, Institut de Recerca Sant Pau (IR SANT PAU), Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona,* [4]*Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de Déu,* [5]*Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII,* [6]*Centro Nacional Análisis Genómico (CNAG),* [7]*Department of Pathology, Hospital Sant Joan de Déu,* [8]*Department of Genetics, Microbiology and Statistics, University of Barcelona,* [9]*Department of Genetic and Molecular Medicine - IPER, Hospital Sant Joan de Déu and Institut de Recerca Sant Joan de Déu,* [10]*Childrens Hospital of Eastern Ontario Research Institute,* [11]*Division of Neurology, Department of Medicine, The Ottawa Hospital,* [12]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [13]*ERN ITHACA,* [14]*Division of Pediatrics, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB),* [15]*Pediatric Department, Donostia University Hospital, Biodonostia Health Research Institute, University of the Basque Country*

496P Recessive missense variants in DARS2 gene as novel cause of axonal Charcot-Marie-Tooth disease

Estévez-arias B[1,2], *Bonello Palot N*[3,4], *Carrera-García L*[1,5], *Ortez C*[1,5,6], *Expósito-Escudero J*[1,5], *Yubero D*[6,7], *Muchart J*[8], *Delmont E*[9], *Nascimento A*[1,5,6], *Hoenicka J*[2,6], *Palau F*[2,6,7,10,11], *Natera-de Benito D*[1,5]

[1]*Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de Déu,* [2]*Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de Déu,* [3]*Marseille Medical Genetics, Aix-Marseille University–Inserm UMR 1251,* [4]*Genetic Department, Timone Hospital, APHM,* [5]*Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de Déu,* [6]*Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII,* [7]*Department of Genetic and Molecular Medicine - IPER, Hospital Sant Joan de Déu and Institut de Recerca Sant Joan de Déu,* [8]*Department of Radiology, Hospital Sant Joan de Déu,* [9]*Reference Center for Neuromuscular Disorders and ALS, APHM, CHU La Timone, Filnemus, ERN Neuro-NMD,* [10]*ERN ITHACA, Barcelona, Spain, 11Division of Pediatrics, Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB)*

579P-595P, 596VP-597VP: EDMD, OPDM, autophagic, extramuscular

579P Myopathies associated with the FHL1 gene: a case series

Ferreira W[1], *Massaro C*[1], *Oliveira H*[1], *Badia B*[1], *Souza P*[1], *Serrano P*[1], *Farias I*[1], *Bezerra M*[1], *Pinto W*[1], *Faria Nunes K*[1], *Oliveira A*[1]

[1]*Universidade Federal de São Paulo - UNIFESP-EPM*

580P SYNE-1 and SYNE-2 mutations: expanding the phenotype and genotype spectrum of Nesprin myopathy

Cheli M[1], *Marchetto G*[1], *Gibertini S*[2], *Bruno C*[3], *Filosto M*[4], *Lattanzi G*[5], *Fiorillo C*[6], *Grandis M*[7], *Malandrini A*[8], *Maioli M*[9], *Mandich P*[10], *Massa R*[11], *Matà S*[12], *Melani F*[13], *Maggi L*[2], *Rubegni A*[14], *Santorelli F*[14], *Tonin P*[1], *Cassandrini D*[14], *Vattemi G*[1]

[1]*Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona,* [2]*Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta,* [3]*Translational and Experimental Myology Centre, Istituto Giannina Gaslini,* [4]*Department of Clinical and Experimental Sciences, NeMO-Brescia Clinical Center for Neuromuscular Diseases,* [5]*IRCCS Istituto Ortopedico Rizzoli,* [6]*Paediatric Neurology and Neuromuscular Disorders Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Istituto Giannina Gaslini,* [7]*IRCCS-Ospedale Policlinico San Martino,* [8]*Department of Medicine, Surgery and Neurosciences,* [9]*ASL8, Centro Sclerosi Multipla,* [10]*IRCCS Ospedale Policlinico San Martino-UOC Genetica Medica,* [11]*Department of Systems Medicine, Centre of Neuromuscular Disorders,* [12]*Careggi University Hospital, Neurology Unit,* [13]*Neurology Unit and Neurogenetics Laboratories,Meyer Children Hospital,* [14]*IRCCS Fondazione Stella Maris*

581P Toxic autophagic vacuolar myopathies and the role of human leukocyte antigen class I molecules and membrane attack complex in its pathogenesis

Labella B[1,2], *Lacene E*[1], *Chanut A*[1], *Leonard-Louis S*[3], *Benveniste O*[3], *Lefeuvre C*[4], *Lafôret P*[4], *Evangelista T*[1,3]

[1]*Association Institut De Myologie,* [2]*University of Brescia,* [3]*APHP- Hôpital Pitié-Salpêtrière,* [4]*Hôpital Raymond-Poincaré*

582P Brain abnormalities in Spinal Muscular Atrophy type 1 with neurodevelopmental disorders

Holanda Mendonca R[1], *Diógenes Alencar Sindeaux R*[1], *Gontijo Camelo C*[1], *Barbante Casella E*[1], *Faria Silva Chillon K*[1], *Jose da Rocha A*[2], *Zanoteli E*[1]

1Hospital das Clinicas FMUSP, 2Dasa Medicina Diagnostica

583P Recurrent pneumothoraces in chronically ventilated adult neuromuscular patients attending the National Hospital for Neurology and Neurosurgery in London

Desikan M[1], *Sir B*[1], *Astin R*[1], *Quinlivan R*[1]

[1]*National Hospital for Neurology and Neurosurgery*

584P Nuclear envelope and splicing alterations in selected muscular dystrophies

Meinke P[1], *Todorow V*[1], *Hintze S*[1], *Schoser B*[1]

[1]*Friedrich-Baur-Institute, LMU*

585P Collagen XIII as the neuromuscular junction organizer

Prasannan A[1], *Norman O*[1], *Heikkinen A*[1], *Pihlajaniemi T*[1]

[1]*Faculty of Biochemistry and Molecular Medicine, University of Oulu*

586P Visualization of degenerative processes of the myofibers on muscle pathology in OPDM based on single nucleus RNA-seq data

Yamanaka A[1,2], *Eura N*[1,2], *Hayashi S*[1], *Sugie K*[2], *Noguchi S*[1], *Nishino I*[1]

[1]*Department of Neuromuscular Research, National Center of Neurology and Psychiatry,* [2]*Department of Neurology, Nara Medical University*

587P White matter lesions and genetic muscular diseases: an overview

*Jaubert P[1], Mario G[2], Stojkovic T[1], **Masingue M**[1]*

[1]Service de Neuromyologie, Centre de Référence Neuromusculaire, APHP, [2]Sorbonne Université, Inserm, Centre de Recherche en Myologie

588P Phenotype variability and natural history of X-linked Myopathy with excessive autophagy running head: natural history of XMEA

Fernández-Eulate G[1], *Alfieri G[2], Spinazzi M[3], Ackermann-Bonan I[4], Duval F[5], Solé G[5], Caillon F[6], Mercier S[7], Pereon Y[8], Magot A[8], Pegat A[9], Salort-Campana E[10], Gorokhova S[11], Krahn M[11], Biancalana V[12], Evangelista T[1], Behin A[1], Metay C[13], Stojkovic T[1]*

[1]Nord/Est/Ile-de-France Neuromuscular Diseases Reference Center, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP, [2]Azienda Ospedaliera Universitaria Sant'Andrea, [3]Neuromuscular Diseases Reference Center, Neurology Department, [4]Nuclear Magnetic Resonance Laboratory, Institut de Myologie, [5]Neuromusuclar Diseases Reference Center "AOC", Nerve-Muscle Unit, Pellegrin Hospital, CHU Bordeaux, [6]Radiology Department, CHU de Nantes, [7]Medical Genetics Department, Neuromuscular Diseases Reference Center "AOC", [8]Neuromuscular Diseases Reference Center "AOC", Laboratoire d'Explorations Fonctionnelles, CHU de Nantes, FILNEMUS, Euro-NMD, [9]Electroneuromyography and Neuromuscular Diseases Unit, PACA-Réunion-Rhône Alpes Neuromusuclar Diseases Reference Center, Pierre Wertheimer Hospital, Hospices Civils de Lyon, [10]Neuromuscular Diseases and ALS Reference Center, FILNEMUS, CHU La Timone, APHM, [11]Medical Genetics Department, CHU La Timone Enfants, APHM, Aix-Marseille University, Inserm, U1251-MMG, 12Diagnostic genetics laboratory, CRU Strasbourg, Strasbourg University, [13]Cardiomyogenetics and Molecular and Cellular Myogenetics Unit, Institut de Myologie, Pitié-Salpêtrière Hospital, APHP

589P Nanopore CRISPR/Cas9-targeted sequencing reveals genetic characteristics and a possible haplotype in oculopharyngodistal myopathy

Eura N[1,2], *Noguchi S[2], Yamanaka A[1,2], Sonehara K[3], Hayashi S[2], Okada Y[3], Sugie K[1], Nishino I[2]*

[1]Department of Neurology, Nara Medical University, [2]Department of Neuromuscular Research, National Center of Neurology and Psychiatry, [3]Department of Genome Informatics, Graduate School of Medicine, The University of Tokyo

590P Genetic heterogeneity in PLIN4 gene: characterization of a new pathogenic expansion causing an autophagic vacuolar myopathy

Carnazzi A[1,2], *Iannibelli E[2], Gibertini S[2], Nicolini De Gaetano L[2], Riolo G[2], Salerno F[2], Čopič A[3], Maggi L[2], Ruggieri A[2]*

[1]Università degli Studi di Milano Statale, [2]Fondazione IRCCS Istituto Neurologico Carlo Besta, [3]Centre de Recherche en Biologie Cellulaire de Montpellier

591P DNA damage in LMNA-related congenital muscular dystrophy

Leconte M[1], *Guesmia Z[1], Bonne G[1], Bertrand A[1]*

[1]Centre De Recherche En Myologie, Sorbonne Université, Inserm

592P A knocked-in mouse model of GNE myopathy maintained physical function up to 70 weeks of age with supplementation of 6'-sialyl lactose

Shin J[1,3], *Choi J[1,2], Seo K[1], Kim H[1], Kim L[2], Park Y[3], Kim D[1,3]*

[1]Pusan National University Yangsan Hospital, [2]NeuraGene, 3Pusan National University

593VP Emerging role of muscle and fibrosis-related microRNAs as biomarkers and therapeutic targets in Emery-Dreifuss muscular dystrophies

Bonanno S[1], *Malacarne C[1], Tarasco M[1,2], Farinazzo G[1], Mattioli E[3,4], Schena E[3,4], Saraceno F[5], Fiorillo C[6], Andreetta F[1], Schirmer E[7], Maggi L[1], Marcuzzo S[1,8], Cavalcante P[1], Lattanzi G[3,4]*

[1]Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, [2]Ph.D. program in Neuroscience, University of Milano-Bicocca, [3]CNR Institute of Molecular Genetics "L.L. Cavalli-Sforza" Unit of Bologna, [4]IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, [5]Biotecnologie genomiche, molecolari e industriali, University of Parma, [6]Neurologia Pediatrica e Malattie Muscolari, Istituto G. Gaslini, [7]Institute of Cell Biology, University of Edinburgh, [8]Brains Lab, Joint Research Platform, Fondazione IRCCS Istituto Neurologico Carlo Besta di Milano,

594P *FUS/TLS* as a potential regulator of *PABPN1* in skeletal muscle?

Mouigni H[1,2,3], *Altin N[1,2,3], Ohana J[1,2,3], Kondili M[1,2,3], Dhiab J[1,2,3], Muraine L[1,2,3], Lemaitre M[1,2,3], Meunier P[1,2,3], Butler-Browne G[1,2,3], Mouly V[1,2,3], Bigot A[1,2,3], Negroni E[1,2,3], Trollet C[1,2,3]*

[1]Centre Of Research In Myology, [2]Sorbonne Université, [3]INSERM,

595P ACTA1-related cardiomyopathy: emerging genotypic and phenotypic patterns among patients with ACTA1-related myopathy with cardiac involvement

Mcanally M[1], *Potticary A*[1], *Hayes L*[2], *Clayton J*[3], *Haliloğlu G*[4], *Donkervoort S*[1], *Yang M*[5], *Gibbons M*[6], *Gross B*[7], *Foley A*[1], *Guglieri M*[8], *Lee T*[9], *Munot P*[10], *Sarkozy A*[10], *Muntoni F*[10,11], *Straub V*[8], *Laing N*[3,12], *Beggs A*[13], *Bönnemann C*[1], *for the ACTA1-Cardiomyopathy Study Group*[14,15,16,17,18,19,20,21,22]

[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, NIH,* [2]*Department of Neurology, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School,* [3]*Centre for Medical Research University of Western Australia, Harry Perkins Institute of Medical Research, QEII Medical Centre,* [4]*Division of Pediatric Neurology, Department of Pediatrics, Hacettepe University Faculty of Medicine,* [5]*Department of Pediatrics and Neurology, University of Colorado School of Medicine, Children's Hospital Colorado,* [6]*Department of Pediatrics-Clinical Genetics and Metabolism, University of Colorado School of Medicine, Children's Hospital Colorado,* [7]*Division of Neurology, Children's Hospital of Philadelphia,* [8]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trusts,* [9]*Department of Pediatrics, Columbia University Medical Center,* [10]*Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children, NHS Trust,* [11]*NIHR Great Ormond Street Hospital Biomedical Research Centre,* [12]*Neurogenetics Unit, Department of Diagnostic Genomics, PathWest Laboratory Medicine, QEII Medical Centre,* [13]*Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School,* [14]*Division of Human Genetics, Children's Hospital of Philadelphia,* [15]*Department of Neurology, Central Adelaide Local Health Network/Royal Adelaide Hospital,* [16]*Adelaide Medical School, The University of Adelaide,* [17]*Department of Genetics & Molecular Pathology, SA Pathology,* [18]*Department of Paediatric Neurology, Second Faculty of Medicine Charles University and University Hospital Motol,* [19]*Department of Neurology, University of Pennsylvania,* [20]*Division of Internal Medicine, Massachusetts General Hospital,* [21]*Division of Pediatric Neurology, Oregon Health and Science University,* [22]*Department of Pediatrics and Cardiology, University of Colorado School of Medicine, Children's Hospital Colorado*

596VP Elevated VCP ATPase activity correlates with disease onset in multisystem proteinopathy-1

Robinson S[1], *Findlay A*[1], *Schiava M*[2], *Daw J*[1], *Diaz-Manera J*[2], *Chou T*[3]

[1]*Department of Neurology, Washington University School of Medicine,* [2]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trusts,* [3]*Division of Biology and Biological Engineering, California Institute of Technology*

597VP Vacuolar myopathy with permanent weakness: case report with imaging, muscle biopsy, and molecular features

Cotta A[1], *Carvalho E*[1], *da-Cunha-Júnior A*[1], *da Silveira E*[2], *Costa-e-Silva C*[2], *Nunes-Neves S*[1], *Valicek J*[1], *Vargas A*[1]

[1]*The Sarah Network of Rehabilitation Hospitals,* [2]*The Sarah Network of Rehabilitation Hospitals*

619P-642P, 643VP: FSHD

619P Normal and borderline-sized D4Z4 alleles in FSHD1-mimics: a multicentric Italian review of cases

Gadaleta G[1], *Vercelli L*[1], *Urbano G*[1], *Rolle E*[1], *Torri F*[2], *Pugliese A*[3], *Maggi L*[4], *Tupler R*[5], *Filosto M*[6], *Rodolico C*[3], *Ruggiero L*[7], *Ricci G*[2], *Siciliano G*[2], *Mongini T*[1]

[1]*Department of Neuroscience "Rita Levi Montalcini", Neuromuscular Unit, University of Turin,* [2]*Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa,* [3]*Department of Clinical and Experimental Medicine, University of Messina,* [4]*Neurology IV-Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta",* [5]*Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia,* [6]*Department of Clinical and Experimental Sciences, University of Brescia; Unit of Neurology, ASST Spedali Civili; NeMO-Brescia Clinical Center for Neuromuscular Diseases,* [7]*Department of Neurosciences and Reproductive and Odontostomatological Sciences, University of Naples "Federico II"*

620P Novel outcome measures to quantify longitudinal changes in motor function in FSHD

Hayward L[1], *Andrade E*[1], *Ridout B*[2], *Penka J*[2], *Stauffer J*[2], *Tulchin-Francis K*[3], *Lowes L*[3], *King O*[1], *Watts G*[1]

[1]*Univ of Massachusetts Chan Medical School,* [2]*LittleSeed WSV Technology LLC,* [3]*Nationwide Children's Hospital*

621P The rarest subtype of a rare disease: Infantile Facio-Scapulo-Humeral Dystrophy

Yunisova G[1], *Arduç Akçay A*[2], *Eraslan S*[3], *Avci Ş*[3], *Eren İ*[4], *Özdağ Acarli A*[5], *Kayserili H*[3], *Oflazer P*[5]

[1]*Koc University Hospital, Muscle Disease Center,* [2]*Koç University Hospital, Department of Pediatrics, Pediatric Neurology,* [3]*Koç University Hospital, Genetic Diseases Diagnosis and Evaluation Center,* [4]*Koç University Hospital, Department of Orthopedics and Traumatology,* [5]*Koç University, Koç University Hospital, Department of Neurology, Muscle Diseases Center*

622P An unusual case of double trouble of Facioscapulohumeral dystrophy (FSHD) and coexisting congenital myopathy uncovered by whole genome sequencing

Kulshrestha R[1], *Emery N*[1], *Strachan K*[1], *Willis T*[1,2], *Sewry C*[1], *Morley-Davies A*[3]

[1]*Robert Jones and Agnes Hunt Hospital, Oswestry, UK,* [2]*University of Chester Medical School, Chester, UK,* [3]*University Hospital of North Midlands, Stoke-on- Trent, UK*

623P Muscular Dystrophy in the Japanese nationwide registry of muscular dystrophy (Remudy)

Takizawa H[1], *Yoshioka W*[2], *Mori-Yoshimura M*[1], *Saito Y*[2], *Nishino I*[2], *Nakamura H*[3], *Matsumura T*[4]

[1]*Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry,* [2]*Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry,* [3]*Department of Clinical Research Support, National Center Hospital, National Center of Neurology and Psychiatry,* [4]*Department of Neurology, NHO Osaka Toneyama Medical Center*

624P A new double-trouble phenotype: fascioscapulohumeral muscular dystrophy and familial amyotrophic lateral sclerosis

Alonso-pérez J[1], *León-Hernández J*[1], *Henao-Ramírez M*[1], *Méndez-Hernández L*[2], *Sánchez R*[2], *Martínez-Bugallo F*[3], *Prieto-Morín C*[3]

[1]*Neuromuscular Disease Unit, Neurology Department, Hospital Universitario Nuestra Señora de Candelaria, Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC),* [2]*Neurophysiology Department, Hospital Universitario Nuestra Señora de Candelaria,* [3]*Genetic Department, Hospital Universitario Nuestra Señora de Candelaria*

625P From phenotype to genotype: diagnosis pitfalls in atypical FSHD cases

Torri F[1], *Strafella C*[2], *Vercelli L*[3], *Gadaleta G*[3], *Risi B*[4], *Colantoni L*[2], *Giardina E*[2], *Filosto M*[4], *Mongini T*[3], *Siciliano G*[1], *Ricci G*[1]

[1]*Department of Clinical and Experimental Medicine, University of Pisa,* [2]*Genomic Medicine Laboratory-UILDM, Santa Lucia Foundation IRCCS,* [3]*Neuromuscular Unit, Department of Neurosciences Rita Levi Montalcini, University of Turin,* [4]*Neuromuscular Omnicenter, NeMO, Fondazione Serena Onlus*

626P Disability questionnaire of FSHD1 correlates with the in-person examination

Lee J[1], *Shin J*[2], *Shin J*[3]

[1]*Kyungpook National University Hospital,* [2]*Pusan National University Yangsan Hospital, Yangsan,* [3]*Hallym medical center, Dongtan Sacred Heart Hospital*

627P The FORCE(TM) platform achieves robust and durable DUX4 suppression and improves muscle function in Facioscapulohumeral muscular dystrophy mouse model

Picariello T[1], *Natoli T*[1], *Yoder N*[1], *Yao M*[1], *Valdivia B*[1], *Tahaei E*[1], *Johnson J*[1], *Qiu Q*[1], *More P*[1], *Schlaefke L*[1], *Yang S*[1], *Basiri B*[1], *Weeden T*[1], *Beskrovnaya O*[1], *Zanotti S*[1]

[1]*Dyne Therapeutics*

628P Development of a CRISPR/CasX 4q telomeric region ablation strategy for FSHD1 using an isogenic hiPSC line and a FSHD1 fibroblast cell line

Lama C[1], *de Graaf N*[1,2], *Bou Akar R*[1], *Danaus P*[3], *Suel-Petat L*[4], *Nectoux J*[3], *Authier F*[1,5], *Relaix F*[1], *Richard I*[4], *Malfatti E*[1,5]

[1]*Université Paris Est Créteil, INSERM, IMRB - Hôpital Henri-Mondor,* [2]*The Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center,* [3]*Assistance Publique - Hôpitaux de Paris, APHP, Centre Universitaire Paris, Hôpital Cochin, Laboratoire de Génétique et Biologie Moléculaires,* [4]*Généthon, INSERM, Unité de recherche Integrare, UMR_S951 - Université Paris-Saclay, Université d'Évry,* [5]*Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital*

629P Co-producing UK care quality standards in Facioscapulohumeral muscular dystrophy (FSHD) in partnership with people with FSHD, carers and healthcare professionals: a qualitative focus group study

Leone E[1], *Pandyan A*[2], *Rogers A*[1], *Kulshrestha R*[3], *Hill J*[1], *Philp F*[4]

[1]*Keele University,* [2]*Bournemouth University,* [3]*The Robert Jones and Agnes Hunt Orthopaedic Hospital, Gobowen,* [4]*University of Liverpool*

630P Genetic diversity and clinical implications of Facioscapulohumeral muscular dystrophy in the Indian population

Lemmers R[1], *Venugopalan Y V*[2], *van der Vliet P*[1], *Reyaz A*[2], *Mishra R*[2], *Ahmad T*[2], *Kretkiewicz M*[1], *Macken W*[3], *Efthymiou S*[3], *Bhatia R*[2], *Dominik N*[3], *Houlden H*[3], *Morrow J*[3], *Wilson L*[3], *Hanna M*[3], *Bugiardini E*[3], *van der Maarel S*[1], *Padma Srivastava M*[2]

[1]*Leiden University Medical Centre,* [2]*All India Institute of Medical Sciences,* [3]*University College London*

631P Respiratory function and trajectories in Facioscapulohumeral muscular dystrophy (FSHD): a clinical audit

Robinson E[1], *Lees E*[1], *Moat D*[1], *Michell-Sodhi J*[1], *Richardson M*[1], *Wong K*[1], *Grover E*[1], *Schiava M*[1], *Bolano C*[1], *Salman D*[1], *Guglieri M*[1], *Elseed M*[1], *McCallum M*[1], *Diaz-Manera J*[1], *James M*[1], *Straub V*[1], *Marini Bettolo C*[1], *Pace F*[1], *Muni-Lofra R*[1], *Tasca G*[1]

[1]*John Walton Muscular Dystrophy Research Centre*

632P A human skeletal muscle-on-chip model for Facioscapulohumeral muscular dystrophy: improving maturation and complexity

Augustinus R[1], *Franken M*[1], *van der Maarel S*[1], *Pijnappel P*[2], *de Greef J*[1]

[1]*Leiden University Medical Center,* [2]*Erasmus Medical Center*

633P Penetrance of 5RU founder allele and correlation of D4Z4 methylation levels to severity in large kindred with FSHD

Butterfield R[1], *Dunn D*[2], *Duval B*[2], *Moldt S*[1], *Weiss R*[2]

[1]*Unviersity of Utah, Department of Pediatrics,* [2]*Unviersity of Utah, Department of Human Genetics*

634P Retrospective analysis of muscle biopsy findings in a cohort of patients with Facioscapulohumeral Dystrophy Type 1

Ruggiero L[1], *Pezzella M*[1], *Di Leo R*[1], *Vitale F*[1], *Russo R*[1], *Grasso C*[1], *Iapoce M*[1], *Boemia V*[1], *Tupler R*[2], *Fiorillo C*[3], *Zoppi D*[1]

[1]*Policlin Universita Federico Ii - Clinica 2 Neurologia,* [2]*Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena.,* [3]*Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences, University of Genoa,*

635P Pain impacts quality of life, psychological disorders and exercise in a large international cohort of patients with facioscapulohumeral muscular dystrophy

Knox R[1], *Wang L*[2], *Elsheikh B*[3], *LoRusso S*[4], *Zhao S*[3], *Eichinger K*[5], *Higgs K*[6], *Lewis L*[5], *Walker M*[6], *Sansone V*[7], *Leung D*[8], *Sacconi S*[9], *Mul K*[10], *Shieh P*[11], *Butterfield R*[12], *Johnson N*[13], *Bugiardini E*[14], *McDermott M*[5], *Tawil R*[5], *Statland J*[6]

[1]*Washington University School Of Medicine,* [2]*University of Washington,* [3]*The Ohio State University,* [4]*Kaiser Permanente,* [5]*University of Rochester Medical Center,* [6]*University of Kansas Medical Center,* [7]*The NEMO Clinical Center, University of Milan,* [8]*Kennedy Krieger Institute,* [9]*Nice University,* [10]*Radboud University,* [11]*University of California,* [12]*University of Utah,* [13]*Virginia Commonwealth University,* [14]*University College London*

636P Longitudinal insights into childhood onset Facioscapulohumeral dystrophy: a five-year natural history study

Dijkstra J[1,2], *Boon H*[1,2], *Koekkoek A*[2], *Goselink R*[3], *Pelsma M*[4], *Houwen-van Opstal S*[4], *Van Alfen N*[5], *Van Engelen B*[1], *Voermans N*[1], *Erasmus C*[2]

[1]*Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center,* [2]*Department of Pediatric Neurology, Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital, Radboud University Medical Centre,* [3]*Department of Neurology, Jönköping, Region Jönköping County, and Department of Biomedical and Clinical Sciences, Linköping University,* [4]*Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Amalia Children's Hospital, Radboud University Medical Center,* [5]*Department of Neurology, Clinical Neuromuscular Imaging Group, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center*

637P RelnForce: A bicentric, randomized, double blind, placebo-controlled pilot study to evaluate the efficacy and safety of satralizumab in FSHD1

Pini J[1,2], *Aleman A*[3], *Breiner A*[3], *Cavalli M*[1], *Puma A*[1], *Villa L*[1], *Gaki E*[4], *McIver T*[4], *Okumu S*[5], *Sidiropoulos P*[5], *Lochmüller H*[3], ***Saconni S***[1,2]

[1]*Peripheral Nervous System and Muscle Department, University Côte d'Azur, CHU Nice,* [2]*University Cote d'Azur, Inserm, CNRS, Institute for Research on Cancer and Aging of Nice (IRCAN),* [3]*Ottawa Hospital Research Institute,* [4]*Roche Products Ltd, 5F. Hoffmann-La Roche Ltd*

638P Interleukin-6 as a Biomarker for Disease Activity, Progression and Muscle Composition in Facioscapulohumeral Dystrophy: Insights from Longitudinal Studies

Saconni S[1,2], *PINI J*[1,2], *Martinuzzi E*[3], *Puma A*[1], *Villa L*[1], *Cavali M*[1], *Ezaru A*[1], *Garcia J*[1], *Glaichenhaus N*[3]

[1]*Peripheral Nervous System and Muscle Department, University Côte d'Azur, CHU Nice,* [2]*University Cote d'Azur, Inserm, CNRS, Institute for Research on Cancer and Aging of Nice (IRCAN),* [3]*University Cote d'Azur, CNRS, Inserm, Institute of Molecular and Cellular Pharmacology, Sophia Anitpolis, France*

639P **The other face of Facioscapulohumeral Muscular Dystrophy: exploring facial weakness using muscle ultrasound**

Vincenten S[1], *Van Doorn J*[1], *Teeselink S*[1], *Rasing N*[1], *Padberg G*[1], *Voermans N*[1], *van Engelen B*[1], *van Alfen N*[1], *Mul K*[1]

[1]*Radboudumc, department of Neurology*

640P Efficacy and safety of EPI-321, an investigational single dose Epigenome editing therapy targeting D4Z4 in Facioscapulohumeral Muscular Dystrophy (FSHD)

Boregowda S[1], *Zheng H*[1], *Agrawal V*[1], *Norton A*[1], *Wasala N*[1], *Collin de l'Hortet A*[1]
[1]*EPICRISPR Biotechnologies, Inc.*

641P Modeling cell type specific and sporadic *DUX4* gene expression in FSHD

Sasaki-Honda M[1,2], *Sakurai H*[1], *Rada-Iglesias A*[2]
[1]*CiRA, Kyoto University,* [2]*IBBTEC, University of Cantabria*

642P 4qA D4Z4 methylation test as a valuable complement for differential diagnosis in patients with FSHD-like phenotype

Xia X[1], *Cheng N*[1], *Liu Y*[1], *Zhu W*[1], *Zhao C*[1]
[1]*Huashan Hospital, Fudan University*

643VP Molecular imaging of muscle involvement in Facioscapulohumeral Muscular Dystrophy using multispectral optoacoustic tomography

Monforte M[1], *Bortolani S*[1], *Ravera B*[2], *Marchese D*[2], *Qiu Y*[3], *Burton N*[3], *Torchia E*[2], *De Spirito M*[2], *Ricci E*[2], *Tasca G*[4]
[1]*Fondazione Policlinico Universitario A. Gemelli IRCCS,* [2]*Università Cattolica del Sacro Cuore,* [3]*iThera Medical GmbH,* [4]*John Walton Muscular Dystrophy Research Centre, Newcastle University*

677P-686P, 687P: RNA in NMD: clinical insights, pathomechanisms and treatments

677P The Splice Index as a prognostic biomarker of strength and function in Myotonic Dystrophy type 1

Provenzano M[1,2], *Ikegami K*[1,2], *Bates K*[1,2], *Hartman J*[1,2], *Jones A*[1,2,3], *Butler A*[1,2,3], *Berggren K*[1,2], *Hung M*[4], *Kiefer M*[1,2,5], *Thornton C*[6,7], *Johnson N*[1,2], ***Hale M***[1,2], *on behalf of the Myotonic Dystrophy Clinical Research Network (DMCRN)*
[1]*Department of Neurology, Virginia Commonwealth University,* [2]*Center for Inherited Muscle Research, Virginia Commonwealth University,* [3]*Children's Hospital of Richmond at Virginia Commonwealth University, Pediatric Therapy Services,* [4]*College of Dental Medicine, Roseman University of Health Sciences,* [5]*Department of Physical Therapy, Virginia Commonwealth University,* [6]*Department of Neurology, University of Rochester School of Medicine and Dentistry,* [7]*Center for RNA Biology, University of Rochester School of Medicine and Dentistry*

678P Unraveling calcium dysregulation and autoimmunity in immune mediated Rippling muscle disease

Nath S[1], *Dasgupta A*[2], *Dubey D*[1], *Kokesh E*[1], *Liewluck T*[1], *Beecher G*[3], *Pittock S*[1], *Doles J*[2], *Litchy W*[1], *Milone M*[1]
[1]*Mayo Clinic Department of Neurology,* [2]*Department of Anatomy, Cell Biology, & Physiology, Indiana University,* [3]*Faculty of Medicine & Dentistry - Medicine Dept, University of Alberta*

679P Clinical and molecular characterization of DMD pseudo-3'-terminal exons

Frair E[1], *Nicolau S*[1,2,3], *Meyer* [A1,2,4], *Vetter T*[1,2], *Dunn D*[5], *Gabel L*[1], *Waldrop M*[1,2,3], *Weiss R*[5], *Flanigan K*[1,2,3]
[1]*Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital,* [2]*Department of Pediatrics, The Ohio State University College of Medicine,* [3]*Department of Neurology, The Ohio State University,* [4]*Division of Genetic and Genomic Medicine, Nationwide Children's Hospital, 5Department of Human Genetics, The University of Utah*

680P Developing effective RNA editing approaches to target the nonsense mutation in the key functional region of *DMD*

Lam H[1,2], *Uzwyshyn-Jones K*[1], *Ma S*[1], *Muntoni F*[2], *Meng J*[1,3], *Zhou H*[1,3]
[1]*Genetic and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London,* [2]*The Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health,* [3]*NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London*

681P A novel COL11A1 variant in a child with neuromuscular findings: expanding the genotypic and phenotypic spectrum of COL11A1-related disease

Mcanally M[1], *Potticary A*[1], *Donkervoort S*[1], *Hu Y*[1], *Huryn L*[3], *Pais L*[2], *Harper A*[4], *Foley A*[1], *Bönnemann C*[1]
[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, NIH,* [2]*Program in Medical and Population Genetics, Broad Institute of MIT and Harvard,* [3]*National Eye Institute, NIH,* [4]*Department of Neurology, Division of Child Neurology, Children's Hospital of Richmond at VCU*

continued on next page

682P Differential splicing of *OBSCN* throughout human cardiac and skeletal muscle development

Oghabian A[1,2], *Jonson P*[1,3], *Johari M*[1,12], *Andres D*[4], *Munell F*[5], *Soriano J*[6], *Duran M*[7], *Sinisalo J*[8], *Tolppanen H*[9], *Tolva J*[10], *Hackman P*[1,3], *Savarese M*[1,3], *Udd B*[1,3,4,11]

[1]*Folkhälsan Research Center,* [2]*Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki,* [3]*Department of Medical Genetics, Medicum,* [4]*Department of Neurology, Vaasa Central Hospital,* [5]*Child Neurology Unit. Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute (VHIR),* [6]*Unitat De Malalties Neuromusculars Pediàtriques, Hospital Universitari Vall D'hebron,* [7]*Histology Department, Vall D'hebron University Hospital,* [8]*Maternal Fetal Medicine Unit, Department of Obstetrics, Universitat Autònoma de Barcelona, Hospital Vall D'hebron,* [9]*Helsinki University Central Hospital,* [10]*Transplantation Laboratory, Department of Pathology,* [11]*Neuromuscular Research Center, Department of Neurology, Tampere University and University Hospital,* [12]*Harry Perkins Institute of Medical Research, Centre for Medical Research, University of Western Australia*

683P Phase IIa trial assessing the efficacy and safety of Enpatoran in patients with Dermatomyositis and Polymyositis: NEPTUNIA rationale and study design

Aggarwal R[1], *Roy S*[2], *Thömmes G*[3], *Weinelt D*[3], *Chitkara D*[4], ***Denis D***[5]

[1]*University of Pittsburgh,* [2]*Ares Trading SA, an affiliate of Merck KGaA,* [3]*Merck Healthcare KGaA,* [4]*EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA,* [5]*EMD Serono, Inc., an affiliate of Merck KGaA*

684P Complex duplications containing terminal exon duplications in the DMD gene

Meyer A[1,2], *Nicolau S*[1], *Dunn D*[3], *Gabel L*[1], *Frair E*[1], *Weiss R*[3], *Flanigan K*[1,2]

[1]*Nationwide Children's Hospital,* [2]*The Ohio State University,* [3]*University of Utah*

685VP Reduction of dystrophin-targeting microRNAs increases expression of clinically relevant dystrophin isoforms

Fiorillo A[1,2], *McCormack N*[2], *Calabrese K*[2], *Sun C*[2], *Tully C*[2], *Heier C*[1,2]

[1]*Virginia Commonwealth University,* [2]*Children's National Hospital*

686P Identification and characterization of actionable deep intron 8 *IGHMBP2* hotspot pathogenic variants through motor neuron RNAseq and whole genome

Silverstein S[1,2,3], *Donkervoort S*[1], *Cassini T*[4], *Vetrini F*[5,6], *Conboy E*[5,6], *Comer A*[7], *Treat K*[5,6], *Liaqat K*[5,6], *Mantcheva L*[5,6], *Patankar A*[8], *Bharucha-Goebel D*[1,9], *Foley A*[1], *Chao K*[10], *Neuhaus S*[1], *Grunseich C*[8], *Bonnemann C*[1]

[1]*Neuromuscular and Neurogenetics Disorders of Childhood Section, NINDS, NIH,* [2]*Rutgers New Jersey Medical School,* [3]*Undiagnosed Diseases Program, NIH,* [4]*Vanderbilt University Medical Center,* [5]*Department of Medical and Molecular Genetics, Indiana University School of Medicine,* [6]*Undiagnosed Rare Disease Clinic, Indiana University School of Medicine,* [7]*Department of Neurology, Indiana University School of Medicine,* [8]*Neurogenetics Branch, NINDS, NIH,* [9]*Department of Neurology, Children's National Hospital,* [10]*The Broad Institute of MIT and Harvard*

687P Splicing switching of alternative last exons due to a deletion including canonical polyadenylation site in *COL6A2* gene causes recessive UCMD

Saito Y[1], *El Sherif R*[2,3], *Awaya T*[4], *Hayashi S*[1], *Noguchi S*[1], *Nishino I*[1]

[1]*Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry,* [2]*Myo-Care Neuromuscular Center, Myo-Care National Foundation,* [3]*School of Medicine, New Giza University,* [4]*Department of Anatomy and Developmental Biology, Graduate School of Medicine and Faculty of Medicine, The University of Kyoto*

18:15-18:45	**Short Oral Presentations 4** North Hall **641P, 630P, 638P, 639P, 640P** *Moderator: Nicol Voermans, Radboud University Medical Centre*	**Short Oral Presentations 5** Terrace 2A **586P, 50P, 97P, 96P, 51P** *Moderator: Piera Smeriglio. Institut de Myologie*	**Short Oral Presentations 6** Terrace 2B **496P, 686P, 594P, 595P, 403P** *Moderator: Nigel Laing, Harry Perkins Institute of Medical Research*
19:00-20:00	**Industry Symposium 5** South Hall 1 **Catering provided by the sponsor for this session**, available from 30 minutes prior to the start of the symposium	**Industry Symposium 6** South Hall 2 **Catering provided by the sponsor for this session**, available from 30 minutes prior to the start of the symposium	

Thursday 10th October 2024

07:00-15:00	**Congress desk open**	
07:15-08:15	**NMD Board Meeting** Club E (separate registration required)	
08:15-09:15	**Industry Symposium 7** South Hall 1 **Catering provided by the sponsor for this session**, available from 30 minutes prior to the start of the symposium	**Industry Symposium 8** South Hall 2 **Catering provided by the sponsor for this session**, available from 30 minutes prior to the start of the symposium
09:30-11:00	**Topic 2: NMD Around the World** Congress Hall *Moderators: Hernan Gonorazky, The Hospital for Sick Children, Canada & Rasha El Sherif, Newgiza University, Egypt* **05INV** Advancing neuromuscular disorders in Senegal, West Africa, through collaborative networks and available resources ***Rodriguez Cruz P***[1,2,3], [1]*Centro Nacional de Análisis Genómico (CNAG),* [2]*Neurology Department, CHNU de Fann,* [3]*Université Cheikh Anta Diop de Dakar* **06INV** What about management of neuromuscular diseases in Latin America? ***Monges S***[1] [1]*Hospital de Pediatría J.P. Garrahan* **07INV** Neuromuscular disorders in India: New World meets the Old ***Venugopalan Y V***[1] [1]*All India Institute of Medical Sciences* **08INV** An African perspective on muscle diseases ***Heckmann J***[1] [1]*University of Cape Town*	
11:00-11:30	**Morning refreshments, exhibition and posters** Congress Hall Foyer, Forum Hall and Forum Foyer	
11:00-11:30	**Myology Café - Meet the WMS Myology Developments Across the World Committee** Forum Hall Foyer	
11:30-13:30	**Topic 2: NMD Around the World** Congress Hall *Moderators: Sharon Aharoni, Schneider Childrens' Medical Center, Israel & Jorge Bevilacqua, Hospital Clínico Universidad De Chile & Clinica Dávila, Chile*	
11:30-11:45	**07O** Rare neuromuscular disease specific mega clinics: a proposal to bridge the gap in resource limited settings ***Ramesh Babu R***[1,2], *Krishna G*[1,2], *Satyam P*[1,2], *Rao S*[3], *Maganthi M*[2], *Agnes Mathew A*[1,2] [1]*Synapse Neuro Centre & Child Development Centre, Bangalore Baptist Hospital,* [2]*Bangalore Baptist Hospital,* [3]*Organization of Rare Diseases*	
11:45-12:00	**08O** To manually or mechanically cough: that is the question. Cough augmentation in children with neuromuscular disorders: a feasibility study ***Human A***[5], *Corten L*[3], *Morrow B*[4] [1]*Department of Physiotherapy, School of Health Care Sciences, Sefako Makgatho Health Sciences University,* [2]*Department of Health and Rehabilitation Sciences (Division Physiotherapy),* [3]*School of Sport and Health Sciences (Physiotherapy), University of Brighton,* [4]*Department of Paediatrics and Child Health, University of Cape Town,* [5]*Department of Physiotherapy, School of Health Care Sciences, University of Pretoria*	
12:00-12:15	**09O** The clinical and molecular landscape of genetic neuromuscular disorders in Senegal, West Africa ***Rodriguez Cruz P***[1,2,3], *Diagne R*[2,3], *Diop A*[4], *Diouf A*[5], *Ndong M*[6], *Senghor H*[2], *Dieng S*[6], *Oko C*[2], *Traoré M*[7], *Mbaye K*[8], *Seck L*[2], *Sy M*[2], *Sow A*[2,9], *Diagne N*[2], *Martorell Sampol L*[10], *Nascimiento A*[10], *Beltran S*[1], *Ndiaye R*[3], *Ndiaye M*[2,3], *Diop A*[2,3] [1]*Centro Nacional de Análisis Genómico (CNAG),* [2]*Neurology Department, CHNU de Fann,* [3]*Université Cheikh Anta Diop de Dakar,* [4]*Neurology Department, Centre Hospitalier National de Pikine,* [5]*Centre Talibou Dabo,* [6]*Centre Hospitalier National d'Enfants Albert Royer,* [7]*Centre Hospitalier Roi Baudouin,* [8]*Centre Hospitalier Régional de Ziguinchor,* [9]*Centre Hospitalier National pour Enfants de Diamniadio,* [10]*Hospital San Joan de Deu*	

12:15-12:30	**10O** The neonatal screening of SMA in Ukraine: the 18 months of experience ***Olkhovych N***[6], *Servais L*[2], *Makukh H*[3], *Grechanina O*[4], *Veropotvelyan M*[5], *Samonenko N*[6], *Mytsyk N*[2], *Barvinskaya O*[2], *Kormoz S*[2], *Shklyarskaya T*[6], *Gorovenko N*[7] *[1]Expert Centre of Neonatal Screening, [2]MDUK Oxford and NIHR, University of Oxford, [3]Lviv Regional Centre of Neonatal Screening, [4]Kharkiv Regional Centre of Neonatal Screening, [5]Kryviy Rig Regional Centre of Neonatal Screening, [6]National Children's Specialized Hospital "OHMATDYT" MoH, [7]National University of Health Care named after P.L. Shupika*
12:30-12:45	**11O** Genetic profile of Brazilian patients with LAMA2-related dystrophies ***Camelo C***[1], *Moreno C*[1], *Artilheiro M*[1], *Fonseca A*[1], *Gianetti J*[2], *Barbosa A*[3], *Donis K*[4], *Saute J*[4], *Pessoa A*[5], *VanderLinden H*[6], *Gonçalves A*[7], *Kulikowski L*[1], *Kok F*[1], *Zanoteli E*[1] *[1]University Of Sao Paulo, [2]Universidade Federal de Minas Gerais, [3]Fundação Hospitalar do Estado de Minas Gerais, [4]Hospital de Clínicas de Porto Alegre, [5]Children's Hospital Albert Sabin, [6]Rehabilitation Center Dr. Henrique Santillo, [7]University of Porto*
12:45-13:00	**12O** Clinical, paraclinical features and classification of myositis in Vietnam ***Le S***[1], *Nguyen Le Trung H*[2] *[1]University Medical Center of Hochiminh, [2]University of Medicine and Pharmacy of Hochiminh*
13:00-13:15	**13O** Genomic neuromuscular disorders in Turkey originate from a vast background ***Topaloğlu H***[1] *[1]Yeditepe University, Pediatrics*
13:15-13:30	**14O** Inherited Neuromuscular disorders in India: Outcomes of 1000 probands in the ICGNMD study at AIIMS New Delhi ***Venugopalan Y V***[1], *Macken W*[2,3], *Wilson L*[2], *Rani N*[1], *Reyaz A*[1], *Ahmad T*[1], *Dalal A*[4], *Vandrovcova J*[2], *Dominik N*[2], *Consortium ICGNMD-Consortium*[5], *Tallapaka K*[6], *Lemmers R*[7], *Reilly M*[2], *Hanna M*[2,3], *Bhatia R*[1], *Pitceathly R*[2,3], *Houlden H*[2], *Thangaraj K*[4,6], *Straub V*[8], *Srivastava P*[1] *[1]All India Institute of Medical Sciences, [2]Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, [3]NHS Highly Specialised Service for Rare Mitochondrial Disorders, Queen Square Centre for Neuromuscular Diseases, The National Hospital for Neurology and Neurosurgery, [4]Centre for DNA Fingerprinting and Diagnostics, Hyderabad, [5]https://www.ucl.ac.uk/genomic-medicine-neuromuscular-diseases/global-contributor-list, [6]Centre for Cellular & Molecular Biology, [7]Department of Human Genetics, Leiden University Medical Center (LUMC), [8]John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust*
13:30-14:45	**Lunch, exhibition and posters** Congress Hall Foyer, Forum Hall and Forum Foyer
13:30-14:45	**Career Development Session - Engagement with industry** Zoom and Panorama Rooms, 1st floor (separate registration required and lunch is provided)
15:30-17:30	**Poster viewing / Group activity** (separate registration required)
17:30-20:00	**Group activity networking reception** Kaiserstein Palace (separate registration required)

Friday 11th October 2024

06:45-17:15	**Congress desk open**
07:30-08:30	**Interesting Case Discussions** 📍 South Hall 2 *Moderators: A. Reghan Foley, National Institutes of Health, USA & Hans-Hilmar Goebel, Charité – Universitätsmedizin Berlin, Germany* **Case 1:** HIV-associated inclusion body myositis in a young woman *Jeannine Heckmann, University of Cape Town, South Africa* **Case 2:** A muscle disorder presenting with Resistant Hypercalcaemia *Ashirwad Merve, University College London Hospitals, UK* **Case 3**: TUBA4A associated congenital myopathy with centronuclear findings and protein aggregates *Cristiane Moreno, Universidade de São Paulo, Brazil* **Case 4**: Proximal and facial weakness: Beyond FSHD *Carmen Paradas Lopez, Virgen del Rocío Hospital, Spain* **Case 5**: ADSSL1 -associated myopathy presented with EDMD like phenotype *Hacer Durmus, Istanbul Faculty of Medicine, Turkey*
08:30-08:45	**Comfort break**
08:45-10:15	**Topic 3: RNA in NMD: Clinical Insights, Pathomechanisms and Treatments** 📍 Congress Hall *Moderators: Liubov Gushchina, The Abigail Wexner Research Institute, Nationwide Children's Hospital, USA & Emma Rybalka, Victoria University, Australia*
08:45-09:15	**09INV** An overview of the RNA pathomechanisms in neuromuscular diseases, ***Swanson M***[1] [1]*University of Florida College of Medicine*
09:15-09:45	**10INV** Clinical and diagnostic utility of RNA/transcriptome: An overview of role of RNA in disease gene discovery and diagnostics ***Yoon G***[1] [1]*The Hospital for Sick Children*
09:45-10:00	**15O** Spatial transcriptomics analysis of Becker and Duchenne skeletal muscle to decipher histopathological alterations in dystrophinopathies ***Heezen L***[1], *Mao Q*[1], *van Putten M*[1], *Diaz Manera J*[2], *Kan H*[3], *Niks E*[4], *Aartsma-Rus A*[1], *Nicolau S*[5], *Flanigan K*[5,6,7], *Mahfouz A*[1,8,9], *Spitali P*[1] [1]*Department of Human Genetics, Leiden University Medical Center,* [2]*Faculty of Medical Sciences, Newcastle University,* [3]*Department of Radiology, Leiden University Medical Center,* [4]*Department of Neurology, Leiden University Medical Center,* [5]*Center for Gene Therapy, The Abigail Wexner Research Institute at Nationwide Children's Hospital,* [6]*Department of Pediatrics, The Ohio State University,* [7]*Department of Neurology, The Ohio State University,* [8]*Delft Bioinformatics Lab, Delft University of Technology,* [9]*Leiden Computational Biology Center, Leiden University Medical Center*
10:00-10:15	**16O** Lost in translation: pathogenic translation of GGC repeats in novel and toxic proteins in Oculopharyngodistal myopathy (OPDM) ***Boivin M***[1], *Schmitt L*[1], *Grandgirard E*[1], *Morlet B*[1], *Negroni L*[1], *Goetz-Reiner P*[1], *Lefebvre E*[1], *Maglott A*[1], *Eberling P*[1], *Oulad-Abdelghami M*[1], *Deng J*[2], *Charlet-Berguerand N*[1] [1]*IGBMC,* [2]*Peking University First Hospital*
10:15-10:45	**Morning refreshments, exhibition and posters** 📍 Congress Hall Foyer, Forum Hall and Forum Foyer
10:15-10:45	**Myology Café - Meet the WMS Sustainability Committee** 📍 Forum Hall Foyer
10:45-12:15	**Topic 3: RNA in NMD: Clinical Insights, Pathomechanisms and Treatments** 📍 Congress Hall *Moderators: Gisèle Bonne, Institut de Myologie, France & Silvère Van Der Maarel, Leiden University Medical Center, The Netherlands*
10:45-11:15	**11INV** RNA as biomarkers in neuromuscular diseases, including monitoring progression, in clinical trial design, as outcomes ***Spitali P***[1] [1]*Leiden University Medical Center*
11:15-11:45	**12INV** RNA therapeutics in neuromuscular diseases, including new developments, and challenges ***Arechavala Gomeza V1***[1,2] [1]*Biobizkaia Health Research Institute,* [2]*Ikerbasque, Basque Foundation for Science*

11:45-12:00	**17O** Schwann cell transduction and PMP22 target engagement in non-human primates supports translation of RNAi-based gene therapy for CMT1A ***Wallace L***[1], *Thangaraj M*[1], *Stavrou M*[2], *Price B*[3], *Zender G*[1], *Bayazit M*[1], *Taylor N*[1], *Kleopa K*[2], *Harper S*[1,4] [1]*Nationwide Children's Hospital,* [2]*The Cyprus Institute of Neurology & Genetics,* [3]*Armatus Bio,* [4]*Department of Pediatrics, The Ohio State University College of Medicine*
12:00-12:15	**18O** Breaking ground in CMT1B treatment: AAV9-mediated dual RNAi and gene replacement therapy targeting schwann cells improves myelination and peripheral nerve function in mice ***McCulloch M***[1,2], *Munezero D*[1], *Paripati A*[1], *Zhu J*[1], *Amini Chermahini G*[1], *Chuah R*[1], *Rashnonejad A*[1,2,3] [1]*Nationwide Children's Hospital (Center for Gene Therapy),* [2]*The Ohio State University (Molecular, Cellular, and Developmental Biology Graduate Program),* [3]*The Ohio State University (Department of Pediatrics)*
12:30-13:30	**WMS General Assembly / Poster viewing for non-members** South Hall 2
12:30-14:00	**Lunch, exhibition and posters** Congress Hall Foyer, Forum Hall and Forum Foyer
13:45-14:15	**Sponsor Meeting** South Boardroom 2
14:15-15:15	**Poster Session 3** Forum Hall (refreshments provided)

55P-75P, 76VP-78VP: Distal myopathies, MFM

55P Novel mutations and genotype-phenotype correlation in a multicenter cohort of GNE myopathy in China

Jiao K[1], *Zhang J*[1], *Li Q*[2], *Lv X*[3], *Hong D*[6], *Zhao Z*[4], *Wang Z*[5], *Zhu W*[1]

[1]*Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University, and National Center for Neurological Disorders (NCND),* [2]*Xiangya Hospital, Central South University,* [3]*Department of Neurology and Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital of Shandong University,* [4]*Department of Neuromuscular Disease, Third Hospital of Hebei Medical University,* [5]*The First Affiliated Hospital of Fujian Medical University,* [6]*Dtment of Neurology and Department of Medical Genetics, The First Affiliated Hospital of Nanchang University*

56P Mutational screening of Distal Myopathy gene *ACTN2* reveals an aggregation hot-spot in the actin-binding domain

Ranta-aho J[1,2], *Jonson P*[1,2], *Sarparanta J*[1,2], *Udd B*[1,3], *Savarese M*[1,2]

[1]*Folkhälsan Research Center,* [2]*University of Helsinki,* [3]*Tampere University and Tampere University Hospital*

57P Phenotypic description of 40 patients with p.Ser55Phe variant in the *MYOT* gene: MYOT-MUR study

Martínez Marín R[1], *Aledo Serrano M*[1], *Mena Bravo A*[1], *Lorenzo Diéguez M*[1], *García Leal A*[1], *Zmork Martínez G*[1], *Pérez Lucas J*[2], *Pérez García E*[1]

[1]*Hospital Universitario La Paz,* [2]*Hospital Universitario Del Tajo*

58P *ADSSL1* myopathy in a neuromuscular cohort in Northern India

Reyaz A[1], *Macken W*[2,3], *Rani N*[1], *Ahmad T*[1], *Tarane K*[1], *Danish M*[1], *ICGNMD Consortium*[5], *Bhatia R*[1], *Pitceathly R*[2,3], *Thangaraj K*[4,6], *Topf A*[7], *Straub V*[7], *Srivastava P*[1], *Hanna M*[2,3], *Venugopalan Y V*[1]

[1]*All India Institute Of Medical Sciences (AIIMS),* [2]*Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology,* [3]*NHS Highly Specialised Service for Rare Mitochondrial Disorders, Queen Square Centre for Neuromuscular Diseases, The National Hospital for Neurology and Neurosurgery,* [4]*Centre for DNA Fingerprinting and Diagnostics,* [5]*https://www.ucl.ac.uk/genomic-medicine-neuromuscular-diseases/global-contributor-list,* [6]*Centre for Cellular & Molecular Biology, Hyderabad, India,* [7]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

59P Clinical and genetic spectrum of GNE myopathy in a neuromuscular cohort in northern India

Rani N[1], *Macken W*[2,3], *Reyaz A*[1], *Ahmad T*[1], *Tarane K*[1], *Danish M*[1], *Consortium ICGNMD-Consortium*[5], *Bhatia R*[1], *Pitceathly R*[2,3], *Thangaraj K*[4,6], *Topf A*[7], *Straub V*[7], *Srivastava P*[1], *Hanna M*[2,3], *Venugopalan Y V*[1]

[1]*All India Institute Of Medical Sciences,* [2]*Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK,* [3]*NHS Highly Specialised Service for Rare Mitochondrial Disorders, Queen Square Centre for Neuromuscular Diseases, The National Hospital for Neurology and Neurosurgery,* [4]*Centre for DNA Fingerprinting and Diagnostics,* [5]*https://www.ucl.ac.uk/genomic-medicine-neuromuscular-diseases/global-contributor-list, UCL, UK,* [6]*Centre for Cellular & Molecular Biology,* [7]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

60P Evaluation of aggrephagy markers in genetically defined MyofibrillarMyopathies

Iannibelli E[1], *Gibertini S*[1], *Maruotti A*[2], *Salerno F*[1], *Cheli M*[3], *Vattemi G*[3], *Tonin P*[3], *Tasca G*[4], *Bortolani S*[5], *Pegoraro E*[6], *Previtali S*[7], *Garibaldi M*[8], *Merlonghi G*[8], *Filosto M*[9,10], *Carnazzi A*[11,1], *Nicolini De Gaetano L*[1], *Riolo G*[1], *Ruggieri A*[1], *Maggi L*[1]

1Istituto Neurologico Carlo Besta Fondazione IRCCS, [2]Libera Università Maria SS Assunta, [3]University of Verona, [4]Newcastle University and Newcastle Hospitals NHS Foundation Trusts, [5]Fondazione Policlinico Universitario Agostino Gemelli IRCCS, [6]University of Padova, [7]IRCCS Ospedale San Raffaele, [8]Sapienza University of Rome, Sant'Andrea Hospital, [9]University of Brescia, 10NeMO-Brescia Clinical Center for Neuromuscular Diseases, [11]University of Milan

61P Characteristics of muscle computed tomography in a family with *HSPB8*-related rimmed vacuolar myopathy

Kobayashi M[1], *Abe E*[1], *Wada C*[1], *Yokoyama E*[2], *Hara K*[3], *Nakayama T*[4], *Inoue-Shibui A*[5], *Suzuki N*[6], *Izumi R*[5], *Aoki M*[5], *Nishino I*[7], *Ishihara T*[1], *Toyoshima I*[1]

[1]Department of Neurology, NHO Akita National Hospital, [2]Department of Rehabilitation, Akita Prefectural Center for Rehabilitation and Psychiatric Medicine, [3]Department of Neurology, Japanese Red Cross Akita Hospital, [4]Department of Neurology, Yokohama Rosai Hospital, [5]Department of Neurology, Tohoku University Graduate School of Medicine, [6]Department of Rehabilitation Medicine, Tohoku University Graduate School of Medicine, [7]Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry

62P Axial involvement as a prominent feature in *SMPX*-related distal myopathy

Omar Mohamed Salman D[1], *C. Bolano-Diaz C*[1], *Muni-Lofra R*[1], *Wong K*[1], *Elseed M*[1], *Harris E*[1,2], *Diaz-Manera J*[1], *Guglieri M*[1], *Marini-Bettolo C*[1], *Straub V*[1], *Tasca G*[1]

[1]The John Walton muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University, [2]Northern Genetics Service, Institute of Genetic Medicine

63P Identifying the disease-causing variant in a large family, with a late-onset dominant distal myopathy

Turku T[1], *Savarese M*[1], *Johari M*[1,2], *Soininen M*[1], *Hoischen A*[3,4], *Steehouwer M*[3], *Roos A*[5,6], *Preuße C*[7,8], *Stenzel W*[7], *Wallgren-Pettersson C*[1], *Pelin K*[1], *Udd B*[1], *Hackman P*[1]

[1]The Folkhälsan Research Center, [2]Harry Perkins Institute of Medical Research, Centre for Medical Research, [3]Department of Human Genetics, Radboud University Medical Center, [4]Department of Internal Medicine, Radboud Institute for Molecular Life Sciences, Radboud Expertise Center for Immunodeficiency and Autoinflammation and Radboud Center for Infectious Disease (RCI), Radboud University Medical Center, [5]Pediatric Neurology, Faculty of Medicine, University Children's Hospital, University of Duisburg-Essen, [6]Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute, [7]Department of Neuropathology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health (BIH), [8]Department of Neuropediatrics, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin Institute of Health (BIH)

64P Effects of autophagy stimulation in the Tibial muscular dystrophy mouse model

Sarparanta J[1,2], *Suel-Petat L*[3], *Luque H*[1,2], *Jonson P*[1,2], *Deste G*[4], *Vihola A*[1], *Barresi R*[4], *Udd B*[1,2,5], *Richard I*[3]

[1]Folkhälsan Research Center, [2]Medicum, University of Helsinki, [3]Généthon, [4]San Camillo IRCCS, [5]Neuromuscular Research Center, Tampere University Hospital

65P Striking periscapular muscle hypertrophy as the presenting symptom in a 5-month old infant diagnosed with a *MYH7* congenital myopathy: report of a case

Deconinck N[1], *Coppens S*[2], *Vilain C*[2], *Remiche G*[3], *Semal B*[2], *Presiozi M*[4], *Lecomte S*[5], *Dontaine P*[1]

[1]Department of Paediatric neurology and neuromuscular reference center, HUDERF (HUB), ULB, [2]Department of Genetics, Erasme Hospital,ULB, [3]Neuromuscular reference center, Erasme Hospital, ULB, [4]Department of Imaging, HUDERF, ULB, [5]Department of anatomopathology, CHU Brugmann, ULB

66P Clinical and molecular complexity in Desminopathy: description of a novel variant in *DES* gene

Torri F[1], *Torella A*[2], *Ricci G*[1], *Ciurli B*[1], *Piluso G*[2], *Demidov G*[3], *Onore M*[2], *Spampanato C*[2], *Zanobio M*[2], *Rahman S*[2], *Cetrangolo V*[2], *Nigro V*[2], *Siciliano G*[1]

[1]Department of Clinical and Experimental Medicine, University Of Pisa, [2]Department of Precision Medicine, University of Campania "Luigi Vanvitelli", [3]Institute of Medical Genetics and Applied Genomics, University of Tübingen

67P *ADSS1* Myopathy in Korea: a comprehensive analysis of clinical, laboratory, radiological, pathological, and genetic features

Kim S[1], *Choi Y*[1], *Kim W*[2], *Park H*[1], *Choi Y*[1]

[1]Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, [2]Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine,

68P Induced muscle and liver absence of *Gne* in postnatal mice does not result in structural or functional muscle impairment

Mitrani-Rosenbaum S[1], *Harazi A*[1], *Yakovlev L*[1], *Ilouz N*[1], *Selke P*[2], *Horstkorte R*[2], *Argov Z*[3]

[1]*Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Medical Center,* [2]*Institute for Physiological Chemistry, Medical Faculty, Martin-Luther-University Halle-Wittenberg,* [3]*Department of Neurology, Hadassah Hebrew University Medical Center*

69P Medaka fish Oryzias latipes a new vertebrate model for Titinopathies: the HMERF case study

Cetrangolo V[1,2], *Savarese M*[1,5], *Linari M*[4], *Polishchuk E*[2], *Conte I*[7], *Nigro V*[2,3], *Udd B*[1,5,6]

[1]*Folkhäsan Reseach Centre,* [2]*Telethon Institute of Genetics and Medicine,* [3]*Università degli Studi della Campania "Luigi Vanvitelli",* [4]*University di Firenze,* [5]*Department of Medical and Clinical Genetics, Medicum, University of Helsinki,* [6]*Department of Neurology, Vaasa Central Hospital, 7University of Naples "Federico II"*

70P Defining the landscape of *TIA1* and *SQSTM1* Digenic Myopathy

Fernández-eulate G[1], *Panos-Basterra P*[2], *Theuriet J*[3], *Nadaj-Pakleza A*[4], *Magot A*[5], *Lannes B*[6], *Marcorelles P*[7], *Behin A*[1], *Masingue M*[1], *Caillon F*[8], *Malek Y*[3], *Fenouil T*[9], *Bas J*[10], *Menassa R*[11], *Michel-Calemard L*[11], *Streichenberger N*[9], *Simon J*[12], *Bouhour F*[3], *Evangelista T*[1], *Métay C*[13], *Pegat A*[3], *Stojkovic T*[1]

[1]*Centre de Référence des maladies Neuromusculaires Nord/Est/Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, APHP,* [2]*Department of Neurology, Princesa University Hospital, Madrid, Spain,* [3]*Service ENMG et de pathologies neuromusculaires, centre de référence des maladies neuromusculaires PACA-Réunion-Rhône-Alpes, Hôpital Neurologique P. Wertheimer, Hospices Civils de Lyon,* [4]*Centre de Référence des Maladies Neuromusculaires Nord/Est/Ile-de-France, ERN EURO-NMD, Service de Neurologie, Hôpitaux Universitaires de Strasbourg,* [5]*Centre de Référence des Maladies Neuromusculaires AOC, Laboratoire d'Explorations Fonctionnelles, FILNEMUS, Hôtel-Dieu, CHU de Nantes,* [6]*Département de Pathologie, Hôpitaux Universitaires de Strasbourg,* [7]*Département de Pathologie, Hopital Universitaire de Brest,* [8]*Service de Radiologie et Imagerie Médicale Hôtel-Dieu, CHU Nantes,* [9]*Service d'anathomopathogie, Centre de Biologie et Pathologie Est (CBPE), Hospices Civils de Lyon,* [10]*Service de Neurologie, Centre Hospitalier de Valence,* [11]*Service de Biochimie et Biologie Moléculaire, Centre de Biologie et Pathologie Est (CBPE), Hospices Civils de Lyon,* [12]*Service de Neurologie, Hospices Civils de Colmar,* [13]*Unité Fonctionnelle de Cardiogénétique et Myogénétique moléculaire et cellulaire, Centre de Génétique Moléculaire et Chromosomique, Pitié-Salpêtrière Hospital, APHP*

71P Phase II/III and efficacy confirmation study of aceneuramic acid for GNE myopathy in Japan

Suzuki N[1,10], *Mori-Yoshimura M*[2], *Katsuno M*[3,4], *Takahashi M*[5], *Yamashita S*[6], *Oya Y*[2], *Hashizume A*[3,4], *Yamada S*[3], *Nakamori M*[5], *Izumi R*[1], *Kato M*[1], *Warita H*[1], *Tateyama M*[1], *Kuroda H*[1], *Asada R*[7], *Yamaguchi T*[8], *Nishino I*[9], *Aoki M*[1]

[1]*Department of Neurology, Tohoku University Hospital,* [2]*Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry (NCNP),* [3]*Department of Neurology, Nagoya University Hospital,* [4]*Department of Clinical Research Education, Nagoya University Graduate School of Medicine,* [5]*Department of Neurology, Osaka University Hospital,* [6]*Department of Neurology, Kumamoto University Hospital,* [7]*Innovative and Clinical Research Promotion Center, Gifu University Hospital,* [8]*Division of Biostatistics, Tohoku University Graduate School of Medicine,* [9]*Department of Neuromuscular Research, National Institute of Neuroscience and Department of Genome Medicine Development, Medical Genome Center, National Center of Neurology and Psychiatry (NCNP), 10Department of Rehabilitation Medicine, Tohoku University Graduate School of Medicine*

72P Skeletal muscle pathology in plectinopathies

Winter L[1]

[1]*Medical University of Vienna*

73P Peripheral Neuropathy in Myofibrillar Myopathies (MFM) and *MFM* gene-related myopathies

Wannarong T[1], *Milone M*[1], *Selcen D*[1], *Dyck P*[1], *Liewluck T*[1]

[1]*Mayo Clinic*

74P Update on GNE-myopathy: introduction of tissue and blood biomarkers and a novel homozygous missense variant associated with early disease onset and proximal involvement

Roos A[1,7,10], *Dobelmann V*[1], *Hentschel A*[2], *Hagenacker T*[3], *Derksen A*[4], *Osmanovic A*[5], *Evangelista T*[6], *Gangfuss A*[7], *Kaiser F*[8], *Schara-Schmidt U*[7], *Ruck T*[1], *Savarese M*[9], *Lochmüller H*[4]

[1]*Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University ,* [2]*Leibniz-Institut für Analytische Wissenschaften -ISAS- e.V.,* [3]*Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Duisburg-Essen University,* [4]*Children's Hospital of Eastern Ontario (CHEO) Research Institute,* [5]*Essen Centre for Rare Diseases (EZSE), University Medicine Essen, Duisburg-Essen University,* [6]*Functional Unit of Neuromuscular Pathology, Neuropathology Department and Institute of Myology, Pitié-Salpêtrière Hospital, APHP, Sorbonne University,* [7]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioural Sciences, University Duisburg-Essen,* [8]*Institute of Human Genetics, University Medicine Essen, Duisburg-Essen University,* [9]*Tampere Neuromuscular Center, Folkhälsan Research Center,* [10]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute*

75P Evaluation of clinico-pathological and genetic spectrum of *FLNC* mutations in Indian cohort

Sharma M[1], *Dhall A*[1], *Jassal B*[1], *Suri V*[1], *Faruq M*[1], *Shamim U*[1], *Bhatia R*[1], *Venugopalan Y V*[1], *Chakarwarti B*[1], *Gulati S*[1]

[1]*Neuropathology Lab, AIIMS*

76VP Myofibrillar Myopathy with cardiomyopathy, lipid accumulation and sarcoplasmic reticulum dilation

Cotta A[1], *Carvalho E*[1], *da-Cunha-Júnior A*[1], *Menezes M*[1], *da Silveira E*[2], *Costa-e-Silva C*[2], *da-Silva-Neto R*[1], *Cauhi A*[1], *Valicek J*[1], *Vargas A*[1]

[1]*The Sarah Network of Rehabilitation Hospitals,* [2]*The Sarah Network of Rehabilitation Hospitals*

77VP GNE myopathy: Phenotypic diversity in 10-year study of National registry in Japan and correlation of the diaphragm with respiratory function

Yoshioka W[1], *Mori-Yoshimura M*[1], *Oba M*[1], *Saito Y*[1], *Oya Y*[1], *Eura N*[1], *Hayashi S*[1], *Kimura Y*[1], *Sato N*[1], *Nakamura H*[1], *Noguchi S*[1], *Nishino I*[1]

[1]*National Center of Neurology and Psychiatry*

78VP Pathogenic *NARS1* mutations identified as the cause of neurodevelopmental delay, microcephaly and peripheral neuropathy in two related patients

Vlachou V[1], *Abed Alrahman R*[1], *Majumdar A*[1]

[1]*Bristol Royal Hospital for Children*

182P-203P: SMA outcome measures and registries

182P Impact of nusinersen on the health-related quality of life and caregiver burden in patients with Spinal Muscular Atrophy with symptom onset before age 6 months

Lee Y[1], *Bae H*[1], *Shim Y*[2], *Cho J*[3], *Yun J*[4], *Lee H*[5], *Chae J*[6], *Kwon S*[1]

1Department of Paediatrics, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, [2]*Department of Pediatrics, Korea University Ansan Hospital,* [3]*Department of Pediatrics, Seoul National University Bundang Hospital,* [4]*Department of Genetic counselling, Graduate School of Ewha Womans University,* [5]*Division of Paediatric Neurology, Department of Paediatrics, Yongin Severance Hospital, Yonsei University College of Medicine,* [6]*Department of Pediatrics, Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital, Seoul National University College of Medicine*

183P CuidAME: The Spanish longitudinal Registry of SMA patients. A global view in 2024

Nascimento Osorio A[1], *García Uzquiano R*[1], *Puig C*[1], *Fernandez M*[2], *Ñungo N*[3], *Exposito J*[1], *Calvo R*[4], *Alvarez M*[5], *Lopez M*[6], *Martinez E*[7], *Grimalt M*[8], *Fernandez J*[9], *Navarro V*[10], *Urbano M*[11], *Martinez M*[12], *Gonzalez D*[13], *Sariego A*[14], *Sardina M*[15], *Marti I*[16], *CuídAME Study Group*[1]

[1]*Hosp. Sant Joan De Deu Neuromuscular unit,* [2]*La Paz University Hospital,* [3]*La F e University and Polytechnic Hospital,* [4]*University Regional Hospital of Malaga,* [5]*Vall d'Hebron Hospital, Barcelona, Spain,* [6]*Virgen del Rocío University Hospital,* [7]*Hospital Clínico Universitario Virgen de la Arrixaca,* [8]*Son Espases University Hospital,* [9]*Reina Sofía University Hospital,* [10]*University Hospital of Burgos,* [11]*Río Hortega University Hospital,* [12]*Albacete University Hospital Complex,* [13]*University Hospital Nuestra Señora de Candelaria,* [14]*Marqués de Valdecilla University Hospital,* [15]*Maternal-Children's Hospital of Badajoz,* [16]*Donostia University Hospital*

184P The integration of PROMs and clinician reported data: a holistic approach to characterise disease burden and treatment impact

Walker H[1], *Page J*[1], *Murphy L*[1], *Segovia S*[1], *Karkkainen E*[1], *Cavalcante E*[2], *Madden M*[2], *Adcock K*[3], *Farrugia M*[4], *Irwin J*[5], *Lilleker J*[6], *McConville J*[7], *Merrison A*[8], *Parton M*[9], *Ryburn L*[10], *Muni-Lofra R*[1], *Scoto M*[2], *Marini-Bettolo C*[1]

[1]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [2]*Dubowitz Neuromuscular Centre, Great Ormond Street Hospital,* [3]*Muscular Dystrophy UK,* [4]*Institute of Neurological Sciences, Queen Elizabeth University Hospital,* [5]*TreatSMA,* [6]*Manchester Centre for Clinical Neuroscience, Salford & University of Manchester,* [7]*Ulster Hospital,* [8]*Bristol Neuromuscular Disease Centre & South West Neuromuscular Disease network,* [9]*Queen Square Centre for Neuromuscular Diseases, University College London, 10SMA UK*

185P Spinal Muscular Atrophy diagnosis in Latin American: The LATAM RegistrAME clinical registry

Carneiro Batista E[1], *Zanoteli E*[2], *Rodrigues Sant'Anna V*[1], *Miranda Duarte F*[1], *de Piano L*[1], *de Pedri E*[1], *de Albuquerque C*[1], *Pedro I*[1], *Serapião A*[1], *Moia D*[1], *Carioca A*[1], *Sampaio B*[1], *Monfardini F*[1], *dos Santos G*[1], *Soares R*[1], *Silva G*[1], *Berwanger O*[3], *Rizzo L*[1], *Fonseca H*[1], *Medical team at the centers T*[4]

[1]*Hospital Israelita Albert Einstein,* [2]*Departamento de Neurologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP),* [3]*The George Institute for Global Health and Imperial College of London,* [4]*Medical team at the centers: Main medical investigators from the 18 centers participating in LATAM RegistrAME, Eighteen participating centers in six countries*

186P Demographic and clinical characteristics of risdiplam-treated and untreated adult patients with SMA

Gorni K[1], *Batech M*[2], *Guittari C*[3], *Carmona A*[2], *Lee S*[4], *Poll A*[4], *Sutherland C*[5], *Marini-Bettolo C*[6], *Walter M*[7], *Jagut M*[8], *Haberlová J*[9], *Hodgkinson V*[10], *Yiu E*[11], *Murphy L*[6], *TREAT-NMD Global Data systems Oversight Committee (TGDOC)*[4], *TREAT-NMD Global Registry Network for SMA*[4], *Gordish-Dressman H*[12], *Simpson A*[5]
[1]*PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd,* [2]*Aetion Inc.,* [3]*PDMA Neuroscience and Rare Disease, Genentech, Inc.,* [4]*TREAT-NMD Services Ltd,* [5]*Global Access, F. Hoffmann-La Roche Ltd,* [6]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [7]*Department of Neurology, Friedrich Baur Institute, LMU University Hospital, LMU Munich,* [8]*Belgian Neuromuscular Diseases Registry (BNMDR), Sciensano,* [9]*Czech Neurological Society, Society of Paediatric Neurology,* [10]*The University of Calgary, Calgary, Canada,* [11]*Australian Neuromuscular Disease Registry, Murdoch Children's Research Institute,* [12]*Center for Translational Science, Children's National Hospital and the George Washington University School of Medicine and Health Sciences*

187P French HCPs approach to evaluating SMA adult patients with severe disabilities: a qualitative study

Laforêt P[24,2,3], *Montagu G*[4], *Boyer F*[5,6], *Gargiulo M*[7,8], *Pouplin S*[9,10], *Barrière A*[11], *Berling E*[1,2], *Bonnyaud C*[9,10], *Cintas P*[12], *Hogrel J*[7], *Le Goff L*[13], *Marchadier B*[14], *N'Dah Sékou G*[1,2], *Orlikowski D*[2,15,16,17], *Prigent H*[2,17,18], *Ropars J*[19,20], *Salort-Campana E*[21,22], *Stojkovic T*[7,23], *Attarian S*[21,22]
[1]*Centre de référence des maladies neuromusculaires Nord Est IDF, Hôpital Raymond-Poincaré, APHP,* [2]*FHU Phenix,* [3]*U1179 INSERM, Université Versailles-Saint-Quentin-en-Yvelines,* [4]*Recherche, unknowns SAS, Paris, France,* [5]*Service de Médecine Physique et Réadaptation, CHU de Reims,* [6]*EA 3797, Département de Santé Publique, Université de Reims Champagne-Ardenne,* [7]*Institut de Myologie,* [8]*Laboratoire de Psychologie clinique, Psychopathologie et Psychanalyse (EA 4056) Université Sorbonne Paris Cité,* [9]*Laboratoire d'analyse du mouvement, Hôpital Raymond-Poincaré, APHP,* [10]*Unité Recherche UR 20201 ERPHAN, Université Versailles Saint Quentin,* [11]*Consultations pluridisciplinaires des maladies neuromusculaires - Hôpital de la croix rousse, CHU Lyon - L'Escale, Hôpital Femme Mère Enfant,* [12]*Département de Neurologie, Hôpital Pierre-Paul Riquet, CHU de Toulouse,* [13]*Hôpital Mère-Enfant, médecine pédiatrique, CHU Nantes,* [14]*Roche France SAS,* [15]*Service de Réanimation Médicale Adulte, Hôpital Raymond-Poincaré, APHP,* [16]*INSERM CIC1429, Centre d'Investigation Clinique, Hôpital Raymond-Poincaré, APHP,* [17]*UFR Simone Veil, Université Paris-Saclay,* [18]*Service de Physiologie et Explorations Fonctionnelles, Hôpital Raymond-Poincaré, APHP,* [19]*Service de neurologie pédiatrique, CHU de Brest,* [20]*LaTIM INSERM UMR 1101, CHU de Brest,* [21]*Service des Maladies Neuromusculaires et de la SLA, Hôpital de la Timone, APHM,* [22]*INSERM, Marseille Medical Genetics, U1251, Aix-Marseille Université,* [23]*Centre de référence des maladies neuromusculaires, Hôpital de la Pitié-Salpêtrière, AP-HP,* [24]*Nord-Est/Ile-de-France Neuromuscular Reference Center, UMR 1179, Neurology Department, Raymond-Poincaré Hospital, Garches, FHU PHENIX, UVSQ Paris-Saclay University*

188P Easy neurocognitive and social evaluation could detect abnormal neurodevelopment in SMA Type 1

Alvarez Molinero M[1], *Pires N*[2], *Garcia Uzquiano R*[2], *Gómez Garcia de la Banda M*[2], *Costa Comellas L*[1], *Ventura Expósito L*[1], *Munell Casadesús F*[1], *Benezit A*[2], *Gómez Andrés D*[1], *Quijano Roy S*[2]
[1]*Vall Hebron Universitary Hospital,* [2]*Raymond Poincare Hospital*

189P Diagnostic journey of SMA patients in a reference center in Brazil

Rodrigues M[1], *Piauilino Santos Falcão A*[1], *Franco Graça F*[1], *Cavalcanti França M*[1]
[1]*Unicamp*

190P Spectrum of phenotypes in SMA patients with four *SMN2* copies in France (Registre SMA France)

Gomez Garcia De La Banda M[1], *Gerin L*[1], *Ropars J*[2], *Garcia-Uzquiano R*[1], *Saugier-Veber P*[3], *Desguerre I*[4], *Salort-Campana E*[5], *Espil C*[6], *Barnerias C*[4], *Laugel V*[7], *Cances C*[8], *Audic F*[5], *Cintas P*[8], *Tard C*[9], *Le Goff L*[10], *Dieterich K*[11], *Drunat S*[12], *Grimaldi L*[13], *Quijano-Roy S*[1]
[1]*Raymond Poincare Hospital,* [2]*CHU Hospital Brest,* [3]*CHU Rouen,* [4]*Necker Sick Kids Hospital,* [5]*La Timone Hospital,* [6]*CHU Bordeaux,* [7]*CHU Strasbourg,* [8]*CHU Toulouse,* [9]*CHU Lille,* [10]*Hospices mere enfant hospital,* [11]*CHU Grenoble,* [12]*Robert Debre,* [13]*Paris Saclay University*

191P Characterization of patients SMA diagnosed in Algeria

Hallal S[1], *Benchaabi O*[2], *nouioua s*[2], *Yargui L*[1]
[1]*Laboratory of Biochemestry Mustapha Hospital,* [2]*Department of Neurology, EHS Cherchel*

192P A community-based experience with the new 12-Tier functional ability scale for Evolving Spinal Muscular Atrophy (EVOLVE-SMA)

Moore Burk M[1,2], *Johnson K*[2,3], *Crawford T*[4], *Apkon S*[1], *Duong T*[5], *Krosschell K*[6], *EVOLVE-SMA Working Group*[1,4,6]
[1]*Children's Hospital Colorado, University of Colorado School of Medicine,* [2]*Rocky Mountain University of Health Professions,* [3]*Hawai'i Pacific University,* [4]*The Johns Hopkins Hospital,* [5]*Stanford University,* [6]*Feinberg School of Medicine Northwestern University*

193P Use of European rare disease registries to describe the natural history and disease progression of Spinal Muscular Atrophy (SMA) over time

Bennett N[1], *Deltour N*[4], *Garry E*[2], *Ferreras A*[4], *Jacquot E*[4], *McElwee S*[2], *Sajedian R*[2], *Kurteva S*[4], *Boin E*[4], *Poll A*[1], *Davies R*[11], *Walter M*[5], *Jagut M*[6], *Haberlová J*[7], *Cattinari M*[8], *Marini-Bettolo C*[9], *Ekström A*[10], *de Lemus Belmonte M*[3], *Breen K*[3], *Servais L*[12]

[1]*TREAT-NMD Services Ltd,* [2]*Aetion Inc,* [3]*European Medicines Agency (EMA),* [4]*Aetion Germany GmbH,* [5]*Friedrich-Baur-Institute at the Department of Neurology,* [6]*Sciensano,* [7]*Department of Pediatric Neurology,* [8]*FundAME,* [9]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [10]*Queen Silvia Children's Hospital, Sahlgrenska University Hospital, University of Gothenburg,* [11]*Jumping Rivers Ltd, 12University of Oxford and University of Liège*

194P Longitudinal assessment of the Adapted Test for Neuromuscular Disease (ATEND) in individuals living with Spinal Muscular Atrophy (SMA)

Duong T[1], *Muni-Lofra R*[2], *Pasternak A*[3], *Tang W*[1], *Gu B*[1], *Dunaway Young S*[1], *Wilson A*[7], *Harrington A*[4], *de Monts C*[1], *Jeworek A*[5], *Moore Burke M*[8], *Maczek E*[3], *McIntyre M*[7], *Salvatore S*[1], *Smith S*[1], *Smith R*[4], *Hsu L*[1], *He Z*[1], *Glanzman A*[6], *Day J*[1]

[1]*Stanford University,* [2]*John Walton Muscular Dystrophy Research Centre,* [3]*Boston Children's Hospital,* [4]*Helen DeVos Children's Hospital,* [5]*The Ohio State University Wexner Medical Center,* [6]*Children's Hospital of Philadelphia,* [7]*University of Utah,* [8]*Childrens Hospital Colorado*

195P Real-world data on the effectiveness and safety of Onasemnogene abeparvovec in Spinal Muscular Atrophy

Weiß C[1], *Becker L*[1], *Garbade S*[2], *Johannsen J*[3], *Ziegler A*[2]

[1]*Charité - Universitätsmedizin Berlin, Department of Pediatric Neurology and Center for Chronically Sick Children,* [2]*Heidelberg University, Medical Faculty, Center for Pediatric and Adolescent Medicine Department I, Division of Pediatric Neurology and Metabolic Medicine,* [3]*University Medical Center Hamburg-Eppendorf, Department of Pediatrics*

196P Profiling neuroinflammatory markers in CSF from paediatric SMA patients in response to nusinersen treatment

Zhang Q[1], *Hong Y*[2], *Brusa C*[3], *Scoto M*[3], *Cornell N*[3], *Patel P*[1], *Boukhloufi I*[3], *Baranello G*[3], *Muntoni F*[3,4], *Zhou H*[1,4]

[1]*Genetics and Genomic Medicine Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London,* [2]*Infection, Immunity & Inflammation Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London,* [3]*The Dubowitz Neuromuscular Centre, Developmental Neurosciences Research and Teaching Department, Great Ormond Street Institute of Child Health, University College London,* [4]*NIHR Great Ormond Street Hospital Biomedical Research Centre*

197P Survival of SMA type 1 and type 0 infants at the time of disease modifying therapies: results of a 8-year nationwide registry

Coratti G[1], *Pera M*[1], *Agosto C*[2], *D'Amico A*[3], *Ricci F*[4], *Sansone V*[5], *Masson R*[6], *Bruno C*[7], *Varone A*[8], *Pane M*[1], *Mercuri E*[1]

[1]*Child Neurology Unit e Centro Nemo, IRCCS Fondazione Policlinico Gemelli, Università Cattolica del Sacro Cuore,* [2]*Pediatric Pain and Palliative Care Unit, Department of Women and Children's Health, University Hospital of Padova,* [3]*Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesú Children's Hospital IRCCS,* [4]*Division of Child and Adolescent Neuropsychiatry, Department of Public Health and Pediatric Sciences University of Turin,* [5]*Centro Clinico NeMo,* [6]*Pediatric Neurology and Myopathology Units, Neurological Institute "Carlo Besta",* [7]*Center of Translational and Experimental Myology and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS Istituto Giannina Gaslini and University of Genoa,* [8]*Pediatric Neurology, Santobono-Pausilipon Children's Hospital*

198P Longitudinal evaluation of fatigue in adult patients with Spinal Muscular Atrophy and the impact of treatment with disease-modifying drugs

Graca F[1], *Iwabe C*[1], *C França Jr. M*[1]

[1]*University Of Campinas*

199P The use of the Motor Unit Number Index (MUNIX) as a biomarker for disease progression in Late-Onset 5q-Spinal Muscular Atrophy treated with Nusinersen

Holanda Mendonca R[1], *Pedro Soares Baima J*[1], *Jorge Polido G*[1], *Otto Heise C*[1], *Zanoteli E*[1]

[1]*Hospital das Clinicas FMUSP*

200P Minimal detectable change of the Revised Hammersmith Scale in patients with Spinal Muscular Atrophy

O'reilly E[1,2], *Stimpson G*[2], *Rohwer A*[1,2], *Baranello G*[1,2,3], *Muntoni F*[1,2,3], *Scoto M*[1,2,3], *On behalf of SMA REACH UK*[2]

[1]*Great Ormond Street Hospital for Children NHS Foundation Trust,* [2]*Dubowitz Neuromuscular Centre, Institute of Child Health, UCL,* [3]*UCL NIHR GOSH Biomedical Research Centre*

201P Natural history of Spinal Muscular Atrophy patients with 3 and 4 copies of *SMN2* gene – data from the national Spanish registry (CUIDAME)

Aragon Gawinska K[1], *Fernández García M*[2], *Nascimiento Osorio A*[3], *Paradas C*[4], *Sotoca J*[5], *Povedano M*[6], *Moreno A*[7], *Henao M*[8], *Gil C*[9], *Rojas R*[10], *Gómez Caravaca M*[11], *Grimalt M*[12], *Fernández Torron R*[13], *Jericó I*[14], *García Campos O*[15], *Toledo Bravo de Laguna L*[16], *Hervás D*[17], *Tizzano E*[18], *Vázquez Costa J*[1,19,20], *on behalf of CUIDAME Investigators Group*

[1]*Neuromuscular Unit, Department of Neurology, Hospital Universitari i Politecnic La Fe,* [2]*Department of Neuropediatrics, Hospital Universitario La Paz,* [3]*Neuromuscular Unit, Neuropediatric Department, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu,* [4]*Department of Neurology, Hospital Virgen del Rocío,* [5]*Department of Neurology, Hospital universitario Vall d'Hebron,* [6]*Motor Neuron Unit, Neurology Department, Bellvitge Hospital-IDIBELL,* [7]*Neuromuscular Unit, Neurology Department, Hospital Clínico Universitario Virgen de la Arrixaca,* [8]*Department of Neurology, Univeristy Hospital Nuestra Señora de Candelaria,* [9]*Department of Neurology, Univeristy Hospital of Burgos,* [10]*Neuromuscular Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau,* [11]*Department of Neurology, University Hospital Reina Sofia,* [12]*Department of Neuropediatrics, University Hospital Son Espases,* [13]*Department of Neurology, University Hospital Donostia,* [14]*Department of Neurology, Univeristy Hospital of Navarra,* [15]*Department of Pediatric Neurology, Hospital General Universitario of Toledo,* [16]*Department of Pediatric Neurology, University Hospital Materno-Infantil de Canarias,* [17]*Department of Applied Statistics and Operational Research and Quality, Universitat Politècnica de València,* [18]*Department of Clinical and Molecular Genetics and Rare Diseases Unit and Medicine Genetics Group, VHIR, Hospital Vall d'Hebron,* [19]*Department of Medicine, Universitat de València, 20Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)*

202P Descriptive analysis of the Spinal Muscular Atrophy population treated with Nusinersen included in the CuidAME project

Sotoca Fernandez J[1], *Puig C*[2], *García-Uzquiano R*[2], *García-Romero M*[3], *Pitarch-Castellanos I*[4], *Vázquez-Costa J*[4], *Paradas C*[5], *Povedano M*[6], *Gómez-Caravaca M*[7], *Álvarez-Molinuevo M*[8], *Gómez-Andrés D*[8], *Munell F*[8], *Grimalt M*[9], *Calvo R*[10], *Henao M*[11], *Jericó I*[12], *Fernández-García M*[3]

[1]*Neuromuscular Disorders Unit, Neurology Service, Vall d´Hebron Hospital,* [2]*Neuromuscular Unit, Neuropediatrics Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu,* [3]*Pediatric Neurology department, Hospital la Paz,* [4]*Pediatric Neurology Department, Hospital Universitario i Politécnico La Fe,* [5]*Neuromuscular Unit, Neurology Department, Hospital Virgen del Rocío,* [6]*Neurology department, Hospital Universitari de Bellvitge,* [7]*Department of Neurology, University Hospital Reina Sofia, Córdoba, Spain,* [8]*Neuromuscular Unit, Pediatric Neurology department, Hospital Universitari de la Vall d'Hebrón,* [9]*Pediatric Neurology department, Hospital Universitari Son Espases,* [10]*Pediatric Neurology department, Hospital Regional de Málaga,* [11]*Neurology department, Hospital Universitario Nuestra Señora de la Candelaria,* [12]*Neurology department, Hospital de Navarra*

203P Towards a better analysis of *SMN2* structures and variants by complete sequencing of the *SMN* locus in an international cohort of 564 SMA patients

Tizzano E[1,2], *Costa-Roger M*[1,2], *Blasco-Pérez L*[1,2], *Tenés A*[1], *Martínez-Cruz D*[1], *Leno-Colorado J*[1,2], *Civit D*[1,2], *Codina-Sola M*[1,2]

[1]*Department of Clinical and Molecular Genetics Hospital Vall d´Hebron,* [2]*Medicine Genetics VHIR*

247P-265P, 266VP: Neuromuscular disorders around the world

247P A population-based survey on the knowledge, perception and attitudes towards rare diseases and gene therapy in Belgium: focus on Duchenne Muscular Dystrophy

Van Stappen T[1], *Verschelden M*[1], *Samyn W*[2], *Minnebo J*[2], *Mommen M*[1]

[1]*Pfizer,* [2]*Indiville, Leuven*

248P Spinal Muscular Atrophy in Latin American: patient journey observed in regional registry

Carneiro Batista E[1], *Zanoteli E*[2], *Rodrigues Sant'Anna V*[1], *Miranda Duarte F*[1], *de Piano L*[1], *de Pedri E*[1], *de Albuquerque C*[1], *Pedro I*[1], *Serapião A*[1], *Moia D*[1], *Carioca A*[1], *Sampaio B*[1], *Monfardini F*[1], *dos Santos G*[1], *Soares R*[1], *Silva G*[1], *Berwanger O*[3], *Rizzo L*[1], *Fonseca H*[1], *Medical team at the centers T*[4]

[1]*Hospital Israelita Albert Einstein,* [2]*Departamento de Neurologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP),* [3]*The George Institute for Global Health and Imperial College of London,* [4]*Medical team at the centers: Main medical investigators from the 18 centers participating in LATAM RegistrAME, Eighteen participating centers in six countries*

continued on next page

249P Clinical characteristics of the Spinal Muscular Atrophy patients identified in the Brazilian public health system

Batista EC [1], ***Zanoteli E*** [2], Ortega AB[3], Junior MCF[4], .Saute JAM[5], Oliveira ASB.[6], Giannetti JG[7], Pessoa ALS[8], Prufer A[9], Boy R[10], . Junior FGB[1], de Albuquerque CSN[1], Moia DDF[1], Monfardini F[1], Santos GP[1], Soares RVP[1], SilvaGS[1], Rizzo LV[1],. Berwanger O[11], Fonseca HAR[1]

[1]Hospital Israelita Albert Einstein, [2]Departamento de Neurologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP), [3]Hospital Infantil Pequeno Príncipe – Curitiba, [4]Universidade Estadual de Campinas (UNICAMP) - Hospital de Clínicas da Universidade Estadual de Campinas, [5]HCPA - Hospital de Clínicas de Porto Alegre, [6]Universidade Federal de São Paulo-UNIFESP, [7]Universidade Federal de Minas Gerais (UFMG) - Hospital das Clínicas – Belo Horizonte, [8]Hospital Infantil Albert Sabin - HIAS, [9]Universidade Federal do Rio de Janeiro (UFRJ) - Instituto de Puericultura e Pediatria Martagão, [10]Gesteira da UFRJ – Rio de Janeiro, Hospital Universitário Pedro Ernesto – Universidade Estadual do Rio de Janeiro – UERJ, [11]The George Institute for Global Health and Imperial College of London

250P Prevalence of Duchenne Muscular Dystrophy in Italy: a nationwide survey

Cicala G[1,2], Capasso A[1], Ricci M[1], Pane M[1], D'Amico A[3], Bruno C[4], Sansone V[5], Messina S[6], Bello L[7], Masson R[8], Berardinelli A[9], Pini A[10], Ricci F[11], Mongini T[12], Nigro V[13], Comi G[14,15], Battini R[16,17], Arpaia C[1], Coratti G[1], Mercuri on behalf of the Italian DMD group E[1]

[1]Pediatric Neurology, Università Cattolica del Sacro Cuore, [2]The Dubowitz Neuromuscular Centre, University College London, and MRC Centre for Neuromuscular Diseases, Neurosciences Unit, Great Ormond Street Hospital, [3]Department of Neurosciences, Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Hospital, IRCCS, [4]Center of Translational and Experimental Myology, and Dept. of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health, University of Genova, IRCCS Istituto Giannina Gaslini, [5]The NEMO Center in Milan, Neurorehabilitation Unit, University of Milan, ASST Niguarda Hospital, [6]Department of Clinical and Experimental Medicine, University of Messina, [7]Neurology Unit, Azienda Ospedale Padova Università Padova, [8]Fondazione IRCCS Istituto Neurologico Carlo Besta, Developmental Neurology Unit, [9]C. Mondino Foundation, [10]Pediatric Neuromuscular Unit, IRCCS Institute of the Neurological Sciences of Bologna, [11]Child Neuropsychiatry Unit, Department of Public Health and Paediatric Sciences, University of Turin, [12]Neuromuscular Unit, Department of Neurosciences, University of Turin, [13]Medical Genetics and Cardiomyology Unit, Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli" and TIGEM, [14]Neurology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, [15]Dino Ferrari Center, Department of Pathophysiology and Transplantation, University of Milan, [16]Dpt. Neuroscience, IRCCS Stella Maris Foundation, [17]Dpt. Clinical and Experimental Medicine, University of Pisa

251P Latin-SEQ: a collaborative network to provide genetic diagnosis to patients with neuromuscular diseases in Latin America – project update

Topf A[1], Gonzalez-Chamorro A[1], Laurie S[2,3], Papakonstantinou Ntalis A[2,3], Latin-SEQ Consortium[1], Diaz-Manera J[1]

[1]John Walton Muscular Dystrophy Research Centre, [2]Centro Nacional de Análisis Genómico, [3]Universitat de Barcelona

252P Natural history and quality of life study on muscular dystrophies in adulthood (Muskel-LIV): study design and conduct

Nordström S[1,2], Wahlgren L[1,2], Lindberg C[1,2], Tulinius M[1], Sofou K[1,2]

[1]Department of pediatrics, University of Gothenburg, [2]Sahlgrenska University Hospital

253P International Centre for Genomic Medicine in Neuromuscular Diseases: analysis and characterization of the muscular dystrophy cohort from India

Luce L[1], Vengalil S[3], Nashi S[3], Srivastava K[3], Manoj R[3], Reyaz A[4], Chaudhary N[4], Ahmad T[4], Naveena M[5], Vandrovcova J[2], ICGNMD Consortium, Yareeda S[5], Bhatia R[4], Venugopalan VY[4], Srivastava P[4], Nalini A[3], Töpf A[1], Straub V[1]

[1]The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, [2]Department of Neurosciences, National Institute of Mental Health and Neurosciences (NIMHANS), India, [3]Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, [4]Department of Neurology, All India Institute of Medical Sciences, [5]Department of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, India

254P "Where can I find a specialized physiotherapist for someone like me?" - A Norwegian innovation project

Ramberg C[1], Hevnskjel Ringvold G[1], Ladehaug T[2], Stokke S[3], Ørstavik K[4], Dybesland Rosenberger A[1]

[1]National Neuromuscular Centre Norway, University Hospital of North Norway, [2]Neuromuscular Disorders Association of Norway (NMD Norway), [3]Frambu Resource Centre for Rare Disorders, [4]Unit for Inborn and Hereditary Neuromuscular Disorders, Department of Neurology, Oslo University Hospital

255P Relevance of muscle biopsies in the neonatal period: a 52-year retrospective study in the gene-sequencing era

*Bui M[1], Fernández-Eulate G[2], Evangelista T[1], Lacène E[1], Brochier G[1], Labasse C[1], Madelaine A[1], Chanut A[1], Beuvin M[1], Borsato-Levy F[1], Biancalana V[3], Barcia G[2], De Lonlay P[2], Laporte J[4], **Bohm J**[4], Romero N[1]*

[1]Institute of Myology, Sorbonne Université, GHU Pitié-Salpêtrière, [2]Hôpital Necker Enfants Malades, Université Paris Cité, [3]Laboratoire de Diagnostic Génétique, Faculté de Médecine, CHRU, [4]IGBMC,

256P Establishing healthy muscle references and cutoff values for quantitative muscle ultrasound as a foundation for future diagnostic and research use in the neuromuscular clinic

***Haestad C**[1], Ramberg C[1], Rosenberger A[1], Arntzen K[1,2]*

[1]National Neuromuscular Centre Norway, [2]Department of Neurology, University Hospital of North Norway

257P Interim analysis of an integrated interdisciplinary diagnostic pathway in a cohort of unsolved pediatric neuromuscular disorders

***Haliloğlu G**[1], Donkervoort S[2], Öz Yıldız S[1], Özel E[1], Pais L[3,4], Ganesh V[3,4,5], O'Donnell-Luria A[3,4], Bönnemann C[2]*

[1]Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Neurology, [2]Neuromuscular and Neurogenetic Disorders of Childhood Section, National Institute of Neurological Disorders and Stroke, NIH, [3]Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, [4]Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, [5]Department of Neurology, Brigham & Women's Hospital

258P Safety and tolerability of Onasemnogene Abeparvovec for patients with Spinal Muscular Atrophy weighing ≤17 kg and ≤24 months old: phase 4 OFELIA study

***Zanoteli E**[1], Muntadas J[2], Gurgel-Gianetti J[3], Monges S[4], Aliberti P[5], Alecu I[6], Ritter S[7], Martins de Lana J[8], Mumneh N[7], Saute J[9,10]*

[1]University of São Paulo, [2]Hospital Italiano de Buenos Aires, [3]Universidade Federal de Minas Gerais, [4]Hospital de Pediatría S.A.M.I.C. "Prof. Dr. Juan P. Garrahan", [5]Novartis, [6]Novartis Pharmaceuticals, [7]Novartis Gene Therapies, Inc., [8]Novartis Biociências S.A. Pharma, [9]Medical Genetics Service, Hospital de Clinicas de Porto Alegre, [10]Universidade Federal do Rio Grande do Sul

259P The 'muscle toolbox': harmonising diagnosis and follow-up for neuromuscular disorders across three Dutch academic hospitals

***Cameron D**[1], van Doorn J[1], Heskamp L[2], Rauh S[3], Becks R[1], Kruit M[3], Nievelstein R[2], Tromp S[3], Tannemaat M[3], Braakman H[1], Erasmus C[1], Houwen-van Opstal S[1], Niks E[3], van der Pol L[2], Kan H[3], Froeling M[2], Bartels B[2], van Alfen N[1]*

[1]Radboud University Medical Center, [2]University Medical Center Utrecht, [3]Leiden University Medical Center

260P NEUROMYODredger – 3 billion megaproject: expanding the accessibility of exome sequencing for the diagnosis of neurodevelopmental and neuromuscular disorders in nine countries

***Malfatti E**[1], Caramizaru A[2], Lee H[3], Kim J[3], Shoaito H[4], Pennisi A[1], Fahmi N[5], Escobar-Cedillo R[6], Miranda-Duarte A[6], Nouioua S[7], Benchaabi O[7], Martinez P[8], Castiglioni C[9], Dobrescu A[2], Tajsharghi H[10]*

[1]Université Paris Est - APHP, [2]University of Medicine and Pharmacy of Craiova, [3]3billion, Inc., Gangnam-gu, Seoul, Republic of Korea, [4]Reference Center For Neuromuscular Disorders, APHP Henri Mondor University Hospital, [5]Department of Neurology, Faculty of Medicine, Ain Shams University, [6]Instituto Nacional de Rehabilitación, [7]University Centre of Blida, [8]Instituto Nacional del Niño, [9]Clinica Meds, [10]University of Skovde

261P Insights into Facioscapulohumeral dystrophy in African individuals: clinical and molecular findings from a collaborative study

***Rodriguez Cruz P**[1,2,3], Diagne R[2,3], Henning F[4], Naidu K[4], Heckmann J[5], Floudiotis N[5], Malfatti E[6], Kamissoko Y[7], Leturcq F[8], Urtizberea A[9], Tellez M[10], Elsheikh B[10], Beltran S[1], Diop A[2,3], Ndiaye M[2,3], Hodes R[11], Voermans N[12], Van der Vliet P[13], Van der Maarel S[13], Lemmers R[13]*

[1]Centro Nacional de Análisis Genómico (CNAG), [2]Neurology Department, CHNU de Fann, [3]Université Cheikh Anta Diop de Dakar, [4]Division of Neurology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, [5]Neurology Research Group, Neurosciences Institute, University of Cape Town, [6]APHP, Neuromuscular Reference Center Nord-Est-Ile-de-France, Henri Mondor Hospital, Université Paris Est, U955, INSERM Créteil, IMRB, [7]UFR Sciences Médicales, Université Félix Houphouët Boigny, [8]APHP, Cochin Hospital, Department of Genomic Medicine and Systemic Diseases, University of Paris, [9]Institut de Myologie, [10]Department of Neurology, The Ohio State University Wexner Medical Center, [11]American Jewish Joint Distribution Committee, [12]Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, [13]Department of Human Genetics, Leiden University Medical Center

262P A global analysis of the CMT1A locus: implications for the origin and susceptibility to Charcot- Marie-Tooth disease type 1A across populations

***Rodriguez Cruz P**[1,2,3], Alitsiou A[1], Diagne R[2,3], Lia-Baldini A[4], Ghorab K[5], Gallo Diop A[2,3], Ndiaye M[2,3], Beltran S[1], Lao O[7]*

[1]Centro Nacional de Análisis Genómico (CNAG2Neurology Department, CHNU de Fann, [3]Université Cheikh Anta Diop de Dakar, [4]Biochemistry and Molecular Genetics Department, Université de Limoges, [5]Neurology Department, Université de Limoges, [6]Institute de Myologie, [7]Institut de Biologia Evolutiva (CSIC-UPF)

263P Updated genetic testing in heart-transplant recipients in Norway between 1983-2022 uncovering genes relevant to neuromuscular disorders

Benterud A[1,2], *Haug Popperud T*[1,3], *Broch K*[4], *Hasselberg N*[4], *Prøven Bogsrud M*[5], *Berge K*[5], *Haugaa K*[4,6], *Ørstavik K*[1,3]

[1]*Section for Rare Neuromuscular disorders Department of Neurology Oslo University Hospital OUH,* [2]*University of Oslo UIO,* [3]*Member of Euro-NMD,* [4]*Departement of Cardiology Oslo University Hospital OUH,* [5]*Department of Medical Genetics Unit for Heart Genetics Oslo University Hospital OUH,* [6]*SFI ProCardio The Precision Health Center for Optimized Cardiac Care*

264VP A nationwide register study on the epidemiology of Duchenne Muscular Dystrophy (DMD) in Finland

Auranen M[1], *Kyttälä M*[2], *Vesikansa A*[3], *Mehtälä J*[3], *Isohanni P*[4,5], *Kosunen M*[2]

[1]*Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital,* [2]*Pfizer Oy,* [3]*MedEngine Oy,* [4]*Pediatric Neurology, Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital,* [5]*Research Programs Unit, Stem Cells and Metabolism, University of Helsinki*

265P Effective supplementation of 6'-sialyllactose in GNE Myopathy: the results from a placebo-controlled, pilot study

Park Y[1,2], *Kim D*[2,3], *Choi J*[4], *Jung J*[4], *Kim L*[4], *Shin J*[2,3]

[1]*Department of Neurology, Pusan National University Hospital,* [2]*Department of Neurology Pusan National University School of Medicine,* [3]*Department of Neurology Pusan National University Yangsan Hospital, Pusan National University School of Medicine,* [4]*Research Institute of New Drug Development, NeuraGene Inc.*

266VP Cardiovascular comorbidities in Myasthenia Gravis: a systematic review and meta-analysis

Tahir S[1], *Iguh C*[1], *Sadik O*[2], *Duggirala N*[3], *Ezenwa V*[1], *Ahmed S*[1]

[1]*Windsor University School of Medicine,* [2]*Jackson Park Hospital,* [3]*Nri Medical College*

280P-315P, 316VP-317VP: Dystrophinopathies (animals models, biomarkers, brain, genetics)

280P Technology-enabled assessment of cognition to facilitate democratization of brain health in Duchenne Muscular Dystrophy

Thangarajh M[1]

[1]*Viirginia Commonwealth University*

281P Prognostic significance of *ACTN3* genotype in Duchenne Muscular Dystrophy: findings from an Argentine patient cohort

Luce L[1,2,3], *Mazzanti C*[1,2], *Carcione M*[1,2], *Llames Massini C*[1,2], *Buonfiglio P*[4], *Dalamón V*[4], *Bolaño Díaz C*[3,5], *Mesa L*[5], *Dubrovsky A*[5], *Cotignola J*[6,7], *Giliberto F*[1,2]

[1]*Laboratorio de Distrofinopatías, Cátedra de Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires,* [2]*Instituto de Inmunología, Genética y Metabolismo (INIGEM), CONICET - Universidad de Buenos Aires,* [3]*John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [4]*Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (INGEBI) "Dr. Héctor N. Torres", CONICET,* [5]*Instituto de Neurociencias, Fundación Favaloro,* [6]*Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires,* [7]*Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN), CONICET - Universidad de Buenos Aires*

282P Biomarker panel for Duchenne Muscular Dystrophy clinical trials

Tsioutsias I[1], *Bautista A*[1], *Terrill J*[1], *Bakker A*[1], *Pinniger G*[1], *Arthur P*[1]

[1]*The University of Western Australia*

283P Generation of cardiomyocyte cell models for personalized medicine

Nhi P[1], *Åstrand C*[1], *Hedhammar M*[1], *Al-Khalili Szigyarto C*[1]

[1]*KTH Royal Institute of Technology*

284P Suspension bead array profiling of 1018 serum proteins in search for disease progression biomarkers for Duchenne Muscular Dystrophy

Jiménez-Requena Carrasco A[1], *Ajeenah A*[1], *Johansson C*[1], *Naveed A*[5], *Tobin R*[2], *Degan C*[3], *de Vries S*[3], *van der Burgt Y*[3], *Diaz-Manera J*[4], *Guglieri M*[4], *CINRG-DNHS Investigators C, for DMD investigators, Dang U*[2], *Tsonaka R*[3], *Spitali P*[3], *Hathout Y*[5], *Al-Khalili Szigyarto C*[1]

[1]*KTH University, Protein Science Department,* [2]*Carleton University,* [3]*Leiden University Medical Center,* [4]*Newcastle University, 5Binghamton University*

285P AAV-delivered U7snRNA restores full-length dystrophin in patient cell lines with DMD intronic pseudoexon mutations

Beljan J[1], *Gushchina L*[1], *Lin H*[1], *Nicolau S*[1,2,3], *Weiss R*[4], *Flanigan K*[1,2,3]

[1]*Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital,* [2]*Department of Pediatrics, The Ohio State University College of Medicine,* [3]*Department of Neurology, The Ohio State University,* [4]*Department of Human Genetics, The University of Utah*

286P Cognitive deficits in Duchenne muscular dystrophy: Analysis of assessment, mutation location, and social vulnerability

Arun S[1], *Kaat A*[2], *Thangarajh M*[1]

[1]*Virginia Commonwealth University*, [2]*Northwestern University*

287P Localisation of Dystrophin isoforms in the mouse brain: insights into neuropsychiatric comorbidities in Duchenne Muscular Dystrophy

Aghaeipour A[1,2,3], *Tetorou K*[1,2], *Gileadi T*[1,2], *Morgan J*[1,2], *Montanaro F*[1,2], *Muntoni F*[1,2,3]

[1]*The Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health*, [2]*National Institute for Health Research UCL Great Ormond Street Institute of Child Health*, [3]*Neurodegenerative Diseases, UCL Queen Square Institute of Neurology*

288P In patients with Duchenne Muscular Dystrophy fragmented QRS in the lateral lead of the electrocardiography is associated with reduced cardiac function

Yamamoto T[1], *Ogawa S*[1], *Nambu Y*[2], *Bo R*[2], *Matsuo M*[3], *Awano H*[4]

[1]*Nagahama Institute of Bio-science and Technology*, [2]*Department of Pediatrics, Kobe University Graduate School of Medicine*, [3]*Faculty of Health Sciences, Kobe Tokiwa University*, [4]*Research Initiative Center, Organization for Research Initiative and Promotion*

289P Non-tandem duplications in DMD: impacts on genetic counseling and medical decision making

Gross B[1], *Higginbotham E*[2], *Lau L*[2], *Sung W*[2], *Moran O*[3], *Hasnain A*[2,4], *Stavropoulos D*[2,4], *Beaulieu Bergeron M*[5,6], *Boycott K*[7,8], *McNiven V*[9], *Liu R*[10], *Matesanz S*[1,11]

[1]*Division of Neurology, Children's Hospital of Philadelphia*, [2]*Division of Genome Diagnostics, Department of Paediatric Laboratory Medicine*, [3]*Clinical and Metabolic Genetics, The Hospital for Sick Children*, [4]*Department of Laboratory Medicine and Pathobiology, University of Toronto*, [5]*Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario*, [6]*Department of Pathology and Laboratory Medicine, University of Ottawa*, [7]*Department of Genetics, Children's Hospital of Eastern Ontario*, [8]*Department of Pediatrics, University of Ottawa*, [9]*Division of Genetics, Department of Pediatrics, McMaster Children's Hospital*, [10]*Revvity*, [11]*Perelman School of Medicine at the University of Pennsylvania*

290P Developing a non-invasive, in vivo method for evaluating muscle inflammation longitudinally in two mouse models of Duchenne Muscular Dystrophy

MacKinnon A[1], *Rowsell J*[1], *Uaesoontrachoon K*[1], *Mullen A*[1], *Hoffman E*[1,2], *Nagaraju K*[1,2]

[1]*Agada Biosciences Inc.*, [2]*School of Pharmacy and Pharmaceutical Sciences, Binghamton University*

291P Novel insights into the expression and the epigenetic modulation of LKB1, a potential diagnostic and therapeutic player in Duchenne muscular *dystrophy*

Boccanegra B[1], *Mantuano P*[1], *Conte E*[1], *Tulimiero L*[1], *Lenti R*[1], *Quarta R*[1], *Cristiano E*[1], *Decio A*[2], *Cappellari O*[1], *Licandro S*[2], *Fossati G*[2], *Steinkühler C*[2], *De Luca A*[1]

[1]*Department Of Pharmacy - Drug Sciences, University of Bari "Aldo Moro"*, [2]*Preclinical R&D Department, Italfarmaco S.p.A., Cinisello Balsamo*

292P Phenotypic characterization of the D2-mdx mouse for Duchenne Muscular Dystrophy: updates from a natural history study

Tulimiero L[1], *Mantuano P*[1], *Boccanegra B*[1], *Lenti R*[1], *Quarta R*[1], *Cristiano E*[1], *Marinelli M*[1], *Mele A*[1], *Cappellari O*[1], *De Luca A*[1]

[1]*Università Degli Studi Di Bari, Aldo Moro, Dipartimento di Farmacia- Scienze del Farmaco*

293P Evaluation of creatine/creatinine ratio and myostatin as monitoring biomarkers for DMD patients using real-world data

Degan C[1], *Vries S*[1], *Ikelaar N*[1], *Tsonaka R*[1], *Niks E*[1,2], *Spitali P*[1,2]

[1]*Leiden University Medical Center*, [2]*Duchenne Center Netherlands*

294P Identification of disease-specific extracellular vesicle-associated plasma biomarkers for Duchenne muscular dystrophy (DMD) and Facioscapulohumeral Muscular Dystrophy (FSHD)

Bayazit M[1], *Henderson D*[3], *Tawil R*[3], *Flanigan K*[1,2], *Harper S*[1,2], ***Saad N***[1,2]

[1]*Center for Gene Therapy, the Abigail Wexner Research Institute at Nationwide Children's Hospital, ,* [2]*Department of Pediatrics, the Ohio State University*, [3]*Department of Neurology, University of Rochester Medical Center*

295P Diagnostic yield of next-generation sequencing compared with muscle biopsy for diagnosis of MLPA negative Duchenne Muscular Dystrophy

Sanmaneechai O[1], *Meedee M*[1], *Pimchanok K*[1]

[1]*Department of Pediatrics, Faculty of Medicine Mahidol University*

296P Development of monitoring biomarker signatures in Duchenne Muscular Dystrophy

De Vries S[1], *Degan C*[1], *Tobin R*[2], *Jimenéz-Requena A*[3], *Ajeenah A*[3], *Johansson C*[3], *Van der Burgt Y*[1], *Diaz-Manera J*[4], *Guglieri M*[4], *Al-Khalili Szigyarto C*[3], *Spitali P*[1], *Hathout Y*[5], *Tsonaka R*[1], *Dang U*[2], *on behalf of Team: CINRG-DNHS Investigators, on behalf of Team: DMD Investigators*

[1]*Leiden University Medical Center,* [2]*Carleton University,* [3]*KTH Royal Institute of Technology,* [4]*Newcastle University, 5Binghamton University*

297P In-depth behavioral characterization of Duchenne Muscular Dystrophy mouse models lacking one, multiple or all dystrophin isoforms in the brain

Van Putten M[1], *Verhaeg M*[1], *van der Pijl L*[1], *van de Vijver D*[1], *Tanganyika-de Winter C*[1], *Stan T*[1], *Aartsma-Rus A*[1]

[1]*Leiden University Medical Center*

298P Magnetic resonance imaging analyses of the brain of Duchenne Muscular Dystrophy mouse models lacking one, multiple or all dystrophin isoforms

Van Putten M[1], *Verhaeg M*[1], *Suidgeest E*[1], *Kan H*[1], *van der Weerd L*[1], *Aartsma-Rus A*[1]

[1]*Leiden University Medical Center*

299P Detailed natural history study of the D2-mdx and BL10-mdx models for Duchenne Muscular Dystrophy

Van Putten M[1], *Mantuano P*[2], *Boccanegra B*[2], *Tanganyika-de Winter C*[1], *Putker K*[1], *Schneider A*[1], *Tulimiero L*[2], *Mele A*[2], *van de Vijver D*[1], *Gordiss-Dressman H*[3], *Cappellari O*[2], *Aartsma-Rus A*[1], *De Luca A*[2]

[1]*Leiden University Medical Center,* [2]*Section of Pharmacology, Department of Pharmacy,* [3]*George Washington University School of Medicine and Health Sciences*

300P Brain involvement in Duchenne Muscular Dystrophy (BIND)

Tetorou K[1,2], *Aghaeipour A*[1,2], *Gileadi T*[1,2], *Ma S*[1,2], *Perdomo Quinteiro P*[3], *Saoudi A*[5,6], *Ceschi L*[5], *Zarrouki F*[5], *Mitsogiannis M*[7], *Fergus C*[9], *Kelly V*[9], *Zhang L*[4], *Spitali P*[3], *Aoki Y*[8], *Morgan J*[1,2], *Montanaro F*[1,2], *Vaillend C*[5], *Goyenvalle A*[6], *Muntoni F*[1,2]

[1]*The Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health,* [2]*National Institute for Health Research UCL Great Ormond Street Institute of Child Health,* [3]*Human Genetics Department, Leiden University Medical Center,* [4]*Mass Spectrometry and Proteomics Facility, The Ohio State University, Columbus,* [5]*Université Paris-Saclay, CNRS, Institut des Neurosciences Paris-Saclay,* [6]*Université Paris-Saclay, UVSQ, Inserm, END-ICAP,* [7]*Transpharmation Ireland Ltd, Trinity College Institute of Neuroscience,* [8]*Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP),* [9]*Trinity College Institute of Neuroscience, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin*

301P Interactome analysis of dystrophin isoforms in the mouse brain

Tetorou K[1], *Aghaeipour A*[1,2], *Gileadi T*[1,2], *Pablo P*[3], *Zhang L*[4], *Spitali P*[3], *Morgan J*[1,2], *Montanaro F*[1,2], *Muntoni F*[1,2]

[1]*The Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health,* [2]*National Institute for Health Research UCL Great Ormond Street Institute of Child Health,* [3]*Human Genetics Department, Leiden University Medical Center,* [4]*Mass Spectrometry and Proteomics Facility, The Ohio State University*

302P Dystrophin quantification by capillary western immunoassay and western blot across the dystrophinopathy spectrum

Lay J[1], *Flanigan K*[1,2,3], *Nicolau S*[1,2,3]

[1]*Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital,* [2]*Department of Pediatrics, The Ohio State University College of Medicine,* [3]*Department of Neurology, The Ohio State University*

303P A longitudinal study on cognitive and behavioural functioning in Duchenne Muscular Dystrophy

Govaarts R[1], *Weerkamp P*[2], *de Vreede M*[1], *Marini-Bettolo C*[3], *Geagan C*[3], *Hollingsworth K*[4], *Hendriksen J*[2,5], *Kan H*[1,5], *Niks E*[1,5], *Straub V*[3]

[1]*Leiden University Medical Center,* [2]*Kempenhaeghe,* [3]*Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [4]*Newcastle University,* [5]*Duchenne Centre*

304P Multi-modal magnetic resonance imaging protocols in the multi-site Brain Involvement in Dystrophinopathies (BIND) study

Govaarts R[1], *Doorenweerd N*[1,2], *Brogna C*[4], *Clark C*[3], *Guliaeva I*[3], *Hollingsworth K*[5], *MacDonald Fisher P*[6], *Mercuri E*[4], *Niks E*[1], *Parikh J*[5], *Seunarine K*[3], *Smythe L*[3], *Stemmerik M*[6], *Straub V*[2], *Verdolotti T*[4], *Vissing J*[6], *Würgler Slipsager A*[6], *Muntoni F*[3], *Kan H*[1], *Kerkelä L*[3]

[1]*Leiden University Medical Center,* [2]*Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [3]*UCL Great Ormond Street Institute of Child Health,* [4]*Fondazione Policlinico Universitario Agostino Gemelli,* [5]*Newcastle University,* [6]*Rigshospitalet, University of Copenhagen*

305P Investigation of the clinical significance of serum titin in Duchenne Muscular Dystrophy

*Nambu Y[1], **Awano H**[2], Sonehara S[1], Bo R[1], Osawa K[3], Shirakawa T[3], Matsuo M[4]*

[1]Department of Pediatrics, Kobe University Graduate School of Medicine, [2]Organization for Research Initiative and Promotion, Tottori University, [3]Faculty of Health Sciences, Kobe Tokiwa University, [4]Graduate School of Science, Technology and Innovation, Kobe University

306P Evaluating genetic therapies targeting the central nervous system in Duchenne Muscular Dystrophy using high-resolution spatial transcriptomics

***Mao Q**[1], Ahmadi A[1], van Doorne L[1], de Vries S[1], Heezen L[1], Vacca O[2], Aartsma-Rus A[1], van Putten M[1], Goyenvalle A[2], Mahfouz A[1,3,4], Spitali P[1]*

[1]Department of Human Genetics, Leiden University Medical Center, [2]Université Paris-Saclay, UVSQ, Inserm, END-ICAP, [3]Delft Bioinformatics Lab, Delft University of Technology, [4]Leiden Computational Biology Center, Leiden University Medical Center

307P Uncovering the genomic basis of cognitive comorbidities in Duchenne Muscular Dystrophy using spatial transcriptomics in mouse models

***Mao Q**[1], Heezen L[1], de Vries S[1], van Doorne L[1], Aartsma-Rus A[1], van Putten M[1], Mahfouz A[1,2,3], Spitali P[1]*

[1]Department of Human Genetics, Leiden University Medical Center, [2]Delft Bioinformatics Lab, Delft University of Technology, [3]Leiden Computational Biology Center, Leiden University Medical Center

308P Nephrological parameters in boys with Muscular Dystrophy

***Rohlenová M**[1], Zieg J[2], Lauerová B[1], Kumhera M[1], Gloser M[1], Dolanská A[1], Haberlová J[1]*

[1]Department of Pediatric Neurology of Motol University Hospital, [2]Department of Pediatrics of Motol University Hospital

309P Cholesterol defects in Muscular Dystrophy patients and mice cause ambulation dysfunction: insight into statin- and anti-HMGCoAR-induced myopathies

***Bernatchez P**[1], Sun Z[1]*

[1]Department of Anesthesiology, Pharmacology & Therapeutics, St. Paul's Hospital, University of British Columbia

310P Stress exacerbates glucose intolerance in the mdx mouse model of Duchenne Muscular Dystrophy

***Lindsay A**[1,2,3], Salimova E[4,5], Eliades J[4], Zheng G[4], Caeyenberghs K[3], de Veer M[4,5]*

[1]University of Canterbury, [2]University of Otago, [3]Deakin University, [4]Monash University, [5]National Imaging Facility

311P Development and pilot validation of the DuMAND checklist to screen for Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties (DuMAND)

***Geuens S**[1,2], Goemans N[1], Lemiere J[3,4], Doorenweerd N[5], De Waele L[1,2]*

[1]University Hospitals Leuven, Child Neurology, [2]KU Leuven, Department of Development and Regeneration, [3]University Hospitals Leuven, Pediatric Hemato-Oncology, [4]KU Leuven, Department Oncology, Pediatric Oncology, 5Leiden University Medical Center, Radiology

312P Genotype and corticosteroid treatment are associated with distinctive variations in gray matter characteristics among patients with Duchenne Muscular Dystrophy

***Geuens S**[1,2], Van Dessel J[3], Kan H[4,5], Govaarts R[4,5], Niks E[5,6], Goemans N[1], Lemiere J[7,8], Doorenweerd N[4], De Waele L[1,2]*

[1]University Hospitals Leuven, Child Neurology, [2]KU Leuven, Department of Development and Regeneration, [3]Center for Developmental Psychiatry, Department of Neurosciences, UPC-KU, [4]Leiden University Medical Center, C.J. Gorter MRI Center, Department of Radiology, [5]Duchenne Center Netherlands, [6]Leiden University Medical Center, Department of Neurology, [7]University Hospitals Leuven, Pediatric Hemato-Oncology, [8]KU Leuven, Department Oncology, Pediatric Oncology

313P Validation lab: allowing standardized in vitro and in vivo experiments for candidate treatments for Duchenne Muscular Dystrophy

***Stan T**[1], Van De Vijver D[1], Tanganyika-de Winter C[1], van der Pijl L[1], Aartsma-Rus A[1]*

[1]Department of Human Genetics, Leiden University Medical Centre

314P Protein biomarkers predicting clinical milestones in Duchenne Muscular Dystrophy combining natural history and real-world data

*Spitali P[1,2], Ikelaar N[2,3], Barnard A[4], Eng S[5], Hosseini Vajargah S[5], Ha K[5], Kan H[2,6], Vandenborne K[4], Niks E[2,3], **Walter G**[7]*

[1]Human Genetics Department, Leiden University Medical Center, [2]Duchenne Center Netherlands, [3]Department of Neurology, Leiden University Medical Center, [4]Department of Physical Therapy, University of Florida, [5]BioSymetrics, Inc., [6]C.J. Gorter MRI Center, Department of Radiology, Leiden University Medical Center, [7]Department of Physiology and Aging, University of Florida

315P Cardio-metabolic and cytoskeletal proteomic signatures differentiate fear sensitivity in dystrophin-deficient mdx mice

Major G[1], *Herbold C*[1], *Cheng F*[2], *Lee A*[2], *Russell A*[3], *Lindsay A*[1,3,4]

[1]*University of Canterbury,* [2]*Macquarie University,* [3]*Deakin University,* 4*University of Otago*

316VP What you see is what it is: The tales of two brothers with rare intronic dystrophin gene duplication

Khries M[1], *Gowda V*[1]

[1]*Evelina London Children's Hospital*

317VP Overview of a cohort of 35 manifesting dystrophinopathy females – and addressing the forthcoming challenges

Goncalves A[1,2,3], *Sousa A*[3,4], *Garrido C*[3,5], *Cardoso M*[3,4], *Pinto M*[3,6], *Vieira E*[1,2], *Oliveira M*[1,2], *Taipa R*[2,3,6], *Coelho T*[3,4], *Santos M*[3,5], *Santos R*[1,2,3]

[1]*Unidade de Genética Molecular, Centro de Genética Médica Jacinto Magalhães, Unidade de Saúde Local de Santo António,* [2]*Unidade Multidisciplinar de Investigação Biomédica (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS) e Laboratório para a Investigação Integrativa e Translacional em Saúde Populacional (ITR), Universidade do Porto,* [3]*European Reference Center of Neuromuscular Diseases - EURO-NMD, ULSSA,* [4]*Departamento de Neurofisiologia, ULSSA,* [5]*Consulta de Neuromusculares, Unidade de Neurologia Pediátrica, Centro Materno-Infantil do Norte, ULSSA,* [6]*Unidade de Neuropatologia, Departamento de Neurologia, ULSSA*

438P - 440P, 442P - 471P: Myotonic dystrophy

438P Knockdown of *DMPK* in Myotonic Dystrophy Type 1 using CRISPR Cas13

Oh H[1,2], *Todorow V*[1], *Hintze S*[1], *Schoser B*[1], *Meinke P*[1,2]

[1]*Friedrich-Baur-Institute, Munich, Germany,* [2]*Graduate School of Graduate School of Systemic Neurosciences, Ludwig-Maximilians-University Munich*

439P Cardiac abnormalities and management in children with myotonic dystrophy type 1

Bovenkerk D[1], *Van Den Akker R*[2], *Klinkenberg S*[1], *Louw J*[3], *Udink Ten Cate F*[4], *Braakman H*[2]

[1]*Department of Neurology. Maastricht University Medical Center,* [2]*Department of Pediatric Neurology. Amalia Children's Hospital, Radboud University Medical Center,* [3]*Department of Pediatric Cardiology. Maastricht University Medical Center,* [4]*Department of Pediatric Cardiology, Amalia Children's Hospital*

440P Nonclinical data for PGN-EDODM1 demonstrated nuclear delivery, mechanistic and meaningful activity for the potential treatment of DM1

Gilbert J[1], *Klein A*[2], *Lonkar P*[1], *Gutnick A*[1], *Foy J*[1], *Yu S*[1], *Reid T*[3], *Sarkar K*[3], *Cleary J*[3], *Berglund J*[3], *Furling D*[2], ***Holland A***[1]

[1]*PepGen,* [2]*Sorbonne Université,* [3]*University at Albany–SUNY*

442P Cognitive diversity in Congenital Myotonic Dystrophy: implications for early intervention

Dixon M[1], *Butterfield R*[1]

[1]*University Of Utah, Pediatric Neurology*

443P Assessing inter and intra-rater reliability of video hand opening time in Myotonic Dystrophy

Mcintyre M[1], *de Monts C*[2], *Wilson A*[1], *Massey C*[3,4], *Olson S*[1], *Nelson L*[5], *Hageman N*[2], *Tang W*[2], *Dekdeburn J*[6], *Duong T*[2]

[1]*Department of Pediatrics, University of Utah,* [2]*Department of Neurology, Neuromuscular Division, Stanford University,* [3]*Queen Square Centre for Neuromuscular Diseases, University College London NHS Foundation Trust,* [4]*Department of Neuroscience, University of Sheffield,* [5]*Department of Physical Therapy, University of Texas Southwestern Medical Center,* [6]*Department of Neurology, University of Rochester Medical Center*

444P Exploring Hand Myotonia: assessing hand opening and individual finger movements through machine learning

Duong T[1], *de Monts C*[1], *McIntyre M*[3], *Karatsidis A*[2], *Juraver A*[2], *Ataide P*[1], *Hageman N*[1], *Erb K*[2], *Meilleur K*[2], *Day J*[1], *Burton L*[2], *Kanzler C*[2]

[1]*Stanford University,* [2]*Biogen,* [3]*University of Utah*

445P Utilization and costs of healthcare services and labour market affiliation of persons with adult-onset Myotonic Dystrophy – a Danish Register-Based Study (Study II)

Handberg C[1,2], *Rudolfsen J*[3], *Andersen H*[4], *Vissing J*[5], *Rossau C*[6], *Dreyer P*[6], *Olsen J*[3], *Bengtsson S*[3], *Aagaard H*[1], *Werlauff U*[1]

[1]*National Rehabilitation Center for Neuromuscular Diseases and Aarhus University,* [2]*Department of Public Health, Faculty of Health, Aarhus University,* [3]*EY,* [4]*Department of Clinical Medicine - The Department of Neurology, Aarhus University Hospital,* [5]*Copenhagen Neuromuscular Center, Copenhagen University Hospital,* [6]*Department of Anesthesiology and Intensive Care, Aarhus University Hospital*

446P Comorbidities and mortality of persons with adult-onset Myotonic Dystrophy – a Danish Register-Based Study (Study I)

Werlauff U[7], *Rudolfsen J*[2], *Andersen H*[3], *Vissing J*[4], *Rossau C*[5], *Dreyer P*[6], *Olsen J*[2], *Bengtsson S*[2], *Aagaard H*[7], *Handberg C*[6,7]

[1]*Rehabiliterings Center for Muskelsvind,* [2]*EY,* [3]*Department of Clinical Medicine - The Department of Neurology, Aarhus University Hospital,* [4]*Copenhagen Neuromuscular Center, Copenhagen University Hospital,* [5]*Department of Anesthesiology and Intensive Care, Aarhus University Hospital,* [6]*Department of Public Health, Faculty of Health, Aarhus University,* [7]*National Rehabilitation Centre for Neuromuscular Diseases*

447P Atrio-ventricular conduction in a mouse model with Myotonic Dystrophy Type-1: a preliminary study in hDMPK-77Tg mice

Kimura K[1], *Minegishi K*[2], *Motohashi N*[2], *Morita H*[3], *Nakanishi K*[3], *Daimon M*[3], *Takeda N*[3], *Echigoya Y*[4], *Nakamori M*[5], *Aoki Y*[2]

[1]*Departments of Laboratory Medicine/Cardiology, The Institute of Medical Science, The University of Tokyo,* [2]*Department of Molecular Therapy, National Institute of Neuroscience, National Centre of Neurology and Psychiatry,* [3]*Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo,* [4]*Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University,* [5]*Department of Neurology, Graduate School of Medicine, Yamaguchi University*

448P Quantitative analysis of brain atrophy in patients with myotonic dystrophy (DM1) using MRI -multi center analysis

Nakayama T[1], *Matsumura T*[2], *Kuru S*[3], *Kobayashi M*[4], *Suwazono S*[5], *Takahashi M*[6]

[1]*Yokohama Rosai Hospital,* [2]*NHO Toneyama Hospital,* [3]*NHO Suzuka Hospital,* [4]*NHO Akita Hospital,* [5]*NHO Okinawa Hospital,* [6]*Osaka University*

449P Molecular biomarkers in myotonic dystrophy type 1

Slipsager A[1], *Hildonen M*[2], *Godtfeldt Stemmerik M*[1], *Tümer Z*[2], *Dunø M*[2], *Birkedal U*[2], *Vissing J*[1]

[1]*CNMC, Rigshospitalet,* [2]*Department of Genetics, Rigshospitalet*

450P A review of the symptom control clinic, advance care planning and mortality in myotonic dystrophy 1 in a UK neuromuscular centre

Willis T[1,2], *Bassie C*[1], *Fox H*[3], *Kulshrestha R*[1], *Willis D*[2,3]

[1]*Robert Jones and Agnes Hunt hospital,* [2]*University of Chester Medical School,* [3]*Severn Hospice*

451P Gait parameters / cognitive function correlation in a cohort of patients with myotonic dystrophy type 1: a single-center sensor-based gait analysis

Risi B[1], *Pilotto A*[2,3,4], *Rizzardi A*[2,3], *Ferrari E*[1], *Labella B*[2,3], *Zatti C*[2,3], *Hansen C*[5], *Romijnders R*[5], *Caria F*[1], *Damioli S*[1], *Bertella E*[1], *Poli L*[3], *Ferullo L*[2,3], *Olivieri E*[2,3], *Maetzler W*[5], *Padovani A*[2,3], *Filosto M*[1,2]

[1]*NeMO-Brescia Clinical Center for Neuromuscular Diseases,* [2]*Department of Clinical and Experimental Sciences, University of Brescia,* [3]*Department of Continuity of Care and Frailty, Neurology Unit, Spedali Civili Hospital of Brescia,* [4]*Laboratory of Digital Neurology and Biosensors, University of Brescia,* [5]*Department of Neurology, Christian-Albrechts-University of Kiel*

452P Genetic confirmation of myotonic dystrophy type II after allogeneic stem cell transplant

Schaefer J[1], *Saak A*[2]

[1]*Uniklinikum C.G. Carus,* [2]*Ludwig-Maximilians Universität*

453P Characterisation of cell culture models of myotonic dystrophy type I for drug screening by in-cell western and digital droplet PCR

López-Martínez A[1], *Sendino M*[1], *Torres-Conde N*[1], *Al-Ani A*[1], *Martínez-Gonzalez S*[1], *Nuñez-Manchón J*[2], *Nogales-Gadea G*[2], ***Arechavala Gomeza V***[1,3]

[1]*Biobizkaia Health Reseach Institute,* [2]*Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP),* [3]*Ikerbasque, Basque Foundation for Science*

454P Myotonic dystrophy type 1 with progressive supranuclear palsy showing responsiveness to levodopa

Indrawati L[1,2], *Tunjungsari D*[1,2,3], *Nagpal C*[2], *Muljono W*[1], *Ariarini N*[2,3]

[1]*Department of Neurology, Dr Cipto Mangunkusumo Hospital,* [2]*Department of Neurology, Faculty of Medicine, Universitas Indonesia,* [3]*Department of Neurology, Universitas Indonesia Hospital*

455P Psoriasis and myotonic dystrophy type 1: another cutaneous manifestation of a multisystemic disorder

Tufano L[1], *Bucci E*[1], *Antonini G*[1], *Garibaldi M*[1]

[1]*Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome*

456P Gait analysis by IMU sensor in myotonic dystrophy type 1

Tufano L[1], *Bianchini E*[1], *Bucci E*[1], *Antonini G*[1], *Garibaldi M*[1]
[1]*Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome*

457P Mortality rate and predictors of death in the DM1 population, a registry-based study

Bassez G[1], *Kachal A*[1], *Gyenge M*[1], *Hamroun D*[1], *French Myotonic Dystrophy Study Group*
[1]*Institute of Myology*

458P The iDM-Scope Registry: an innovative France-Canada framework to advance Myotonic Dystrophy translational research

Bassez G[1], *Gyenge M*[1], *Hamroun D*[2], *Kachal A*[1], *Evangelista T*[1], *Rodrigue X*[3], *Nury M*[3], *Lochmüller H*[4], *Gagnon C*[5]
[1]*Institute of Myology,* [2]*CHU Montpellier,* [3]*Université Laval,* [4]*The Ottawa Hospital,* [5]*Université Sherbrooke*

459P Correlation of minimally invasive blood biomarkers with muscle-derived molecular signatures in myotonic dystrophy type 2

Kleefeld F[1], *Hentschel A*[5], *Preusse C*[1], *Schoser B*[3], *Stenzel W*[1], *Roos A*[2,5,7]
[1]*Charité - Universitätsmedizin Berlin,* [2]*Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University,* [3]*Friedrich Baur Institute,* [4]*University of Cambridge,* [5]*Leibniz-Institut für Analytische Wissenschaften,* [6]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute,* [7]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioural Sciences, University Duisburg-Essen*

460P Understanding the clinical heterogeneity in myotonic dystrophy type 1: identifying clinical phenotypes using unsupervised clustering

la Fontaine L[1], *Imkamp M*[1], *'t Hoen P*[2], *van As D*[2], *Smulders F*[2], *Bruijnes J*[1], *de Kok J*[1], *Faber C*[1], *Merkies I*[1], *van Kuijk S*[1]
[1]*Maastricht University Medical Centre,* [2]*Radboud University Medical Centre*

461P Evaluation of PGN-EDODM1: FREEDOM-DM1 and FREEDOM2-DM1 clinical trials in myotonic dystrophy type 1

Larkindale J[1], *Shoskes J*[1], *Garg B*[1], *Song G*[1], *Lonkar P*[1], *Babcock S*[1], *Vacca S*[1], *Yu S*[1], *Mellion M*[1]
[1]*PepGen Inc.*

462P Evaluating EEG as an outcome measure for CNS Symptoms in myotonic dystrophy type 1: a clinical trial analysis

Allen S[1], *Kamali T*[1], *Parker D*[1], *Seto A*[2], *Ehrich E*[2], *Wang E*[3], *Sampson J*[1]
[1]*Stanford University,* [2]*Expansion Therapeutics,* [3]*University of Florida*

463P Longitudinal progression of motor function in individuals with myotonic dystrophy type 1: insights from the END-DM1 study

Johnson N[1], *Hung M*[1], *Sansone V*[1], *Subramony S*[1], *Statland J*[1], *Hamel J*[1], *van Engelen B*[1], *Mul K*[1], *Elsheikh B*[1], *Roxburgh R*[1], *Day J*[1], *Swenson A*[1], *Schoser B*[1], *Ragole T*[1], *Greene E*[1], *Shieh P*[1], *Thornton C*[1], *On behalf of DMCRN*
[1]*Virginia Commonwealth University*

464P Advancing preclinical research of myotonic dystrophy type 1 with 3D functional human skeletal muscle tissues

Fernández-Garibay X[1], *Sabater-Arcís M*[2,3], *Núñez-Manchón J*[4], *Tejedera-Villafranca A*[1], *Artero R*[2,3], *Suelves M*[4], *Nogales-Gadea G*[4], *Ramón-Azcón J*[1,5], *Fernández-Costa J*[1]
[1]*Insitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST),* [2]*University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia,* [3]*Incliva Health Research Institute,* [4]*Germans Trias i Pujol Research Institute (IGTP), Universitat Autònoma de Barcelona,* [5]*ICREA-Institució Catalana de Recerca i Estudis Avançats*

465P Factors impacting dysphagia in adult-onset myotonic dystrophy type 1

Berggren K[1], *Kamarunas E*[2], *Johnson N*[1]
[1]*VCU Dept of Neurology, Center for Inherited Muscle Research,* [2]*James Madison University*

466P Multisystemic manifestations in adult patients with classic myotonic dystrophy Type 1

Iterbeke L[1], *Claeys K*[1,2]
[1]*Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, and Leuven Brain Institute (LBI),* [2]*Department of Neurology, University Hospitals Leuven*

467P A multicenter retrospective study in Turkish children with myotonic dystrophy type 1

Oz Tuncer G[1], *Sanri A*[2], *Kurt Bayir G*[1], *Erol İ*[3], *Ardıçlı D*[4], *Öztürk M*[5], *Gazeteci Tekin H*[6], *Kutluk G*[7], *Hergüner Ö*[8], *Tekgül H*[9], *Tütüncü Toker R*[10], *Per H*[11], *Çavuşoğlu D*[12], *Pembegül Yildiz E*[13], *Kömür M*[14], *Türkdoğan D*[15], *Özgör B*[16], *Ayça S*[17], *Turkish Myotonic Dystrophy Type 1 Study Group T*[18]

[1]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Ondokuz Mayıs University,* [2]*Department of Pediatric Genetics University of Health Sciences, Samsun Training and Research Hospital,* [3]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Başkent University,* [4]*Division of Pediatric Neurology, Department of Pediatrics, Ankara City Hospital,* [5]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Kocaeli University,* [6]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Bakırçay University,* [7]*Department of Pediatric Neurology, University of Health Sciences, Antalya Training and Research Hospital,* [8]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Çukurova University,* [9]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Ege University,* [10]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Uludağ University,* [11]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Erciyes University,* [12]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Afyonkarahisar Health Sciences University,* [13]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, İstanbul University,* [14]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Mersin University,* [15]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Marmara University Pendik Training and Research Hospital,* [16]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, İnönü University Turgut Ozal Research,* [17]*Division of Pediatric Neurology, Department of Pediatrics, Faculty of Medicine, Celal Bayar University,* [18]*Turkish Myotonic Dystrophy Type 1 Study Group*

468P Exploring gut microbiome alteration in children with myotonic dystrophy type 1: a pilot study

van Uden A[1,2], *Zweers-van Essen H*[3], *de Baaij-Daalmeyer A*[3], *Ederveen T*[2], *Braakman H*[1]

[1]*Department of Pediatric Neurology, Amalia Children's Hospital, Radboudumc,* [2]*Department of Medical BioSciences, Radboudumc,* [3]*Department of Gastroenterology and Hepatology, Radboudumc*

469P Modal allele change as a predictor of skeletal muscle symptoms progression in myotonic dystrophy type 1

Radovanovic N[1], *Pesovic J*[1], *Peric S*[2,3], *Radenkovic L*[1], *Brkusanin M*[1], *Brajuskovic G*[1], *Rakocevic Stojanovic V*[2,3], *Savic-Pavicevic D*[1]

[1]*University of Belgrade-Faculty of Biology, Center for Human Molecular Genetics,* [2]*University Clinical Centre of Serbia, Neurology Clinic,* [3]*University of Belgrade-School of Medicine*

470P Splicing is improved using a novel AAV-microRNA delivery platform as a treatment for myotonic dystrophy type 1

Cao S[1], *Tomassy G*[1], *Richards B*[1], *Fan W*[1], *Luo Z*[1], *Jackson R*[1], *O'Riordan C*[1], *Goulet M*[1], *Mueller C*[1]

[1]*Genomic Medicine Unit, Sanofi*

471P Interfering with CUG toxic repeats using AAV.U7snRNAs rescue myotonia and splicing defects in myotonic dystrophy type 1

Almeida C[1], *Brinkman A*[1], *Wendt C*[2], *Blatnik A*[2], *Delgado A*[1], *Gushchina L*[1], *Arnold W*[3], *Weiss R*[4], *Wein N*[1,5]

[1]*Center for Gene Therapy, Nationwide Children's Hospital,* [2]*Department of Biological Chemistry and Pharmacology, The Ohio State University,* [3]*Department of Physical Medicine and Rehabilitation, University of Missouri School of Medicine,* [4]*Department of Human Genetics, The University of Utah School of Medicine,* [5]*Department of Pediatrics, The Ohio State University*

598P-618P: Registries, networks and care of NMD

598P The Canadian Neuromuscular Disease Registry: using real-world evidence to further spinal muscular atrophy research in Canada

Crone M[1], *Henley K*[2], *Hodgkinson V*[2], *Dyck A*[2], *Brais B*[3], *Campbell C*[4], *Gonorazky H*[5], *Lochmüller H*[6], *MacKenzie A*[7], *McMillan H*[7], *Oskoui M*[8], *Korngut L*[9], *Selby K*[10], *SMA Investigator Network on behalf of the CNDR Investigator Network*

[1]*Alberta Children's Hospital, University of Calgary,* [2]*Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary,* [3]*Montreal Neurological Institute, McGill University,* [4]*Western University,* [5]*Hospital for Sick Children, University of Toronto,* [6]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario, University of Ottawa,* [7]*Children's Hospital of Eastern Ontario, University of Ottawa,* [8]*Montreal Children's Hospital, McGill University,* [9]*Hotchkiss Brain Institute, University of Calgary,* [10]*BC Children's Hospital, University of British Columbia*

599P The UK Facioscapulohumeral muscular dystrophy Patient Registry: a powerful tool to support clinical research and patient voice in the translational research pathway

Walker H[1], *Muni-Lofra R*[1], *Orrell R*[2], *Graham A*[3], *Norwood F*[4], *Roberts M*[5], *Willis T*[6], *Matthews E*[7], *Mencias M*[7], *Adcock K*[8], *Marini-Bettolo C*[1]

[1]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University,* [2]*UCL Queen Square Institute of Neurology, University College London,* [3]*Patient Representative,* [4]*Department of Neurology, Kings College Hospital,* [5]*Department of Neurology, Salford Royal NHS Foundation Trust,* [6]*Neuromuscular Service, The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust,* [7]*The Atkinson Morley Regional Neurosciences Centre, St George's University Hospital NHS Foundation Trust,* [8]*Muscular Dystrophy UK*

600P The UK Myotonic Dystrophy Patient Registry - empowering clinical research and patient voice with an effective translational research tool

Walker H[1], *Sodhi J*[1], *Turner C*[2], *Adcock K*[3], *Ashley E*[4], *Orrell R*[5], *Monckton D*[6], *Hamilton M*[7], *Hewamadduma C*[8], *Walker M*[9], *Marini-Bettolo C*[1]

[1]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University,* [2]*University College Hospital, National Hospital for Neurology and Neurosurgery,* [3]*Muscular Dystrophy UK,* [4]*Cure Myotonic Dystrophy UK Charity (Cure-DM),* [5]*UCL Queen Square Institute of Neurology, University College London,* [6]*Institute of Molecular Cell and Systems Biology, University of Glasgow,* [7]*West of Scotland Clinical Genetics Service, Queen Elizabeth University Hospital,* [8]*Sheffield Teaching Hospitals NHS Foundation Trust,* [9]*Myotonic Dystrophy Support Group*

601P Gap analysis of 4-year data in the Dutch Dystrophinopathy Database

Meijer-Krom Y[1,3], *Ikelaar N*[1,3], *Bongers J*[1,3], *van de Velden N*[1,3], *Snijder R*[4], *Houwen van Opstal S*[2,3], *Niks E*[1,3]

[1]*Department of Neurology, Leiden University Medical Center,* [2]*Department of Rehabilitation, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center, Amalia Children's Hospital,* [3]*Duchenne Center Netherlands,* [4]*Department of Biobanking, Leiden University Medical Center*

602P FISMA for high quality and interoperable real-world data on dystrophinopathies: FAIR from the start, from concept to reality

Meijer-Krom Y[1,5], *Hoek R*[1,5], *Houwen van Opstal S*[2,5], *van de Velden N*[1,5], *Ikelaar N*[1,5], *van der Holst M*[3,5], *Snijder R*[4], *Niks E*[1,5]

[1]*Department of Neurology, Leiden University Medical Center,* [2]*Department of Rehabilitation, Amalia Children's Hospital, Radboud University Medical Center,* [3]*Department of Orthopedics, Rehabilitation and Physiotherapy, Leiden University Medical Center,* [4]*Biobanking Organization, Leiden University Medical Center,* [5]*Duchenne Center Netherlands*

603P DMD Hub: An established clinical trial accelerator network delivering tools and services to sites, patients and industry in the UK

Heslop E[1], *Gaeta A*[2], *Reuben E*[2], *Johnson A*[2], *Cammish P*[1], *McNiff M*[1], *Riguzzi P*[1], *Muntoni F*[3], *Childs A*[4], *Straub V*[1], *Guglieri M*[1]

[1]*JWMDRC Newcastle University,* [2]*Duchenne UK,* [3]*UCL Great Ormond Street Institute of Child Health,* [4]*Leeds Teaching Hospital*

604P Descriptive analysis of Duchenne Muscular Dystrophy patients included in the Swedish National Registry for neuromuscular disorders

Ekström A[1]

[1]*Queen Silvia Children´s Hospital, Sahlgrenska University Hospital. University of Gothenburg*

605P Dutch LGMD registry: real-world data to facilitate trial rea*diness*

Schrama E[1], *Hoek R*[1], *Bongers J*[1], *Straathof C*[1], *Badrising U*[1], *van Reenen R*[2], *van der Kooi A*[3], *van Duyvenvoorde H*[4], *Krom Y*[1], *Niks E*[1]

[1]*Department of Neurology, Leiden University Medical Center,* [2]*Spierziekten Nederland,* [3]*Department of Neurology, Amsterdam University Medical Center,* [4]*Department of Clinical Genetics, Leiden University Medical Center*

606P Burden of illness for male patients with Duchenne Muscular Dystrophy in a real-world setting, a Swedish registry study

Furby H[1], *Boudreau D*[2], *Ekstrom A*[3], *Freilich J*[4], *Kroksmark A*[5], *Streja E*[4], *Wojtowicz J*[1], *Yang Q*[4], *Zhao J*[4], *De Ford C*[1]

[1]*F. Hoffmann-La Roche, Ltd,* [2]*Genentech, Inc.,* [3]*Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg,* [4]*Parexel International Limited,* [5]*Department of Health and Rehabilitation, Institute of Neuroscience and Physiology, University of Gothenburg*

607P A patient-centered registry for rare neuromuscular disorders with federated FAIR infrastructure: the EURO-NMD Registry Hub

*Atalaia A[1], Wandrei D[2], Lalout N[3,4], Tassoni A[2], A. C. 't Hoen P[3], Athanasiou D[6], D'Angelo C[8], Mancuso M, Kornblum C[12], Kirschner J[13], Pareyson D[14], Bassez G[15], Lamy F[17], de Visser M[21], Silani V[25], Vroom E[6], D. Wilkinson M[28], Lochmuller H[5,13], **Evangelista T**[8,28], ERN EURO-NMD Registry Consortium*

[1]Inserm Center of Research in Myology, Neuro Myology Service, G.H. Pitié Salpêtrière, Sorbonne Université, [2]Clinical Trials Unit, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, [3]Medical BioSciences Department, Radboud University Medical Center, [4]Duchenne Parent Project, [5]Children's Hospital of Eastern Ontario Research Institute, [6]World Duchenne Organisation, [7]Duchenne Data Foundation, [8]European Reference Network for Rare Neuromuscular Diseases EURO NMD, Institute of Myology, University Hospital Pitie-Salpetriere-APHP, [9]Department of Clinical Neurosciences, University of Cambridge, [10]Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, [11]Department of Neurology/Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, [12]Department of Neurology, Neuromuscular Diseases Section, University Hospital Bonn, Bonn, Germany, [13]Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine, MedicalCenter – University of Freiburg, [14]Unit of Rare Neurological Diseases. Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, [15]Neuromuscular Diseases Reference Center, Pitié Salpêtrière University Hospital, APHP, [16]Association Française Contre Les Myopathies, AFM-Telethon, [17]European Patient Organisation for Dysimmune and Inflammatory Neuropathies, [18]Neuromuscular Center, University Hospital Motol, [19]Department of Neurology, Maastricht University Medical Center, and MHeNS, School for Mental Health and Neuroscience, Maastricht University, [20]Department of Neurology, Amsterdam University Medical Center, Location Academic Medical Center, [21]Department of Neurology, University Hospitals Leuven, and Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, and Leuven Brain Institute (LBI), [22]Hospital Universitario Virgen del Rocio, Séville, Spain, [23]Department of Clinical and Experimental Medicine, AOU G. Martino Di Messina, [24]Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, [25]ALS Liga Belgium, Leuven, Belgium, [26]CHRU de Montpellier, Hopital La Colombiere, [27]INIA, Universidad Politecnica de Madrid (UPM), [28]Neuromuscular Pathology Functional Unit; Neuropathology Service, Institute of Myology, University Hospital Pitié-Salpêtrière-APHP

608P Collection of real-world data for Duchenne Muscular Dystrophy patients through a national registry: description of the current cohort in the UK

Brooke M[1], *Wolfe A[1,2], Aslam N[1], Manzur A[2], Muntoni F[1,2], Baranello G[1,2]*

[1]University College London, [2]Great Ormond Street Hospital for Children NHS Foundation Trust

609P Integration of healthcare and research to optimize treatment and collect real-world data in neuromuscular disorders

Verschoof M[1,2], *Slingerland F[1], Roest A[3], de Vreede I[3], Warmenhoven N[4,5], van Beek C[5], de Witte P[5], Bot D[6], van Wageningen H[4,5], Atsma D[7], Straathof C[1,2], Kan H[8], Spitali P[2,9], Snijder R[10], Hoek R[1], van der Holst M[2,5], Meijer-Krom Y[1,2], Niks E[1,2]*

[1]Department of Neurology, Leiden University Medical Center, [2]Duchenne Center Netherlands, [3]Department of Pediatrics, Leiden University Medical Center, [4]Basalt Rehabilitation Center, [5]Department of Orthopedics, Rehabilitation & Physical therapy, Leiden University Medical Center, [6]Department of Dietetics and Social Work, Leiden University Medical Center, [7]Department of Cardiology, Leiden University Medical Center, [8]C.J. Gorter MRI Center, Department of Radiology, Leiden University Medical Center, [9]Human Genetics Department, Leiden University Medical Center, [10]Biobanking Organization, Leiden University Medical Center

610P Facilitating patient/caregiver preparation prior to visit increases quality in neuromuscular care

Edofsson U[1], *Weichbrodt J[1], Sofou K[1]*

[1]The Queen Silvia Children´s Hospital

611P Empowering patient decision-making and enhancing clinical care through the UK Duchenne Muscular Dystrophy patient data collection platform

Reuben E[1], *Gaeta A[1], Johnson A[1], Philippault H[1], Davies E[2], Ferrer-Mallol E[2], Cammish P[3], Guglieri M[3], Ezzamouri B[1]*

[1]Duchenne UK, London, UK, [2]Aparito Ltd, [3]Institute of Human Genetics International Centre for Life Newcastle University

continued on next page

612P Dystrophinopathy in ACTION; Analysis of the first 500 males enrolled in the Advanced Cardiac Therapies Improving Outcomes Network prospective dystrophinopathy registry

Hayes E[1], *Villa C*[2], *Nandi D*[1], *Soslow J*[3], *Mokshagundam D*[4], *Shih R*[5], *Wisotzkey B*[6], *Parent J*[7], *Cunningham T*[8], *Conway J*[9], *Esteso P*[10], *Birnbaum B*[11], *Shugh S*[12], *Raucci F*[13], *Kaufman B*[14], *Soares N*[15], *Kirmani S*[16], *Martinez H*[17], *Gambetta K*[18], *Lal A*[19], *Wittlieb-Weber C*[20]

[1]*The Children's Hospital,* [2]*Cincinnati Children's Hospital,* [3]*Monroe Carell Jr. Children's Hospital at Vanderbilt,* [4]*St. Louis Children's Hospital,* [5]*UF Shands Children's Hospital,* [6]*Phoenix Children's Hospital,* [7]*Riley Hospital for Children,* [8]*Arkansas Children's Hospital,* [9]*Stollery Children's Hospital,* [10]*Boston Children's Hospital,* [11]*Children's Mercy,* [12]*Joe DiMaggio Children's Hospital,* [13]*Children's Hospital of Richmond at VCU,* [14]*Lucille Packard Children's Hospital, Palo Alto, USA,* [15]*Children's Medical Center Dallas, Dallas, USA,* [16]*Children's Wisconsin,* [17]*Le Bonheur Children's Hospital,* [18]*Ann & Robert H. Lurie Children's Hospital of Chicago,* [19]*Pimary Children's Hospital,* [20]*The Children's Hospital of Philadelphia*

613P Contemporary use of ventricular assist devices in Muscular Dystrophy: a report from the ACTION learning collaborative

Nandi D[1], *Hayes E*[1], *Auerbach S*[2], *Bansal N*[3], *Conway J*[4], *Esteo P*[5], *Kaufman B*[6], *Lal A*[7], *Law S*[8], *Mokshagundam D*[9], *Sutcliffe D*[10], *Absi M*[11], *Raskin A*[12], *Friedland-Little J*[13], *Wittlieb-Weber C*[14], *Kroslowitz B*[15], *Lorts A*[15], *Cripe L*[1], *Villa C*[15]

[1]*Division of Cardiology, Department of Pediatrics, Nationwide Children's Hospital,* [2]*Children's Hospital Coloardo,* [3]*Mt Sinai School of Medicine,* [4]*University of Alberta,* [5]*Boston Children's Hospital,* [6]*Lucille Packard Children's Hospital,* [7]*Primary Children's Hospital,* [8]*Morgan Stanley Children's Hospital of New York,* [9]*St. Louis Children's Hospital,* [10]*Children's Mercy Hospital,* [11]*LeBonheur Children's Hospital,* [12]*Children's Hospital of Wisconsin,* [13]*Seattle Children's Hospital,* [14]*Children's Hospital of Philadelphia, 15Cincinnati Children's Hospital Medical Center*

614P Burden on parent caregivers of children with a muscle disease: a qualitative study

Altena-rensen S[1], *van Hattum M*[2], *Braakman H*[1], *Erasmus C*[1],

[1]*Radboudumc Amalia Children's Hospital, Netherlands,* [2]*Hogeschool Arnhem en Nijmegen*

615P Introducing PaLaDIn: improving the use of rare NMD patient data to inform healthcare decision making

Leary R[1], *Allison D*[2], *Cogoni S*[3], *Cornet R*[4], *Roos M*[5], *Davies E*[6], *Schoser B*[7], *Kahtava K*[8], *Ezzamouri B*[9], *Straub V*[1]

[1]*John Walton Muscular Dystrophy Research Centre (Newcastle University),* [2]*TREAT-NMD Services Ltd.,* [3]*Parent Project Italy APS,* [4]*Amsterdam University Medical Centre,* [5]*Leiden University Medical Centre,* [6]*Aparito,* [7]*Ludwig-Maximilians-Universität München,* [8]*FSHD Society, 9Duchenne UK*

616P From New Zealand Neuromuscular Disease Registry to Pūnaha Io - the New Zealand NeuroGenetic Registry & Biobank

Rodrigues M[1,2], *O'Grady G*[3], *Buchanan C*[1], *Fraser L*[1], *Stewart C*[1], *Cleland J*[4], *Roxburgh R*[1,2]

[1]*Health New Zealand - Auckland,* [2]*University of Auckland,* [3]*Starship Children's Hospital,* [4]*Health New Zealand*

617P Using innovative data modelling methods to improve data quality- learning from Adult SMA REACH a real-world data collection study

Segovia Simon S[1], *Verdu-Diaz J*[1], *Karkkainen E*[1], *Page J*[1], *Carver A*[1], *Alvarez G*[1], *Muni-Lofra R*[1], *Mitchell-Sodhi J*[1], *Marini-Bettolo C*[1]

[1]*The John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

618P Global FKRP Registry - the research database for Limb Girdle Muscular Dystrophy 2I/R9

McDonald S[1], *Murphy L*[1], *Alfano L*[2], *Brazzo K*[3], *Johnson N*[4], *Laurent J*[5], *Mathews K*[6], *Thiele S*[7], *Vissing J*[8], *Walter M*[7], *Woods L*[9], *Ørstavik K*[10], *Straub V*[1]

[1]*The John Walton Muscular Dystrophy Research Centre, Newcastle University,* [2]*Center for Gene Therapy at the Research Institute, Nationwide Children's Hospital,* [3]*CureLGMD2i Foundation,* [4]*Virginia Commonwealth University, Department of Neurology,* [5]*LGMD2i Research Fund,* [6]*Carver College of Medicine, University of Iowa,* [7]*Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University,* [8]*Copenhagen Neuromuscular Center, University of Copenhagen,* [9]*Patient representative,* [10]*Section for Rare Neuromuscular disorders, Department of Neurology, Oslo University Hospital*

15:15-15:45	**Short Oral Presentations 7**	**Short Oral Presentations 8**	**Short Oral Presentations 9**
	North Hall	Terrace 2A	Terrace 2B
	69P, 70P, 74P, 71P, 72P	**469P, 470P, 471P, 468P, 203P**	**315P, 314P, 312P, 265P, 262P**
	Moderator: Duygu Selcen, The Mayo Clinic	*Moderator: Nicholas Johnson, Virginia Commonwealth University*	*Moderator: Anna Sarkozy, Great Ormond Street Hospital*

15:45-16:45 **Poster Session 4** Forum Hall (refreshments provided)

98P-109P, 110VP-112VP: ALS/neuropathy

98P Biallelic pathogenic PLEKHG5 variants in a girl with childhood-onset lower motor neuron disease

Çavuşoğlu D[1], *Ataseven Kulali M*[2], *Guzel A*[3], *Olgac Dundar N*[4]
[1]*Departments of Pediatric Neurology, Afyonkarahisar Health Sciences University,* [2]*Departments of Pediatric Genetics, Etlik City Hospital,* [3]*Departments of Neurology, Afyonkarahisar Health Sciences University,* [4]*Department of Pediatric Neurology, Faculty of Medicine, İzmir Katip Celebi University*

99P Genetic odyssey: a journey through inherited neuropathies in our center

Davarasingi V[1], *Krishna G*[1], *Ramesh babu R*[1], *Satyam P*[1], *Mathew A*[1]
[1]*Synapse Neuro center and Child Development Centre*

100P Case series of three children with *SH3TC2*-Related Hereditary Sensorimotor Neuropathy

Moore Burk M[1], *Kelley C*[1], *Silver C*[1], *Gibbons M*[2], *Foster H*[1], *Browning K*[1,2], *Murphy-Zane M*[1,2], *Apkon S*[1,2], *Yang M*[1,2]
[1]*Children's Hospital Colorado,* [2]*University of Colorado School of Medicine*

101P Pediatric Charcot-Marie-Tooth (CMT) Clinic: quality care and preparing for the future

Moore Burk M1, *Kelley C*[1], *Silver C*[1], *Gibbons M*[2], *Foster H*[1], *Browning K*[2], *Murphy-Zane M*[1,2], *Yang M*[1,2], *Apkon S*[1,2]
[1]*Children's Hospital Colorado,* [2]*University of Colorado School of Medicine*

102P Clinical profiles bulbar and limb onset Amyotrophic Lateral Sclerosis patients: A Retrospective Cohort Study

Yunisova G[1], *Üçem S*[2], *Özdağ Acarlı A*[3], *Başak A*[4], *Oflazer P*[3]
[1]*Koc University Hospital,* [2]*Koç University, Koç University Hospital, Department of Neurology,* [3]*Koç University, Koç University Hospital, Department of Neurology, Muscle Diseases Center,* [4]*Koç University, Research Center for Translational Medicine (KUTTAM), NDAL, Department of Molecular Biology and Genetics*

103P NMD670, a first-in-class skeletal muscle ClC-1 Inhibitor in Charcot-Marie-Tooth disease: the SYNAPSE-CMT phase 2 study

Gidaro T[1], *S. Grønnebæk T*[1], *Cornwall C*[1], *Gupte J*[1], *Sampson C*[1], *Kiyasova V*[1], *H. Pedersen T*[1], *A. Quiroz J*[1]
[1]*NMD Pharma*

104P RNA Aptamers as a potential drug candidate for ALS

Niu L[1], *Huang Z*[1], *Akamatsu M*[1]
[1]*Department of Chemistry, University at Albany, State University of New York*

105P Frequency and clinical characterization of *SORD*-Related Neuropathy in a Belgian cohort

Opsomer M[1,2], *Vermeersch P*[3], *Philip V*[1], *Decru B*[3], *Race V*[4], *Dohrn M*[5,6], *Zuchner S*[5], *Claeys K*[1,2]
[1]*Department of Neurology, University Hospitals Leuven,* [2]*Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, and Leuven Brain Institute (LBI) ,* [3]*Clinical Department of Laboratory Medicine, University Hospitals Leuven,* [4]*Center for Human Genetics, KU Leuven and University Hospitals Leuven,* [5]*Dr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Hum Genomics, University of Miami, Miller School of Medicine,* [6]*Department of Neurology, Medical Faculty RWTH Aachen University*

106P Clinical, neurophysiological, and genetic characterization of a 5' UTR PSAP variant: Implications for diagnosis

Donkervoort S[1], *Orbach R*[1], *Silverstein S*[1,2], *Potticary A*[1], *Stenton S*[3], *Karachunski P*[4], *Bönnemann C*[1]
[1]*NNDCS, National Institutes of Health,* [2]*Rutgers New Jersey Medical School,* [3]*Broad Institute of MIT and Harvard,* [4]*University of Minnesota Medical School*

107P Clinical features of FOSMN syndrome in Korea: a comparison with bulbar-onset Amyotrophic Lateral Sclerosis

Choi S[1], *Ju W*[1], *Sung J*[1]
[1]*Department of Neurology, Seoul National University Hospital*

108P Case series: description of *HSBP1* mutations conferring motor neuropathies with overlap features presenting barriers to timely diagnosis

Nardin J[1], *Segall H*[1], *Jones K*[2], *Mehrabyan A*[1]
[1]*UNC Health, 2Duke University*

109P Preserve sense by antisense – a novel allele-specific antisense oligonucleotide therapy for *SPTLC1*-related Hereditary Sensory Neuropathy

*Meng J[1,2], Ma S[1], Wong L[1], Lone M[3], Zhang Q[1], Cheng S[1], Demetriou C[1], Clark A[4], Bennett D[5], Hornemann T[3], Reilly M[1], Muntoni F[1,2], **Zhou H**[1,2]*

[1]University College London, [2]NIHR Great Ormond Street Hospital Biomedical Research Centre, [3]University of Zürich, [4]Queen Mary University, [5]University of Oxford

110VP *FIG4* loss of function: Unraveling the phenotypic spectrum for clinical trial readiness

Boyek G[1], *Orbach R[1], Gottlieb K[2], Duff J[3], Lenk G[4], Bönnemann C[1]*

[1]National Institutes of Health, Neuromuscular and Neurogenetic Disorders of Childhood Section, [2]Elpida Therapeutics, [3]CureCMT4J/Talia Duff Foundation, [4]University of Michigan, Department of Human Genetics

111P Genotype-phenotype analysis of multisystem proteinopathy with neurological involvement

Xia X[1], *Dong Y[1], Chen Y[1], Zhao C[1], Zhu W[1]*

[1]Huashan Hospital, Fudan University

112VP Spinal and Bulbar Muscular Atrophy with easy fatigability and hyperCKemia

Lee J[1]

[1]Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea

148P-181P: SMA Therapies

148P Rapid risdiplam initiation in newborns with Spinal Muscular Atrophy (SMA): A multicenter, retrospective cohort study

Goedeker N[1], *Dierker A[1], Felker M[2], Lakhotia A[3], Rogers A[3], Zaidman C[1]*

[1]Washington University in Saint Louis School of Medicine, [2]Indiana University School of Medicine, [3]University of Louisville School of Medicine

149VP 3D stem cell-derived spinal cord/muscle organoid model for studying and treating neuromuscular diseases

Corti S[1], *D' Angelo A[1], Beatrice F[1], Ongaro J[2], Rinchetti P[1], Faravelli I[1], Miotto M[3], Lodato S[3], Nizzardo M[2], Comi G[1], Ottoboni L[1]*

[1]University Of Milan, [2]Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, [3]Humanitas University

150P Patient, caregiver and healthcare professionals' perspective on spinal bracing in early onset Spinal Muscular Atrophy in the U.K.: a national survey

Quelch W[1], *Taylor F[2], Thorman P[3], Ramjattan H[2], Ramdas S[2,4,5], Ong M[1]*

[1]Department of Paediatric Neurology, Sheffield Children's Hospital, [2]Oxford University Hospitals NHS Foundation Trust, [3]Spinal Muscular Atrophy UK, [4]Department of Paediatric Neurology, John Radcliffe Hospital, [5]MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford

151P Real-world treatment with risdiplam in adults with SMA: a multicentre study

Gorni K[1], *Guittari C[2], Candrilli S[3], Miles L[3], Simpson A[4], Shapouri S[5]*

[1]PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, [2]PDMA Neuroscience and Rare Disease, Genentech, Inc., [3]RTI Health Solutions, [4]Global Access, F. Hoffmann-La Roche Ltd, 5Genentech, Inc.

152P Perceived effects of treatments by SMA adult patients: a French qualitative study

Laforêt P[24,2,3], *Montagu G[4], Boyer F[5,6], Gargiulo M[7,8], Pouplin S[9,10], Barrière A[11], Berling E[1,2], Bonnyaud C[9,10], Cintas P[12], Hogrel J[7], Le Goff L[13], Marchadier B[14], N'Dah Sékou G[1,2], Orlikowski D[2,15,16,17], Prigent H[2,17,18], Ropars J[19,23], Salort-Campana E[20,21], Stojkovic T[7,22], Attarian S[20,21]*

[1]Centre de référence des maladies neuromusculaires Nord Est IDF, Hôpital Raymond-Poincaré, Hôpital Raymond Poincaré, APHP, [2]FHU Phenix, Garches, France, [3]U1179 INSERM, Université Versailles-Saint-Quentin-en-Yvelines, [4]Recherche, unknowns SAS, [5]Service de Médecine Physique et Réadaptation, CHU de Reims, [6]EA 3797, Département de Santé Publique, Université de Reims Champagne-Ardenne, [7]Institut de Myologie, [8]Laboratoire de Psychologie clinique, Psychopathologie et Psychanalyse (EA 4056) Université Sorbonne Paris Cité, [9]Laboratoire d'analyse du mouvement, Hôpital Raymond-Poincaré, APHP, [10]Unité Recherche UR 20201 ERPHAN, Université Versailles Saint Quentin, [11]Consultations pluridisciplinaires des maladies neuromusculaires - Hôpital de la croix rousse, CHU Lyon - L'Escale, Hôpital Femme Mère Enfant, [12]Département de Neurologie, Hôpital Pierre-Paul Riquet, CHU de Toulouse, [13]Hôpital Mère-Enfant, médecine pédiatrique, CHU Nantes, [14]Roche France SAS, [15]Service de Réanimation Médicale Adulte, Hôpital Raymond-Poincaré, APHP, [16]INSERM CIC1429, Centre d'Investigation Clinique, Hôpital Raymond-Poincaré, APHP, [17]UFR Simone Veil, Université Paris-Saclay, [18]Service de Physiologie et Explorations Fonctionnelles, Hôpital Raymond-Poincaré, APHP, [19]Service de neurologie pédiatrique, CHU de Brest, [20]Service des Maladies Neuromusculaires et de la SLA, Hôpital de la Timone, APHM, [21]INSERM, Marseille Medical Genetics, U1251, Aix-Marseille Université, [22]Centre de référence des maladies neuromusculaires, Hôpital de la Pitié-Salpêtrière, AP-HP, [23]LaTIM INSERM UMR 1101, CHU de Brest, [24]Nord-Est/Ile-de-France Neuromuscular Reference Center, UMR 1179, Neurology Department, Raymond-Poincaré Hospital, Garches, FHU PHENIX, UVSQ Paris-Saclay University

153P Long-term effectiveness of risdiplam in non-ambulant SMA patients with prolonged disease duration

Weng W[1,2], *Shieh J*[1], *Huang H*[1], *Tsai L*[1]
[1]*National Taiwan University Hospital,* [2]*National Taiwan University College of Medicine*

154VP Usage of disease modifying therapies in Spinal Muscular Atrophy and existing disparities: a population-based study from the MDA MOVR database

McLaren N[1], *Joo D*[1], *Nowak R*[1], ***Roy B***[1]
[1]*Yale University School of Medicine*

155P The experience of parents as they make treatment decisions for their child with Spinal Muscular Atrophy and the factors that influence these decisions: a narrative review

Leach M[1], *Finanger E*[1], *Izumi S*[1]
[1]*Oregon Health and Science University*

156P Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma in clinically silent and childhood-onset SMA individuals from Serbia

Brkusanin M[1], *Kosac A*[2], *Brankovic-Sreckovic V*[2], *Jovanovic K*[3], *Karanovic J*[1], *Matijasevic Jokovic S*[1], *Garai N*[1], *Pesovic J*[1], *Radovanovic N*[1], *Radenkovic L*[1], *Dobrijevic Z*[4], *Nikolic D*[3,5], *Stevic Z*[5,6], *Brajuskovic G*[1], *Milic-Rasic V*[2,5], *Savic-Pavicevic D*[1]
[1]*University of Belgrade-Faculty of Biology, Centre for Human Molecular Genetics,* [2]*Clinic for Neurology and Psychiatry for Children and Youth,* [3]*University Children's Hospital Tirsova, University Clinical Centre of Serbia,* [4]*Institute for the Application of Nuclear Energy-INEP, Department for Metabolism,* [5]*University of Belgrade-School of Medicine,* [6]*Neurology Clinic, University Clinical Centre of Serbia*

157P Functional progression post Nusinersen therapy in Spinal Muscular Atrophy Type 2: a comprehensive 18-month analysis from a South Indian centre

Banavara Shyamprasad S[1], *Khandekar G*[1], *Ramesh Babu R*[1,2], *Maganthi M*[2], *Krishna G*[1], *Kumar A*[2], *Mathew A*[1,2]
[1]*Synapse Neuro Center, Bengaluru, India,* [2]*Bangalore Baptist Hospital*

158P Results of the nationwide pilot project of newborn screening for SMA in Czech Republic

Gloser M[1], *Lauerova B*[1], *Rohlenova M*[1], *Kumhera M*[1], *Dolanska A*[1], *Jurikova L*[2], *Haberlova J*[1]
[1]*Faculty Hospital Motol,* [2]*Neuromuscular Center, Department of Pediatric Neurology, University Hospital Brno and Faculty of Medicine, Masaryk University*

159P Acute liver failure failure post gene therapy in Spinal Muscular Atrophy

Satyam P[1,2], *Krishna G*[1,2], *Ramesh Babu R*[1,2], *Maganthi M*[2], *K.S L*[2], *H.R S*[3], *Mathew A*[1,2]
[1]*Synapse Neuro and Child Development Center,* [2]*Bangalore Baptist Hospital,* [3]*Gleneagles Global Hospital*

160P Risdiplam real-world experience in paediatric patients with Spinal Muscular Atrophy type 2

Nascimento Osorio A[1], *Expósito-Escudero J*[1], *Medina J*[1], *Valle M*[1], *Roca S*[1], *Moya O*[1], *Natera De-Benito D*[1], *Latre C*[1], *Ortez C*[1], *Carrera-García L*[1]
[1]*Hospital Sant Joan De Deu*

161P Long-term safety of Onasemnogene Abeparvovec for patients with Spinal Muscular Atrophy: real-world findings from the RESTORE Registry

Servais L[1,2], *Alecu I*[3], *Lopez-Leon S*[4], *Ilic A*[3], *Brueckner A*[3], *Benguerba K*[5], *Reyna S*[6], *Dabbous O*[6], *Mumneh N*[6], *Finkel R*[7]
[1]*University of Oxford,* [2]*Neuromuscular Reference Center, University and University Hospital of Liège,* [3]*Novartis Pharmaceuticals Switzerland,* [4]*Novartis Pharmaceuticals USA,* [5]*Novartis Gene Therapies Switzerland GmbH,* [6]*Novartis Gene Therapies USA,* [7]*Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital*

162P Real-world outcomes following Onasemnogene Abeparvovec in patients with SMA and Invasive Ventilatory support: findings from the RESTORE Registry

Servais L[1,2], *Shieh P*[3], *Goedeker N*[4], *Waldrop M*[5,6], *Bo R*[7], *Erbas Y*[8], *Raju D*[9], *Benguerba K*[10], *Reyna S*[9], *Wolff D*[9], *Finkel R*[11]
[1]*University of Oxford,* [2]*Neuromuscular Reference Center, University and University Hospital of Liège,* [3]*David Geffen School of Medicine at UCLA,* [4]*Washington University School of Medicine,* [5]*Nationwide Children's Hospital,* [6]*The Ohio State University College of Medicine,* [7]*Kobe University Graduate School of Medicine,* [8]*SMA Europe,* [9]*Novartis Gene Therapies, Inc.,* [10]*Novartis Gene Therapies Switzerland,* [11]*Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital*

163P Real-World outcomes following Onasemnogene Abeparvovec in patients with SMA and One SMN2 gene copy: findings from the RESTORE Registry

Servais L[1,2], *Mathews K*[3], *Bernes S*[4], *Lakhotia A*[5], *Tizzano E*[6], *Raju D*[7], *Benguerba K*[8], *Reyna S*[7], *Dabbous O*[7], *Finkel R*[9]

[1]*University of Oxford,* [2]*University and University Hospital of Liège,* [3]*University of Iowa Carver College of Medicine,* [4]*University of Arizona College of Medicine,* [5]*University of Louisville, Norton Children's Medical Group,* [6]*Hospital Vall d'Hebron,* [7]*Novartis Gene Therapies, Inc.,* [8]*Novartis Gene Therapies Switzerland GmbH,* [9]*Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital*

164P Meta-analysis of clinical impact of Onasemnogene Abeparvovec treatment of Spinal Muscular Atrophy patients

Reyna S[1], *Dabbous O*[1], *Wallach S*[1], *Patel A*[1], *Toro W*[1], *Ritter S*[1]

[1]*Novartis Gene Therapies, Inc.*

165P Health Care Resource Use (HCRU) for patients with Spinal Muscular Atrophy (SMA) Types 2 or 3 in the UK

Reyna S[1], *Toro W*[1], *Patel A*[1], *Saleh S*[2], *Dabbous O*[1]

[1]*Novartis Gene Therapies, Inc.,* [2]*American University of Beirut*

166P Fertility outcomes in risdiplam-treated male patients with Spinal Muscular Atrophy (SMA): a multicenter case series

Erdler M[1], *Coskery S*[2], *Frey M*[3], *Lopez M*[4]

[1]*Department of Neurology, Clinic Donaustadt,* [2]*Children's of Alabama,* [3]*Memorial Healthcare Institute for Neuroscience,* [4]*Division of Pediatric Neurology, Department of Pediatrics, Heersink School of Medicine, University of Alabama*

167P SnRNAseq analysis of muscle samples of patients with SMA reveals novel pathogenic pathways and open avenues for new therapeutic strategies

Collins C[1], *Gokul-Nath R*[1], *Katsikis P*[1], *Fernández-Simón E*[1], *Villalobos E*[1], *Monceau A*[1], *Reza M*[1], *Mehra P*[1], *Laidler Z*[1], *Clark J*[1], *Rojas-García R*[2], *Tasca G*[1], *Marini-Bettolo C*[1], ***Diaz-Manera J***[1]

[1]*Newcastle University,* [2]*Neuromuscular Disorders Unit, Hospital Sant Pau*

168P Long-term effects of risdiplam in adult Spinal Muscular Atrophy: a 24-month prospective study on clinical, functional, and patient-reported outcome measures

Iterbeke L[1], *Claeys K*[1,2]

[1]*Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven, and Leuven Brain Institute (LBI),* [2]*Department of Neurology, University Hospitals Leuven*

169P Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated Spinal Muscular Atrophy

Roos A[1,4,5], *Schmitt L*[2], *Hansmann C*[2], *Hezel S*[2], *Salmanian S*[2], *Hentschel A*[3], *Meyer N*[1], *Della Marina A*[1], *Kölbel H*[1], *Kleinschnitz C*[2], *Schara-Schmidt U*[1], *Leo M*[2], *Hagenacker T*[2]

[1]*Department of Pediatric Neurology, Center for Neuromuscular Disorders, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen,* [2]*Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen,* [3]*Leibniz-Institut Für Analytische Wissenschaften-ISAS-e.V.,* [4]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute,* [5]*Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University*

170P Apitegromab in Spinal Muscular Atrophy: baseline characteristics of participants enrolled in the phase 3 SAPPHIRE study

Crawford T[1], *Servais L*[2], *Krueger J*[3], *Kölbel H*[4], *Gomez Garcia M*[5,6,7], *Cances C*[8], *Kuntz N*[9,10], *Finkel R*[11], *Yao B*[12], *Zhao G*[12], *Marantz J*[12], *Darras B*[13], *Mercuri E*[14,15]

[1]*Department of Neurology, Johns Hopkins Medical,* [2]*Department of Pediatrics, University of Oxford,* [3]*Helen Devos Children's Hospital Neurology-Grand Rapids,* [4]*Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen,* [5]*Institut de Myologie, I-Motion Clinical Trials Platform,* [6]*APHP, Pediatric Neurology Department, Hôpital Armand Trousseau, Centre Référent pour les Maladies Neuromusculaires Nord/Est/Ile de France,* [7]*APHP, Pediatric Neurology and ICU Department, Université Paris Saclay, DMU Santé de l'Enfant et de l'Adolescent, Hôpital Raymond Poincaré,* [8]*AOC (Atlantic-Oceania-Caribbean) Reference Centre for Neuromuscular Disorders, Paediatric Clinical Research Unit/Paediatric Multi-Thematic Module CIC 1436, Neuropaediatric Department, Toulouse University Hospital,* [9]*Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago,* [10]*Department of Pediatrics, Northwestern University Feinberg School of Medicine,* [11]*Center for Experimental Neurotherapeutics St. Jude Children's Research Hospital,* [12]*Scholar Rock, Inc.,* [13]*Department of Neurology, Boston Children's Hospital, Harvard Medical School,* [14]*Centro Clinico Nemo, U.O.C. Neuropsichiatria Infantile Fondazione Policlinico Universitario Agostino Gemelli IRCCS,* [15]*Pediatric Neurology Unit, Catholic University*

171P Newborn Spinal Muscular Atrophy screening: 2-year results of multi-center experience in Turkey

Ünver O[1], *Öztürk G*[1], *Sakarya Güneş A*[2], *Özçelik A*[3], *Maraş Genç H*[4], *Saltık S*[5], *Akbeyaz İ*[1], *Tekin Orgun L*[2], *Karakayalı B*[1], *Acar Arslan E*[2], *Cırdı G*[2], *Ceylan A*[6], *Gökdemir Y*[7], *Özbaş Akkaya A*[8], *Erdem Eralp E*[7], *Karadağ Saygı E*[9], *Karadağ B*[7], *Kara B*[2], *Topaloğlu H*[10], *Türkdoğan D*[1]

[1]*Marmara University School of Medicine, Pendik Training and Research Hospital, Department of Paediatrics, Division of Paediatric Neurology,* [2]*Kocaeli University School of Medicine, Department of Paediatrics, Division of Paediatric Neurology,* [3]*Gaziantep University School of Medicine, Department of Paediatrics, Division of Paediatric Neurology,* [4]*İstanbul University İstanbul School of Medicine, Department of Paediatrics, Division of Paediatric Neurology,* [5]*İstanbul University Cerrahpaşa, Cerrahpaşa School of Medicine, Department of Paediatrics, Division of Paediatric Neurology,* [6]*Ankara Yıldırım Bayezit University Bilkent City Hospital Department of Medical Genetics,* [7]*Marmara University School of Medicine, Pendik Training and Research Hospital, Department of Pulmonology,* [8]*Marmara University Institute of Health Sciences, Department of Neurological Rehabilitation,* [9]*Marmara University School of Medicine, Pendik Training and Research Hospital, Department of Physical therapy and rehabilitation,* [10]*Yeditepe University School of Medicine, Department of Paediatrics, Division of Pediatric Neurology*

172P FUS protein expression in the myopathology of 5q-associated Spinal Muscular Atrophy type 3

Kölbel H[1], *Dobelman V*[2], *van Haute L*[3], *Lancene E*[4], *Kollipara L*[5], *Della Marina A*[1], *Horvath R*[6], *Schara-Schmidt U*[1], *Ruck T*[2], *Schoser B*[7], *Evangelista T*[4], *Roos A*[1,2,8]

[1]*Department of Paediatric Neurology, Center for Neuromuscular Disorders in Children and Adolescents, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Clinic Essen,* [2]*Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University,* [3]*MRC Mitochondrial Biology Unit, University of Cambridge,* [4]*Neuromuscular Morphology Unit, Neuropathology department and Myology Institute, GHU Pitié-Salpêtrière,* [5]*Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V.,* [6]*NextGenSeek Ltd., Cambridge CB18QY,* [7]*Friedrich-Baur-Institute, Department of Neurology, LMU Klinikum München,* [8]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute*

173P A multidisciplinary approach to address the challenges posed by new phenotypes of symptomatic SMA patients treated with innovative therapies

Gaume M[1], *Viallard L*[2], *Vialle R*[1], *Desguerre I*[3], *de Lattre C*[4], *Cunin V*[5], ***Vuillerot C***[6]

[1]*University Institute for Spine Surgery, Armand Trousseau Hospital, Sorbonne University,* [2]*CHU Rennes, Pediatric Physical Medicine and Rehabilitation Department,* [3]*Hôpital Necker Enfants Malades, Service de Neurologie Pédiatrique APHP,* [4]*ESEAN-APF Pediatric Rehabilitation Center,* [5]*Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant de Lyon, Service & Orthopédie et Traumatologie Pédiatrique,* [6]*Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Service de médecine physique et réadaptation pédiatrique, Pathophysioloy and Genetics of Neuron and Muscle, Lyon University*

174P Risdiplam in type 2 and 3 Spinal Muscular Atrophy: results of a cohort of adult Italian patients. A 3-year follow-up

Ruggiero L[1], *Russo A*[1], *Iodice R*[1], *Dubbioso R*[1], *Tozza S*[1], *Esposito G*[2], *Zoppi D*[1]

[1]*Department of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico II of Naples,* [2]*Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II*

175P Thrombospondin-4 as potential cerebrospinal fluid biomarker for therapy response in pediatric 5q-associated spinal muscular atrophy patients

Dobelmann V[1], *Roos A*[1,2,3], *Hentschel A*[4], *Della Marina A*[2], *Leo M*[5], *Schmitt L*[5], *Maggi L*[6], *Schara-Schmidt U*[2], *Hagenacker T*[5], *Ruck T*[1], *Koelbel H*[2]

[1]*Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf,* [2]*Department of Pediatric Neurology, Developmental Neurology, and Social Pediatrics, Center for Neuromuscular Disorders in Children and Adolescents, Center for Translational Neuro- and Behavioral Sciences (C-TNBS) University Duisburg-Essen,* [3]*Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute,* [4]*Leibniz Institute of Analytical Sciences, ISAS,* [5]*Department of Neurology, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen,* [6]*Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico "Carlo Besta"*

176P Acceptability, feasibility, safety and potential efficacy of an optimised rehabilitation for treated patients with SMA in UK: ACE SMA

Lilien C[1], *Hill S*[1], *Mavrommati F*[1,2], *Ramjattan H*[3], *Taylor F*[3], *Collett J*[2], *Servais L*[1,4]

[1]*Strong, MDUK Oxford, Department of Paediatrics, University of Oxford,* [2]*Oxford Brookes University,* [3]*Oxford University Hospital,* [4]*Centre Hospitalier Régional de Références des Maladies Neuromusculaires, Hospital of la Citadelle and University Hospital Liège*

177P Effect of gene therapy on the epigenetic and transcriptional stability of SMA

Smeriglio P[1], *Grandi F*[1], *Arnould A*[1], *Pezet S*[1], *Marais T*[1], *Mazzucchi S*[1], *Astord S*[1], *Cohen-Tannoudji M*[1]

[1]*Sorbonne Université, INSERM, Institut de Myologie, Centre de Recherche en Myologie*

178P Spinal muscular atrophy type II skeletal muscle treated with Nusinersen and Risdiplam shows SMN restoration but mitochondrial deficiency

Grandi F[1], *Astord S*[1], *Pezet S*[1], *Gidaja E*[1], *Mazzucchi S*[1], *Chapart M*[1], *Vasseur S*[1], *Mamchaoui K*[1], *Smeriglio P*[1]

[1]*INSERM UMR 974*

179P Intravenous and intrathecal Onasemnogene Abeparvovec gene therapy in symptomatic and presymptomatic SMA: long-term follow-up study

Darras B[1], *Farrar M*[2,3], *Mercuri E*[4], *Strauss K*[5,6,7], *Day J*[8], *Chien Y*[9], *Masson R*[10], *Bernardo R*[11], *Alecu I*[12], *Dodd N*[13], *Mehl L*[14], *Connolly A*[15,16]

[1]*Boston Children's Hospital, Harvard Medical School,* [2]*Sydney Children's Hospital Network,* [3]*School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney,* [4]*Department of Paediatric Neurology and Nemo Clinical Centre, Catholic University,* [5]*Clinic for Special Children,* [6]*Penn Medicine-Lancaster General Hospital,* [7]*University of Massachusetts School of Medicine,* [8]*Stanford University Medical Center,* [9]*National Taiwan University Hospital,* [10]*Fondazione IRCCS Istituto Neurologico Carlo Besta,* [11]*Novartis Global Drug Development – Neuroscience & Gene Therapy,* [12]*Novartis Pharmaceuticals,* [13]*Novartis Gene Therapies, Inc.,* [14]*BioMedical Research, Novartis,* [15]*Center for Gene Therapy, Nationwide Children's Hospital,* [16]*The Ohio State University College of Medicine*

180P Interim results from RESPOND: a study of nusinersen in children with Spinal Muscular Atrophy (SMA) previously treated with onasemnogene abeparvovec (OA)

Masson R[1], *Proud C*[2], *Finkel R*[3], *Parsons J*[4], *Kuntz N*[5], *Foster R*[6], *Li W*[7], *Chary S*[7], *Sohn J*[7], *Fradette S*[7], *Youn B*[7], *Paradis A*[7]

[1]*Fondazione IRCCS Istituto Neurologico "Carlo Besta",* [2]*Children's Hospital of The King's Daughters,* [3]*St. Jude Children's Research Hospital,* [4]*Children's Hospital Colorado,* [5]*Ann & Robert H. Lurie Children's Hospital of Chicago,* [6]*Biogen,* [7]*Biogen*

181P Investigating the developmental expression of the SMN protein in brain in a Spinal muscular atrophy mouse model

Demetriou C[1], *Frontzek K*[3], *Zhou H*[2], *Muntoni F*[1], *Baranello G*[1]

[1]*The Dubowitz Neuromuscular Centre, Developmental Neurosciences Department, Great Ormond Street Institute of Child Health, University College London,* [2]*Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London,* [3]*University College London Hospitals NHS Foundation Trust*

234P-246P, 497P-513P, 514VP-515VP: Myasthenia Gravis, NMJ1-2, Periodic paralysis

234P Congenital Myasthenic Syndromes in adults: clinical features, diagnosis and long-term prognosis

Theuriet J[1,2], *Villar-Quiles R*[2], *Stojkovic T*[2], *Eymard B*[2]

[1]*Hospices Civils de Lyon,* [2]*Institut de Myologie*

235P Cross sectional study of 187 patients with Congenital Myasthenia Syndrome, describing the clinical phenotypes, genetic mutations, and single point standardised assessment scores

Ramdas S[1,2], *Ramjattan H*[3], *Hennehan L*[4], *Natera De Benito D*[5], *Nascimiento A*[5], *Della Marina A*[6], *Schara-Schmidt U*[6], *Munot P*[7], *Simmons E*[7], *Maggi L*[8], *Gallone A*[9], *Nadaj Pakleza A*[10], *Chanson J*[10], *Marini-Bettolo C*[11], *Moat D*[11], *Paz Guerrero-Molina M*[12], *Dominguez-González C*[12,13], *Jungbluth H*[14,15], *Sheehan J*[14], *Palace J*[4]

[1]*Department of Paediatric Neurology, John Radcliffe Hospital,* [2]*MDUK neuromuscular centre, Department of Paediatrics, University of Oxford,* [3]*Children's Therapies & Gait, Oxford Children's Hospital, John Radcliffe Hospital,* [4]*Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital,* [5]*Neuromuscular Unit, Hospital Sant Joan de Deu,* [6]*Department of Pediatric Neurology, Neuromuscular Centre for Children and Adolescents, Center for Translational Neuro- and Behavioral Sciences, University Duisburg–Essen, University Hospital Essen,* [7]*Dubowitz Neuromuscular Centre, Great Ormond Street Hospital,* [8]*Neuroimmunology and Neuromuscular Diseases Unit, Foundation IRCCS Neurological Institute Carlo Besta,* [9]*Neurophysiology Unit, Foundation IRCCS Neurological Institute Carlo Besta,* [10]*Centre de Référence des Maladies Neuromusculaires NEIdF, ERN EURO-NMD, Service de Neurologie, Hôpitaux Universitaires de Strasbourg,* [11]*The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [12]*Neuromuscular Unit, Department of Neurology, Hospital Universitario 12 de Octubre,* [13]*Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER),* [14]*Department of Paediatric Neurology – Neuromuscular Service, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust,* [15]*Randall Centre for Cell and Molecular Biophysics, Muscle Signalling Section, Faculty of Life Sciences and Medicine (FoLSM), King's College London*

236P Real-world experience with C5 complement inhibition and FcRn modulation in Myasthenia Gravis

Huntemann N[1], *Nelke C*[1], *Schroeter C*[1], *Meuth S*[1], *Ruck T*[1]

[1]*Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf*

237P Advancing the understanding of VAMP1-related Congenital Myasthenic Syndrome: phenotypic insights, favorable response to 3,4-diaminopyridine, and clinical characterization of five new cases

Natera De Benito D[1], *Pugliese A*[2], *Polavarapu K*[3], *Guergueltcheva V*[4], *Tournev I*[5], *Todorova A*[6], *Ribeiro J*[7], *M Fernández-Mayoralas D*[8], *Ortez C*[1], *Martorell L*[1], *Estevez-Arias B*[1], *Matalonga L*[9], *Laurie S*[9], *Jou C*[1], *Lau J*[3], *Thompson R*[3], *Shen X*[10], *Engel A*[10], *Nascimento A*[1], *Lochmuller H*[3], *Selcen D*[10]

[1]*Hospital Sant Joan De Déu,* [2]*IRCCS Centro Neurolesi "Bonino-Pulejo",* [3]*Children' s Hospital of Eastern Ontario Research Institute,* [4]*University Hospital Sofiamed, Sofia University St. Kliment Ohridski,* [5]*University Hospital "Alexandrovska", Medical University,* [6]*Genetic Medico-Diagnostic Laboratory 'Genica",* [7]*Coimbra University Hospital Centre,* [8]*Hospital Universitario Quirónsalud,* [9]*Centro Nacional de Análisis Genómico,* [10]*Mayo Clinic*

238P NMD670, a first-in-class skeletal muscle ClC-1 Inhibitor in Myasthenia Gravis: the SYNAPSE-MG dose-finding study

Gidaro T[1], *S. Grønnebæk T*[1], *Cornwall C*[1], *Gupte J*[1], *Sampson C*[1], *Kiyasova V*[1], *H. Pedersen T*[1], *A. Quiroz J*[1]

[1]*NMD Pharma A/S, DK-8200*

239P The association between disease severity and utilities, mental health, fatigue, sleep disturbances and sick leave in patients with Myasthenia Gravis

Brackx F[1], *Goffart B*[2], *Linthoudt T*[2], *De Ruyck F*[2], *Phillips G*[2], *Dewilde S*[1], ***Claeys K***[3,4]

[1]*SHE BV,* [2]*Argenx,* [3]*University Hospitals Leuven, Department of Neurology,* [4]*KU Leuven, Department of Neurosciences, Laboratory for Muscle Diseases and Neuropathies*

240P Late presentation *DOK7* Congenital Myasthenia Syndrome (CMS), misdiagnosed as Myasthenia Gravis (MG)– a case series

Henehan L[1], *Rossini E*[1,2], *Dong Y*[3], *Beeson D*[4], *Ramdas S*[5,6], *Leite I*[1,4], *Palace J*[1,4]

[1]*Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals Trust,* [2]*Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome,* [3]*Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford,* [4]*Nuffield Department of Clinical Neurosciences, University of Oxford,* [5]*Department of Paediatric Neurology, John Radcliffe Hospital,* [6]*MDUK neuromuscular centre, Department of Paediatrics, University of Oxford*

241P Long term follow-up of CHRNE Congenital Myasthenic Syndrome (CMS) – a retrospective multi-centre cohort study

Henehan L[1], *Khries M*[2], *Ramjattan H*[3,4], *Dong Y*[5], *Everett R*[1], *Munot P*[6], *Jungbluth H*[2,7], *Beeson D*[8], *Ramdas S*[3,9], *Palace J*[1,8]

[1]*Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals Trust,* [2]*Department of Paediatric Neurology, Neuromuscular Service, Evelina London Children's Hospital, Guy's and St. Thomas' Hospital NHS Foundation Trust, Children's Neurosciences Centre,* [3]*Department of Paediatric Neurology, John Radcliffe Hospital,* [4]*Children's Therapies & Gait, Oxford Children's Hospital, John Radcliffe Hospital,* [5]*Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford,* [6]*Dubowitz Neuromuscular Centre, Great Ormond Street Hospital,* [7]*Randall Centre for Cell and Molecular Biophysics, Muscle Signalling Section. Faculty of Life Science and Medicine, King's College London,* [8]*Nuffield Department of Clinical Neurosciences, University of Oxford,* [9]*MDUK neuromuscular centre, Department of Paediatrics, University of Oxford*

242P Efgartigimod in AChR and non-AChR generalized Myasthenia Gravis: a single center experience

Antozzi C[1], *Frangiamore R*[1], *Rinaldi E*[1], *Vanoli F*, *Bonanno S*[1], *Maggi L*[1], *Mantegazza R*[1]

[1]*Neuroimmunology and Muscle Pathology Unit, Fondazione Irccs Istituto Neurologico C. Besta*

243P The effect of Nav1.4 Ile582Val gain-of-function mutation on mouse skeletal muscle excitability is sex specific

Suetterlin K[1,2,3], *Mannikko R*[2], *Matthews E*[5], *Maitland S*[4], *Greensmith L*[2], *Hanna M*[2], *Tan S*[2,6]

[1]*John Walton Centre for Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University,* [2]*Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology,* [3]*AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University,* [4]*Newcastle University,* [5]*St George's University, University of London,* [6]*Guy's and St Thomas' NHS Foundation Trust*

244P A natural history study of Congenital Myasthenic Syndromes, to establish reliable outcome measures suitable for clinical and research assessment

Ramjattan H[1], *English H*[1], *Hennehan L*[2], *Ramdas S*[3,4], *Palace J*[2]

[1]*Oxford University Hospitals NHS Foundation Trust,* [2]*Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital,* [3]*Department of Paediatric Neurology, John Radcliffe Hospital,* [4]*MDUK neuromuscular centre, Department of Paediatrics, University of Oxford*

245P Exploring the relationship between an instrumented walking test and community physical activity in individuals with Congenital Myasthenic Syndrome

Ramjattan H[1], English H[1], Ramdas S[2,3], Esser P[4], Palace J[5]

[1]Oxford University Hospitals NHS Foundation Trust, [2]Department of Paediatric Neurology, John Radcliffe Hospital, [3]MDUK neuromuscular centre, Department of Paediatrics, University of Oxford, [4]Centre for Movement Occupation and Rehabilitation Sciences (MORES), Oxford Brookes University, [5]Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital

246P Factors affecting the diagnostic delay of Myasthenia Gravis

Marlet I[1], Andersen R[1], Axelsen K[1], Andersen L[1], Wissing J[1], Witting N[1]

[1]Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet

497P AChR-positive generalized Myasthenia Gravis patients unresponsive to new targeted molecular therapies: a single-centre case series

Rossini E[1,2], Marando D[1], Morino S[2], Leonardi L[2], Tufano L[1], Lauletta A[1], Forcina F[1], Garibaldi M[1,2], Antonini G[1], Fionda L[2]

[1]Neuromuscular Disease Centre, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sant'Andrea Hospital, Sapienza University of Rome, [2]Neuromuscular and Rare Disease Centre, Neurology Unit, Sant'Andrea Hospital

498P Neuromuscular centre effect on prevalence of Congenital Myasthenic Syndrome (CMS) in the UK

Rossini E[1,2], Henehan L[1], Everett R[1], Dong Y[3], Marini Bettolo C[4], Munot P[5], Jungbluth H[6], Beeson D[7], Ramdas S[8,9], Palace J[1,7]

[1]Department of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals Trust, [2]Neuromuscular Disease centre, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sant'Andrea Hospital, Sapienza University of Rome, [3]Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, [4]John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, [5]Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, [6]Department of Paediatric Neurology, Neuromuscular Service, Evelina London Children's Hospital, Guy's and St. Thomas' Hospital NHS Foundation Trust, Children's Neurosciences Centre, [7]Nuffield Department of Clinical Neurosciences, University of Oxford, [8]Department of Paediatric Neurology, John Radcliffe Hospital, [9]MDUK Neuromuscular centre, Department of Paediatric Neurology, University of Oxford

499P Exploring the impact of diet and physical activity on episodic muscle weakness and paralysis in HypokalemicPeriodicParalysis: a qualitative interview study

Welland N[1,2], Hagen Venås B[1,2], Ellefsen-Martinsen M[1], Ludt Fossmo H[1,3,4], Dybesland Rosenberger A[5], Dahl H[6], Ørstavik K[3], Nordstrøm M[1,3]

[1]Frambu Resource Center for Rare Disorders, [2]Department of Clinical Service, Division of Clinical Neuroscience, Oslo University Hospital, [3]Unit for Inborn and Hereditary Neuromuscular Disorders (EMAN), Department of Neurology, Oslo University Hospital, [4]Vikersund Rehabilitation Centre, [5]National Neuromuscular Centre (NMK), University Hospital of North Norway, [6]The Neuromuscular Disorders Association of Norway (NMD Norway)

500P The 6-minute walk test in a small group of patients with Congenital Myasthenic Syndromes

Bulut N[1], Aydın Yağcıoğlu G[2], Demir A[3], Gürbüz İ[1], Yılmaz Ö[1], Haliloğlu G[3]

[1]Hacettepe University Faculty of Physical Therapy and Rehabilitation, [2]University of Health Sciences, Gulhane Faculty of Health Sciences, Orthosis-Prosthesis Program, [3]Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Pediatric Neurology

501P Validation of ME&MG, a novel digital device for patients with Generalized myasthenia Gravis: the DOMYA Study

Berling E[1], Orlikowski D[1], Nicolas G[2], Prigent H[2], N'Dah-Sekou G[2], Carment L[3], Gorin C[3], Klaeyle L[3], Touré Cuq E[3], Aras E[4], Zinaï S[3], ***Laforêt P***[2]

[1]Nord-Est/Ile-de-France Neuromuscular Reference Center, UMR 1179, CIC 1429, Neurology Department, Raymond-Poincaré Hospital, Garches, FHU PHENIX, UVSQ Paris-Saclay University, [2]Nord-Est/Ile-de-France Neuromuscular Reference Center, UMR 1179, Neurology Department, Raymond-Poincaré Hospital, Garches, FHU PHENIX, UVSQ Paris-Saclay University, [3]Ad Scientiam, [4]Alexion Pharmaceuticals Inc

502P Cognitive functioning in Myasthenia Gravis: an Italian cohort study

Marcassoli A[1], Raggi A[1], Lanza M[1], Curatoli C[1], Fornari A[1], Leonardi M[1], Maggi L[2], Bonanno S[2], Mantegazza R[2], Antozzi C[2], Vanoli F[2], Frangiamore R[2]

[1]Neurology, Public Health and Disability Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, [2]Neurology 4 Unit, Neuroimmunology and Neuromuscolar diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta

503P Corticosteroid dose tapering in patients with generalised Myasthenia Gravis on zilucoplan: an interim analysis of RAISE-XT

Boroojerdi B[1], *Freimer M*[2], *Genge A*[3], *Hewamadduma C*[4,5], *Leite M*[6], *Beau Lejdstrom R*[7], *Grimson F*[8], *Savic N*[7], *Howard Jr. J*[9]

[1]*UCB Pharma,* [2]*Department Of Neurology, The Ohio State University Wexner Medical Center,* [3]*Clinical Research Unit, The Montreal Neurological Institute,* [4]*Academic Neuroscience Unit, Sheffield Teaching Hospitals Foundation Trust,* [5]*Sheffield Institute for Translational Neurosciences (SITRAN), University of Sheffield,* [6]*Nuffield Department of Clinical Neurosciences, University of Oxford,* [7]*UCB Pharma,* [8]*UCB Pharma UK,* [9]*Department Of Neurology, The University of North Carolina at Chapel Hill*

504P Myonuclear abnormalities in Hypokalemic Periodic Paralysis due to ATP1A2 variant

Yae Y[1,2], *Ogasawara M*[1,3], *Nonaka I*[1], *Hayashi S*[1], *Iida A*[4], *Okamura-Oho Y*[5], *Noguchi S*[1], *Nishino I*[1,4]

[1]*Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry,* [2]*Department of Pediatrics and Child Health, Kurume University School of Medicine,* [3]*Department of Pediatrics, Showa General Hospital,* [4]*Department of Clinical Genome Analysis, Medical Genome Center, National Center of Neurology and Psychiatry,* [5]*Faculty of Human Life Science, Jissen Women's University*

505VP Safety and effectiveness of ravulizumab in gMG: evidence from a global registry

Narayanaswami P[1], *Macwan S*[2], *Winkley J*[3], *Gordon A*[4], *Pulley M*[5], *Greene E*[6], *Zeinali L*[7], *Rodrigues E*[7], *Yegin A*[7], *Howard Jr J*[8]

[1]*Beth Israel Deaconess Medical Center/Harvard Medical School,* [1]*Alexion, AstraZeneca Rare Disease,* [2]*Eisenhower Health Center, Rancho Mirage,* [3]*Baptist Health Medical Group Neurology,* [4]*Northwest Neurology, Ltd.,* [5]*University of Florida College of Medicine,* [6]*Houston Methodist,* [7]*Alexion, AstraZeneca Rare Disease,* [8]*The University of North Carolina at Chapel Hill School of Medicine*

506VP Long-term efficacy and safety of ravulizumab in adults with AChR-Ab+ gMG: final results from the phase 3 CHAMPION MG open-label extension

Vu,T[1]

[1]*Alexion, AstraZeneca Rare Disease*

507P Late-onset and milder phenotypes in a *DOK7* Myasthenic Syndrome cohort to rethink the natural history of a perceived severe disease

Brisson J[1,2,3,4], *Villeneuve J*[5], *Nicolas L*[3], *Mathieu J*[1,2], *Gagnon C*[1,3,4]

[1]*Groupe de Recherche Interdisciplinaire Sur Les Maladies Neuromusculaires (GRIMN), Centre intégré Universitaire de Santé et de Services Sociaux du Saguenay-Lac-St-Jean,* [2]*Centre de Recherche du Centre Intégré Universitaire du Saguenay-Lac-St-Jean, Clinique des Maladies Neuromusculaires,* [3]*Faculté de Médecine et Des Sciences De La Santé, Université de Sherbrooke,* [4]*Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), Université de Sherbrooke,* [5]*Direction des Soins Infirmiers, de l'Enseignement, de la Recherche et de l'innovation, CIUSSS Saguenay-Lac-Saint-Jean*

508P Clinical and genetic features of patients with Myotonia Congenita in Korea

Choi Y[1], *Kim S*[1], *Hong J*[2], *Park H*[1], *Choi Y*[1]

[1]*Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine,* [2]*Department Of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine*

509P A real-life experience with Eculizumab and Efgartigimod in generalized Myasthenia Gravis patients

Fionda L[1], *Pane C*[2], *Di Stefano V*[3], *Cuomo N*[2], *Sarnataro A*[2], *Vinciguerra C*[4], *Bevilacqua L*[4], *Brighina F*[3], *Rini N*[3], *Puorro G*[2], *Marsili A*[2], *Garibaldi M*[5], *Saccà F*[2]

[1]*Neuromuscular and Rare Disease Center, Sant'Andrea Hospital,* [2]*Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University,* [3]*Biomedicine, Neuroscience and Advanced Diagnostic (BIND) Department, University of Palermo,* [4]*Neurology Unit, Medicine, Surgery and Dentistry Department, University of Salerno,* [5]*Neuroscience, Mental Health and Sensory Organs (NESMOS) Department, Faculty of Medicine and Psychology, SAPIENZA University of Rome*

510P Eculizumab versus rituximab for refractory anti-acetylcholine receptor antibody-positive generalized Myasthenia Gravis: a single-center experience

Durmus H[1], *Cakar A*[1], *Parman Y*[1]

[1]*Istanbul Faculty of Medicine*

continued on next page

511P Blood biomarkers in a cohort of patients with CHRNE-associated Congenital Myasthenic Syndrome

Della Marina A[1], Koutsoulidou A[2], Natera de Benito D[3], Tykocinski L[4], Tomazou M[5], Georgiou K[2], Kölbel H[1], Nascimento A[3], Ortez C[3], Lochmüller H[6,7,8,9], Phylactou L[2], Ruck T[10], Abicht A[11,12], Schara-Schmidt U[1], Kale D[13], Hentschel A[13], Roos A[1,6,10]

[1]Department of Pediatric Neurology, Center for Neuromuscular Disorders in Children and Adolescents, Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University Duisburg-Essen, [2]Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, [3]Neuromuscular Unit, Department of Neurology, Sant Joan de Deu Hospital, [4]Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, [5]Department of Bioinformatics, The Cyprus Institute of Neurology and Genetics, [6]Children's Hospital of Eastern Ontario Research Institute, [7]Division of Neurology, Department of Medicine, The Ottawa Hospital, [8]Brain and Mind Research Institute, University of Ottawa, [9]Centro Nacional de Análisis Genómico (CNAG), [10]Department of Neurology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, [11]Friedrich-Baur Institute, Ludwig Maximilian University, [12]Medical Genetics Center, [13]Leibniz-Institut für Analytische Wissenschaften -ISAS- e.V.

512P Investigating muscle specific kinase agonist antibody treatment for Agrn and ColQ Congenital Myasthenic Syndromes

Ho K[1,2], Adjei-Afriyie O[1,2], Carmona R[1], Ray R[2], Zeldin J[1,2], O'Neil D[1], Vanhauwaert R[4], Spendiff S[1], Lochmüller H[1,2,3]

[1]Research Institute of Children's Hospital of Eastern Ontario, [2]Department of Cellular and Molecular Medicine, University of Ottawa, [3]Brain and Mind Research Institute, University of Ottawa, [4]argenx

513P Deposition of MAC and IgG subclasses at the neuromuscular junction in LRP4+ Myasthenia Gravis

Hoffmann S[1], Meisel A[1], Brokamp K[1], Helmig L[1], Schülke-Gerstenfeld M[2], Rückert J[3], Pumberger M[4], Schömig F[4], Ruck T[5], Pawlitzki M[5], Stenzel W[6], ***Preusse C***[1,2,6]

[1]Department of Neurology and NeuroCure Clinical Research Center, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany, [2]Department of Neuropediatrics and NeuroCure Clinical Research Center, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany, [3]Department of Thoracic Surgery, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), [4]Center for Musculoskeletal Surgery, Charité - Universitätsmedizin Berlin, [5]Department of Neurology, University Hospital Düsseldorf, [6]Department of Neuropathology, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH)

514VP Latent tuberculosis infection in Myasthenia Gravis patients in a low-incidence regio*n*

Carbonero C[1], Arias M[2], Mozo L[3], Palacios J[4], ***Moris De La Tassa G***[1]

[1]Neurology Service. HUCA. SESPA, [2]Neumology Service. HUCA. SESPA, [3]Immunology Service. HUCA. SESPA, Oviedo, Spain, [4]Microbiology Service. HUCA. SESPA

515VP *SCN4A* loss of function zebra fish model: insights into myopathy and sudden infant death

Ader F[1], Pittman A[1], Matthews E[1], Osborn D[1]

[1]St Georges University of London

318P-358P, 343VP, 359VP-360VP: DMD - clinical care and cases reports, BMD

318P DMD splice site point mutation in intron 68 maintains the reading frame and almost full-length dystrophin expression with cell-specific pattern

Białobrzeska M[1], Przymuszała M[1], Potulska-Chromik A[2], Kostera-Pruszczyk A[2], Stępniewski J[1], Florczyk-Soluch U[1], Dulak J[1]

[1]Jagiellonian University Kraków, [2]Medical University of Warsaw

319P MRI gluteal/thigh muscle fat fraction detects NSAD motor task failures in men with Becker muscular dystrophy

Rock K[1], Willcocks R[1], Barnard A[1], Forbes S[1], Lott D[1], Senesac C[1], Rooney W[2], Baetscher E[2], Subramony S[1], Chahin N[1], Kamal O[1], Hinkle J[1], Corwine A[1], Huerta O[2], Walter G[1], Vandenborne K[1]

[1]University Of Florida, [2]Oregon Health and Science University

320P Clinical characterization of a large single-centre cohort of patients with Becker Muscular Dystrophy

Riguzzi P[1,2], Borland H[1], Bourke J[1], Marini Bettolo C[1], James M[1], Muni Lofra R[1], Diaz-Manera J[1], Tasca G[1], Elseed M[1], Grover E[1], Geagan C[1], Schiava M[1], Bolano Diaz C[1], Michell-Sodhi J[1], Moat D[1], Wong K[1], Pegoraro E[2], Bello L[2], Straub V[1], Guglieri M[1]

[1]John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, [2]Department of Neurosciences, University of Padova

321P A new world: proposed model for physical therapist evaluation and management following implementation of newborn screening for Duchenne Muscular Dystrophy

Smith M[1], *Iammarino M*[1], *Reash N*[1], *Steiner C*[1], *Chagat S*[2], *Meyer A*[3,1], *Alfano L*[1,4], *Lowes L*[1,4]

[1]*Center for Gene Therapy, Nationwide Children's Hospital,* [2]*Department of Neurology, Nationwide Children's Hospital,* [3]*Division of Genetic and Genomic Medicine, Nationwide Children's Hospital,* [4]*Department of Pediatrics, The Ohio State University*

322P Rasch evaluation of North Star Ambulatory Assessment and North Star Assessment for Limb-Girdle type Muscular Dystrophies in Becker Muscular Dystrophy

Lowes L[1], *James M*[2], *Alfano L*[1], *Mayhew A*[2], *Eagle M*[3], *McDonald C*[4], *Vissing J*[5], *Phan H*[6], *Donovan J*[7], *MacDougall J*[7]

[1]*Nationwide Children's Hospital,* [2]*John Walton Muscular Dystrophy Research Centre, The Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University,* [3]*ATOM International,* [4]*University of California Davis,* [5]*Rigshospitalet, University of Copenhagen,* [6]*Rare Disease Research,* [7]*Edgewise Therapeutics*

323P Caregiver burden with Duchenne and Becker Muscular Dystrophy in Japan

Ishizaki M[1], *Kobayashi M*[2], *Nakamura A*[3], *Maeda Y*[1], *Ueyama H*[1], *Matsumura T*[4]

[1]*Department of Neurology, National Hospital Organization Kumamoto Saishun Medical Center,* [2]*Department of Neurology, National Hospital Organization Akita National Hospital,* [3]*Department of Neurology, National Hospital Organization Matsumoto Medical Center,* [4]*Department of Neurology, National Hospital OrganizationOsaka Toneyama Medical Center*

324P A longitudinal study of creatine kinase, creatinine levels, and appendicular lean mass index in pediatric Becker Muscular Dystrophy

Horn P[1,2], *Zygmunt A*[1,2], *Vilaisaktipakorn P*[1], *Sharaf T*[1,3], *Shiuan Y*[2], *Rybalsky I*[1], *Reebals L*[1], *Bange J*[1], *Tian C*[1,2]

[1]*Neurology Division, Cincinnati Children's Hospital,* [2]*College of Medicine, University of Cincinnati,* [3]*Miami University*

325P Is upper extremity contracture progression related to changes in upper extremity function in Duchenne Muscular Dystrophy? An international multicenter natural history study

Van Der Holst M[1,2], *Italianer M*[2], *Wolfe A*[3], *Chesshyre M*[4], *Voit T*[5], *Straub V*[6], *de Lucia S*[7], *Servais L*[8,9], *Hogrel J*[7], *Pelsma M*[10], *de Groot I*[10], *Houwen S*[10], *Muntoni F*[3], *Niks E*[1]

[1]*Leiden University Medical Center, Department of Neurology, Department of Orthopaedics, Rehabilitation and Physiotherapy,* [2]*Basalt Rehabilitation, department of Innovation, Quality and Research,* [3]*University College London Great Ormond Street Institute of Child Health,* [4]*Dubowitz Neuromuscular Centre, University College London Great Ormond Street Institute of Child Health,* [5]*NIHR GOSH Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London,* [6]*John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust,* [7]*Institute of Myology, Pitié-Salpêtrière Hospital,* [8]*MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford,* [9]*Neuromuscular Reference Center, Department of Paediatrics, University and University Hospital of Liege,* [10]*Radboud University Medical Center*

326P Acute adverse events after Zoledronic acid infusion are uncommon in patients with Duchenne Muscular Dystrophy previously treated with oral bisphosphonates

Vilaisaktipakorn P[1], *Nasomyont N*[1,2], *Hornung L*[1,2], *Tian C*[1,2], *Wasserman H*[1,2], *Rutter M*[1,2]

[1]*Cincinnati Children's Hospital Medical Center,* [2]*College of Medicine University of Cincinnati*

327P Correlation of biomarkers and timed function tests in pediatric Becker Muscular Dystrophy

Vilaisaktipakorn P[1], *Zygmunt A*[1,2], *Sharaf T*[3], *Shiuan Y*[2], *Horn P*[1,2], *Bange J*[1], *Reebals L*[1], *Rybalsky I*[1], *Tian C*[1,2]

[1]*Cincinnati Children's Hospital Medical Center,* [2]*College of Medicine University of Cincinnati,* [3]*Miami University of Ohio*

328P Navigating Dystrophinopathies: dual diagnosis and their implications

Bhimarao Nagaraj C[1,2], *Reebals L*[1], *Zygmunt A*[1,2], *Tian C*[1,2]

[1]*Cincinnati Children's Hospital,* [2]*University of Cincinnati*

329P Siblings with Duchenne Muscular Dystrophy: a chart review to explore associations between age of diagnosis and clinical disease outcomes

Bhimarao Nagaraj C[1,2], *Brahmamdam V*[1,2], *Pilipenko V*[1], *Armstrong N*[3], *Zygmunt A*[1,2], *Rybalsky I*[1,2], *Reebals L*[1], *Tian C*[1,2]

[1]*Cincinnati Children's Hospital,* [2]*University of Cincinnati,* [3]*Foundation for Angelman Syndrome Therapeutics*

330P Trends in creatine kinase levels and 10-meter walk-run velocity in pediatric Becker Muscular Dystrophy treated with glucocorticoid steroids

Zygmunt A[1,2], *Vilaisaktipakorn P*[1], *Sharaf T*[1,3], *Shiuan Y*[2], *Horn P*[1,2], *Bange J*[1], *Reebals L*[1], *Rybalsky I*[1], *Tian C*[1,2]

[1]*Cincinnati Children's Hospital Medical Center,* [2]*University of Cincinnati Medical Center,* [3]*Miami University of Ohio*

331P A Phase 1/2 clinical trial of the antisense oligonucleotide BMN 351 now actively recruiting boys with exon 51–skip-amenable Duchenne Muscular Dystrophy

*Duis J[1], **Neil D**[1], Qi Y[1], Larimore K[1], Rosen O[1], Robinson M[1], Velazquez P[1], Gupta S[1], Lilienstein J[1], Cosgrove J[1]*
[1]BioMarin Pharmaceutical Inc

332P Physician and caregiver concordance in Duchenne Muscular Dystrophy patients in Europe, Japan, and the USA: a multi-national survey

***Posner N**[1], Talaga A[1], Strober J[3], Ishigaki K[2], Cappelleri J[1], Dukacz S[1], Aslam Z[1], Morton E[4], Iqbal H[4], Chatterton E[4], DeCourcy J[4]*
[1]Pfizer, [2]Tokyo Women's Medical University, [3]UCSF Benioff Children's Hospital, [4]Adelphi Real World,

333P Real-World symptom progression in Duchenne Muscular Dystrophy patients in Europe, Japan, and the USA: results from a multi-national survey

***Posner N**[1], Talaga A[1], Strober J[3], Ishigaki K[2], Cappelleri J[1], Dukacz S[1], Aslam Z[1], Morton E[4], Iqbal H[4], Chatterton E[4], DeCourcy J[4]*
[1]Pfizer, [2]Tokyo Women's Medical University, [3]UCSF Benioff Children's Hospital, [4]Adelphi Real World,

334P GrowDMD: an international study on transition of youth with Duchenne Muscular Dystrophy (DMD)

***Friedrich S**[1], Langer T[1], Reeskau G[2], Rodger S[1], Willems J[1], de Angelis F[3], Brigladori B[4], Guastafierro E[4], Leonardi M[4], Marcassoli A[4], Moroni I[4], Nardocci N[4], Fournier A[5], Frei J[6], Gutierrez Rojas R[5], Kraus De Camargo O[6], Pozniak K[6], Swain A[6], Gorter J[6], Osman H[7]*
[1]University Hospital Freiburg, [2]Deutsche Gesellschaft für Muskelkranke e.V., [3]Parent Project APS, [4]Fondazione IRCCS Istituto Neurologico Carlo Besta, [5]CHU Sainte-Justine, [6]CanChild – McMaster University, [7]Muscular Dystrophy Canada

335P Transition in Duchenne Muscular Dystrophy: understanding healthcare providers' roles in an international context

***Friedrich S**[1], Langer T[1], Reeskau G[2], Rodger S[1], Willems J[1], de Angelis F[3], Brigladori B[4], Guastafierro E[4], Leonardi M[4], Marcassoli A[4], Moroni I[4], Nardocci N[4], Fournier A[5], Frei J[6], Gutierrez Rojas R[5], Kraus De Camargo O[6], Pozniak K[6], Swain A[6], Gorter J[6], Osman H[7]*
[1]University Hospital Freiburg, [2]Deutsche Gesellschaft für Muskelkranke e.V., [3]Parent Project APS, [4]Fondazione IRCCS Istituto Neurologico Carlo Besta, [5]CHU Sainte-Justine, [6]CanChild – McMaster University, [7]Muscular Dystrophy Canada

336P Quantifying the burden-of-illness of Duchenne Muscular Dystrophy in Belgium: an interim analysis of a site-based survey

***De Waele L**[1,2], Cremers J[3], Debien E[3], Gielis E[1], Maenen V[1], Vanoppen I[3], Van Stappen T[4], Beeckman L[4], Posner N[5], Dukacz S[5], Jiang L[5], Evans J[6], Wu Y[6], Jones C[6], Meeus L[7], Claeys K[3,8]*
[1]Department of Child Neurology, University Hospital Leuven, [2]Department of Development and Regeneration, KU Leuven, [3]Department of Neurology, University Hospital Leuven, [4]Pfizer Belgium, [5]Pfizer USA, [6]Prime HCD, [7]Duchenne Parent Project Belgium, [8]Laboratory for Muscle Diseases and Neuropathies, Department of Neurosciences, KU Leuven

337P Functional assessments used in routine care for Duchenne Muscular Dystrophy in the USA: a survey of Certified Duchenne Care Centers

***Camino E**[1], Freed M[1], Schrader R[1], Signorovitch J[2], Zhong J[2], Bi S[2], Ward S[3], Veerapandiyan A[4]*
[1]Parent Project Muscular Dystrophy, [2]Analysis Group Inc., [3]Collaborative Trajectory Analysis Project, [4]Arkansas Childrens Hospital

338P Very late-onset Becker Muscular Dystrophy caused by a new DMD variant

***Soltanzadeh P**[1], Boutros N[1]*
[1]University of California (UCLA)

339P Exploring the content validity of Patient-Reported Outcome (PRO) measures to capture the patient experience of Becker Muscular Dystrophy (BMD)

***Bronson A**[1], Mellor K[2], Kilburn N[1], Marshall C[1], Al-zubeidi T[2]*
[1]Edgewise Therapeutics, [2]Clarivate

340P Upper extremity assessment in Becker Muscular Dystrophy: a functional and MRI data approach

***Bellam P**[1], Rock K[1], Willcocks R[1], Barnard A[1], Forbes S[1], Lott D[1], Senesac C[1], Rooney W[2], Baetscher E[2], Subramony S[1], Chahin N[1], Dixon L[1], Walter G[1], Vandenborne K[1]*
[1]University Of Florida, [2]Oregon Health and Science University

341P Incidental DMD in-frame deletions identified by prenatal array CGH: inter and intra-familial phenotype variability

***Munell F**[1], Gomez Andres D[1], Costa Comellas L[1], Alvarez M[1], Raul[1], Plaja A[1], Castells N[1], Abuli A[1], Rovira E[1]*
[1]Hospital Universitari Vall d'Hebron

342P Use of psychopharmacological drug in Duchenne Muscular Dystrophy: a European multi-centre study

Muntoni F[1,11], *Weerkamp P*[2,3], *Miranda R*[4], *Collin P*[5], *Vroom E*[6], *Niks E*[7,13], *Vissing J*[8], *Desquerre I*[9], *Straub V*[10], *Mercuri E*[12], *Hendriksen J*[2,3,13]

[1]*UCL GOS Institute of Child Health,* [2]*Kempenhaege, Centre for Neurological Learning Disabilities,* [3]*School for Mental Health and Neuroscience, Maastricht University,* [4]*Department of Psychobiology, Universidad Complutense de Madrid,* [5]*Department of Child and Adolescent Psychiatry,* [6]*World Duchenne Organization,* [7]*Department of Neurology, Leiden University Medical Center,* [8]*Department of Neurology, Rigshospitalet,* [9]*Imagine Institute des Maladies Genetiques Necker Enfant Maladies Foundation,* [10]*John Walton Muscular Dystrophy Research Centre, Newcastle University,* [11]*Dubowitz Neuromuscular Centre, UCL Institute of Child Health,* [12]*Department of Paediatric Neurology, Catholic University,* [13]*Duchenne Centre Netherlands*

343VP Duchenne Muscular Dystrophy: the critical role of pulmonary infection in survival outcomes

Wahlgren L[1,2], *Kroksmark A*[3], *Tulinius M*[2], *Sofou K*[1,2]

[1]*The Queen Silvia Children's Hospital, Sahlgrenska University Hospital,* [2]*Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg,* [3]*Department for Health and Rehabilitation/ Physiotherapy, University of Gothenburg*

344P DMD-YOUNG: paediatric palliative care for children with a slowly progressive neuromuscular disorder in transition to adulthood

Annexstad E[1], *Ramberg C*[2], *Rosenberger A*[2], *Nordstrøm M*[1,3]

[1]*Frambu Competence Center for Rare Diagnoses, Paediatric Palliative Care Unit,* [2]*National Neuromuscular Centre (NMK), University Hospital of North Norway,* [3]*Section for Rare Neuromuscular Disorders and EMAN, Oslo University Hospital*

345P Becker Muscular Dystrophy (BMD): natural history

Yuksel D[1], *Ustun C*[1], *Akyuz E*[2]

[1]*University of Health Sciences Turkey, Ankara Etlik City Hospital, Department of Pediatric Neurology and Neuromuscular Diseases Unit,* [2]*University of Health Sciences Turkey, Ankara Etlik City Hospital, Department of Physical Medicine and Rehabilitation*

346P Cognitive profile of children with Duchenne and Becker Muscular Dystrophies

Ngawa M[1], *Legaye L*[2], *François L*[2], *Majerus S*[2], *Servais L*[3]

[1]*Division of Child Neurology, Reference Center for Neuromuscular Diseases, Department of Paediatrics, University Hospital Liege & University of Liege,* [2]*Faculty of Psychology, Speech and Language Therapy and Education, University of Liege,* [3]*MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford*

347P Project HERCULES – building an evidence base to inform clinical care and access to medicines in DMD

Godfrey J[1], *Reuben E*[2], *Chandler F*[3]

[1]*JG Zebra Consulting,* [2]*Duchenne UK, 3Sanofi*

348P A national plan of action to raise Awareness and Improve Medical care of Duchenne Muscular Dystrophy (AIM-DMD)

Akinci G[1], *Coskun A*[2], *Koken O*[3], *Ardicli D*[4], *Cinar E*[1], *Okur T*[1], *Ayanoglu C*[5], *Bektas Ontas H*[4], *Ontas E*[6], *Cakir T*[7], *Komur M*[8], *Yuksel D*[9], *Yis U*[10], *Topaloglu H*[5]

[1]*UHS, Izmir Faculty of Medicine, Dr Behcet Uz Children's Hospital, Department of Pediatric Neurology,* [2]*Ataturk Sanatoryum Training and Research Hospital, Department of Pediatric Neurology,* [3]*Akdeniz University, Faculty of Medicine, Department of Pediatric Neurology,* [4]*Bilkent City Hospital, Department of Pediatric Neurology,* [5]*Yeditepe University, Department of Pediatric Neurology,* [6]*Ankara University, Department of Public Health, Epidemiology,* [7]*DMD Families Society,* [8]*Mersin University, School of Medicine, Department of Pediatric Neurology,* [9]*UHS, Etlik City Hospital, Department of Pediatric Neurology,* [10]*Dokuz Eylul University, School of Medicine, Department of Pediatric Neurology*

349P Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker Muscular Dystrophy (BMD)

Barthel B[1], *Madden M*[1], *Thaler L*[1], *Evanchik M*[1], *Koch K*[1], *Donovan J*[1], *Collins S*[1], *Phan H*[2], ***Russell A***1

[1]*Edgewise Therapeutics,* [2]*Rare Disease Research*

350P Multi-parametric MRI of lower leg muscle in patients with Becker Muscular Dystrophy

Gerhalter T[1], *Schunk V*[1], *Baudin P*[2], *Rauh S*[3], *Tkotz K*[1], *Zaiss M*[1], *Roemer F*[1], *Dörfler A*[1], *Uder M*[1], *Gazzerro E*[4], *Nagel A*[1]

[1]*University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU),* [2]*Neuromuscular Investigation Center, Institute of Myology,* [3]*Leiden University Medical Center,* [4]*Charité University of Medicine and Max Delbrück Center of Molecular Medicine*

351P Sevasemten, a fast myosin inhibitor, in adults with Becker Muscular Dystrophy results in reduced muscle damage biomarkers and functional stabilization

Donovan J[1], *Phan H*[2], *Russell A*[1], *Barthel B*[1], *Thaler L*[1], *Kilburn N*[1], *Amato M*[1], *MacDougall J*[1]
[1]*Edgewise Therapeutics,* [2]*Rare Disease Research*

352P Severe gastrointestinal problems in Duchenne Muscular Dystrophy: a case series

Zielman- Blokhuis A[2], *Tytgat K*[3], *Groothuis J*[1], ***Houwen S***[1]
[1]*Department of Rehabilitation, Radboud University Medical Centre,* [2]*Department of Rehabilitation, Sint Maartenskliniek,* [3]*Department of Gastroenterology, Amsterdam University Medical Center*

353P Applying a decision-making framework for expanded access to Duchenne Muscular Dystrophy

Rouet J[1], *Duro-Ocana P*[1], *Lawrence C*[1], *Zanker S*[1]
[1]*Bionical Emas*

354P 3-Year outcomes in Colombian patients under 7 years old with Duchenne Muscular Dystrophy early treated with ataluren

Toro C[1], *Ruiz-Ospina E*[2], *Castellar-Leones S*[3], *Ladino-Cortés L*[2], *Bolaños-Almeida C*[2], *Bobadilla-Quesada E*[2], *Maradei-Anaya S*[2], *Ortiz-Giraldo B*[4], *Acosta-Aragón M*[5], *Guerra-Araujo V*[11], *Alvarez-Montañez A*[6], *Silvera-Redondo C*[7], *Pachajoa H*[8], *Londoño-Mesa I*[9], *Torres-Nieto M*[11], *Del Río-Ospina L*[10]
[1]*El Comité,* [2]*Fundación Hospital de la Misericordia,* [3]*Universidad Nacional de Colombia,* [4]*Hospital San Vicente Fundación,* [5]*Hospital Universitario San José ESE,* [6]*Clínica General del Norte,* [7]*Universidad del Norte,* [8]*Centro de Investigaciones en Anomalías Congénitas y Enfermedades Raras, Universidad Icesi. ,* [9]*Fundación Clínica Infantil Club Noel,* [10]*Unidad Materno-Infantil del Tolima,* [11]*Asociación Colombiana de Neurología Infantil (ASCONI), Bogotá*

355P A comprehensive education and training programme for healthcare professionals in care and research for Duchenne Muscular Dystrophy developed from DMD Care UK and the DMD Hub

Turner C[1], *Geuens S*[2], *Heslop E*[1], *Johnson A*[3], *Straub V*[1], *Guglieri M*[1]
[1]*University Of Newcastle,* [2]*UZ Leuven,* [3]*Duchenne UK*

356P A retrospective review of adult Duchenne Muscular Dystrophy patients in a UK centre of excellence and report the results of adherence to the standards of care guidelines for cardiac management

Willis T[1,2], *Kulshrestha R*[1], *Jones J*[1]
[1]*Robert Jones and Agnes Hunt hospital,* [2]*University of Chester Medical School*

357P Correlation between height, weight, and body mass index z-scores and clinical outcome assessments in young boys with Duchenne Muscular Dystrophy

Schiava M[1], *Dang U*[2], *Wood C*[3], *Wong S*[4], *Muni Lofra R*[1], *Ward L*[5], *Mayhew A*[1], *Tawil R*[6], *Willis T*[7], *Griggs R*[6], *Guglieri M*[1]
[1]*John Walton Muscular Dystrophy Research Centre, Clinical and translational Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trusts,* [2]*Carleton University,* [3]*Great North Children's Hospital, Royal Victoria Infirmary,* [4]*Bone, Endocrine, Nutrition Research Group in Glasgow, Human Nutrition, University of Glasgow,* [5]*Division of Endocrinology and Metabolism, Children's Hospital of Eastern Ontario, and University of Ottawa,* [6]*Department of Neurology, University of Rochester Medical Centre.,* [7]*Robert Jones and Agnes Hunt Orthopaedic Hospital, NHS Foundation Trust*

358P Long-term changes of motor function in Becker Muscular Dystrophy

Bello L[1], *Riguzzi P*[1], *Capece G*[1], *Penzo M*[1], *Petrosino A*[1], *Sogus E*[1], *Mastellaro S*[1], *Caroli M*[1], *Villa M*[1], *Sabbatini D*[1], *Gorgoglione D*[1], *Vianello S*[1], *Sorarù G*[1], *Pegoraro E*[1]
[1]*Department of Neurosciences, DNS, University of Padova*

359VP Social difficulties and care burden of adult Duchenne Muscular Dystrophy in Japan: A questionnaire survey based on the Japanese Registry of Muscular Dystrophy (Remudy)

Mori-Yoshimura M[1], *Ishigaki K*[2], *Shimizu-Motohashi Y*[3], *Ishihara N*[4], *Yoshida S*[5], *Unuma A*[1], *Nakamura H*[6]
[1]*Department of Neurology, National Center Hospital, National Center Of Neurology And Psychiatry,* [2]*Department of Pediatrics, Tokyo Women's Medical College,* [3]*Department of Child Neurology, National Center Hospital, National Center Of Neurology And Psychiatry,* [4]*Medical Genome Center, National Center Of Neurology And Psychiatry,* [5]*Department of Psychiatry, National Center Hospital, National Center Of Neurology And Psychiatry,* [6]*Department of Clinical Research Support, National Center Hospital, National Center of Neurology and Psychiatry*

360VP Making DMD/BMD research data FAIR: the case of heterogeneous brain (BIND) data

Siminiuc S[1], *Sakellariou E*[1], *Queralt Rosinach N*[3], *Pedomo Quinteiro P*[4], *Spitali P*[3], *Paliouras G*[1,2], *Muntoni F*[5]
[1]*Duchenne Data Foundation,* [2]*National Center for Scientific Research "Demokritos,* [3]*Leiden University Medical Center, Leiden, Netherlands,* [4]*Universidad Politécnica de Madrid,* [5]*University College London*

516P-536P, 537VP: Metabolic and mitochondrial myopathies

516P Fanconi Syndrome-induced severe Osteomalacic Myopathy: an uncommon side effect of Tenofovir Disoproxil Fumarate

Dang H[1], *Nguyen T*[2]
[1]*Neurology, University Medical Center Ho Chi Minh City,* [2]*University of Medicine and Pharmacy at Ho Chi Minh City*

517P Clinical characteristics and genetic analysis of Chronic Progressive External Ophthalmoplegia

Choi S[1], *Lee S*[1], *Choi K*[1]
[1]*Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute*

518P Proteomic characterization of polyglucosan bodies in skeletal muscle in glycogenin-1 deficiency

Visuttijai K[1], *Hedberg-Oldfors C*[1], *Costello D*[2], *Bermingham N*[3], *Oldfors A*[1]
[1]*Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg,* [2]*Department of Neurology, Cork University Hospital and College of Medicine and Health, University College Cork,* [3]*Department of Neuropathology, Cork University Hospital*

519P Insights into Primary Mitochondrial Myopathies: baseline characteristics and potential biomarkers from a natural history study

Martín Jiménez P[1], *Bermejo Guerrero L*[1], *Blázquez A*[2], *Serrano Lorenzo P*[2], *Hernández Lain A*[3], *Lucas Gómez B*[4], *Martín M*[5], *Domínguez González C*[1]
[1]*Neuromuscular Disorders Unit, Neurology Department, Hospital Universitario 12 de Octubre,* [2]*Mitochondrial Diseases Laboratory, Hospital Universitario 12 de Octubre,* [3]*Department of Neuropathology, Hospital Universitario 12 de Octubre,* [4]*Neuromuscular Unit Nursing, Hospital Universitario 12 de Octubre,* [5]*Genetics Department, Hospital Universitario 12 de Octubre*

520P Periodic paralysis in a child with Thermosensitive Mitochondrial Trifunctional Protein Deficiency

Al-Amrani F[1], *Ruiter J*[2], *Doolaard M*[2], *Kumar A*[3], *Ferdinandusse S*[2], *Al-Thihli K*[4]
[1]*Pediatric Neurology Unit, Department of Child Health, Sultan Qaboos University Hospital,* [2]*Laboratory Genetic Metabolic Diseases, Department of Clinical Chemistry, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam UMC, University of Amsterdam,* [3]*Department of Radiology, Sultan Qaboos University,* [4]*Department of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University*

521P Methodology and design of a study to characterize the disease course in a large dataset of patients with Thymidine Kinase 2 Deficiency

Domínguez-González C[1,2,3], *Nascimento A*[3,4], *Ma Y*[5], *Panahloo Z*[5], *Boudiaf N*[5], *Kim R*[6], *VanMeter S*[6], *Brunnert M*[7], *Hirano M*[8]
[1]*Neuromuscular Diseases Unit, Neurology Department, Hospital Universitario 12 de Octubre,* [2]*Research Institute (imas12), Hospital Universitario 12 de Octubre ,* [3]*Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III,* [4]*Neuromuscular Unit, Sant Juan de Deu Hospital,* [5]*UCB Pharma Ltd,* [6]*UCB Biosciences Inc,* [7]*UCB Pharma Ltd,* [8]*Department of Neurology, Columbia University Irving Medical Center*

522P Idiopathic hyperCKemia and myalgia- keep looking till you find a cause

Shekhar L[1], *Majumdar A*[1]
[1]*Bristol Royal Hospital for Children*

523P Rare Disease Register: McArdle Disease and Glycogenoses

Finnigan P[1], *Godfrey R*[1,2], *Arikan E*[1], *Bythel M*[3], *Aston J*[3], *Mohamed K*[1], *Quinlivan R*[1]
[1]*MRC Centre for Neuromuscular Diseases and Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London Hospital,* [2]*Division of Sport, Health and Exercise Sciences, College of Health, Medicine and Life Sciences, Brunel University,* [3]*National Disease Registration Service, NHS Digital, National Cancer Registration and Analysis Service*

524P Grip strength in McArdle disease

Finnigan P[1], *Godfrey R*[1,2], *Pattni J*[1], *Mohamed K*[1], *Quinlivan R*[1]
[1]*MRC Centre for Neuromuscular Diseases and Institute of Neurology, National Hospital for Neurology and Neurosurgery, University College London Hospital, London, UK,* [2]*Division of Sport, Health and Exercise Sciences, College of Health, Medicine and Life Sciences, Brunel University, London, UK*

525P Management of seizures in patients with Primary Mitochondrial Diseases: consensus statement from the inter-ERNs mitochondrial working group

*Mancuso M[1], **Evangelista T**[9], Papadopoulou M[2], Ng Y[3,4], Ardissone A[5], Bellusci M[6], Bertini E[7], Di Vito L[8], Fons C[10], Hikmat O[11], Horvath R[12], Klopstock T[13,14,15], Kornblum C[16], Lamperti C[5], Licchetta L[8], Molnar M[17], Varhaug K[18], O'Callaghan M[10], Pressler R[19,20], Consortium InterERN group on mitochondrial diseases (ERNs NMD, EYE, RND)*
[1]Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, [2]Department of Pediatric Clinical Epileptology, Sleep Disorders and Functional Neurology, University Hospital of Lyon, Member of the ERN EpiCARE, [3]Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute AND National Institute for Health and Care Research (NIHR) Newcastle Biomedical Research Centre (BRC), Newcastle University, [4]NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon Tyne Hospitals NHS Foundation Trust, [5]Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, [6]Reference Center for Inherited Metabolic Disorders MetabERN, Mitochondrial Disorders Research Group (imas12), '12 de Octubre' University Hospital, [7]Research Unit of Neuromuscular Disease, Translational Pediatrics and Clinical Genetics, Bambino Gesu' Children's Research Hospital, IRCCS, [8]IRCCS Istituto delle Scienze Neurologiche di Bologna, Full Member of the European Reference Network for Rare and Complex Epilepsies (EpiCARE), [9]Department of Neuropathology, Functional Unit of Neuromuscular pathology and Department of Neuromyology, Institute of Myology, EURO-NMD coordination, Pitié- Salpêtrière Hospital, APHP Sorbonne University, [10]Epilepsy and Neurometabolics Units, Pediatric Neurology Department, Hospital Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, [11]Department of Paediatrics and Adolescent Medicine, Haukeland University Hospital, Bergen and Department of Clinical Medicine (K1), University of Bergen, [12]Department of Clinical Neurosciences, University of Cambridge, [13]Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, Ludwig-Maximilians-Universität München, [14]German Center for Neurodegenerative Diseases (DZNE), [15]Munich Cluster for Systems Neurology (SyNergy), [16]Department of Neurology, Section of Neuromuscular Diseases, University Hospital Bonn, [17]Institute of Genomic Medicine and Rare Disorders, Semmelweis University, [18]Department of Neurology, Haukeland University Hospital, [19]UCL Great Ormond Street Institute of Child Health, [20]Great Ormond Street Hospital for Children

526P Clinical spectrum and treatment in paediatric *TANGO2* deficiency disorder

***Ortez Gonzalez C**[1], Ortuño B[1], Sarquella-Brugada G[1], Meavilla S[1], García-Cazorla Á[1], Expósito-Escudero J[1], O' Callaghan M[1], Natera De-Benito D[1], Darling A[1], Nascimento A[1], Julià N[1], Carrera-García L[1]*
[1]Hospital Sant Joan De Deu

527P Small molecule adenylosuccinic acid supports muscle metabolism in *Adss1* deficient muscle phenotypes

***Rybalka E**[1,2,3], Kourakis S[1,2], Yates T[1], Bagaric R[1,2], Qi B[1,2], Ali B[1,2], Khandari N[4], Peterson A[5], Yan X[1], Kuang J[1], Nijagal B[5], Deveson-Lucas D[4], Timpani C[1,2,3]*
[1]Victoria University, Institute for Health and Sport, [2]Australian Institute for Musculoskeletal Science, Inherited and Acquired Myopathies Program, [3]The University of Melbourne, Department of Medicine – Western Health, Melbourne Medical School, [4]Monash University, Monash Genomics and Bioinformatics Platform, Biomedical Discovery Institute, [5]The University of Melbourne, Metabolomics Australia, Bio21 Institute

528P A novel homozygous variant of uncertain significance in *ETFDH* suspected of causing severe Metabolic Syndrome and Myopathy

***Fajre F**[1], González D[2], Urra A[1], Madariaga G[3], Pizarro B[4], Díaz-Jara J[4], Bevilacqua J[1,5]*
[1]Departamento de Neurología y Neurocirugía, Clínica Dávila, [2]Servicio de Neurología, Hospital Regional de Talca, [3]Servicio de Neurología, Hospital de Cauquenes, [4]Centro de Imagenología, Hospital Clínico Universidad de Chile, [5]Departamento de Neurología y Neurocirugía, Hospital Clínico Universidad de Chile

529P Paucisymptomatic late onset Pompe disease: lessons from the clinical, radiological and histopathological long-term follow-up of an untreated patient

***Fernández-eulate G**[1,2], Caillaud C[3], Lacene E[4], Labasse C[4], Brochier G[4], Carlier R[5], Evangelista T[4,6], Laforêt P[7]*
[1]Pitié-salpêtrière Hospital, [2]Institut Necker-Enfants Malades, INSERM U1151, BioSPC (ED562), Université Paris Cité, [3]Metabolic Biochemistry Laboratory, Necker Enfants Malades University Hospital, APHP, [4]Unité de Morphologie Neuromusculaire, Institut de Myologie, Pitié-Salpêtrière University Hospital, APHP, [5]Radiology department, Ambroise-Paré University Hospital, APHP, [6]Functional unit of neuromuscular pathology, Neuropathology department, Pitié-Salpêtrière University Hospital, APHP, [7]Nord-Est-Ile-de-France, Service de Neurologie, FHU Phenix, Centre de Référence de Pathologie Neuromusculaire, Raymond Poincaré Hospital, Garches, APHP, Garches, and UVSQ, Paris-Saclay University

continued on next page

530P Biallelic missense variants in *C2orf69* cause mitochondrial dysfunction associated with early-onset neurodegeneration and autoinflammation

Oh R[1,2], *Maier M*[3], *Blaser S*[1,4], *Cameron J*[1,5], *Lafreniere A*[1,6], *Hawkins C*[1,6], *Reversade B*[3,7,8,9], *Yoon G*[1,10]
[1]*University Of Toronto,* [2]*Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children,* [3]*Laboratory of Human Genetics and Therapeutics, Genome Institute of Singapore, A(*) STAR, Biopolis,* [4]*Division of Neuroradiology, Department of Diagnostic Imaging, The Hospital for Sick Children,* [5]*Department of Paediatric Laboratory Medicine, The Hospital for Sick Children,* [6]*Division of Pathology, Department of Paediatric Laboratory Medicine, The Hospital for Sick Children,* [7]*Institute of Molecular and Cell Biology, A(*)STAR, Biopolis,* [8]*Medical Genetics Department, Koç University School of Medicine,* [9]*Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore,* [10]*Division of Neurology, Department of Paediatrics, The Hospital for Sick Children*

531P The French Registry of Glycogen Storage Disease Type 3

Masingue M[1], *Decostre V*[2], *Bello M*[3], *Do Cao J*[4], *Labrune P*[4], *Laforêt P*[3]
[1]*Service de Neuromyologie, Centre de Référence Neuromusculaire, APHP,* [2]*Institut de myologie, Groupe Hospitalier Pitié-Salpêtrière, APHP. Université Paris Sorbonne,* [3]*Centre de Référence des Maladies NeuroMusculaires Nord - Est - Ile-de-France, Filnemus,* [4]*APHP, Université Paris-Saclay, Hôpital Antoine Béclère*

532P Clinical, pathological, and genetic characteristics of 27 Spanish patients with POLG-related disorders

Bermejo Guerrero L[1], *Restrepo-Vera J*[2,3,4], *Martín – Jiménez P*[1], *Blázquez A*[5], *Serrano-Lorenzo P*[5], *Navarro-Riquelme M*[5], *Hernández-Laín A*[6], *Juntas-Morales R*[2], *Martí R*[3,4], *Martín M*[7], *Domínguez – González C*[1,4]
[1]*Neuromuscular Disorders Unit, Neurology Department, Hospital Universitario 12 de Octubre,* [2]*Neuromuscular Disorders Unit, Neurology Department, Hospital Vall d'Hebron,* [3]*Research Group on Neuromuscular and Mitochondrial Diseases, Vall d'Hebron Research Institute,* [4]*Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III,* [5]*Mitochondrial Diseases Laboratory, Hospital Universitario 12 de Octubre,* [6]*Department of Neuropathology, Hospital Universitario 12 de Octubre,* [7]*Genetics Department, Hospital Universitario 12 de Octubre*

533P Long-term follow-up Deoxynucleoside therapy for Late Onset Thymidine Kinase 2 Deficiency patients

Durmus H[1], *Gedikbaşı A*[1], *Ceylaner S*[1], *Kıyan E*[1], *Gulsen Parman Y*[1]
[1]*Istanbul Faculty of Medicine*

534P Clinical and genetic characterization of Brazilian patients with TK2 deficiency

Moreno C[1], *Tácio Quadros Santos Monteiro Fonseca A*[1], *Cunha Artilheiro M*[1], *Macedo Serafim da Silva A*[1], *de Paula Estephan E*[1], *Abdo Paiva M1, Gontijo Camelo C*[1], *Santos Pessoa A, Paranhos Miranda Covalesk A, Tomaselli P*[1], *Scarpellini G*[1], *Gurgel-Giannetti J*[1], *Holanda Mendonça R*[1], *Maroco Cruzeiro M*[1], *Marques Júnior W*[1], *Ferreira da Rosa Sobreira C*[1], *Hirano M*[1], *Andres Nascimento A*[1], *Schlesinger D*[1], *Zanoteli E*[1]
[1]*Universidade de São Paulo*

535P Cytochrome c oxidase (COX) deficiency due to a novel homozygous *COX6B1* pathogenic missense variant

Oldfors C[1], *Jennions E*[2], *Olsson-Engman M*[3], *Visuttijai K*[1], *Wiksell Å*[4], *Fluriach Dominguez N*[5], *Kollberg G*[1], *Oldfors A*[1]
[1]*Department of Laboratory Medicine, University of Gothenburg,* [2]*Department of Pediatrics, University of Gothenburg,* [3]*Department of pediatrics, Blekinge Hospital,* [4]*Department of Pediatric Radiology, Queen Silvias Children's Hospital,* [5]*Department of Pediatric Opthalmology, Queen Silvias Children's Hospital*

536P Biallelic variants in *BCS1L* cause a novel neuromuscular phenotype with motor neuronopathy

Orbach R[1], *Maio N*[2], *Donkervoort S*[1], *Foley A*[1], *Chao K*[3], *Lehky T*[4], *Silverstein S*[1], *Potticary A*[1], *Rouault T*[2], *Butterfield R*[5], *Bönnemann C*[1]
[1]*Neuromuscular and Neurogenetic Disorders of Childhood Section (NNDCS)/National Institute of Neurological Disorders and Stroke (NINDS)/NIH,* [2]*Molecular Medicine Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)/NIH,* [3]*Program in Medical and Population Genetics, Center for Mendelian Genomics, Broad Institute of MIT and Harvard,* [4]*Electromyography Section, National Institute of Neurological Disorders and Stroke (NINDS)/NIH,* [5]*Departments of Pediatrics and Neurology, University of Utah*

continued on next page

537VP Evaluation of the Scottish rhabdomyolysis and metabolic myopathy gene panel highlights limitations of genetic test criteria and a postcode lottery in access to testing

He Z[1], *Longman C*[10], *Farrugia M*[5], *Fletcher E*[2], *Robb Y*[2], *McWilliam C*[3], *Ross A*[4], *Brennan K*[5], *Davenport R*[6], *Hopkins P*[7], *Horrocks I*[8], *Joseph S*[8], *Harvie J*[9], *Kerrigan S*[9], *Stewart K*[10], *Brennan K*[5], *Miller-Hodges E*[11]
[1]*University Of Glasgow,* [2]*South East Scotland Genetic Service, Western General Hospital,* [3]*East of Scotland Regional Genetics Service, Ninewells Hospital,* [4]*North of Scotland Regional Genetics Service,* [5]*Institute of Neurology, Queen Elizabeth Hospital,* [6]*Department of Clinical Neurosciences, NHS Lothian,* [7]*Malignant Hyperthermia Unit, St James's University Hospital,* [8]*Paediatric Neurosciences Unit, Royal Hospital for Children,* [9]*Dept of Reumatology, Forth Valley Royal Hospital,* [10]*West of Scotland Centre for Genomic Medicine, QUEH,* *11Scottish IMD Service*

656P-676P: Pompe disease

656P AAV gene therapy in the Pompe canine model demonstrates correction of the muscle and CNS disorder with immune tolerance to human GAA

Byrne B[1], *Pope M*[1], *Gentry M*[1], *Sun R*[1], *Gurda B*[1], *Trivedi P*[1], *Cloutier D*[1], *Saba S*[1], *Fuller D*[1], *Coleman K*[1], *Corti M*[1]
[1]*University of Florida*

657P Cipaglucosidase alfa + miglustat in late-onset Pompe disease: two non-ambulatory patients switching from high-dose, high-frequency alglucosidase alfa

Byrne B[1], *Castelli J*[2], *Jain V*[2], *Sitaraman Das S*[2], *Zhang J*[2]
[1]*University of Florida,* [2]*Amicus Therapeutics, Inc.*

658P High-risk screening for Late-Onset Pompe Disease in China: an expanded Multicenter Study

Zhu B[1,2,3], *Jiao K*[1,2,3], *Chang X*[4], *Yao X*[5], *Zhu W*[1,2,3]
[1]*Department of Neurology, Huashan Hospital Fudan University,* [2]*National Center for Neurological Disorders (NCND),* [3]*Huashan Rare Disease Center, Shanghai Medical College, Huashan Hospital, Fudan University,* [4]*Department of Neurology, First Hospital, Shanxi Medical University,* [5]*Department of Neurology, The First Affiliated Hospital of Sun Yat-sen University*

659P Unlocking long-term insights: antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease

Theunissen M[1], *Ditters I*[2], *van Doorn P*[1], *van den Hout J*[2], *Hoogeveen-Westerveld M*[3], *Jacobs E*[3], *van der Ploeg A*[2], *van der Beek N*[1]
[1]*Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center,* [2]*Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC - Sophia Children's Hospital, University Medical Center,* [3]*Department of Clinical Genetics, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center*

660P Safety and efficacy of switching to avalglucosidase alfa in patients with late-onset Pompe disease previously deteriorating on alglucosidase alfa

Potters L[1], *Theunissen M*[1], *Wagenmakers M*[2], *van Doorn P*[1], *van der Ploeg A*[3], *van der Beek N*[1]
[1]*Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center,* [2]*Department of Internal Medicine, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center,* [3]*Department of Pediatrics, Center for Lysosomal and Metabolic Diseases, Erasmus MC - Sophia Children's Hospital, University Medical Center*

661P Sensitivity to Change and Meaningful Change Thresholds of the Quick Motor Function Test (QMFT) in Pompe Disease

van der Beek N[1], *Sjöström-Bujacz A*[2], *Daskalopoulou C*[3], *Papageorgiou D*[3], *An Haack K*[4], *Gallego V*[5], *DasMahapatra P*[5], *Thibault N*[5], *Zaher A*[6], *Armstrong N*[5], *Kruijshaar M*[1], *van der Ploeg A*[1]
[1]*Erasmus MC University Medical Center,* [2]*IQVIA, Solna, Sweden,* [3]*IQVIA,* [4]*Sanofi France,* [5]*Sanofi US,* [6]*Sanofi Canada*

662P The novel *GAA* variant p.R190G: expanding the spectrum of late onset Pompe disease and possible implications for screening in the Chinese population

Jiao K[1], *Jacobs E*[2], *Yue D*[3], *Boonman J*[2], *Zhao C*[1], *Pijnappel W*[2], *Zhu W*[1]
[1]*Department of Neurology and Rare Disease Center, Huashan Hospital, Fudan University,* [2]*Department of Clinical Genetics, Erasmus University Medical Center,* [3]*Department of Neurology, Jing'an District Center Hospital of Shanghai*

663P Screening for Pompe disease and its differential diagnoses

Sekulic A[1], *Todorovic T*[1], *Peric S*[1], *Basta I*[1], *Ivanovic V*[1], *Rakocevic-Stojanovic V*[1], *Bozovic I*[1], *Palibrk A*[1], *Viric V*[1]
[1]*University of Belgrade, Faculty of Medicine, Belgrade*

664P From past to present: Pompe disease, pseudodeficiency, and genetic challenges

Giliberto F[1,2], *Buonfiglio P*[3], *Luce L*[1,2,4], *Llames Massini C*[1,2], *Carcione M*[1,2]

[1]*Laboratorio de Distrofinopatías, Cátedra de Genética, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires,* [2]*Instituto de Inmunología, Genética y Metabolismo (INIGEM), UBA-CONICET,* [3]*Laboratorio de Fisiología y Genética de la Audición. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres" (INGEBI-CONICET),* [4]*John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust*

665P Spanish Pompe Registry: overview based on the 130 patients included

Martínez Marín R[1], *Reyes Leiva D*[2], *Nascimento Osorio A*[3], *Muelas N*[4], *Domínguez C*[5], *Rojas Marcos Í*[6], *Paradas C*[6], *Olivé M*[7], *Matas A*[8], *Gómez Caravaca M*[10], *Barba Romero M*[9], *Mendoza M*[11], *de León J*[12], *Gutiérrez A*[13], *Rabasa M*[14], *Segovia S*[7], *Díaz Manera J*[15]

[1]*Hospital Universitario La Paz,* [2]*Hospital San Joan Despi,* [3]*Servicio de Neuropediatría, Hospital Sant Joan de Deu,* [4]*Hospital La Fe,* [5]*Hospital Universitario 12 de Octubre,* [6]*Hospital Virgen del Rocío,* [7]*Hospital de la Santa Creu i Sant Pau,* [8]*Hospital Clinic, Barcelona, Spain,* [9]*Hospital Unviversitario de Albacete,* [10]*Hospital Universitario Juan Ramón Jiménez,* [11]*Hospital Universitario Doctor Negrín,* [12]*Hospital Universitario Nuestra Señora de la Candelaria,* [13]*Hospital Insular,* [14]*Hospital de Fuenlabrada, 15John Walton Muscular Dystrophy Research Center*

666P MyoScreen™ Infantile and Late-Onset Pompe human skeletal muscle disease models for drug discovery and development of next-generation gene therapies

Young J[1], *Morozzi G*[1], *Travard L*[1], *Yennek S*[2], *Lagerstedt J*[2], *Zablocki A*[1], *Martin A*[1], *Flaender M*[1], *Lorintiu O*[1], *Dupont A*[1], *Autier V*[1], ***Ventre E***[1], *Darimont B*[1], *Selig L*[1]

[1]*Cytoo,* [2]*Novo Nordisk*

667P Glycogen response to enzyme replacement therapy in patients with Pompe disease

Stemmerik M[1], *Vissing J*[1]

[1]*Copenhagen Neuromuscular Centre, Rigshospitalet*

668P Pompe Registry: Real-world experience of patients with late-onset Pompe disease who switched therapy from alglucosidase alfa to avalglucosidase alfa

Schoser B[1], *Toscano A*[2], *Foster M*[3], *Sparks S*[3], *Kishnani P*[4], *on behalf of the Pompe Registry sites*

[1]*Friedrich-Baur-Institut LMU München,* [2]*Reference Center for Rare Neuromuscular Disorders, University of Messina,* [3]*Sanofi,* [4]*Duke University Medical Center*

669P The FORCE(TM) platform enables TfR1-mediated delivery of enzyme replacement therapy to muscle and central nervous system, resolving Pompe pathology in mice

Picariello T[1], *Vieira B*[1], *Johnson J*[1], *Schlaefke L*[1], *Russo R*[1], *Chang A*[1], *Cui J*[1], *Yang S*[1], *Rinaldi S*[1], *Weeden T*[1], *Zanotti S*[1], *Beskrovnaya O*[1]

[1]*Dyne Therapeutics*

670P Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease

Roberts M[1], *Cole D*[2], *Geberhiwot T*[3], *Hughes D*[4], *Lachmann R*[5], *Murphy E*[6], *Sharma R*[7], *Jain V*[8], *Moffat E*[9], *Rutecki J*[8], *Clarke S*[9], *Deegan P*[10]

[1]*Salford Royal NHS Foundation Trust,* [2]*University Hospital of Wales,* [3]*Institute of Metabolism and Systems Research, University of Birmingham,* [4]*Lysosomal Storage Disorders Unit, Royal Free London NHS Foundation Trust and University College London,* [5]*National Hospital for Neurology and Neurosurgery, University College London Hospitals,* [6]*Charles Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, University College London Hospitals,* [7]*The Mark Holland Metabolic Unit, Salford Royal Foundation NHS Trust,* [8]*Amicus Therapeutics, Inc.,* [9]*Amicus Therapeutics UK Ltd,* [10]*Lysosomal Disorders Unit, Addenbrooke's Hospital*

671P Miglustat: a first-in-class enzyme stabiliser for late-onset Pompe disease

Mozaffar T[1], *Roberts M*[2], *Byrne B*[3], *Dimachkie M*[4], *Hopkin R*[5], *Kishnani P*[6], *Schoser B*[7], *van der Ploeg A*[8], *Brudvig J*[9], *Fox B*[9], *Holdbrook F*[9], *Jain V*[9], *Johnson F*[9], *Zhang J*[9], *Parenti G*[10]

[1]*University of California,* [2]*Salford Royal NHS Foundation Trust,* [3]*University of Florida,* [4]*Department of Neurology, University of Kansas Medical Center,* [5]*Department of Human Genetics, Cincinnati Children's Hospital Medical Center,* [6]*Duke University Medical Center,* [7]*Friedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, LMU Munich,* [8]*Erasmus MC University Medical Center,* [9]*Amicus Therapeutics, Inc.,* [10]*Metabolic Unit, Department of Translational Medical Sciences, University of Naples Federico II*

672P New insights into Pompe disease using Raman-microscopy

Hintze S[1], *Krois E*[2], *Wieland K*[3], *Meinke P*[1], *Haisch C*[2], *Schoser B*[1]

[1]*Friedrich-Baur-Institut at the LMU Hospital,* [2]*Lasers and Particles Chair of Analytical Chemistry Technical University Munich,* [3]*Competence Center CHASE GmbH Technical University Vienna*

673P Magnetization transfer Imaging in Late-Onset Pompe disease

Croce M[1], Naz F[2], Barzaghi L[2,3,4], Paoletti M[3], Mongini T[5], Gasperini S[6], Filosto M[7], Maggi L[8], Sechi A[9], Grandis M[10,11], Sacchini M[12], Sciacco M[13], Vercelli L[5], Bonizzoni C[3], Bergsland N[14], Santini F[15,16], Deligianni X[15,16], Gandini in Wheeler-Kingshott C[1,17,18], Ravaglia S[1], Pichiecchio A[1,3]

[1]Department of Brain and Behavioral Sciences, University of Pavia, [2]Department of Mathematics, University of Pavia, [3]Advanced Imaging and Radiomics Center, Neuroradiology Department, IRCCS Mondino Foundation, [4]INFN,Group of Pavia, [5]Neuromuscular Center, AOU Città Della Salute e della Scienza, University of Turin, [6]Department of Pediatrics, University of MILANO-BICOCCA, Fondazione MBBM, San Gerardo Hospital, [7]Nemo Brescia Clinical Center for Neuromuscular Diseases, [8]Neuroimmunology and Neuromuscular Diseases Unit, Fondazione IRCCS Istituto Neurologico 'CARLO BESTA', [9]Regional Coordinator Center for Rare Diseases, Academic Hospital of Udine, [10]University of Genova, [11]IRCCS Ospedale Policlinico San Martino, [12]Unit of Hereditary Metabolic and Muscular Disorders,Meyer Children University Hospital, [13]IRCCS fondazione CA' Granda Ospedale Maggiore Policlinico, Neuromuscular and Rare Disease Unit, [14]Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, [15]Department of Radiology, University Hospital Basel, [16]Basel Muscle MRI, Department of Biomedical Engineering, University of Basel, [17]Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, Faculty of Brain Sciences ,University College London, [18]Brain MRI 3T Research Centre, IRCCS Mondino Foundation

674P Quantification of skeletal muscle glycogen in Late Onset Pompe patients using carbon MR spectroscopy at 3 Tesla

Gonzalez Chamorro A[1,3], Wilson I[2], Bolaño C[1,3], Hollingsworth K[2], James M[1,3], Wong K[1,3], Fitzsimmons S[1,3], Diaz Manera J[1,3], Thelwall P[2]

[1]The John Walton Muscular Dystrophy Research Centre, Newcastle University, [2]The Newcastle Magnetic Resonance Centre, Newcastle University, [3]The Newcastle upon Tyne Hospitals NHS Foundation Trust

675P Understanding skeletal muscle pathology and function in Late-Onset Pompe disease: insights from Proteomic and Transcriptomic Analyses

Schaiter A[1], Lohanadan K[2], van der Ven P[2], Hentschel A[3], Mensch A[4], Hahn A[5], Kornblum C[6], Stenzel W[7], Krämer H[8], Rosenbohm A[9], Bartkuhn M[10], Roos A[11,12,13], Schänzer A[1]

[1]Institute of Neuropathology, Justus Liebig Universitypathology, [2]Institute for Cell Biology, University of Bonn, [3]Leibniz-Institute für Analytische Wissenschaften – ISAS – e.V., [4]Department of Neurology, University Medicine Halle, [5]Department of Child Neurology Justus Liebig University, [6]Department of Neuromuscular Diseases, Center for Neurology, University Hospital Bonn, [7]Department of Neuropathology, Charité – Universitätsmedizin, [8]Department of Neurology, Justus Liebig University, [9]Clinic of Neurology, University Hospital Ulm, [10]Institute of Biomedical Informatics and Systems Medicine Science Unit for Basic and Clinical Medicine, Institute for Lung Health (ILH) Platform for Genomics and Bioinformatics, Justus Liebig University, [11]Department of Pediatric Neurology, Centre for Neuromuscular Disorders, Centre for Translational Neuro- and Behavioral Sciences, University Duisburg-Essen, [12]Brain and Mind Research Institute, Children's Hospital of Eastern Ontario Research Institute, [13]Department of Neurology, University Hospital Düsseldorf, Heinrich Heine University

676P Impact of discontinuation and reintroduction of alglucoidase alpha in patients with late-onset Pompe disease

Andrejic N[1], Viric V[2], Andabaka M[3], Bozovic I[2], Palibrk A[2], Ivanovic V[2], Basta I[2], Stevic Z[2], Peric S[2]

[1]Medical Faculty University of Belgrade, [2]University Clinical Centre of Serbia - Neurology Clinic, [3]Clinic of Neurology and Psychiatry for Children and Youth, Belgrade

705LBP - 710LBP, 711VP, 712LBP - 717LBP, 719LBP - 733LBP,, 735LBVP, 736LP - 738LBP: Late Breaking

705LBP Epilepsy in childhood neuromuscular disorders: Is it truly rare?

Acar Arslan E[1], Öztürk G[1], İyişenyürek Ş[1], Akbeyaz H[1], Bıkmazer B[1], Karayakalı B[1], Ünver O[1], Türkdoğan D[1]

[1]Marmara University Pendik Research and Training Hospital

706LBP Evaluation of children diagnosed with muscular dystrophy panel

Ayca S[1], Orak S[1], Polat M[1], Çam S[2]

[1]Celal Bayar University, School of Medicine, Department of Pediatric Neurology, [2]Celal Bayar University, School of Medicine, Department of Medical Genetics

707LBP Transcriptomics reveals DMD-driven cell dynamics and mechanisms of fibroblast inflammatory tissue priming in human dystrophic muscle

Barthelemy F[1,2], Chesmore K[1,3], Scripture-Adams D[1,2], Nelson S[1,3,4,5], Miceli M[1,2]

[1]Center for Duchenne Muscular Dystrophy at UCLA, Los Angeles, USA, [2]Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine and College of Letters and Sciences, University of California, [3]Department of Human Genetics, David Geffen School of Medicine, University of California, [4]Institute for Precision Health, David Geffen School of Medicine, University of California, [5]Department of Pathology and Laboratory Medicine, David Geffen School of Medicine,

708LBP Clinical trial readiness in a rare and underserved disease: Learnings from community engagement and the lived experience in Becker muscular dystrophy (Becker)

Bronson A[1], *Cameron M*[3], *Tencer S*[1], *Engel P*[2], *Jackson S*[2], *Krieger K*[1], *Donovan J*[1]
[1]*Edgewise Therapeutics,* [2]*Engage Health,* [3]*AdvocacyWorks Consulting*

709LBP Longer-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with nonambulatory SMA: Results from the 48-month TOPAZ study

Crawford T[1], *De Vivo D*[2], *Krueger J*[3], *Mazzone E*[4], *Song G*[5], *Marantz J*[5], *Gueye M*[5], *Yu D*[5], *Yao B*[5], *Umans K*[5], *Darras B*[6,7], *on behalf of the TOPAZ Study Team*[8]
[1]*John Hopkins Hospital, Department of Neurology,* [2]*Columbia University, Irving Medical Center,* [3]*Helen Devos Children's Hospital Neurology - Grand Rapids,* [4]*Catholic University,* [5]*Scholar Rock, Inc.,* [6]*Boston Children's Hospital, Department of Neurology,* [7]*Harvard Medical School,* [8]*TOPAZ Study Team includes clinical trial investigators, physical therapists, study coordinators, and Scholar Rock (sponsor) staff*

710LBP Exploring higher doses of nusinersen in spinal muscular atrophy: final results from part B of the 3-part DEVOTE study

Crawford T[1], *Finkel R*[2], *Mercuri E*[3], *Day J*[4], *Montes J*[5], *Garcia Romero M*[6], *Sumner C*[1], *Sohn J*[7], *Monine M*[7], *Paradis A*[7], *Sun P*[7], *Foster R*[8], *Gambino G*[8], *Makepeace C*[7], *Fradette S*[7], *Farewell R*[7], *on behalf of the DEVOTE Study Group*
[1]*John Hopkins Hospital,* [2]*St Jude Children's Research Hospital,* [3]*Catholic University,* [4]*Stanford University School of Medicine,* [5]*Columbia University Irving Medical Center,* [6]*Hospital La Paz,* [7]*Biogen, 8Biogen*

711LBVP Genetic susceptibility for thrombotic microangiopathies in a 10-month-old child affected by SMA type 1

D'Alessandro R[1,2], *Somà A*[1], *Salvalaggio A*[1], *Guarnone E*[1], *Cavallina I*[1], *Rolle E*[1], *Rossi F*[1], *Vacchetti M*[1], *Mongini T*[2], *Ricci F*[1]
[1]*Department of Public Health and Pediatric Sciences, Section of Child and Adolescent Neuropsychiatry, University of Turin,* [2]*Department of Neurosciences, Neuromuscular Unit, University of Turin*

712LBP Epigenetic liquid biopsy for Duchenne and Becker muscular dystrophy

Hart S[1], *Fattal-Valevsky A*[2], *Lavi R*[2], *Sagi L*[2], *Shemer R*[1], *Dor Y*[1], ***Dor-Wolman T***[1]
[1]*Hadassh Hebrew Univesity Medical Center,* [2]*Tel Aviv Sourasky Medical Center*

713LBVP Heterozygous truncating variants in DAG1 are associated with sporadic and familial isolated hyperCKemia

Fiorillo C[1,7], *Traverso M*[1], *Baratto S*[1], *Panicucci C*[1], *Bruno C*[1,7], *Grandis M*[5,7], *Innes A*[3], *Torella A*[2,6], *Picillo E*[2,6], *Onore M*[2,6], *Politano L*[2,6], *Nigro V*[2,6], *Scala M*[1,7], *Barresi R*[4]
[1]*Gaslini Children Hospital, Genova, Italy,* [2]*Telethon Institute of Genetics and Medicine (TIGEM),* [3]*Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary,* [4]*IRCCS San Camillo Hospital,* [5]*IRCCS Ospedale Policlinico San Martino,* [6]*Department of Precision Medicine, University "Luigi Vanvitelli",* [7]*Department of Neurosciences, University of Genoa*

714LBP Can 5q SMA neonatal screening be a sustainable reality in middle-income countries? The experience of Minas Gerais state in Brazil

Giannetti J[1], *Januário J*[1], *Milanez L*[1], *Sacramento A*[1], *Moura A*[1], *Braga T*[1], *Pinhati C*[1], *Carvalho N*[1]
[1]*Universidade Federal de Minas Gerais, Belo Horizonte*

715LBP Juvenile ALS associated with the SPTLC1 gene: a diagnostic challenge

Gomez Montoya S[1], *Veneruzzo G*[2], *Monges S*[1]
[1]*Department of Neurology, Hospital de Pediatría J.P. Garrahan,* [2]*Genomics laboratory, Hospital de Pediatría J.P. Garrahan*

716LBP Distinct muscle regeneration capability of mesenchymal stromal cells derived from human iPS cells in Ullrich congenital muscular dystrophy model mice

Goto M[1], *Takenaka-Ninagwa N*[1], *Yoshioka-Bourgeois C*[1], *Miki M*[1], *Sakurai H*[1]
[1]*Center for iPS Cell Research and Application, Kyoto University*

717LBP Distinct muscle regeneration capability of mesenchymal stromal cells derived from human iPS cells in Ullrich congenital muscular dystrophy model mice

Zhai W[1,2], ***Jiao K***[1], *Wang N*[1], *Yu L*[3], *Huang X*[4], *Li W*[5], *Hu C*[5], *Chen X*[1], *Zhu B*[1], *Zhang J*[1], *Chang X*[6], *Zhong H*[1], *Zhao C*[1], *Zhu S*[2], *Zhu W*[1]
[1]*Huashan Hospital, Fudan University,* [2]*Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University,* [3]*Department of Neurology, The First Affiliated Hospital of Soochow University,* [4]*School of Computing, Mathematics, and Engineering, Charles Sturt University,* [5]*Department of Neurology, National Children's Medical Center, Children's Hospital of Fudan University,* [6]*Department of Integrative Biology and Physiology, University of Minnesota Medical School*

719LBP Duchenne muscular dystrophy gene editing therapy with CRISPR/high-fidelity Cas12Max

Luk A[1,4], *Lin J*[2], *Jin M*[2], *Li Z*[3], *Li T*[4], *Shi L*[4], *Yang H*[5], *Li G*[4]

[1]*HuidaGene Therapeutics,* [2]*Department of Neurology, First Affiliated Hospital, Fujian Medical University,* [3]*Lingang Laboratory,* [4]*HuidaGene (Shanghai) Therapeutics Co., Ltd,* [5]*Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences*

720LBP Initial data following 24 weeks of treatment with WVE-N531 in patients with DMD: findings from Part B (FORWARD-53) of a phase 1b/2 open-label study

Malhi S[1], *Servais L*[2], *Bader M*[3], *AlQurashi M*[4], *Tillinger M*[1], *Paulson D*[1], *Angelov A*[1], *Kaviya A*[1], *Hu X*[1], *Narayanan P*[1], *Hart A*[1], *Haegele J*[1], *Singh K*[1], *Rheinhardt J*[1], *Ghosh A*[1], *Saint S*[1], *Bhatia S*[1], *McClure T*[1], *Casey C*[1], *Li-Kwai-Cheung A*[1]

[1]*Wave Life Sciences,* [2]*Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust,* [3]*The Specialty Hospital (TSH), Advanced Clinical Center,* [4]*Istiklal Hospital, Clinical Research Unit*

721LBP Multi-modal benefits of deramiocel (CAP-1002) in late-stage patients with DMD: A new treatment approach to target skeletal and cardiac muscle pathogenesis (HOPE-2-OLE Trial – 36-month data)

McDonald C[1], *Villa C*[2], *Tian C*[2], *Zygmunt A*[2], *Soslow J*[3], *Ollberding N*[2], *Hor K*[4], *Harmelink M*[5], *Varadhachary A*[6], *Apkon S*[7], *Romana V*[8], *Desai U*[8], *Hogan N*[8], *Maharry K*[8], *Awadalla M*[8], *Marban L*[8]

[1]*UC Davis Health,* [2]*Cincinnatti Children's Hospital,* [3]*Vanderbuilt University Medical Center,* [4]*Nationwide Children's Hospital,* [5]*Children's Hospital of Wisconsin,* [6]*Washington University,* [7]*Children's Hospital Colorado,* [8]*Capricor Therapeutics*

722LBP Evaluating the effectiveness of clinical tools in determining the causes of recurrent rhabdomyolysis

Nandakumar D[1], *Breland C*[1], *Bhai S*[1]

[1]*University Of Texas Southwestern Medical School*

723LBP The genetic diagnosis of neuromuscular diseases beyond whole genome sequencing: a next step in testing

Nigro V[1,2], *Di Letto P*[1], *Rahman S*[1], *Zanobio M*[1], *Romano F*[1], *Scarpato M*[1], *Vicidomini G*[1], *Giacobbe C*[1], *Picillo E*[1], *Spampanato C*[1,2], *Del Vecchio Blanco F*[1], *Piluso G*[1], *Politano L*[1], *Torella A*[1,2]

[1]*University of Campania Luigi Vanvitelli,* [2]*Telethon Institute of Genetics and Medicine*

724LBP The natural history of pediatric Becker muscular dystrophy: a single center retrospective cohort study and muscle ultrasound characterization

Piccoli C[1], *Glanzman A*[2], *Gross B*[2], *Yum S*[2]

[1]*Stanford University,* [2]*Children's Hospital of Philadelphia*

725LBP Meaningful Within-Patient Change (MWPC) thresholds for North Star Ambulatory Assessment (NSAA) and Modified Pediatric Outcomes Data Collection Instrument (PODCI) in patients with Duchenne Muscular Dystrophy (DMD)

Posner N[1], *Bushmakin A*[1], *Mazar I*[1], *Shen Q*[1], *Duckacz S*[1], *Ines M*[1], *Aslam Z*[1], *Cappelleri J*[1]

[1]*Pfizer, Inc.*

726LBP Long-term safety and tolerability of delandistrogene moxeparvovec in Duchenne muscular dystrophy: phase 1 to phase 3 clinical trials

Proud C[1], *McDonald C*[2], *Mercuri E*[3], *Muntoni F*[4], *Zaidman C*[5], *Dharia S*[6], *Mason S*[6], *Meng J*[6], *Murphy A*[7], *Palatinsky E*[6], *Reid C*[7], *Wandel C*[8], *Mendell J*[6]

[1]*Children's Hospital of The King's Daughters,* [2]*UC Davis,* [3]*Pediatric Neurology Institute, Catholic University and Nemo Pediatrico, Fondazione Policlinico Gemelli IRCCS,* [4]*Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, University College London, and Great Ormond Street Hospital Trust,* [5]*Washington University in Saint Louis,* [6]*Sarepta Therapeutics, Inc.,* [7]*Roche Products Ltd,* [8]*F. Hoffmann-La Roche Ltd*

727LBP Evidence for a role of eotaxin family proteins as inflammatory mediators and biomarkers in inclusion body myositis: new insights in the disease pathogenesis

Riolo G[1], *Gibertini S*[1], *Iannibelli E*[1], *Carnazzi A*[1,2], *Nicolini De Gaetano L*[1], *Salerno F*[1], *Ruggieri A*[1], *Bonanno S*[1], *Marcuzzo S*[1], *Cavalcante P*[1], *Maggi L*[1]

[1]*Neuroimmunology and Neuromuscular Diseases Unit - Fondazione IRCCS Istituto Neurologico Carlo Besta,* [2]*Ph.D. program in Pharmacological Biomolecular Sciences, Experimental and Clinical, University of Milan*

728LBP Post-Authorisation Safety Study (PASS). Mexiletine effectiveness in patients with non-dystrophic myotonia: interim analysis findings

Rosenbohm A[1], *Vicart S*[2], *Tard C*[3], *Jayaseelan D*[4], *Sedehizadeh S*[5], *Schneider-Gold C*[6], *Adetoro N*[7], *Zozulya-Weidenfeller A*[8]

[1]*University of Ulm,* [2]*Pitié-Salpêtrière University Hospital,* [3]*CHRU Lille,* [4]*National Hospital for Neurology and Neurosurgery,* [5]*Nottingham University Hospitals NHS Trust,* [6]*St. Josef-Hospital,* [7]*Lupin Research,* [8]*Lupin EMEA*

729LBP Protein biomarkers of muscle injury exhibit differential reduction with subject age and time in adults with Becker muscular dystrophy

Russell A[1], Barthel B[1], Schrama E[2], Koeks Z[2], van de Velde N[2], Verschuuren J[2], Donovan J[1], Niks E[2], Spitali P[2]
[1]Edgewise Therapeutics, [2]University of Leiden

730LBP Double trouble: a comprehensive study into unrelated genetic comorbidities in adult patients with Facioscapulohumeral muscular dystrophy type I

Saconni S[1,2], Tammam G[3,4], Ezaru A[1], Slioui A[1], Monforte M[5], Tasca G[6], Villa L[1], Cavalli M[1], Salviati L[7], van der Vliet P[8], Lemmers R[8], Pini J[1,2], van der Maarel S[8], Puma A[1]
[1]Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Nice University Hospital, [2]Institute for Research on Cancer and Aging of Nice, CNRS, INSERM, Côte d'Azur University, [3]Department of Brain and Behavioral Sciences, University of Pavia, [4]IRCCS Mondino Foundation, [5]Institute of Neurology, Catholic University School of Medicine, [6]John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trust, [7]Clinical Genetics Unit, Department of Women's and Children's Health, University of Padua, [8]Department of Human Genetics, Leiden University Medical Center

731LBP Efficient exon skipping and dystrophin restoration after a single in vivo dose of Antisense Oligonucleotide Conjugate (AOC) in the mdx mouse model for Duchenne muscular dystrophy

Stan T[1], Van De Vijver D[1], Tanganyika-de Winter C[1], Post E[2], van Geel R[2], Türkmen N[2], van Delft F[2], Aartsma-Rus A[1]
[1]Leiden University Medical Center (LUMC), [2]Synaffix BV

732LBP Post-exercise biomarkers of muscle injury are reduced by Sevasemten, a fast myosin inhibitor, in adults with Becker muscular dystrophy

Stemmerik M[1], Russel A[2], Frølich S[1], Receveur N[1], Slipsager A[1], Barthel B[2], Donovan J[2], MacDougall J[2], Vissing J[1]
[1]Copenhagen Neuromuscular Center, Rigshospitalet, [2]Edgewise Therapeutics

733LBP Development of KT323 as a potent and safe gene therapy candidate for facioscapulohumeral muscular dystrophy (FSHD) through high throughput AAV capsid and cargo engineering

Tabebordbar S[1], Seshadri S[1], Brown K[1], Dang C[1], Tabebordbar S[1], Marsh E[1], Salmun G[1], Hakim C[1], Jenquin J[1], Stricker J[1], Ferguson B[1], Fielden M[1]
[1]Kate Therapeutics

735LBP First in class ASO targeting IGHMBP2 cryptic splice variant: efficacy and safety

Tyner C[1], Smieszek S[1], Przychodzen B[1], Johnson C[1], Polymeropoulos C[1], Birznieks G[1], Polymeropoulos M[1]
[1]Vanda Pharmaceuticals Inc.

736LBP Solving challenging titinopathy cases via multi-omics

Zhang Y[1], Xu L[1], Lei Y[2], Bönnemann C[3], Chan S[2], Javed A[1]
[1]School of Biomedical Sciences, LKS faculty of Medicine, The University of Hong Kong, [2]Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, [3]Neuromuscular and Neurogenetic Disorders of Childhood Section, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health

737LBP Full-length RNA sequencing in FSHD identifies novel isoforms and intergenic transcripts activated by DUX4

Zheng D[1], van den Heuvel A[1], Balog J[1], M. Willemsen I[1], Kloet S[1], J. Tapscott S[2,3], Mahfouz A[1,4], M. van der Maarel S[1]
[1]Leiden University Medical Center, [2]Fred Hutchinson Cancer Center, [3]University of Washington, [4]Delft University of Technology

738LBP Non-invasive optoacoustic muscle imaging in Late-onset Pompe disease – a translational and multicenter approach

Wagner A[1,2], Tan L[2,3], Zschüntzsch J[4], Meyer S[4], Stobbe A[4], Bruex H[4], Regensburger A[2,3], Alves F[4,5], Jüngert J[3], Rother U[6], Danko V[2,3], Türk M[7], Schmidt S[8], Vorgerd M[9,10], Schlaffke L[9], Wölfle J[3], Hahn A[11], Mensch A[12], Winterholler M[13], Trollmann R[3], Heiß R[8], Raming R[2,3], Knieling F[2,3]
[1]Department of Pediatric Neurology, Charité University Hospital Berlin, [2]Translational Pediatrics, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, [3]Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, [4]Translational Molecular Imaging, Max-Planck Institute for Multidisciplinary Sciences (MPI-NAT), [5]Clinic for Haematology and Medical Oncology, Institute of Diagnostic and Interventional Radiology, University Medical Center Göttingen, [6]Department of Vascular Surgery, University Hospital Erlangen, [7]Department of Neurology, University Hospital Erlangen, [8]Institute of Radiology, University Hospital Erlangen, [9]Department of Neurology, BG-University Hospital Bergmannsheil; Ruhr-University Bochum, [10]Heimer Institute for Muscle Research; BG-University Hospital Bergmannsheil, [11]Department of Child Neurology; Justus-Liebig-Universität Giessen, [12]Department of Neurology; Martin-Luther-Universität Halle-Wittenberg, [13]Sana Krankenhaus Rummelsberg

16:45-17:15	**Short Oral Presentations 10** North Hall **181P, 177P, 178P, 180P, 179P** *Moderator: Laurent Servais, University of Oxford*	**Short Oral Presentations 11** Terrace 2A **656P, 675P, 673P, 674P, 358P** *Moderator: Pascal Laforêt, Hôpital Raymond Poincaré*	**Short Oral Presentations 12** Terrace 2B **536P, 109P, 513P, 512P, 241P** *Moderator: Heike Kölbel, Universitätsmedizin Essen*
19:15-01:00	**Networking Dinner** Municipal House (separate registration required)		

Saturday 12th October 2024

07:15-14:00	**Congress desk open**
07:45-08:45	**Clinical Trial Updates** Congress Hall *Moderators: Francesco Muntoni, University College London, Great Ormond Street Hospital, UK & Tina Duong, Stanford University, USA*
07:45-08:00	**19O** Muscle MRI outcomes in patients with Duchenne Muscular Dystrophy treated with delandistrogene moxeparvovec: Findings from EMBARK Part 1 ***Vandenborne K***[1], *Walter G*[2], *Straub V*[3], *Willcocks R*[1], *Forbes S*[1], *Ennamuri S*[4], *Ding K*[4], *Reid C*[5], *Murphy A*[5], *Manfrini M*[6], *Elkins J*[4], *Rodino-Klapac L*[4] [1]*Department of Physical Therapy, University of Florida,* [2]*Department of Physiology and Aging, University of Florida,* [3]*Newcastle University, John Walton Muscular Dystrophy Research Centre,* [4]*Sarepta Therapeutics, Inc.,* [5]*Roche Products Ltd,* [6]*F. Hoffmann-La Roche Ltd*
08:00-08:15	**20O** Preliminary results from a Phase 1-2 gene therapy study of ATA-100, AAV9 vector encoding FKRP, in patients with Limb Girdle Muscular Dystrophy R9 ***Olivier S***[1], *Richard I*[1,2], *Stojkovic T*[3], *Straub V*[4], *Preisler N*[5], *Zanfongnon R*[2], *Buscara L*[2], *Genries-Ferrand S*[2], *Vissing J*[5] [1]*Atamyo Therapeutics,* [2]*Genethon,* [3]*APHP, Reference center for neuromuscular diseases, Institute of Myology,* [4]*John Walton Muscular Dystrophy Research Centre,* [5]*Rigshospitalet*
08:15-08:30	**22O** MExiletine versus lamotrigine in Non-Dystrophic myotonias – a randomised, double-blinded, cross-over trial ***Vivekanandam V***[1,2], *Jayaseelan D*[1], *Skorupinska I*[1], *Germain L*[1], *Matthews E*[3], *Barohn R*[4], *McDermott M*[5], *Hanna M*[1,2] [1]*The National Hospital for Neurology and Neurosurgery, Queen Square National Hospital for Neurology and Neurosurgery, Queen Square,* [2]*Queen Square UCL Institute of Neurology,* [3]*Neurosciences and Cell Biology Research Institute, St George's University of London,* [4]*University of Missouri,* [5]*University of Rochester Medical Center*
08:30-08:45	**21O** Rainbowfish: 2-year efficacy and safety data of risdiplam in infants with presymptomatic SMA ***Servais L***[1,2], *Finkel R*[3], *Farrar M*[4], *Vlodavets D*[5], *Zanoteli E*[6], *Al-Muhaizea M*[7], *Araújo A*[8], *Nelson L*[9], *Jaber B*[10], *Gorni K*[11], *Kletzl H*[12], *Palfreeman L*[13], *Gaki E*[13], *Rabbia M*[14], *Summers D*[13], *Fontoura P*[11], *Bertini E*[15], *on behalf of the RAINBOWFISH Study Group* [1]*MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford,* [2]*Division of Child Neurology, Centre de Références des Maladies Neuromusculaires, Department of Pediatrics, University Hospital Liège & University of Liège,* [3]*Center for Experimental Neurotherapeutics, St Jude Children's Research Hospital,* [4]*Sydney Children's Hospital Network and UNSW Medicine, UNSW Sydney,* [5]*Russian Children Neuromuscular Center, Veltischev Clinical Pediatrics and Pediatric Surgery Research Institute of Pirogov Russian National Research Medical University,* [6]*Department of Neurology, Faculdade de Medicina, Universidade de São Paulo,* [7]*Department of Neurosciences, King Faisal Specialist Hospital & Research Center-Riyadh,* [8]*Pediatrics Department, Faculty of Medicine, Federal University of Rio de Janeiro,* [9]*Department of Physical Therapy, University of Texas Southwestern Medical Center,* [10]*Pharma Development, Safety, F. Hoffmann-La Roche Ltd,* [11]*PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd,* [12]*Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel,* [13]*Roche Products Ltd,* [14]*Genentech, Inc.,* [15]*Research Unit of Neuromuscular and Neurodegenerative Disorders, Bambino Gesù Children's Research Hospital IRCCS*
08:45-09:00	**Comfort Break**

09:00-09:30	**Victor Dubowitz Lecture** Congress Hall *Moderators: Volker Straub, Newcastle University, UK & Jana Haberlová,University Hospital Motol, Czechia* **INV13** AAV delivery of mini-and full-length dystrophins ***Chamberlain J***[1], *Hauschka S*[1], *Regnier M*[1], *Tasfaout H*[1] [1]*University of Washington School of Medicine*
09:30-11:00	**Poster Highlights** *Moderators: Edoardo Malfatti, Université Paris Est, France & Tamara Dangouloff, University Of Liege, Belgium* **09:30- 09:45 23O** Spinal Muscular Atrophy is also a disorder of spermatogenesis ***Magot A***[1], *Reignier A*[2], *Binois O*[3], *Vuillerot C*[4,5], *Yann P*[1] *and the Fermasi Study Group* [1]*Centre de Référence des Mala Neuromusculaires AOC, CHU de Nantes, Filnemus, Euro-NMD, Nantes,* [2]*Service de Médecine et Biologie de la Reproduction, gynécologie médicale, CHU de Nantes,* [3]*Service de Biologie de la Reproduction - CECOS, Hôpital Antoine Béclère, AP-HP, Université Paris Saclay,* [4]*Centre de Référence PACA Réunion Rhône Alpes, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, L'Escale, Service de Médecine Physique et de Réadaptation Pédiatrique, Bron,* [5]*NeuroMyogen Institute, CNRS UMR 5310 - INSERM U1217, University of Lyon* **09:45-10:00 24O** Temporal requirement of dystroglycan glycosylation during brain development and rescue of cortical dysplasia via gene delivery in the fetal stage ***Sudo A***[1], *Kanagawa M*[2], *Kobayashi K*[2], *Endo M*[3], *Minami Y*[3], *Aiba A*[4], *Toda T*[1] [1]*Department of Neurology, The University of Tokyo,* [2]*Division of Molecular Brain Science, Kobe University,* [3]*Division of Cell Physiology, Kobe University,* [4]*Laboratory of Animal Resources, The University of Tokyo* **10:00-10:15 25O** Development of a CRISPR/CasX 4q telomeric region ablation strategy for FSHD1 using an isogenic hiPSC line and a FSHD1 fibroblast cell line ***Lama C***[1], *de Graaf N*[1,2], *Bou Akar R*[1], *Danaus P*[3], *Suel-Petat L*[4], *Nectoux J*[3], *Authier F*[1,5], *Relaix F*[1], *Richard I*[4], *Malfatti E*[1,5] [1]*Université Paris Est Créteil, INSERM, IMRB - Hôpital Henri-Mondor,* [2]*The Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud university medical center,* [3]*Assistance Publique - Hôpitaux de Paris, APHP, Centre Universitaire Paris, Hôpital Cochin, Laboratoire de Génétique et Biologie Moléculaires,* [4]*Généthon, INSERM, Unité de recherche Integrare, UMR_S951 - Université Paris-Saclay, Université d'Évry,* [5]*Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital* **10:15-10:30 26O** Understanding the clinical heterogeneity in myotonic dystrophy type 1: identifying clinical phenotypes using unsupervised clustering ***la Fontaine L***[1], *Imkamp M*[1], *'t Hoen P*[2], *van As D*[2], *Smulders F*[2], *Bruijnes J*[1], *de Kok J*[1], *Faber C*[1], *Merkies I*[1], *van Kuijk S*[1] [1]*Maastricht University Medical Centre,* [2]*Radboud University Medical Centrels* **10:30-10:45 27O** Mass spectrometry as a technique for robust quantification of titin and other large muscle disease-associated proteins ***Smolnikov A***[1], *Padoani D*[1], *Jurczyluk J*[1], *Su Z*[1], *Hamey J*[1], *Wilkins M*[1], *Yuen M*[1,2,3,4], *Oates E*[1,5] [1]*School of Biotechnology and Biomolecular Sciences, Faculty of Science, University Of New South Wales,* [2]*Kids Neuroscience Centre, Kids Research Institute, The Children's Hospital at Westmead,* [3]*Functional Neuromics, Children's Medical Research Institute, The University of Sydney,* [4]*Faculty of Medicine and Health, The University of Sydney, 5Sydney Children's Hospital Network* **10:45-11:00 28O** Minimal detectable change of the Revised Hammersmith Scale in patients with Spinal Muscular Atrophy ***O'reilly E*** [1, 2],*Stimpson G*[2], *Rohwer A*[1,2], *Baranello G*[1,2,3], *Muntoni F*[1,2,3], *Scoto M*[1,2,3], *On behalf of SMA REACH UK*[2] [1]*Great Ormond Street Hospital for Children NHS Foundation Trust,* [2]*Dubowitz Neuromuscular Centre, Institute of Child Health, UCL,* [3]*UCL NIHR GOSH Biomedical Research Centre*
11:00-11:30	**Morning refreshments, exhibition and posters**
11:30-13:30	**Late Breaking News** Congress Hall *Moderators: Ana Topf, John Walton Muscular Dystrophy Research Centre, UK & Alan H. Beggs, Boston Children's Hospital, Harvard Medical School, USA*

11:30 - 11:45 01LBO **Biallelic variants affecting the DST-b isoform cause a severe congenital myopathy presenting with arthrogryposis, muscular hypotonia and dilated cardiomyopathy**

Jacob M[1], *Kölbel H*[2], *Munot P*[3], *Kopajtich R*[1,4], *Achleitner M*[5], *Hahn A*[6], *Schänzer A*[7], *Weis J*[8], *Sewry C*[3,9,10], *Phadke R*[3], *Sukenik-Halevy R*[11,12], *Maroofian R*[13], *Goméz-Andrés D*[14], *Wilson L*[15], *Schara-Schmidt U*[2], *Winkelmann J*[1,4,16], *Roos A*[2,17,18], *Mayr J*[5], *Distelmaier F*[19], *Wagner M*[1,4,20]

[1]*Institute of Human Genetics, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, Munich,* [2]*Department of Neuropediatrics and Neuromuscular Centre for Children and Adolescents, Center for Translational Neuro- and Behavioral Sciences, University Hospital Essen, Duisburg-Essen University,* [3]*Dubowitz Neuromuscular Centre, Great Ormond Street Hospital,* [4]*Institute of Neurogenomics, Helmholtz Munich,* [5]*University Children's Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University,* [6]*Department of Child Neurology, Justus-Liebig-University Giessen,* [7]*Institute of Neuropathology, Justus Liebig University Giessen,* [8]*Institute of Neuropathology, RWTH Aachen University Hospital,* [9]*Wolfson Centre for Neuromuscular Disorders, Robert Jones and Agnes Hunt Orthopaedic Hospital,* [10]*Cellular Pathology, Salford Royal Hospital NHS Foundation Trust, Northern Care Alliance,* [11]*Genetic Institute, Meir Medical Center,* [12]*School of Medicine, Faculty of Medical and Health Sciences, Tel Aviv University,* [13]*Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology,* [14]*Department of Pediatric Neurology, Vall d'Hebron University Hospital, Vall d'Hebron Hospital Campus,* [15]*Department of Clinical Genetics, Great Ormond Street Hospital,* [16]*Munich Cluster for Systems Neurology (SyNergy),* [17]*Department of Neurology, Heinrich Heine University Düsseldorf,* [18]*Division of Neurology, Department of Medicine, Children' s Hospital of Eastern Ontario Research Institute, The Ottawa Hospital, and Brain and Mind Research Institute, University of Ottawa,* [19]*Department of General Pediatrics, Neonatology, and Pediatric Cardiology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University,* [20]*Division of Pediatric Neurology, Developmental Medicine and Social Pediatrics, Department of Pediatrics, Dr. von Hauner Children's Hospital, Ludwig-Maximilian University (LMU) Munich*

11:45 - 12:00 02LBO **Expanding the genetic and phenotypic landscape of replication factor C complex-related disorders: RFC4 deficiency is linked to a multisystemic disorder**

Saito Y[1], *Morimoto M*[2], *Ryu E*[3,4,5], *RFC4 study group, Toro C*[2], *Myung K*[3,6], *Nishino I*[1], *Malicdan M*[2,7]

[1]*Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry,* [2]*National Institutes of Health Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health,* [3]*Center for Genomic Integrity, Institute for Basic Science,* [4]*Department of Biological Sciences, Ulsan National Institute of Science and Technology,* [5]*Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School,* [6]*Department of Biomedical Engineering, Ulsan National Institute of Science and Technology,* [7]*Human Biochemical Genetics Section, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health*

12:00 - 12:15 03LBO **Decoy gene therapy for myotonic dystrophy**

Furling D[1], *Arandel L*[1], *Sureau A*[1], *Cordier A*[1], *Moulay G*[1], *Rouxel C*[1], *Klein A*[1]

[1]*Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie*

12:15 - 12:30 04LBO **Interim clinical data summary: A phase 1b/2a open-label, dose escalation study to evaluate the safety and clinical activity of intramuscular doses of an AAV9-based gene therapy (BB-301) administered to subjects with oculopharyngeal muscular dystrophy (OPMD) with dysphagia**

Amin M[1], *Achlatis E*[1], *Balou S*[1], *Steele C*[2], *Peladeau-Pigeon M*[2], *Barrett E*[2], *Meng D*[2]

[1]*NYU Grossman School of Medicine,* [2]*Swallowing Rehabilitation Laboratory, University Health Network*

12:30- 12:45 05LBO **A phase 1 study of antisense oligonucleotide NS-035 in patients with Fukuyama congenital muscular dystrophy**

Fujino G[1], *Kitamura A*[1], *Takahashi A*[1], *Maeda M*[1], *Kubota A*[1], *Tokuyama Y*[2], *Wada I*[2], *Kobayashi K*[3], *Komaki H*[4], *Taniguchi-Ikeda M*[5], *Ishigaki K*[6], *Toda T*[1]

[1]*The University of Tokyo,* [2]*The University of Tokyo Hospital,* [3]*Kobe University,* [4]*National Center of Neurology and Psychiatry,* [5]*Fujita Health University Hospital,* [6]*Tokyo Women's Medical University*

12:45-13:00 06LBO **CIFFREO, a phase 3, randomized, double-blind, placebo-controlled study of fordadistrogene movaparvovec (FM) in ambulatory participants with Duchenne muscular dystrophy (DMD)**

Muntoni F[1], *Nascimento A*[2], *Shin J*[3], *Guglieri M*[4], *Stettner G*[5], *Veerapandiyan A*[6], *Gallo S*[7], *Shi H*[7], *Gundapaneni B*[7], *Neelakantan S*[7], *Lobello K*[7], *Shen Q*[7], *Levy D*[7], *Mercuri E*[8]

[1]*UCL GOS Institute of Child Health,* [2]*Passeig de Sant Joan de Déu,* [3]*Pusan National University School of Medicine,* [4]*Newcastle University,* [5]*University of Zürich,* [6]*University of Arkansas for Medical Sciences,* [7]*Pfizer Inc,* [8]*Universita' la Cattolica*

Prize Giving Ceremony *Moderator: Marco Savarese, University of Helsinki, Finland*

Introduction to the WMS 2025 Congress, Vienna, Austria

Handover of the WMS flag and close of Congress *Moderator: Volker Straub*

13:30-14:30 **Homeward lunch**